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Abstract 
Although molecular signatures based on transcript expression in breast cancer samples have 
provided new insights into breast cancer classification and prognosis, there are acknowledged 
limitations in current signatures. To provide rational, pathway-based signatures of disrupted 
physiology in cancer tissues that may be relevant to prognosis, this study has directly quantitated 
changed gene expression, between normal breast and cancer tissue, as a basis for signature 
development. The nuclear receptor (NR) family of transcription factors, and their coregulators, are 
fundamental regulators of every aspect of metazoan life, and were rigorously quantified in normal 
breast tissues and ERα positive and ERα negative breast cancers. Coregulator expression was 
highly correlated with that of selected NR in normal breast, particularly from postmenopausal 
women. These associations were markedly decreased in breast cancer, and the expression of the 
majority of coregulators was down-regulated in cancer tissues compared with normal. While in 
cancer the loss of NR-coregulator associations observed in normal breast was common, a small 
number of NR (Rev-ERBβ, GR, NOR1, LRH-1 and PGR) acquired new associations with coregulators 
in cancer tissues. Elevated expression of these NR in cancers was associated with poorer outcome 
in large clinical cohorts, as well as suggesting the activation of ERα -related, but ERα -independent, 
pathways in ERα negative cancers. In addition, the combined expression of small numbers of NR 
and coregulators in breast cancer was identified as a signature predicting outcome in ERα negative 
breast cancer patients, not linked to proliferation and with predictive power superior to existing 
signatures containing many more genes. These findings highlight the power of predictive 
signatures derived from the quantitative determination of altered gene expression between 
normal breast and breast cancers. Taken together, the findings of this study identify networks of 
NR-coregulator associations active in normal breast but disrupted in breast cancer, and moreover 
provide evidence that signatures based on NR networks disrupted in cancer can provide important 
prognostic information in breast cancer patients. 
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1. Introduction 
Breast cancer is one of the most common malignancies worldwide, affecting millions of women 
annually in developed and developing communities. Its prevalence and increasing incidence has 
galvanized significant advances in the treatment options available, and continued advances in 
understanding of its biological underpinnings have revealed that breast cancer is both clinically 
and biologically heterogeneous. Considerable effort has been expended to identify tumor features 
that are prognostic of patient outcome, and/or predictive of responsiveness to particular 
treatment regimens. In this regard, a defining feature of breast cancers is the presence of estrogen 
receptor alpha (ERα), where ERα positive and ERα negative cancers are characterized by major 
differences in biology, sensitivity and response to treatment, and patient outcome.  
While ERα, progesterone receptor (PR) and epidermal growth factor receptor 2 (HER 2) are the 
histopathological markers that underpin current clinical management of breast cancer (Weigel and 
Dowsett, 2010), the imperative for increasingly refined and personalized predictive tools has 
driven the inclusion of molecular profiling in breast cancer prognostication, and there is now a 
significant body of evidence that molecular profiling of transcripts expressed in breast cancer 
samples can contribute to classification of breast cancers and to prognostic signatures (Weigelt et 
al., 2010a), now being tested in clinical trials (www.agendia.com/pages/mindact; (Zujewski and 
Kamin, 2008)). Although molecular-based signatures have revealed a range of breast cancer 
subtypes with distinct responses to treatment and outcome, and can identify patients at higher 
risk of early recurrence, there are acknowledged limitations in the current signatures (Geyer et al., 
2012). These include the striking lack of overlap between signatures derived from different sample 
sets; their primary utility in ERα positive breast cancers and the lack of signatures that are 
predictive in both ERα positive and ERα negative cancers; the contribution of proliferation-related 
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genes to signature performance (Venet et al., 2011); and the complicating influence of transcripts 
present in the variable proportion of normal tissue admixed with the cancer component of 
samples used in signature discovery (Weigelt et al., 2010b). In addition, signatures based on the 
combined complement of genes expressed in cancer tissue at the time of sampling fail to provide 
insight into biological pathways or processes involved in carcinogenesis. 
The emerging evidence for increased immune response activity as a predictor of improved 
prognosis has prompted a focus on signatures that incorporate immune pathways. These are 
proving to be useful in ERα negative breast cancers (Nagalla et al., 2013), but identification of 
proliferation-independent signatures for ERα  positive breast cancers, or signatures predictive in 
both ERα positive and ERα negative cancers, remains challenging. To overcome some of these 
limitations, and also to provide rational, pathway-based signatures of disrupted physiology in 
cancer tissues that may be relevant to prognosis, this study has directly quantitated changed gene 
expression between normal breast, and cancer tissue, as a basis for signature development. Our 
emphasis was two-fold: first, to base the discovery on accurately quantitated differences between 
normal and cancer tissue, and second, to focus on components of a gene family that serves as 
fundamental regulators of metazoan biology and are therefore active in every aspect of human 
physiology. The nuclear receptor (NR) superfamily of transcription factors are crucial in 
reproduction, development, growth, metabolism and homeostasis. In terms of pathophysiology, 
they play key roles in the cardiovascular and immune systems, the central nervous system and the 
musculoskeletal system, and in the genesis and progression of cancer (Conzen, 2008). The NR 
family are expressed in the normal breast, and pan-repression of the majority of NR is associated 
with carcinogenesis (Muscat et al., 2013), highlighting the rationale for a role for NR in 
development and progression of the disease. 
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The cell- and context-specificity of NR action occurs through their interaction with defined groups 
of coregulators, proteins that interact with NR to either activate or repress the transcription of 
specific genes (Lanz et al., 2007; McKenna and O'Malley, 2010). The transcriptional outcome 
regulated by NR is dependent on the complement of coregulators present in the target cell. Using 
human breast specimens (pre-and post-menopausal normal breast, and ERα positive and ERα 
negative breast cancers), we have quantitated all known NR coregulators in the human breast, and 
identified NR-coregulator interactions altered in cancer. We have developed molecular signatures 
independent of proliferation that outperform existing discriminators, and of demonstrated utility 
in both ERα positive and ERα negative breast cancers.  
2. Materials and Methods 
2.1 Human breast tissue cohorts and mRNA profiling by TaqMan low-density array (TLDA) 
The breast tissue cohorts profiled in this study and the TLDA experimental procedures have been 
previously published (Muscat et al., 2013). The present study employs the same experimental 
procedures to profile the expression of 238 coregulators (listed in Supplementary Figure 1) in the 
same human breast tissue cohorts. Briefly, we custom-designed micro-fluidic cards, TaqMan Low 
Density arrays from ABI (Applied BioSystems), which included 238 coregulators (as defined by the 
Nuclear Receptor Signaling Atlas (NURSA: www.nursa.org)) and 16 internal controls for 
normalization (these comprised 18S-Eukaryotic ribosomal RNA; ACTB - Actin, beta; 2M - Beta-2-
microglobulin; GAPDH - Glyceraldehyde-3-phosphatedehydrogenase; GUSB - Glucuronidase, beta; 
HMBS - Hydroxymethylbilane synthase; HPRT1 - Hypoxanthine phosphoribosyltransferase 1; IPO8 - 
Importin 8; PGK1-Phosphoglycerate kinase 1; POLR2A - Polymerase (RNA) II (DNA directed) 
polypeptide A, 220kDa; PPIA - Peptidylprolyl isomerase A (cyclophilin A); RPLP0 - Ribosomal 
protein, large, P0; TBP - TATA box binding protein; TFRC - Transferrin receptor (p90, CD71); UBC - 
Ubiquitin C; YWHAZ - tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
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protein, zeta polypeptide) against which to normalize the expression of the coregulators in normal 
and neoplastic breast tissue. These controls include 18S rRNA, GAPDH and RPLP0, validated real-
time PCR controls in NURSA-supported nuclear receptor profiling studies (Wang et al., 2011). The 
geNorm software embedded within the ABI/intergromics StatMiner V4.1 software package was 
used to compute least expression variation and select the most appropriate, stable and robust 
combination of internal control genes (MRPL19, PGK1, PPIA, TFRC and UBC ) against which to 
normalise the expression data (against the median of the most stable controls). 
For each sample, 1.5 μg of total RNA was reverse transcribed with random hexamers and 
SuperScript III reverse transcriptase (Invitrogen) in a total volume of 45 μl. A total of 100 μl 
reaction mixture containing 50 μl cDNA template (333 ng) in RNase-free water and an equal 
volume of TaqMan
® 
universal master mix (Applied Biosystems, Foster City, CA) was added to each 
TLDA fill reservoir. Four reservoirs per sample were filled. The TLDA includes all coregulators and 
endogenous controls in triplicate. After sealing the plate, it was run on an ABI 7900HT Real Time 
instrument (Applied Biosystems).  
We made use of the delta Ct (ΔCt) values previously obtained for the 48 NR in (Muscat et al., 2013) 
to perform combined analyses of the expression correlation pattern of nuclear receptors and 
coregulators in this study. 
2.2 Normalization of TaqMan Low Density Arrays 
TLDAs were analysed by the relative quantification method of ΔCt. The geNorm (Vandesompele et 
al., 2002) algorithm in the Integromics StatMiner software package was used to select the most 
stable house keeping genes to be used as reference for normalization. The Ct values 
(Supplementary Table 1) of each assayed genes were then normalized against the median of the 
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selected house keeping genes to obtain the ΔCt values. Supplementary Figure 1 shows a boxplot 
of the ΔCt values of all coregulators in each of the 4 cohorts. 
2.3 Filtering of outlier samples 
Ct value measurements above 35 cycles were considered inaccurate. Samples for which more than 
40% of genes had Ct values above 35 were deemed to be outliers and removed from subsequent 
analyses. Three samples (ERneg02TB003, ERneg08RMH456, ERpos07RMH188) were removed 
from both the nuclear receptor and coregulator TLDA data. 
2.4 Principal Component Analysis 
Principal component analysis of coregulator ΔCt values was performed in R with genes as variables 
to investigate the coregulators that best characterize the different patient cohorts. Three 
dimensional scatter plots of samples against the first 3 principal components were generated by 
the Scatterplot3d (Ligges and Machler, 2003) package. 
2.5 Detection of differentially expressed genes 
A moderated t-statistic test based on the limma framework implemented in the HTqPCR (Dvinge 
and Bertone, 2009) software package was used to detect differentially expressed genes. Genes 
having a Benjamini and Hochberg adjusted P-value less than 0.05 and at least 1.5 fold up or down-
regulated were termed differentially expressed (Supplementary Table 2A). 
2.6 Validation of combining NR and coregulator data by investigation of TLDA cross-card batch 
effect 
As NR and coregulator data were derived from distinct TLDA cards, we determined the validity of a 
combined analysis of NR and coregulator data by comparing expression of the housekeeping 
control genes on both the NR and coregulator TLDAs. In addition, unsupervised hierarchical 
clustering of samples based on raw Ct values of all NR and coregulator genes was performed to 
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determine if samples clustered in a batch (array) specific manner. We found expression of the 
control genes to be highly consistent between arrays (r
2
 value 0.98) with no evidence of cross-card 
batch effects in clustering of samples (results not shown).  
2.7 Correlation-based analysis of nuclear receptors and coregulators interactions 
Pairwise Spearman Rank Correlation coefficients were calculated for all possible pairs of nuclear 
receptors and coregulators in a cohort-specific manner. Two genes were considered highly 
correlated if the Spearman Rank Correlation coefficient was ≥ 0.7 or ≤ -0.7. 
2.8 Pathways and functional analysis 
Differentially expressed coregulators were separated into two groups based on the direction of 
change in expression (up- or down-regulated). The Ingenuity Pathways Analysis (IPA) Package was 
used to detect over-represented functional annotations and canonical pathways associated with 
up-regulated or down-regulated coregulators.  Given the very small number of genes that were 
up-regulated, we assessed only enriched functional annotations for this group and retained 
annotations with enrichment P-value of less than 0.05. For down-regulated coregulators, over-
represented canonical pathways with Bonferroni adjusted P-values of less than 0.05 were 
retained.  
2.9 Breast cancer microarray datasets 
In order to establish nuclear receptors and coregulators associated with prognosis, we compiled a 
large cohort of breast cancer gene expression microarrays with associated clinical data from 
previously published work. In total, we compiled 2227 breast cancer cases (of which 2189 were 
annotated with survival data) from multiple datasets profiled on the Affymetrix Hg133A platform 
and an additional 1992  breast cancer cases (of which 1853 were annotated with survival data) 
from the METABRIC study (Curtis et al., 2012) profiled on the Illumina HT-12 v3 platform. 
Supplementary Table 3 lists the microarrays datasets included in our analysis.  
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fRMA (Frozen Robust Multiarray nalysis) normalization (McCall et al., 2010) was performed on 
the Affymetrix microarrays to enable combined analysis of the multiple datasets. This algorithm 
utilizes pre-computed estimates of probe-specific effects and variances obtained from large 
publicly available databases. These pre-computed values are then used in concert with 
information from new array(s) for normalization and summarization, allowing separately 
processed datasets to be compared. fRMA normalized expression values were retrieved from 
inSilicoDb via its Bioconductor package. Illumina HT-12 v3 array data (EGAD00010000210 and 
EGAD00010000211) were downloaded from the European Genome Phenome Archive and the 
normalized expression values as published in the METABRIC publication were used. 
To identify genes correlated with ERα  expression, breast cancer microarrays profiled on 
Affymetrix Human HG133A arrays (listed in Supplementary Table 3) were divided into ERα  
positive and ERα - subsets based on the associated IHC ERα  status. Pairwise Spearman Rank 
Correlation coefficients were calculated for each gene profiled on the array with each of the 
nuclear receptors: ESR1, REV-ERα Bβ, GR, NOR1, LRH-1 and PR. Spearman Rank Correlation 
coefficient ≥ 0.7 or ≤ -0.7 were used to filter for genes showing high expression correlation with 
these nuclear receptors in either ERα positive or ERα negative breast cancers. 
2.10 Identification of nuclear receptors and coregulators associated with prognosis 
We employed the process outlined in Supplementary Figure 2 to identify nuclear receptors and 
coregulators, expression of which associates with patient survival. In this process, samples from 
each of the microarray platforms were randomly divided into two groups, one used for training 
and the other for validation. The Training and Validation sets were of comparable size, as was the 
ratio of patients with events to those without events. A bootstrap approach was employed to 
identify genes significantly associated with breast cancer survival in the Training Set. Specifically, 
we randomly sampled with replacement from the Training Sets and performed Univariate Cox 
Regression on the randomly selected subgroup. This process (sampling with replacement followed 
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by Univariate Cox Regression) was repeated 1000 times. We then defined an r-index for each gene 
as the ratio of times out of the 1000 analyses that the gene showed significant association with 
survival (Adjusted Cox Regression P-value ≤ 0.05). We used distant metastasis free survival (DMFS) 
for samples where that information is available. For samples without associated DMFS 
information, the following survival measures in order of decreasing preference were used: relapse 
free survival (RFS), disease free survival (DFS) and disease specific survival (DSS).  
For the Affymetrix Training samples, we identified 80 coregulators and 23 nuclear receptors with 
an r-index ≥ 0.75; 43 coregulators and 5 nuclear receptors were identified in the Illumina Training 
Set. Genes with an r-index of at least 0.75 on both Affymetrix and Illumina platforms were then 
selected for Multivariate Cox Regression adjusting for ERα  status and node status. This process 
identified 3 nuclear receptors and 16 coregulators, expression of which significantly associates 
with patient survival independent of ERα  status and node status on both microarray platforms 
(Supplementary Table 4). 
2.11 Validation of NR and coregulators centered gene signature 
Breast cancer microarray samples from the Validation Sets were used to assess whether the 
nuclear receptors and coregulators identified can predict patient survival. We assessed the 
performance of 3 gene signatures: (i) 19-gene signature (19 nuclear receptors and coregulators 
listed in Supplementary Table 4); (ii) 3-NR signature (PPARδ, PGR and GR); and (iii) 3 NR plus 
cytoskeletal gene signature (PPARδ, PGR, GR, CFL1 and GSN). 
For each signature, samples from the Validation Sets were assigned risk scores calculated on the 
signed average of the signature genes expression (by the “sig.score” function from the genefu R 
package (Haibe-Kains et al., 2011)). In this method, the sample risk score is calculated as the 
average of the weighted expression of the genes in each signature. We used the sign and 
magnitude of the Univariate Cox Regression coefficient of expression of each gene obtained from 
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all samples of the Discovery Sets as the input coefficients into sig.score. Samples were then 
classified into 3 different risk groups based on the assigned risk scores: low (bottom tertile), 
intermediate (middle tertile) and high (top tertile). The performance of each gene signature was 
then assessed on Kaplan Meier and a Concordance Index [as detailed in (Harrell et al., 1996)]. The 
Concordance Index represents the probability that, for a pair of randomly chosen comparable 
patients, the patient with the higher risk prediction will experience an event before the lower risk 
patient.  
Further, using the Validation samples (Supplementary Figure 2) of METABRIC dataset, we tested 
the prognostic power of the 3NR, 3NR+cytoskeletal genes and the 19 genes in breast cancer 
subgroups identified by immunohistochemical marker staining.  Subtype classification as assigned 
in the METABRIC dataset was used to categorize samples into subgroups (Normal-like, Basal, 
Luminal A, Luminal B, HERα 2). Then the risk prediction method as described above is used to test 
the prognostic power of the signatures in each of the subtypes. In this analysis, we estimated 
input coefficients into sig.score in a subtype specific manner instead of using all Discovery 
samples.  
Prognostic performance of the NR and coregulator based signatures identified was assessed in 
comparison to 48 other published signatures (Venet et al., 2011) with the same sample cohorts 
and outcome association method detailed above.  
3. Results 
3.1 Expression of coregulators differs between normal and breast cancer tissues 
Supervised hierarchical cluster analysis demonstrates that a majority of coregulators were 
expressed differently in breast cancers compared with normal breast and that the expression of 
many coregulators also differs between ERα positive and ERα negative cancers (Figure 1A). 
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This observation is supported by unsupervised Principal Component Analysis (PCA), with normal 
and cancer samples clustering into two relatively well-defined subgroups reflecting the change in 
coregulator expression in cancer samples compared with normal tissue (Figure 1B). Expression 
levels of coregulators showed greater variation among cancer samples, evidenced by the greater 
spread observed on the PCA plot. In addition, expression profiles of coregulators also differ 
between ERα positive and ERα negative breast cancers. This difference is more evident when PCA 
was performed on the cancer samples independently of the normal samples (Figure 1C).  
The changed expression of the majority of coregulators between normal and cancer cohorts 
supports the view that the separation of cohorts based on coregulator expression reflects multiple 
coregulator changes, each with an individually small contribution to the phenotype, rather than a 
few coregulators with a large effect on the phenotype. This is reflected in the small proportion of 
variance of each gene captured by each principal component in the PCA analysis (Supplementary 
Figure 3A). The first principal component only accounted for ~55% of the total variance in the 
dataset with each subsequent principal components capturing small increases in cumulative 
variance (Supplementary Figure 3B). 
3.2 Pan-repression of coregulators in neoplastic breast tissues 
The majority of coregulators showed decreased expression in cancer compared with normal 
tissue, with coregulator repression more pronounced in ERα negative than ERα positive cancers 
(Figure 1A and Figure 2). 
Overall, ERα negative breast cancers are associated with more extensive disruptions in the 
coregulator transcriptome, with an increased number of genes differentially expressed plus an 
increase in the magnitude of the change in expression (Figure 2, Supplementary Table 2A). Cluster 
A in Figure 2 highlights coregulators that are down-regulated in both ERα positive and ERα 
negative breast cancers compared with normal breast. Cluster B in Figure 2 shows coregulators 
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with increased expression in either ERα positive or ERα negative cancers; cluster C in Figure 2 
highlights coregulator expression that differs between ERα positive and ERα negative tumors.  
Using a moderated t-test implemented in the HTqPCR package, we identified differentially 
expressed coregulators. On the criterion of at least 1.5 fold up or down-regulation and Benjamini 
Hochberg adjusted P-value ≤ 0.05, we found 101 (42%) of the 238 coregulators profiled in ERα 
positive cancer samples are differentially expressed compared with normal, of which 11 genes are 
up-regulated and 90 down-regulated. In ERα negative cancers compared with normal, 203 (85%) 
of the 238 coregulators are differentially expressed, of which only 3 coregulators are up-regulated 
and the other 200 down-regulated (Figure 2, Supplementary Table 2B).  
Although a minority of coregulators are up-regulated in either ERα positive or ERα negative breast 
cancers compared with normal breast, most (10/12, 83%) of these are associated with Cellular 
Growth and Proliferation, and predicted to be activated, according to functional annotation on IPA 
(Fisher Exact p-value = 1.03E-05, activation z-score=2.307, Supplementary Table 5A). Of the up-
regulated coregulators, only CNNE1 is specifically up-regulated in  ERα negative breast cancers 
while CNNA2 and TRIP13 are up-regulated in both ERα positive and ERα negative cancers; the 
other 9 coregulators are up-regulated specifically in ERα positive cancers (Figure 2B, 
Supplementary Table 2B). 
In contrast with the specific association of coregulators up-regulated in breast cancer with NR 
pathways involved in proliferation and disease progression, coregulators that were down-
regulated in either ERα positive or ERα negative breast cancers compared with normal were 
associated with a large range of NR pathways (Supplementary Table 5B). Among the most 
significantly down-regulated pathways in breast cancer are Estrogen Receptor Signaling; RAR 
activation; Glucocorticoid Receptor Signaling, Aryl Hydrocarbon Receptor Signaling; TR-RXR 
Activation; and PPAR signaling. As noted above, the numbers of down-regulated pathways in 
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cancer compared with normal was greater for ERα negative than for ERα positive breast cancers 
(Supplementary Table 5B). 
3.3 Relationships between expression of NR and coregulators in normal breast and breast cancer 
To explore the potential functional parallels between NR and coregulators, we determined the 
correlation between NR and coregulator expression in each of the four breast cohorts (ERα 
positive, ERα negative, premenopausal normal, postmenopausal normal). This was done by 
combining the coregulator expression data of this study with previously published expression data 
for NR (Muscat et al., 2013) measured in the same cohort of samples. We first examined the 
pairwise expression correlation between each nuclear receptor and coregulator. Figure 3A shows 
the numbers of coregulators with expression highly correlated (Spearman Rank Correlation ≥ 0.7 
or ≤ -0.7) with that of each nuclear receptor, with NR ranked by decreasing NR-coregulator 
associations in normal postmenopausal breast samples, where the most abundant NR-coregulator 
associations are observed. Transcript levels of NR such as RARγ, RORγ, VDR, RARβ, HNF4γ, RXRβ, 
COUP-TF1/2, MR and PPARγ are correlated with the largest number of coregulators in these 
tissues. Although fewer associations are evident in normal premenopausal samples, and in either 
ERα positive or ERα negative breast cancers, cancer-related gains and losses in NR-coregulator 
association are observed (Figure 3A). For example, expression of RARβ correlates strongly with 97 
coregulators specifically in postmenopausal normal but not in any of the other three sample 
cohorts. Likewise, expression of RXRα shows strong inter-correlation with multiple coregulators 
specifically in ERα positive cancer samples. In contrast, AR expression correlates with fewer 
coregulators and the correlation is only observed in ERα positive cancer samples. All nuclear 
receptors display positive correlation with coregulators except for PPARγ, expression of which 
strongly and negatively correlates with more than 30 coregulators only in normal breast tissues 
(Supplementary Table 6).  
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A major cancer-associated shift in the expression correlation patterns of nuclear receptors and 
coregulators is supported by Figure 3B, which illustrates the proportion of strongly correlated NR-
coregulator pairs that are observed only in normal breast, ERα positive or ERα negative samples as 
well as those commonly observed in multiple cohorts. Only 36% of all highly correlated NR-
coregulator pairs are common to both normal and cancer samples (Figure 3B: ERα positive and 
Normal; ERα negative and Normal; ERα positive and ERα negative and Normal) while 31% are 
observed only in normal samples (Figure 3B: Normal only) and 32% are acquired correlations 
observed only in cancer samples (Figure 3B: ERα positive only; ERα negative only; ERα positive and 
ERα negative). 
The proportion of highly correlated NR-coregulator pairs in ERα negative cancer samples not 
observed in normal samples is much higher (Figure 3B: ERα negative only, 26%) compared to that 
observed in ERα positive cancer samples (Figure 3B: ERα positive only, 3%). This suggests that 
overall, ERα negative breast cancers are associated with increased dysregulation of the NR-
coregulator interaction network compared with ERα positive cancers. 
Several nuclear receptors displayed pan-ERα status changes in expression correlation with 
coregulators. Of particular interest are the nuclear receptors ERβ, LXRα and PPARγ which show 
either no or negative correlation with most coregulators in normal breast samples but strong 
positive correlation with coregulators in cancer (Figure 3C). Other nuclear receptors display ERα  
status-specific shifts in expression correlation with coregulators (Figure 3D). AR, ESRRγ, RORγ, 
RXRα and RXRγ are highly correlated with multiple coregulators in ERα positive cancers and these 
correlations are disrupted in ERα negative cancers. In contrast, REV-ERBβ, GR, NOR1, LRH-1 and 
PGR displayed the opposite pattern and acquire strong correlations with multiple coregulators 
specifically in ERα negative cancers. 
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3.4 NR-coregulator interactions acquired in cancer have stronger prognostic power than NR-
coregulator interactions disrupted between normal and cancer 
To determine whether nuclear receptors that become strongly correlated with coregulators in ERα 
negative breast cancer (Figure 3D panel 1) are associated with DMFS, we made use of published 
microarray datasets with associated clinical information (Validation samples, refer to 
Supplementary Figure 2 and Materials and Methods). The prognostic value of those nuclear 
receptors with disrupted correlations with multiple coregulators in ERα negative cancers (Figure 
3D panel 2) was also explored. 
Breast cancer cases were classified into low, intermediate and high risk-groups based on risk 
scores calculated from the expression of the nuclear receptors in each of Panel 1 and Panel 2 in 
Figure 3D. Kaplan Meier plots of the probability of DMFS of the risk-groups for ERα positive and 
ERα negative breast cancers show that the expression of nuclear receptors displaying acquired 
correlations with multiple coregulators in ERα negative cancers (Group 1: Rev-ERBβ, GR, NOR1, 
LRH-1 and PGR) significantly segregates patients at low from those at high risk (Figure 4), and this 
is confirmed in an independent dataset (Supplementary Figure 4). The expression of nuclear 
receptors showing disrupted interactions (Group 2: AR, ESRRγ, RORγ, RXRα and RXRγ) has no 
predictive power for patient survival in ERα negative cancers while having modest predictive 
power in ERα positive cancers (Figure 4 and Supplementary Figure 4).  
Given that Group 1 (Rev-ERα Bβ, GR, NOR1, LRH-1 and PGR) included NR linked with ERα  
expression and/or function, we asked whether the genes that acquired correlations with Group 1 
NR in ERα negative cancers were ERα-associated, perhaps reflecting ERα-independent signaling in 
these cancers. Genes most strongly correlated with ERα were identified in the Affymetrix datasets 
(921 genes; Pearson correlation coefficient ≥ 0.7 or ≤ -0.7), and their correlation with the Group 1 
NR determined. While GR and LRH-1 were correlated with few/no ERα-correlated genes in ERα 
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positive cancers, they acquired such correlations in ERα negative cancers (Figure 5), supporting the 
possibility that these NR may be involved in ERα-associated but ERα-independent pathways. 
Although correlations were detected between PGR and these genes in ERα negative cancers, the 
significance level did not pass the cut-off threshold of 0.7 (not shown). 
3.5 Prognostic value of nuclear receptors and coregulators in breast cancer 
The prognostic power of the small number of nuclear receptors that acquired correlation with 
multiple coregulators in breast cancers (Figure 4) raised the question of whether coregulators, 
alone or in combination with nuclear receptors, were associated with breast cancer outcome. To 
address this question, we performed a comprehensive survey of the association of all nuclear 
receptor and coregulator expression levels with patient survival in large cohort of publicly 
available breast cancer microarray datasets. In total, we compiled gene expression data from over 
4000 breast cancer tissue microarrays profiled on two microarray platforms: Affymetrix Hg133A 
(2189 samples) and Illumina HT-12 v3 (1853 samples) (Supplementary Table 3).  Given the 
multiplicity of markers already linked to clinical outcome in breast cancer, and the challenges in 
identifying prognostic gene signatures that perform better than chance alone (Venet et al., 2011), 
we employed the rigorous analytical approach outlined in Supplementary Figure 2 (Materials & 
Methods). Using the Affymetrix Training samples, as previously noted, we identified 80 
coregulators and 23 NR having r-index ≥ 0.750, and 43 coregulators and 5 NR for the Illumina 
Training Set. 
There were 3 nuclear receptors (GR, PGR, PPARδ) and 16 coregulators with expression profiles 
robustly associated with patient survival, independent of ERα status or node status on both 
microarray platforms (listed in Supplementary Table 4). These genes have functional roles relevant 
to cancer biology including: cell cycle regulation (CDKN1C, CCNA2, CCNE1, PA2G4), cytoskeletal 
organisation (CLF1, GSN), chromatin modifiers (SMARCA2, HMGB2), known oncogenes or cancer-
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related genes (RPL7A, NSD1, PRAME, FUS), and also include 4 (36%) of the 11 genes that are 
increased in cancer compared with normal breast (Figure 2: TRIP13, CCNE3, CCNA2, PRAME). 
Figure 6A represents a heatmap of the r-index of each of the 19 genes which represent the 
number of times out of 1000 bootstrap Cox regression analyses of different sample subgroups in 
which the expression of the gene is found to be associated with survival. The r-index thus 
represents the robustness of a gene’s association with patient survival. 
The combined expression of the 19 genes identified can segregate low-risk from high-risk breast 
cancers. Samples from the Validation Sets (1094 samples profiled on Affymetrix Hg133A and 927 
samples profiled on Illumina HT-12 v3) were classified into 3 different risk groups based on risk 
scores calculated from the expression of the 19 genes: low (bottom tertile), intermediate (middle 
tertile) and high (top tertile). Kaplan Meier analysis showed significant segregation of the three 
risk-groups (Figure 6B and Figure 6C). Furthermore, classification of samples into low, 
intermediate and high risk-groups on expression profiles of just the 3 nuclear receptors (GR, PGR, 
PPARδ) also results in significant segregation of low, intermediate and high-risk samples (Figure 
6D). We also observed that addition of the two genes known to be involved in cytoskeletal 
organization (CFL1 and GSN) into the survival model together with the 3 NR resulted in further 
separation of the risk groups (Figure 6E). 
We also tested the prognostic power of the 3NR, 3NR+cytoskeletal genes and the 19-gene 
signature in breast cancer subgroups identified by immunohistochemical marker staining. The 
signatures had little or no predictive power in Basal and HERα 2 subtypes, but identified subgroups 
of patients with different prognosis in the Luminal A, Luminal B and Normal-like subtypes (not 
shown). 
3.6 Performance comparison 
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A limitation of current breast cancer signatures is that most have been shown to be no more 
strongly associated with outcome than random sets of genes, although signatures containing over 
100 genes are more significant (Venet et al., 2011). We compared the performance of NR and 
coregulator centered gene signatures with 48 other published breast cancer signatures (compiled 
from (Venet et al., 2011)). Using samples from our Validation Sets, we calculated sample risk 
scores based on the expression of the genes in each signature. The association of the calculated 
risk scores with patient survival was then tested by Univariate Cox Regression and Concordance 
Index.  
Figure 7 shows the Concordance Index for each gene signature calculated for (i) all samples in the 
Validation Sets (Figure 7A) and (ii) ERα negative samples of the Validation Sets (Figure 7B). The 19-
gene signature performance is comparable to signatures of larger sizes, in all cases (Figure 7A) and 
more particularly in ERα negative cases (Figure 7B). The signatures for the 5 NR that acquired 
correlations in in ERα negative cancer (from Figure 4); and the 3 NR Plus Cytoskeletal gene 
signatures do not rank well when all samples of the Validation Sets are used (Figure 7A), they are, 
however, able to predict patient survival for ERα negative samples better than signatures with 
larger gene numbers (Figure 7B). We also observed that prediction accuracy of gene signatures 
varies, depending on the microarray platform used, with some signatures performing better on 
one microarray platform than the other. In ERα negative breast cancers, there are two published 
signatures that have comparable or fewer numbers of genes than the NR-coregulator signatures 
identified in this study, namely the Yu (Yu et al., 2007) (14 genes) and Buffa (Buffa et al., 2010) (3 
genes) signatures (Figure 7B). There was no overlap between the 19-gene NR-coregulator 
signature identified in this study, and the genes contained within either the Yu or Buffa signatures, 
nor did functional analysis reveal any overlap, with the Yu signature being associated with cell 
surface receptor linked signal transduction, immune response and cell motility (not shown).  
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It is known that most of the genes in breast cancer signatures are correlated with proliferation, 
and this is a major confounder in outcome prediction (Venet et al., 2011). To assess the impact of 
proliferation on the prognostic power of the NR-coregulator gene signatures that we identified, 
we adjusted the signature genes expression using the meta-PCNA signature, which comprises the 
genes most strongly correlated with Proliferating Cell Nuclear Antigen (PCNA) gene expression 
(Venet et al., 2011). We found that while for ERα positive cancers, meta-PCNA adjustment 
reduced the prognostic power of most of the gene signatures we examined, it had minimal impact 
for ERα negative cancers and the 19-gene signature; the 5 NR that acquired correlations in cancer 
signature (from Figure 4); and the 3 NR plus cytoskeletal gene signature remained predictive of 
outcome in this cohort (Supplementary Figure 5). 
4. Discussion 
This study comprises the first combined profiling of nuclear receptors and coregulators in the 
human breast. Notable strengths include the robust quantitation of coregulator transcripts in 
cohorts of curated human breast tissues, both normal and cancer, plus validation cohorts 
comprising of all publicly available breast cancer microarray datasets across all platforms. In this 
regard the study provides significant pathophysiologically relevant insights to supplement studies 
based on cell line models (Kittler et al., 2013). Our findings reveal an almost pan-repression of 
coregulator expression in neoplastic breast tissue and show that ERα negative cancers are 
associated with more widespread disruptions of the coregulator transcriptome. In addition, the 
study highlights important cancer-associated shifts in nuclear receptor and coregulator expression 
patterns. We then complemented the expression profiling of nuclear receptors and coregulators 
with a comprehensive survey of the prognostic value of NR and coregulators in published breast 
cancer microarrays to identify nuclear receptors and coregulators with high prognostic 
significance. 
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The coregulator transcriptome was strikingly disrupted in cancer compared with normal breast, 
with a small number of coregulators up-regulated and the majority repressed. Up-regulation was 
overwhelmingly associated with proliferation, consistent with different regulatory networks being 
operative in both ERα positive and ERα negative breast cancers; differential expression of the two 
cyclins CCND1 and CCNE1 in ERα positive and ERα negative cancers suggest different mechanisms 
for controlling progression of G1 to S phase of the cell cycle in these two subgroups. CCND1 is up-
regulated in ERα positive and down-regulated in ERα negative cancers, consistent with published 
reports that ERα can induce CCND1 expression (Cicatiello et al., 2010). It is possible that in ERα 
negative cancers progression from G1 to S phase is mediated through CCNE1, which is specifically 
up-regulated in ERα negative cancers in contrast with the decreased level of CCND1. In addition, 
the coregulators VAV3, a Rho GTPase guanine nucleotide exchange factor, and SPDEF, the SAM 
pointed domain containing ETS transcription factor, are up-regulated specifically in ERα positive 
breast cancers and down-regulated in ERα negative breast cancers, consistent with previously 
published reports that VAV3 overexpression enhances ERα-mediated signaling (Doolan et al., 
2008), and that SPDEF is associated with patient survival in ERα positive breast cancers (Sood et 
al., 2009). Up-regulation of both RARα and CRABP2 (cellular retinoic binding protein 2) specifically 
in ERα positive cancers is further evidence for differential regulation, in the case of retinoic 
signaling, in ERα positive and ERα negative breast cancer subgroups. 
Pan-repression of coregulator expression in neoplastic breast tissues was not unexpected given 
our earlier observation that breast cancer is associated with a pan-repression of nuclear receptors 
except for EAR2, AR, RARα and the NR4A subgroup (Muscat et al., 2013). The specific mechanisms 
whereby repression of nuclear receptors and coregulators is involved in breast cancer 
pathogenesis are unclear. In cancers multiple NR-mediated pathways associated with cell 
differentiation were repressed, eg Retinoic Acid Activation and Glucocorticoid Receptor Signaling 
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pathways; with up-regulation of cell cycle related genes this would have a net effect of increased 
cell growth and proliferation. 
In the absence of detailed genomic localization maps and protein-protein interaction data for most 
nuclear receptors and coregulators in breast cancer tissues, and the impossibility of 
experimentally deriving functional data from human tissue cohorts, we determined the correlation 
between NR and coregulator expression as a measure of functional relatedness. While setting very 
strong correlation thresholds for significance, we acknowledge that correlated expression 
indicates, but does not prove, functional co-operation. Nevertheless, this approach has revealed 
interesting insights into the complex regulatory networks of nuclear receptors in the human 
breast. 
First, most of the strong NR-coregulator correlations occurred in the normal postmenopausal 
breast, with NR including RARγ, RORγ, VDR, RARβ, HNF4γ, RXRβ, COUP-TF1/2, MR and PPARγ 
associating with the largest number of coregulators, and pointing to the potential for active 
signaling networks around these receptors in normal breast. These NR were also associated with 
coregulators in pre-menopausal breast, but less frequently. Many if not all of these associations 
were lost in cancer, consistent with the overall down-regulation both of NR (Muscat et al., 2013) 
and coregulators (this study) in cancer compared with normal tissue. NR that acquired expression 
correlations (Rev-ERBβ, GR, NOR1, LRH-1, PR) specifically in ERα negative breast cancers predicted 
poorer outcome for those patients, suggesting the potential for clinically significant activation of 
new signaling networks associated with unrestrained cancer biology involving these NR specifically 
in ERα negative breast cancers. Interestingly, NR whose associations with coregulators are 
disrupted in ERα negative breast cancers are not as strongly associated with patient outcome. This 
finding is particularly interesting in the context of regulatory networks, given that cancer is not 
simply a disease with a genetic basis but is ultimately driven by perturbations at the network level 
(Creixell et al., 2012). During cancer development, it is likely that signaling processes are not 
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simply disrupted but are also re-wired resulting in new signaling landscapes favorable to the 
development of the cancer cells. It is therefore perhaps logical that those re-wired signaling 
processes favoring maintenance and progression of cancer will have a stronger impact on patient 
outcome. 
Secondly, we observed a positive correlation between the expression of most nuclear receptors 
and coregulators, with the exception of PPARγ, ERβ and RXRγ, expression of which inversely 
correlates with multiple coregulators specifically in normal but not cancer tissues. It is arguably 
more logical for the expression of nuclear receptors to be positively correlated with that of 
coregulators for co-operational control of gene regulation. It is more unexpected to observe 
patterns of widespread inverse correlations, as in the case of PPARγ; PPARγ and its coregulator 
PPARγC1A are both strongly down-regulated in both ERα positive and ERα negative cancers, 
consistent with reports that the presence of PPARγ is associated with an anti-tumorigenic effect 
(Bonofiglio et al., 2006; Lu et al., 2005; Suzuki et al., 2006). PPARγ positively correlates with very 
few genes, among which are the tumor suppressor CAV1, the testosterone 17-beta-
dehydrogenase gene HSD17B13 and the aldo-keto reductase AKR1C1/AKR1C2 gene. HSD17B13 is 
involved in estrogen biosynthesis and responsible for converting estrone to estradiol-17beta while 
AKR1C1/AKR1C2 catalyses the reduction of progesterone to the inactive 20α-hydroxy-
progesterone. Both HSD17B13 and AKR1C1/AKR1C2 are strongly down-regulated, consistent with 
attenuated steroid metabolism, in both ERα positive and ERα negative cancer samples. The strong 
positive correlation of PPARγ with HSD17B13 and AKR1C1/AKR1C2 in normal breast only, its 
repression in cancer and the striking inverse correlation pattern between PPARγ and multiple 
coregulators suggest that dysregulation of this NR might contribute to altered steroid metabolism 
and thereby to aberrant control of estrogen and progesterone mediated signaling in breast cancer. 
The demonstration that NR-coregulator associations in normal breast are disrupted in cancer, and 
the acquisition of associations unique to cancer tissues, signal the potential for NR-coregulator 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24 
networks not only to be implicated in the biology of breast cancer but also relevant to clinical 
outcome. Testing of such possibilities, in order to discover meaningful associations between gene 
signatures and clinical outcome, is fraught with pitfalls in that most current breast cancer 
signatures are not robust across datasets and microarray platforms, and moreover are no more 
strongly associated with outcome than random sets of genes (Venet et al., 2011). This is probably 
due to the extremely high individual variability of sampled tumor expression profiles resulting in 
passenger signals overwhelming the real cancer signature. To circumvent this limitation, we 
employed a bootstrap resampling approach on 2 different microarray platforms. There were only 
19 genes (3 nuclear receptors (GR, PGR, PPARδ) and 16 coregulators) with expression profiles 
robustly associated with patient survival, independent of ERα or node status on both microarray 
platforms. Low levels of expression of the signature genes identify patients with a significantly 
lower probability of distant metastases, across both the microarray platforms, whereas high 
expression is associated with poorer prognosis. Low expression of the 3 NR alone, or of the 3 NR 
with the cytoskeletal genes, also stratified patients with better prognosis. Two of the 3 NR in the 
19-gene signature (GR, PPARδ) have been identified by ChIP-chip to be central nodes in a 
regulatory network of NR and associated transcription factors in MCF-7 cells (Kittler et al., 2013), 
and their robust association with clinical outcome identified in this study highlights the importance 
of signaling networks specifically associated with these 3 NR in breast cancer. 
To evaluate how well NR-coregulator-based signatures performed in comparison to other 
published breast cancer signatures, and mindful of the weak predictive power of published 
signatures containing fewer than 100 genes, the performance of the NR-coregulator-based 
signatures was compared to that of all published breast cancer signatures. The performance of the 
19-gene NR-coregulator-based signature is comparable to many other signatures of much larger 
sizes in predicting outcome for all breast cancer samples (both ERα positive and ERα negative), 
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highlighting the power of predictive signatures derived from the quantitative determination of 
altered gene expression between normal breast and breast cancers.  
This study highlights major differences in coregulator expression and NR-coregulator interaction 
between ERα positive and ERα negative breast cancers that reflects divergent regulatory controls 
in these two breast cancer subtypes. Specifically, a majority of the profiled coregulators (81%) are 
differentially expressed between ERα positive and ERα negative breast cancers, with ERα negative 
cancers being associated with an increase in both the number of coregulators being repressed as 
well as an increase in the magnitude of the repression. The change in coregulator expression is 
associated with ERα-specific perturbations in NR-coregulator expression. Specifically, RXRα, TRα, 
COUP-TF2, RORγ showed strong associations of with multiple coregulators in ERα positive breast 
cancers suggesting the increased importance of retinoic signaling in this subtype and consistent 
with proliferation being a major influence on patient outcome in ERα positive cancers. ERα 
negative cancers, on the other hand, are associated with acquired interactions between REV-ERBβ, 
TR4, GR, PPARα, NOR1, LRH-1 and a large number of coregulators. NR-coregulator interactions 
acquired specifically in ERα negative cancers have the potential to impact a wide range of cellular 
pathways and processes including chromatin remodeling, glucocorticoid receptor signaling and 
cell cycle regulation. Overall, our results suggest that ERα negative breast cancer is associated with 
increased severity in perturbation of normal NR-coregulator interactions and that there exists 
significant differences in the way normal gene regulatory networks are altered in these breast 
cancers. As a consequent, some NR and coregulators have stronger influence on patient outcome 
in ERα negative or positive breast cancer compared to the other. We observed that the 3NR plus 
cytoskeletal genes obtained the highest Concordance Index for ERα negative cancer, with its 
performance in predicting outcome for ERα positive cancer less robust. In addition, PCNA-
adjustment has minimal influence on the prognostic power of most gene signatures in ERα 
negative cancers. It is thus possible that while proliferation is a major influence on outcome 
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association in ERα positive cancers, it is not the principal factor that influences outcome for ERα 
negative breast cancers. ERα negative breast cancer outcomes might be driven by factors including 
cell movement and metastasis, as suggested by the strong influence of cytoskeletal genes in 
predicting patient outcome for this subgroup. In addition, we demonstrated that NR showing 
acquired correlations with multiple coregulators specificially in ERα negative cancers have stronger 
influence on patient outcome in these cancers. This observation emphasizes the importance of 
examining not only “loss-of-function” disruptions but also “gain-of-function” perturbations in the 
search for therapeutic and prognostic markers for breast cancer. 
In conclusion, this study has identified networks of nuclear receptor-coregulator interactions 
active in normal breast but disrupted in breast cancer, and moreover provides evidence that 
signatures based on NR networks disrupted in cancer can provide important prognostic 
information in breast cancer patients, including ERα negative patients, for whom existing 
prognostic measures are limited. 
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7. Figure Legends 
Figure 1 – Expression profile of coregulators in different sample cohorts 
Figure 1A Clustered heatmap of coregulators delta Ct values supervised by cohort illustrating that 
a majority of coregulators expression differs between Normal and Cancer and also between ERα 
positive and ERα negative cancers. Figure 1B is a 3D plot of samples against the first 3 PCA 
components (unsupervised PCA analysis) illustrating the separation between Cancer and Normal 
samples. Figure 1C shows a similar plot of a PCA analysis of Cancer samples independently of 
Normal samples reflecting the difference in coregulator expression in ERα negative compared to 
ERα positive breast cancers. Samples are colored based on cohort: light blue (Premenopausal 
Normal), dark blue (Postmenopausal Normal), orange (ERα positive cancers) and red (ERα negative 
cancers). 
Figure 2 – Differentially expressed coregulators 
Clustered heatmap of the log2 (Fold change) of significantly differentially expressed coregulators 
(adj. P-value ≤ 0.05 and at least 1.5 fold up or down regulated) illustrating that coregulator 
repression is more pronounced in ERα negative compared to ERα positive cancers. Panel A 
highlights a cluster of coregulators that are down regulated in both ERα positive and ERα negative 
breast cancers compared to normal breast. Panel B shows a cluster of coregulators with increased 
expression in either ERα  positive or ERα negative cancers. Panel C highlights a subset of 
coregulators whose expression differs between ERα negative and ERα positive tumors. 
Figure 3 – Expression correlation patterns of nuclear receptors and coregulators 
Figure 3A Bar plot of the numbers of coregulators highly correlated (Spearman Rank Correlation ≥ 
0.7) with each nuclear receptor in each of the 4 cohorts, ranked by NR with greatest numbers of 
associations in post-menopausal normal samples. Figure 3B Pie chart showing the proportions of 
highly correlated NR-coregulator gene pairs that are observed uniquely or in multiple cohorts as a 
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fraction of all highly correlated gene pairs observed. Figure 3C lists nuclear receptors displaying 
pan-cancer changes in correlation pattern with coregulators. Figure 3D lists coregulators showing 
ERα  status specific correlation pattern with coregulators. For each panel of Figure 3C and 3D, 
cohorts are listed in rows and all coregulators are tiled across columns. Heatmap cells are colored 
according to the Spearman Rank Correlation coefficients of each NR-coregulator pair. 
Figure 4 – Prognostic value of NR displaying ERα -status specific expression correlations with 
coregulators 
Kaplan Meier plots of the probability of survival for samples classified into Low, Intermediate and 
High risk groups based on the expression profile two different groups of nuclear receptors: Group 
1 (Rev-erbβ, GR, NOR1, LRH-1 and PR) and Group 2 (AR, ERRΥ, RORγ, RXRα, RXRγ). Samples from 
the Validation Sets (Supplementary Figure 2) were used for this analysis (927 samples profiled on 
Illumina HT12v3 arrays). Log rank Pval represent the log rank p-value for the Kaplan Meier curves. 
Cox.Reg.Pval is the univariate Cox Regression P-value for the association of sample risk scores with 
patient survival. C-index represents the Concordance Index calculated as detailed in (Harrell et al., 
1996). 
Figure 5 – Possible roles of other nuclear receptors in ERα -associated but ERα -independent 
pathways 
Expression correlation profiles in ERα  positive versus ERα - cancers of 921 genes whose 
expression correlate highly with ESR1, REV-ERBβ, GR, NOR1 or LRH-1 (Spearman Rank correlation 
coefficients ≥ 0.7 or ≤ -0.7). Heatmap values represent pairwise Spearman rank correlation 
coefficients. 
Figure 6 – Nuclear receptors and coregulators with prognostic values 
Figure 6A Heatmap of r-index values of the 19-gene signature. The r-index is a measure of the 
robustness of a gene’s association with survival and represents the number of analyses out of 
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1000 Cox Regression analyses of randomly sampled subgroups of samples in which the gene is 
found to be significantly associated with patient survival. Figure 6B Kaplan Meier plot showing 
significant segregation of samples (1094 validation samples profiled on Affymetrix Hg133a arrays) 
classified into Low, Intermediate and High risk-groups based on the expression of the 19 genes. 
Figure 6C Similar to Figure 6B but using a second set of 927 validation samples profiled on Illumina 
HT12v3 arrays. Figure 6D and Figure 6E Kaplan Meier plot showing significant segregation of 1094 
validation samples profiled on Affymetrix Hg133a arrays classified into Low and High risk-groups 
based on the expression of (Figure 6D) the 3 nuclear receptors GR, PGR and PPARδ; and (Figure 6E) 
the 3 nuclear receptors and two cytoskeletal genes CFL1 and GSN. 
Figure 7 – Comparison of NR/coregulator based gene signature with other published signatures. 
Figure 7A Concordance indices of 48 published signatures and 3 NR/coregulator based signatures 
computed using 1094 samples profiled on Affymetrix Hg133a arrays (blue) and 927 samples 
profiled on Illumina HT12v3 arrays (red). Both ERα  positive and ERα negative samples were 
included in the analysis. Figure 7B Similar to Figure 7A but concordance indices were calculated 
using only ERα negative samples. 
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8. Supplementary Figure legends 
Supplementary Figure 1 – Boxplot of coregulator delta Ct values in each of the 4 sample cohorts. 
Y-axis represents delta Ct values. 
Supplementary Figure 2- Schematic diagram of survival analysis approach 
Diagram outlines approach employed to identify nuclear receptors and coregulators whose 
expression significantly associates with breast cancer patient survival. 
Supplementary Figure 3 – Principal component analysis.  
Supplementary Figure 3A - Scatter plot of factor loadings for the first 2 principal components. 
Supplementary Figure 3B - Proportion of variance captured by each of the first 10 principal 
components. 
Supplementary Figure 4 – Prognostic value of NR displaying ERα -status specific expression 
correlations with coregulators 
Kaplan Meier plots of the probability of survival for samples classified into Low, Intermediate and 
High risk groups based on the expression profile two different groups of nuclear receptors: Group 
1 (REV-ERBβ, GR, NOR1, LRH-1 and PGR) and Group 2 (AR, ESRRγ, RORγ, RXRα and RXRγ). Samples 
from the Validation Sets (Supplementary Figure 2) were used for this analysis (1094 breast cancers 
profiled on Affymetrix Hg133A arrays). Log rank Pval represent the log rank p-value for the Kaplan 
Meier curves. Cox.Reg.Pval is the univariate Cox Regression P-value for the association of sample 
risk scores with patient survival. C-index represents the Concordance Index calculated as detailed 
in (Harrell et al., 1996). 
Supplementary Figure 5 – Effect of PCNA adjustment 
Supplementary Figure 5A: Concordance indices obtained for the 48 published signatures and 3 
NR/coregulator based signatures computed using ERα  positive samples profiled on Affymetrix 
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Hg133a arrays unadjusted (black) or adjusted for meta-PCNA expression (grey). Supplementary 
Figure 5B: similar to 5A but values computed using ERα - samples. 
 
9. Supplementary Table legends 
Supplementary Table 1 – Ct values of all coregulators 
Supplementary Table 2A – Differentially expressed coregulators 
List of coregulators found to be differentially expressed when comparing Cancer vs. Normal, ERα + 
vs. Normal, ERα negative vs. Normal, and ERα negative vs. ERα + cohorts. riteria for differential 
expression are Benjamini-Hochberg adjusted P-value less than 0.05 and at least 1.5 fold up or 
down regulated. 
Supplementary Table 2B – Up regulated coregulators 
List of coregulators up regulated in either ERα  positive or ERα negative breast cancers annotated 
with whether the gene is associated with Cellular Growth and Proliferation according to Ingenuity 
Functional Analysis. 
Supplementary Table 3 – Microarray datasets used in survival analysis 
Supplementary Table 3 lists the microarray breast cancer datasets used in survival analysis 
Supplementary Table 4 – Nuclear receptors and coregulators significantly associated with patient 
survival on both Affymetrix and Illumina platforms 
Supplementary Table 4 lists the 3 nuclear receptors and 16 coregulators found to be significantly 
associated with patient survival in both the Affymetrix and Illumina datasets. The r-index 
represent the number of times out of 1000 bootstraps Univariate Cox Regression in which the 
gene were found to be significantly associated with survival (P-value ≤ 0.05). Multivariate Cox 
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regression was performed adjusted for ERα  status and node status. P-values are adjusted for 
multiple testing using Benjamini-Hochberg method. 
Supplementary Table 5 – Ingenuity Pathways analysis of differentially expressed coregulators 
Supplementary Table 5A lists over-represented functional annotations associated with up-
regulated coregulators. Supplementary Table 5B lists significantly over-represented canonical 
pathways associated with down-regulated coregulators. Cell values represent the significance of 
enrichment (Bonferroni adjusted P-value). 
Supplementary Table 6 – Numbers of highly correlated coregulators associated with each nuclear 
receptor. 
Supplementary Table 6A lists the number of highly correlated coregulators associated with each 
nuclear receptor at Spearman Rank Correlation ≥ 0.7 or ≤ -0.7. Supplementary Table 6B lists the 
number of highly correlated coregulators associated with each nuclear receptor at Spearman Rank 
Correlation ≥ 0.6 or ≤ -0.6. 
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Highlights 
• Nuclear receptor (NR) transcription factors are crucial in reproduction, development, 
growth and metabolism  
• NR-coregulator interactions are altered between normal and cancerous breast  
• Molecular signatures based on NR and coregulators predict outcome in breast cancer 
patients 
• Signatures are independent of proliferation and outperform existing discriminators  
• The power of predictive signatures based on altered gene expression between 
normal breast and breast cancers is demonstrated 
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AFFYMETRIX (2189 samples) ILLUMINA (1853 samples) 
Training Set 
1095 samples
Random split Random split 
Select genes significantly associated with survival on both platforms  
( r-index >= 0.750 ) 
Multivariate Cox Regression 
(adjusting for ER status and NODE status) 
19-Genes Signature 
Validate using Validation Sets
Bootstrap Cox Regression Analysis
Random sampling with replacement
Univariate Cox Regression
Calculate r-index
( number of signicant results out of 1000 analyses)
repeat 
1000 times
r-index
(Aymetrix samples)
r-index
(Illumina samples)
Validation Set 
1094 samples
Training Set 
926 samples
Validation Set 
927 samples
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Time(years)No. At Risk
Low 223 221 202 181 169 149 136 124 110 94 76
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Log rank Pval:1.5E-06 
Cox P-val: 2.94E-05
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Kaplan−Meier Curve
0 1 2 3 4 5 6 7 8 9 10
Time(years)No. At Risk
Low 229 216 199 167 155 134 122 109 101 85 66
Intermediate 226 219 201 176 145 123 110 103 92 75 56
High 234 218 191 167 145 118 102 90 77 66 48
Log rank Pval:2.5E-03 
Cox P-val: 9.28E-05
Log rank Pval: 3.6E-04
Cox P-val: 4.2E-04
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Supplementary Table 1: Ct values of all co-regulators profiled on TLDA
ERneg01.06.058ERneg01.06.066ERneg01.06.075ERneg01.07.109ERneg01.08.120ERneg01.08.138
AES 24.793 24.675 23.577 25.266 25.007 23.482
ANKRD11 27.063 28.306 28.436 29.760 29.847 28.923
ANP32A 26.403 27.309 26.612 27.224 28.138 27.174
APPBP2 27.537 29.379 28.807 29.078 29.052 28.427
APPL1 32.558 33.640 33.300 33.103 33.965 33.945
ARID1A 25.014 25.520 25.939 25.139 25.410 24.853
ARID1B 24.811 26.984 26.010 26.084 27.433 26.233
ARID5A 29.112 30.546 30.446 31.690 33.040 31.067
BAG1 28.962 30.411 30.762 30.207 40.000 30.443
BAZ1B 26.375 27.295 27.238 27.018 27.466 27.451
BCL11A 26.608 28.303 26.739 29.296 31.516 30.788
BCL11B 29.869 29.490 32.149 33.170 31.918 32.330
BCL3 27.297 27.345 28.172 27.920 27.178 27.387
BLOC1S1 26.817 27.052 27.731 27.654 27.380 26.822
BRCA1 28.959 30.422 30.245 30.218 31.107 31.211
BRCA2 27.922 29.249 29.618 30.222 31.393 29.706
BRD8 27.798 29.477 28.271 29.263 30.604 29.027
C1D 40.000 40.000 40.000 40.000 40.000 40.000
CALCOCO1 26.422 26.814 26.518 27.246 27.301 26.947
CALR 20.618 22.763 22.431 22.324 24.026 23.161
CARM1 25.124 27.162 26.724 27.298 26.275 26.567
CASP8AP2 29.278 30.736 29.132 30.243 32.423 30.850
CAV1 27.957 28.512 28.088 25.303 28.135 27.124
CCNA1 30.159 30.979 40.000 30.978 36.641 34.128
CCNA2 29.441 30.751 30.989 29.944 31.482 30.986
CCND1 22.883 24.605 26.829 26.771 28.926 23.851
CCND3 26.071 27.931 27.506 28.280 28.765 27.800
CCNE1 29.255 29.570 29.842 29.212 33.418 31.012
CDC25B 25.970 27.801 27.501 26.744 27.421 27.579
CDK7 27.816 29.360 29.356 28.574 29.761 28.777
CDK9 27.305 27.110 28.085 27.541 27.624 27.027
CDKN1C 31.642 32.603 29.168 32.851 31.967 31.182
CFL1 24.921 26.123 25.792 25.867 26.947 26.037
CITED1 17.765 19.996 40.000 35.121 40.000 35.115
CMTM2 36.206 40.000 23.269 37.145 40.000 22.668
COPS2 26.531 27.699 28.010 27.179 28.736 27.359
COPS5 29.350 31.266 30.905 30.479 31.979 31.276
CRABP2 25.456 26.573 27.873 21.815 26.153 24.412
CREBBP 25.455 26.451 25.463 26.396 26.458 25.632
CTBP1 30.490 31.406 30.672 31.168 31.261 30.232
CTBP2 26.755 28.954 27.868 28.311 28.640 27.488
D4S234E.GPS2 26.305 27.743 27.650 27.682 28.709 27.851
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DAP3 23.005 25.025 25.448 23.571 25.219 25.237
DAXX 26.219 27.887 27.728 27.616 28.243 27.201
DDX17 26.068 26.562 25.717 26.725 27.379 27.243
DDX20 26.977 28.584 28.152 28.006 29.412 28.127
DDX5 23.613 24.631 24.605 24.982 25.176 23.051
DDX54 28.858 29.688 29.325 28.957 30.322 29.163
DHX9 25.872 27.409 27.468 27.101 28.026 26.968
DNTTIP2 26.024 28.792 28.318 28.470 29.847 29.042
EDF1 24.555 25.064 25.524 24.901 26.178 25.586
EFCAB6 25.063 18.311 33.227 25.498 34.355 33.441
ELL 29.613 30.259 30.418 30.310 30.658 30.045
EP300 27.619 28.519 27.732 28.681 28.332 28.662
FAF1 27.664 29.288 27.737 29.104 30.451 28.680
FHL2 27.964 29.848 27.376 26.393 29.332 25.332
FLII 26.362 27.810 28.299 27.207 27.500 27.673
FOXH1 35.866 34.999 36.074 33.595 34.348 31.325
FOXO1 29.113 28.856 30.131 29.593 29.555 28.213
FUS 24.960 26.065 25.710 26.156 27.903 25.480
GADD45GIP1 27.494 29.145 29.238 28.806 29.594 29.265
GMEB1 28.244 28.434 28.810 28.511 29.707 28.529
GMEB2 40.000 40.000 33.899 40.000 38.692 37.401
GNB2L1 21.910 23.163 22.376 23.005 24.262 23.249
GSN 24.866 25.433 24.849 25.023 25.417 23.848
HDAC1 26.732 28.723 27.892 27.820 29.135 28.649
HDAC2 25.353 28.150 27.043 26.175 28.942 27.742
HDAC3 28.196 29.807 28.876 29.516 30.509 29.404
HDAC4 29.647 30.187 30.247 30.687 30.739 29.824
HEY1 31.133 33.242 32.931 32.281 32.305 31.875
HIPK3 26.446 27.695 26.687 26.869 27.618 27.528
HMGB1 28.553 29.412 28.618 29.838 30.899 28.760
HMGB2 25.085 26.015 24.835 26.617 28.383 26.830
HNRNPU 22.175 23.278 22.978 22.804 24.067 22.942
HR 31.178 30.751 28.680 30.575 30.228 31.352
HTATIP 27.051 28.590 28.107 28.172 28.661 28.452
IQWD1 26.931 29.550 28.638 27.644 28.193 28.333
ITGB3BP 28.637 30.097 29.283 29.490 32.073 30.939
JAZF1 30.403 30.435 29.676 30.267 31.461 30.631
JMJD1C 28.466 29.923 28.903 29.870 29.844 29.031
LATS2 29.139 29.736 29.350 29.395 29.540 29.246
LCOR 28.080 29.050 29.207 28.487 29.117 28.321
LOC100132910.RPL7A26.065 25.775 26.811 26.686 27.655 26.582
MCRS1 26.455 27.747 28.312 28.305 27.947 27.665
MED1 28.030 29.141 29.515 29.366 27.188 26.893
MED12 26.981 27.758 27.296 27.167 27.748 27.865
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MED14 27.989 28.884 28.458 27.907 28.863 28.479
MED15 26.670 27.625 27.259 27.487 27.771 27.491
MED24 25.740 28.870 29.361 28.265 28.561 24.534
MED30 27.834 30.908 30.272 28.629 32.190 27.094
MGMT 29.893 30.139 28.981 30.604 32.081 29.932
MLL2 25.655 26.491 26.902 26.932 26.570 26.252
MMS19 26.420 28.509 28.341 27.714 29.057 27.579
MNAT1 30.312 30.965 30.784 30.919 31.104 30.163
MTA1 27.472 28.762 28.615 28.303 29.545 28.412
MTA2 25.241 26.415 26.299 26.010 26.793 26.789
MUC1 28.712 27.098 26.851 27.323 22.953 24.951
MYST2 26.971 28.371 27.850 28.074 28.722 27.754
NCOA1 25.559 27.254 26.631 28.092 25.778 26.855
NCOA2 27.565 28.981 28.202 28.914 28.321 28.745
NCOA3 27.223 27.551 27.622 27.824 27.531 27.439
NCOA4 29.183 28.815 30.400 29.817 29.910 28.708
NCOA5 27.309 27.931 27.946 28.328 28.298 27.905
NCOA6 27.849 29.059 28.046 28.777 29.510 28.799
NCOA7 27.401 29.870 29.622 29.813 30.899 29.691
NCOR1 26.129 27.444 27.546 27.695 27.686 27.530
NCOR2 26.164 27.908 25.669 26.656 27.769 27.150
NEDD4 31.182 32.033 30.013 31.569 30.803 30.150
NONO 24.653 26.016 24.895 24.717 25.748 25.340
NR2C2AP 27.721 29.856 28.610 29.683 29.311 29.582
NRBF2 30.039 30.773 30.481 30.265 31.209 30.406
NRIP1 31.157 32.787 33.316 32.244 33.059 32.054
NRIP2 35.275 40.000 40.000 36.009 40.000 32.889
NSD1 27.765 28.890 27.847 28.776 29.494 28.283
PA2G4 27.303 28.552 28.763 28.360 29.099 28.422
PADI4 35.587 35.575 40.000 34.597 40.000 35.586
PAK6 29.919 29.904 28.432 30.713 28.622 28.121
PARK7 28.702 29.369 29.699 28.050 29.528 28.803
PARP1 27.289 28.413 28.273 28.338 28.296 28.051
PCAF 28.330 28.449 28.969 29.506 30.322 29.904
PELP1 25.987 27.779 27.941 27.679 28.698 27.563
PHB2 21.295 24.435 24.781 23.615 25.266 24.343
PIAS1 27.449 28.194 27.878 28.572 28.087 28.313
PIAS2 27.784 29.844 29.133 28.172 30.115 29.258
PIAS3 26.952 27.858 27.365 25.692 27.716 26.431
PIAS4 27.829 29.382 28.770 29.393 28.164 28.224
PIN1 31.756 32.630 31.699 32.761 34.553 32.380
PLAGL1 28.172 28.677 28.903 28.588 30.731 30.386
PNRC1 28.284 29.729 29.607 29.714 30.985 29.747
PNRC2 27.914 28.812 29.061 29.083 29.612 28.883
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PPARGC1A 35.182 35.371 31.257 35.037 34.777 30.314
PPARGC1B 29.203 30.003 29.635 30.896 31.534 30.353
PPM1D 28.856 30.327 29.847 30.671 31.060 29.700
PRAME 25.603 27.629 28.293 29.856 40.000 40.000
PRIC285 27.212 28.898 29.305 32.083 31.804 29.539
PRMT1 28.117 29.722 29.556 28.013 31.385 29.790
PRMT2 25.374 27.472 26.074 26.450 27.216 26.586
PROX1 32.228 31.984 30.279 34.615 32.396 31.030
PRPF6 29.177 30.118 29.231 29.821 40.000 29.029
PSCD3 31.879 32.788 31.502 31.903 31.690 31.319
PSMC3 25.384 26.792 26.302 25.893 28.449 27.404
PSMC3IP 29.939 30.584 30.437 30.288 31.133 40.000
PSMC4 25.589 27.474 27.248 26.334 28.792 27.099
PSMC5 27.066 28.280 27.846 28.299 28.796 25.772
PSME3 25.189 26.651 27.390 26.170 26.708 27.180
PTEN 30.489 31.113 30.438 33.150 32.853 31.200
PTK2B 28.185 27.816 29.415 29.323 29.684 30.363
PTMA 18.421 19.817 19.865 19.807 21.066 19.529
PTMS 23.983 26.841 25.779 25.877 26.934 24.776
PUS1 27.878 29.257 29.909 29.172 30.660 29.661
RAD54L2 27.313 28.297 28.291 28.180 28.501 28.664
RAN 23.844 25.327 25.089 24.478 26.437 25.700
RANBP9 26.269 27.641 27.027 26.815 28.368 26.670
RB1 27.001 28.513 28.858 28.884 29.017 27.504
RBM14 26.133 27.515 27.043 27.244 27.731 26.384
RBM39 26.613 27.591 26.516 27.644 29.149 27.696
RBM9 26.882 29.128 27.507 27.941 28.564 27.604
RCHY1 29.740 31.080 31.146 30.749 31.666 30.526
RELA 23.711 25.447 25.505 25.200 25.432 25.585
RERE 27.423 27.827 27.905 27.400 27.611 26.967
RNF14 28.386 30.006 28.788 29.154 30.477 28.644
RNF4 26.430 27.294 27.680 26.551 26.698 27.122
RPL7 23.357 25.156 24.480 24.087 26.555 25.249
SAFB 34.549 32.887 32.732 34.113 35.333 33.921
SAFB2 27.839 28.233 28.045 28.676 28.825 28.050
SAP30 28.346 29.259 27.870 28.782 28.854 29.180
SART3 26.140 27.306 27.015 26.988 27.624 27.271
SCAND1 26.395 27.818 27.469 27.348 28.424 28.067
SENP1 26.511 27.443 28.550 28.092 28.535 28.204
SF3A1 24.825 25.811 25.321 25.548 26.142 25.803
SFPQ 23.848 25.325 24.952 25.021 25.859 25.063
SIN3A 27.144 28.486 27.845 28.848 28.515 27.917
SIN3B 26.835 28.665 27.697 28.382 28.330 28.264
SIRT1 29.442 30.316 28.923 29.669 30.534 29.914
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SIX3 32.694 35.473 29.305 33.762 40.000 33.312
SMAD3 29.999 30.872 29.838 31.046 30.935 29.591
SMARCA2 26.060 27.269 26.377 28.067 28.366 27.831
SMARCA4 24.461 26.461 26.741 28.355 26.136 25.883
SMARCD1 26.096 27.418 27.766 27.514 27.887 27.116
SMARCD3 31.582 31.549 30.883 31.025 31.370 30.490
SMARCE1 26.956 28.313 28.525 28.356 28.185 27.948
SNW1 26.603 27.903 27.735 27.864 29.141 27.729
SPDEF 35.216 36.052 32.639 30.373 27.991 27.009
SPEN 28.676 29.184 29.075 29.074 29.751 29.104
SQSTM1 22.765 23.940 24.079 24.242 24.604 23.052
SRA1 26.364 28.087 27.800 27.380 29.203 27.493
SRY 40.000 22.739 40.000 21.757 40.000 18.486
SS18 25.540 26.901 25.580 26.961 28.070 27.049
STAT3 24.363 25.982 25.554 26.921 26.545 26.123
SUB1 27.661 30.282 29.344 30.053 31.027 30.074
SUMO1 24.223 26.929 26.842 26.761 27.451 26.911
SUPT6H 26.745 27.660 27.813 27.507 28.100 27.342
SVIL 25.013 28.068 27.525 26.113 29.102 26.935
TADA2L 29.742 30.555 30.026 30.745 30.612 31.467
TADA3L 26.397 27.659 26.951 27.613 27.113 27.700
TAF10 24.113 25.723 25.800 25.664 25.643 25.616
TBL1X 28.007 29.813 28.786 30.847 28.519 30.364
TBL1XR1 26.362 25.732 25.460 26.204 27.401 26.460
TCF20 26.229 28.158 27.305 27.999 28.673 28.534
TCF21 21.897 27.115 40.000 25.872 40.000 40.000
TDG 27.214 28.574 28.062 28.641 28.911 28.372
TGFB1I1 40.000 32.433 29.652 30.808 30.389 28.861
TGIF1 25.286 28.417 26.262 26.351 26.373 26.019
TGS1 27.849 29.415 28.879 28.906 29.756 28.956
TMF1 27.800 28.613 28.589 28.176 29.724 28.869
TP53 27.372 26.786 26.846 27.109 28.783 28.918
TRIM24 28.386 29.469 29.587 28.525 28.638 28.862
TRIM28 23.947 25.596 24.918 24.014 26.519 24.339
TRIP10 27.362 28.574 28.663 27.750 29.868 27.563
TRIP11 28.511 28.932 28.831 28.737 29.075 28.334
TRIP12 27.129 27.198 27.777 27.605 27.703 27.309
TRIP13 26.307 28.718 29.267 26.309 30.310 29.023
TRIP4 28.875 29.859 29.111 30.033 30.243 29.474
TRIP6 27.077 28.219 27.198 26.631 28.252 28.522
TRRAP 26.683 27.333 26.812 27.001 27.395 27.548
TSC2 27.561 29.528 28.425 29.262 27.570 28.727
TSG101 26.448 27.858 27.299 27.271 28.316 28.361
TXNRD2 28.521 29.657 29.164 29.520 28.418 28.932
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UBA3 26.098 27.735 28.029 27.945 29.199 28.342
UBE2I 23.635 25.617 24.594 25.909 25.373 24.938
UBE2L3 30.958 31.082 29.407 31.568 31.111 31.137
UBE3A 26.926 27.808 27.012 27.281 27.710 28.199
UBR5 26.913 27.222 27.804 27.736 28.312 27.832
UIMC1 28.237 27.974 27.948 28.895 29.959 28.739
UNC45A 28.065 29.885 27.996 29.159 29.562 28.617
UXT 25.719 27.521 26.787 26.073 27.830 27.431
VAV3 29.913 30.580 30.744 29.026 29.042 27.773
WDR77 27.071 28.744 28.272 27.315 29.834 28.993
XRCC5 25.040 25.780 25.914 25.613 26.143 25.380
YWHAH 27.828 28.725 27.929 28.961 28.510 28.389
ZFPM2 32.250 31.944 30.030 32.311 31.443 30.406
ZMIZ1 25.557 26.730 26.895 25.635 25.896 25.410
ZMIZ2 24.392 25.878 25.949 27.145 26.492 26.009
ZNF143.JDP2 28.388 29.416 29.298 29.495 29.980 29.223
ZNF335 29.790 30.073 29.891 30.150 30.573 30.300
ZNF461 29.424 31.237 30.926 31.632 32.735 32.154
ZNF653 28.600 30.673 29.497 29.921 29.802 29.736
ZNHIT3 28.396 29.298 29.443 29.061 29.298 30.056
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ERneg01.08.145ERneg02TB003ERneg04.09.127ERneg04TB157ERneg05.07.084ERneg05.07.091ERneg05.07.100
24.906 28.675 25.345 26.328 26.373 23.766 25.918
27.613 34.759 29.783 29.509 29.406 28.543 29.479
26.872 30.559 28.262 28.871 28.371 26.682 28.176
27.746 40.000 30.029 30.897 29.612 28.247 28.740
33.196 40.000 34.930 35.358 33.842 33.232 35.350
24.695 34.845 26.879 27.112 26.640 25.012 26.943
26.250 32.949 27.337 27.908 26.853 26.143 27.828
31.090 31.818 31.493 32.032 31.449 30.949 31.954
31.414 34.796 31.148 32.459 32.384 30.993 32.090
26.567 35.488 28.093 28.662 27.927 27.513 28.540
28.603 35.460 29.827 28.816 28.570 31.477 33.048
29.525 34.786 31.321 31.220 31.955 30.548 33.541
27.470 33.965 27.255 29.754 28.458 26.895 28.021
27.478 31.632 28.261 28.665 28.203 26.785 28.699
28.575 40.000 31.467 34.940 34.097 30.600 31.850
30.785 40.000 31.105 32.449 31.960 30.529 31.405
28.586 39.104 29.720 30.538 29.796 28.616 29.931
40.000 31.748 40.000 40.000 40.000 31.282 34.431
26.774 34.228 27.983 27.927 27.971 26.641 28.335
21.600 31.670 23.273 25.248 23.231 22.925 23.527
26.124 40.000 28.388 29.058 28.075 26.359 27.834
29.745 40.000 31.851 31.199 31.052 30.987 31.562
28.592 34.013 28.748 29.031 29.460 27.777 28.189
33.746 40.000 32.419 34.650 31.405 34.594 33.868
28.781 40.000 31.780 31.591 30.874 30.619 30.614
27.922 31.761 26.263 25.844 27.668 24.612 26.104
28.329 30.777 28.728 29.310 27.955 27.099 28.438
29.360 33.563 30.732 32.213 30.552 30.329 32.162
28.256 35.499 27.870 29.405 29.177 27.372 29.665
28.780 31.389 29.913 30.283 29.967 28.442 29.470
27.767 36.687 28.320 29.998 29.466 26.448 28.480
30.063 35.180 32.413 31.914 32.159 31.769 32.014
25.889 28.709 26.341 26.678 26.511 25.836 25.956
40.000 35.161 40.000 24.718 40.000 3.684 33.883
21.606 40.000 36.480 40.000 40.000 20.597 35.519
27.268 35.829 28.126 29.824 28.485 27.156 28.197
29.385 40.000 31.124 31.519 30.956 28.575 31.040
24.268 29.837 26.550 26.105 26.841 20.484 23.612
28.629 34.814 27.335 28.123 28.244 26.062 27.433
30.856 35.509 31.700 32.565 31.544 30.685 32.033
27.916 32.207 28.888 29.319 29.898 28.394 28.843
26.460 34.261 27.570 29.241 27.883 27.146 28.268
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23.936 31.518 25.408 26.671 25.292 23.074 26.794
27.610 36.719 28.321 29.504 28.423 27.561 28.911
26.233 34.714 26.761 27.085 27.407 26.376 27.439
27.931 40.000 29.118 30.587 28.797 28.430 30.136
23.792 32.113 25.130 25.919 25.715 24.641 25.805
29.478 28.874 30.223 30.024 30.143 29.710 31.392
26.367 40.000 27.883 30.514 28.646 26.513 28.311
28.563 35.063 29.142 30.201 28.899 28.746 30.017
24.588 30.907 25.325 26.267 26.676 24.484 25.704
35.595 40.000 33.958 35.153 36.412 33.681 33.990
30.015 40.000 31.010 31.511 30.957 30.340 31.357
28.057 36.473 28.824 30.996 29.679 27.678 29.339
28.604 33.459 29.776 30.666 28.831 28.732 30.224
27.219 33.927 27.204 29.195 30.629 28.353 27.268
26.134 33.178 26.793 28.496 28.450 26.269 28.181
40.000 34.618 35.313 28.959 29.512 34.894 27.745
29.421 35.608 29.529 30.848 30.650 28.714 30.169
26.226 33.387 26.732 27.763 26.985 26.322 27.444
28.768 33.162 29.348 29.371 29.428 29.086 29.541
28.696 40.000 29.781 30.896 29.867 28.646 29.988
34.596 29.155 37.327 40.000 40.000 35.129 40.000
22.241 29.449 23.467 25.262 24.525 22.468 24.255
25.009 31.048 26.242 25.997 26.505 24.714 26.053
27.533 35.425 28.825 30.272 28.944 27.618 29.568
26.769 40.000 29.091 30.689 28.536 28.101 29.766
29.245 36.219 30.051 31.075 29.702 28.823 30.517
29.788 40.000 30.881 31.587 30.881 30.105 31.284
33.088 33.068 32.513 34.032 34.408 32.661 32.150
26.437 40.000 28.449 29.790 28.847 26.844 28.503
29.427 32.431 29.929 29.871 31.070 28.677 31.104
25.205 32.713 28.165 27.472 27.614 26.011 27.294
22.600 32.789 23.648 25.447 24.218 23.020 24.747
31.549 40.000 32.061 31.101 31.026 32.502 31.787
27.970 36.130 29.037 29.979 29.373 27.722 28.630
27.420 40.000 29.245 30.889 29.194 28.545 30.204
29.628 37.775 31.566 32.393 29.540 29.751 31.063
29.393 40.000 32.125 32.845 31.430 29.701 31.850
29.019 40.000 30.285 31.639 30.452 27.861 30.663
29.191 33.921 29.634 30.243 31.106 28.117 30.442
28.593 35.741 28.848 31.594 29.618 28.480 29.917
27.688 31.054 26.564 27.889 28.132 26.192 27.493
27.918 36.511 29.106 29.649 29.131 27.313 29.407
27.701 40.000 27.421 31.459 30.555 26.112 24.693
27.160 38.059 28.110 29.282 29.081 26.854 28.867
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27.911 40.000 29.420 30.897 28.921 27.960 29.610
27.088 40.000 28.792 29.733 28.503 27.028 28.365
27.381 40.000 25.356 30.509 28.929 28.580 25.610
27.321 35.681 31.933 31.926 26.540 28.302 32.544
30.213 34.912 32.227 30.526 30.361 29.385 31.116
26.768 33.125 26.821 27.887 27.990 26.356 27.896
27.950 35.346 29.084 31.032 28.578 28.205 30.089
30.767 40.000 31.740 32.578 30.762 30.334 31.299
28.530 31.743 29.634 29.413 29.694 29.147 29.260
25.819 35.637 26.973 28.720 27.355 25.922 27.429
25.346 30.803 24.576 29.864 32.192 25.744 26.819
27.025 35.979 27.789 29.497 29.027 28.028 28.070
26.629 34.314 27.456 28.896 28.386 26.543 28.232
27.617 40.000 28.596 31.202 29.363 27.573 29.177
28.135 35.782 27.978 29.465 28.790 26.678 28.249
29.302 36.413 29.841 32.342 29.909 29.267 31.359
28.483 33.612 28.786 29.659 29.136 28.025 29.342
29.020 34.973 29.624 30.593 29.125 28.593 29.935
29.991 40.000 30.644 31.142 30.339 29.133 31.808
26.408 36.174 27.502 29.372 28.050 26.541 28.419
26.729 31.512 28.828 28.501 28.661 27.370 28.140
30.573 40.000 30.780 33.012 31.549 30.613 29.991
24.171 34.416 25.857 27.765 26.825 24.052 26.190
29.709 35.839 31.134 31.058 30.963 29.083 30.555
30.335 31.571 31.855 30.237 31.404 28.678 31.296
32.991 40.000 32.839 31.845 33.763 32.834 32.622
40.000 40.000 40.000 40.000 35.570 35.035 40.000
27.463 33.448 29.246 30.567 29.936 28.037 29.682
28.553 32.175 29.344 40.000 29.338 28.233 29.702
27.099 36.260 40.000 37.810 37.970 40.000 38.106
27.706 33.282 30.811 30.198 30.102 26.508 30.328
28.963 40.000 29.541 30.304 29.805 28.352 30.184
27.506 34.505 29.150 30.381 28.997 28.088 28.825
28.631 40.000 30.129 30.835 30.303 28.470 30.409
26.229 36.399 28.800 30.437 28.071 27.911 29.560
25.259 31.494 25.660 27.236 24.826 24.456 25.967
27.971 36.109 28.279 30.495 29.569 27.739 28.970
27.271 40.000 30.169 31.431 29.883 29.617 30.258
26.954 33.995 27.695 29.339 28.124 26.727 27.615
29.189 30.719 28.992 29.778 30.024 28.818 29.895
31.998 33.596 34.949 33.618 32.615 32.584 34.225
29.715 37.983 31.154 30.205 28.437 29.966 30.336
29.848 40.000 30.983 30.699 30.799 29.824 31.211
28.633 30.485 29.276 28.573 29.335 28.689 29.915
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31.470 40.000 35.565 33.477 26.788 40.000 33.223
40.000 36.744 32.210 31.637 31.643 30.574 32.129
29.138 38.278 30.979 31.382 30.890 30.125 31.676
29.578 40.000 31.745 34.120 34.834 29.546 27.711
29.237 34.970 30.661 30.760 29.551 30.113 30.636
28.767 33.565 30.615 31.575 30.508 29.295 30.480
26.065 32.747 27.782 27.910 27.710 26.355 28.442
29.194 40.000 32.391 33.578 35.394 33.608 36.230
28.946 33.528 28.829 29.283 29.791 29.364 30.301
31.907 40.000 33.252 33.975 40.000 31.187 33.078
26.035 34.353 27.970 28.345 27.634 26.523 26.682
29.709 40.000 31.504 40.000 40.000 40.000 32.290
26.804 34.990 28.001 29.888 27.803 25.360 28.192
27.548 36.123 29.309 30.994 29.314 28.131 29.790
25.647 36.021 27.816 29.221 27.853 26.177 28.057
32.005 32.093 33.309 31.316 31.729 31.789 33.339
28.316 33.471 30.427 30.727 28.995 29.312 31.692
18.219 27.001 20.352 21.516 21.712 19.477 20.047
26.210 31.724 27.622 27.153 25.983 25.187 26.848
29.439 40.000 30.803 31.735 30.863 29.929 32.092
27.685 32.638 29.622 29.424 28.315 28.107 29.370
25.025 30.138 26.686 28.222 26.706 25.303 27.284
26.524 37.059 27.534 29.717 28.898 26.509 27.871
29.130 36.265 28.671 31.178 29.474 27.275 28.995
26.645 33.500 27.582 29.037 28.287 26.549 28.063
27.858 31.621 28.204 28.404 27.907 27.371 28.124
27.529 40.000 29.196 29.806 29.665 27.720 28.612
29.629 40.000 32.038 33.751 31.633 29.776 31.659
24.501 33.932 25.787 27.537 26.270 24.701 26.084
27.214 34.945 27.718 29.511 29.128 27.256 27.998
28.557 40.000 29.773 40.000 29.976 28.773 29.821
27.012 33.426 27.830 29.412 28.049 26.724 28.570
24.452 28.433 23.682 25.692 25.097 23.719 25.153
34.443 40.000 34.920 36.108 35.552 34.674 35.874
28.024 40.000 29.100 29.826 29.056 28.044 29.529
29.151 31.102 29.881 29.221 29.894 28.489 29.041
26.655 34.230 28.492 29.910 28.451 27.567 29.222
28.055 31.711 28.525 29.330 27.992 27.023 27.962
27.779 40.000 28.891 29.040 29.521 28.159 28.827
25.333 28.360 26.150 26.950 25.976 25.355 26.434
24.407 31.445 25.821 26.920 25.867 24.701 25.924
28.355 38.887 29.340 31.304 29.842 27.777 29.741
27.874 40.000 28.748 30.278 29.447 28.086 29.657
29.538 37.751 30.729 33.164 31.231 28.593 31.064
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31.743 40.000 40.000 34.699 31.335 31.677 40.000
31.004 32.094 29.899 30.408 31.344 28.877 30.638
26.487 35.456 28.367 28.900 27.890 27.084 28.545
25.841 33.686 26.862 29.231 28.010 26.457 27.226
27.187 36.922 28.304 30.111 28.408 27.571 28.800
27.018 37.310 31.774 31.868 31.560 30.598 30.354
27.499 40.000 28.782 28.609 29.658 24.320 28.798
27.120 32.738 28.464 29.298 28.457 27.424 28.388
35.710 33.256 27.427 33.162 33.327 26.579 27.392
28.934 40.000 29.771 30.844 30.479 28.410 30.566
22.907 30.274 25.013 25.388 24.802 22.886 24.382
27.728 31.851 28.784 30.074 28.472 26.804 28.284
23.205 40.000 24.047 24.338 24.699 40.000 24.816
25.721 40.000 28.281 28.356 27.790 25.881 27.532
24.896 31.539 27.055 27.315 26.703 26.100 26.984
30.323 31.547 32.019 30.472 31.168 30.641 31.816
25.613 31.091 27.516 27.720 27.030 26.447 27.125
26.563 34.405 26.599 28.291 28.149 27.073 28.572
27.810 34.715 27.872 28.664 28.084 27.808 27.870
29.453 34.958 31.764 31.611 32.047 30.386 31.372
27.116 34.150 28.338 29.521 28.072 26.996 27.968
25.408 32.311 25.364 28.068 26.532 25.155 26.477
27.995 36.239 29.676 30.857 30.421 28.812 30.439
26.414 33.797 27.378 27.765 27.079 26.183 26.660
27.272 33.719 28.700 29.475 28.477 27.512 29.104
40.000 40.000 37.930 28.727 27.867 40.000 38.742
27.589 28.984 28.426 27.514 29.732 28.085 29.640
30.285 40.000 30.726 31.353 40.000 29.431 29.601
25.552 34.466 27.440 29.165 27.957 25.898 27.813
28.143 40.000 29.473 30.317 29.596 28.856 30.029
28.502 40.000 30.009 30.669 29.297 28.074 29.289
28.651 32.186 29.629 30.316 27.017 26.695 30.347
27.710 40.000 29.021 31.062 29.652 27.448 30.224
25.592 34.811 26.432 28.157 26.524 24.302 26.196
28.357 40.000 28.843 30.409 29.999 28.294 29.639
28.490 40.000 29.663 30.819 30.627 28.058 29.418
26.597 38.167 27.958 29.175 28.794 26.981 28.191
27.178 40.000 29.885 30.371 28.507 29.503 29.918
29.094 40.000 30.035 31.865 30.469 28.646 30.541
27.344 35.317 28.434 29.477 28.890 30.168 30.160
26.489 31.412 27.580 28.071 27.803 27.670 28.738
28.871 28.498 29.639 28.791 29.582 28.404 29.236
27.042 32.054 28.115 29.694 28.950 26.662 28.511
28.762 36.368 29.990 30.862 30.087 29.316 30.110
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27.556 40.000 28.993 30.830 28.649 27.327 28.855
25.544 33.979 25.887 27.861 26.913 25.156 26.092
30.757 33.098 30.334 31.359 30.739 30.347 30.149
27.266 40.000 27.749 29.958 29.704 26.986 27.810
26.957 34.265 28.122 28.740 28.841 26.829 28.635
28.210 34.002 29.743 30.425 29.849 28.219 29.881
29.147 33.877 29.561 30.183 29.554 29.069 30.068
26.861 40.000 27.347 29.473 27.417 26.277 27.595
27.453 35.403 28.227 30.709 29.225 25.792 29.839
27.716 34.249 28.213 29.774 28.074 28.190 30.264
24.345 34.548 26.620 28.450 26.685 25.247 26.388
27.927 33.811 29.373 29.448 29.199 27.842 40.000
30.224 40.000 31.093 31.010 32.939 30.879 30.612
26.052 33.194 26.155 28.176 26.782 24.074 25.578
25.098 29.995 26.844 26.953 27.225 26.239 27.703
29.214 31.605 29.882 30.301 29.521 28.802 29.261
30.317 33.945 31.178 32.029 31.305 30.003 31.486
30.762 31.360 32.212 29.517 32.011 31.578 32.647
29.601 35.748 31.151 31.225 31.353 29.385 30.929
28.794 40.000 30.427 30.711 29.721 29.334 30.006
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ERneg05RMH325ERneg05WH097ERneg06RMH389ERneg06RMH427ERneg07RMH019ERneg07RMH130ERneg07RMH843
27.299 26.550 25.705 25.424 25.725 27.062 25.639
30.122 29.401 29.440 28.651 29.637 28.347 27.102
31.145 28.757 30.673 28.596 28.604 28.216 26.930
33.219 31.114 30.794 29.211 29.731 30.095 28.887
35.676 35.591 34.172 34.001 34.245 35.928 33.388
27.515 27.161 26.645 25.431 26.018 26.782 25.577
28.787 27.414 28.835 26.969 27.965 28.264 27.057
32.303 31.505 32.394 31.353 31.730 31.841 30.104
40.000 30.395 32.056 32.254 32.383 31.500 30.844
28.994 27.906 28.941 28.286 28.765 28.370 27.924
40.000 28.637 34.660 30.577 29.393 28.727 27.578
32.306 33.685 32.919 30.822 31.063 32.253 32.081
28.295 28.610 28.304 27.940 28.362 29.231 27.606
29.521 29.122 27.909 27.321 28.321 29.307 26.527
40.000 40.000 40.000 31.339 32.406 33.393 28.416
34.396 32.163 32.230 32.205 32.466 31.209 29.753
31.988 30.128 29.851 28.472 29.242 29.984 28.379
27.168 40.000 19.460 40.000 40.000 40.000 40.000
29.590 28.562 27.885 27.269 27.409 27.556 26.229
24.754 23.884 23.617 24.002 24.423 23.817 22.234
30.033 27.707 29.113 27.951 28.307 27.752 26.313
34.068 30.886 31.728 30.488 31.105 30.307 29.068
30.334 29.770 29.312 28.038 28.504 28.451 28.535
40.000 33.409 35.090 36.285 35.012 34.294 30.920
32.706 30.459 32.270 31.767 32.262 30.809 29.971
27.198 26.674 27.141 26.440 27.428 25.187 22.384
29.377 29.704 28.342 28.421 28.681 29.844 27.192
30.870 30.029 32.509 31.507 31.945 33.522 30.677
30.098 29.600 29.351 28.791 28.818 27.967 26.550
31.483 29.586 31.675 30.228 30.242 28.910 29.058
31.004 29.889 29.409 28.535 28.362 29.090 27.951
33.213 32.293 32.616 32.189 32.374 32.921 31.164
27.447 26.583 27.054 26.175 26.936 26.233 26.556
35.466 35.447 20.723 34.562 34.234 40.000 40.000
23.780 40.000 22.874 40.000 40.000 19.537 40.000
30.584 28.023 28.716 28.657 28.695 29.783 27.430
32.514 31.769 30.817 30.649 31.835 31.502 29.656
30.303 23.770 30.096 24.529 25.783 24.643 25.562
29.779 28.708 27.701 27.083 27.509 27.638 25.878
33.197 33.686 31.986 31.617 32.755 32.424 31.349
30.703 28.675 30.282 28.648 29.160 29.385 26.552
27.834 29.427 28.214 28.836 28.423 28.763 25.997
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26.802 24.747 26.539 25.863 25.627 25.024 23.320
29.886 29.966 29.184 29.178 29.352 28.461 27.464
27.991 27.416 27.296 26.995 26.675 26.851 26.085
31.557 30.537 29.997 29.502 29.319 29.876 27.437
25.919 25.248 25.472 24.192 24.652 25.101 24.513
29.980 29.739 29.937 30.079 31.062 30.919 29.599
31.344 29.178 29.796 28.039 28.253 28.803 26.012
30.494 29.567 30.002 29.712 30.114 28.927 28.054
25.390 26.054 26.359 26.127 26.092 27.308 26.063
34.972 36.896 33.676 33.145 34.111 38.901 33.067
32.114 31.343 31.376 30.950 31.075 31.607 30.722
31.918 29.820 30.102 29.154 29.053 29.070 27.497
30.878 29.668 29.889 29.228 29.939 29.314 28.204
30.203 28.701 29.101 28.686 28.368 27.259 25.605
28.584 28.458 28.309 27.418 27.448 27.754 25.950
35.690 34.582 33.778 40.000 40.000 28.203 34.228
33.041 31.487 30.799 30.783 30.047 30.699 29.732
28.181 26.601 26.698 26.537 26.977 27.148 25.438
28.091 28.923 28.558 28.240 29.981 29.197 29.647
31.407 30.465 30.483 29.477 30.137 29.790 29.053
40.000 40.000 40.000 40.000 40.000 36.793 32.948
25.825 24.819 23.579 24.757 24.279 25.107 23.321
27.398 26.830 26.816 25.591 25.873 25.374 26.136
30.773 30.229 30.661 28.682 29.535 29.540 28.508
32.864 28.915 31.097 28.806 29.593 29.261 26.690
31.290 30.490 29.540 30.063 30.150 31.216 29.409
31.199 30.678 30.985 30.166 30.042 30.880 28.636
34.048 33.274 33.189 32.302 32.925 32.643 32.806
31.992 29.418 29.884 29.255 29.064 28.196 27.243
40.000 31.570 31.681 30.199 30.921 29.814 30.254
29.069 27.540 29.274 27.833 28.276 27.783 25.019
26.188 24.843 24.766 24.153 24.497 24.211 22.289
34.182 32.052 32.526 32.368 33.192 30.925 28.783
30.586 30.058 29.209 28.434 29.490 29.376 28.635
31.969 30.491 29.650 28.772 29.860 29.595 27.682
32.835 30.684 31.778 30.493 31.319 29.712 28.597
33.687 32.268 31.885 31.892 31.946 32.716 31.001
32.255 31.630 30.784 30.405 30.497 30.911 29.615
31.520 30.210 30.293 30.267 30.069 29.708 29.216
31.786 30.528 30.379 28.944 29.167 30.168 28.367
27.878 26.716 27.420 27.594 27.419 27.788 26.527
30.535 29.736 29.240 28.607 29.208 28.703 27.379
32.907 31.240 31.520 30.484 28.361 30.246 27.818
29.195 29.026 29.086 27.672 28.295 28.926 26.957
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32.030 29.432 30.368 29.811 29.910 29.489 28.107
31.101 29.070 29.279 28.289 27.829 28.116 26.753
30.368 30.017 29.602 29.247 27.333 28.662 26.613
33.551 31.465 33.234 31.610 33.186 31.635 29.971
31.452 30.955 30.712 29.966 31.708 33.685 30.104
28.120 28.127 27.755 26.496 27.011 27.290 27.121
31.646 29.594 30.372 28.708 28.745 29.350 27.199
32.181 31.163 31.002 30.744 30.987 31.099 29.756
29.271 28.929 29.446 29.032 29.107 29.100 27.698
28.937 27.852 28.429 27.383 27.875 27.567 27.166
26.641 25.945 24.885 27.978 23.825 26.670 25.416
30.359 30.183 29.635 28.294 28.570 29.025 27.323
28.390 28.210 27.741 27.554 27.513 28.012 27.550
32.067 30.444 30.007 28.891 29.815 29.617 26.984
29.093 29.803 28.420 27.817 27.770 28.889 27.269
31.337 31.477 31.155 30.628 31.055 30.097 29.035
30.833 30.025 29.595 28.604 29.099 29.651 27.302
30.795 30.585 30.139 29.323 29.658 29.927 28.280
40.000 29.984 32.133 30.809 30.604 31.096 29.519
30.871 28.705 28.931 28.551 28.571 28.089 26.143
29.054 28.373 28.130 27.536 28.258 27.828 26.645
32.924 32.865 29.808 29.159 31.602 31.052 29.283
27.407 27.222 26.747 26.322 26.679 27.061 25.116
32.031 29.950 30.722 29.795 30.606 30.652 29.239
34.544 31.747 40.000 31.539 31.519 30.240 30.271
35.779 33.324 33.386 32.197 40.000 31.944 31.985
40.000 28.274 37.142 33.154 34.004 40.000 40.000
30.733 29.675 29.556 29.803 29.622 29.098 28.037
31.455 30.223 30.236 29.661 30.357 29.381 28.496
40.000 28.129 33.357 40.000 29.293 40.000 36.662
30.993 29.569 30.599 28.447 30.938 29.973 28.046
30.495 30.167 29.028 29.139 29.745 29.986 28.801
29.670 29.890 30.016 29.166 29.456 30.034 27.201
33.342 31.557 30.349 30.225 29.980 31.227 28.887
31.500 29.725 30.338 28.055 29.850 29.252 25.860
27.781 24.558 26.401 25.599 26.216 26.999 22.835
31.946 29.852 28.551 29.247 28.923 29.179 27.624
32.177 30.672 30.313 29.788 29.735 30.124 27.925
29.453 27.825 29.226 29.149 28.317 27.398 26.641
30.084 30.354 28.758 28.994 29.550 30.615 28.726
35.332 33.216 33.534 33.344 33.468 33.183 32.875
32.658 27.743 31.360 30.193 30.099 28.464 27.654
32.323 30.546 30.812 40.000 29.746 30.092 28.850
30.991 29.880 29.818 28.979 29.333 28.219 29.201
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34.775 35.685 34.073 34.495 40.000 33.640 31.571
32.573 31.701 31.917 31.918 31.663 31.927 30.868
32.349 31.733 32.009 30.654 31.019 30.399 29.641
31.973 29.342 40.000 28.928 36.956 31.751 28.389
32.208 30.451 31.462 30.690 30.846 31.689 29.945
31.535 30.760 31.066 29.803 31.139 30.961 28.820
29.622 28.514 28.702 27.457 28.225 27.611 26.047
35.868 34.228 36.363 32.385 32.714 31.559 31.577
30.684 29.989 29.501 29.484 30.314 29.837 28.598
36.701 34.899 33.451 33.257 33.475 33.006 32.038
28.860 28.248 27.877 27.548 28.418 27.823 27.041
31.835 30.569 32.507 31.596 40.000 30.856 29.315
29.571 29.429 28.845 27.424 28.622 28.633 26.510
30.015 30.043 29.628 28.617 29.132 29.124 28.186
28.860 28.526 28.298 27.511 28.399 28.297 25.909
33.168 32.098 32.081 30.825 31.555 31.812 31.808
31.895 30.895 30.182 30.326 29.589 30.698 30.247
22.217 20.233 21.932 20.793 20.737 20.179 19.185
29.252 25.850 27.459 26.679 27.565 27.323 25.095
31.939 30.677 31.291 30.170 30.900 30.421 28.211
29.358 28.384 28.968 28.841 29.109 28.573 27.406
28.685 27.025 27.351 27.054 27.596 26.980 24.116
30.605 29.784 29.183 27.658 28.306 28.556 26.063
31.251 30.333 29.643 29.938 29.491 29.406 28.230
29.058 28.504 28.715 27.568 28.148 28.631 26.603
28.259 28.657 28.926 27.701 27.961 28.425 27.243
32.700 29.267 29.909 29.004 28.973 28.826 27.015
34.310 32.368 32.858 32.326 32.118 32.318 31.005
27.862 26.558 27.165 26.580 27.062 26.517 25.811
28.420 29.292 28.086 27.090 27.533 28.763 28.275
32.486 30.667 29.389 29.604 30.199 30.946 28.397
29.218 29.028 28.465 27.473 28.366 28.863 26.853
26.170 25.121 25.455 25.328 25.829 24.994 22.933
34.115 34.529 33.186 32.225 32.733 35.064 32.148
30.049 29.767 29.100 28.497 28.860 29.407 28.330
29.835 29.511 28.904 29.270 29.803 28.862 27.191
30.261 29.123 29.200 28.486 28.897 28.839 26.759
27.988 28.498 28.122 27.695 28.476 29.007 26.872
30.448 29.779 29.410 28.197 28.697 28.169 25.792
27.133 26.466 26.624 25.627 26.287 26.398 25.206
27.029 26.430 26.450 26.021 26.759 26.632 24.226
32.197 30.547 31.259 29.429 29.863 28.902 27.417
29.965 28.653 29.179 28.599 28.788 28.521 27.956
33.426 31.880 32.166 31.171 31.630 31.500 29.710
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40.000 31.903 40.000 34.283 36.337 27.763 32.791
32.664 30.215 32.347 29.664 30.202 30.050 29.942
29.592 27.445 28.810 28.122 28.108 28.464 27.462
29.457 26.940 28.277 27.227 28.087 27.377 26.587
30.790 29.869 29.588 28.423 28.669 28.906 27.493
32.590 31.787 32.307 31.181 31.841 31.745 29.535
40.000 29.438 29.920 28.125 26.244 28.547 26.333
29.149 28.714 28.455 28.310 28.412 28.572 27.378
28.328 34.161 27.837 27.892 27.640 30.427 35.340
31.695 30.314 30.700 29.484 29.682 29.852 28.503
25.899 25.753 23.740 25.533 25.383 25.499 23.848
29.825 29.258 28.189 28.366 29.166 29.855 28.370
40.000 40.000 18.463 17.973 23.878 40.000 22.124
29.029 28.342 28.140 27.734 28.072 27.511 25.461
27.629 27.195 27.482 26.858 27.453 27.153 25.244
36.382 30.261 33.569 31.084 31.422 29.441 29.054
27.853 27.169 27.529 26.765 27.468 27.044 25.755
29.181 29.176 28.564 28.210 26.243 28.866 26.545
30.645 27.851 29.798 28.181 28.982 28.210 25.970
32.210 31.378 31.597 31.477 29.377 31.280 30.049
29.697 29.615 28.638 27.655 28.504 28.512 27.513
26.624 27.424 26.394 27.205 26.549 27.398 25.207
30.164 28.369 29.234 28.475 29.191 30.094 28.817
27.980 27.126 28.332 26.980 27.089 27.807 26.627
29.996 27.551 29.444 28.593 28.611 27.795 26.763
40.000 40.000 27.764 28.907 29.133 40.000 28.025
30.995 29.234 30.544 28.938 29.759 27.675 27.707
33.154 34.220 31.986 31.137 32.187 30.284 31.501
29.399 28.631 28.275 27.647 28.547 28.070 26.915
31.043 29.916 30.643 29.423 30.403 30.127 27.185
31.226 29.810 30.272 29.681 29.401 30.318 27.906
30.699 28.430 29.034 28.190 29.986 30.351 25.036
31.424 30.076 30.448 29.948 29.889 29.687 28.496
27.594 26.545 26.887 25.838 27.101 26.826 24.466
31.189 29.173 30.075 29.214 29.325 28.621 28.546
31.344 30.586 29.147 29.639 29.350 29.701 28.796
28.775 28.247 28.067 27.615 28.256 28.082 27.178
31.913 28.866 31.747 30.425 31.128 29.254 26.931
32.572 30.233 30.857 29.592 30.213 29.984 27.953
32.423 28.642 30.951 29.926 30.215 27.946 27.400
28.275 27.598 27.990 27.038 27.641 27.096 25.467
28.707 29.431 28.704 28.767 29.574 29.686 28.250
29.024 28.645 28.716 28.356 28.795 28.805 27.570
31.644 31.280 30.729 30.112 30.530 29.112 28.412
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32.136 29.708 30.205 29.609 28.932 29.942 27.268
28.611 27.928 26.949 26.543 27.058 27.013 24.661
32.866 31.720 31.250 30.607 31.185 30.831 30.653
31.670 28.928 29.145 27.977 28.621 29.137 25.838
29.307 28.548 28.866 27.745 28.443 27.524 26.371
40.000 30.475 29.578 29.796 28.943 31.561 29.331
30.643 30.643 30.017 29.563 30.327 28.859 28.557
28.991 28.296 27.482 27.536 28.059 28.795 24.274
30.699 30.277 30.303 28.352 28.436 31.336 27.111
29.134 30.310 29.615 29.050 29.440 29.081 27.320
28.260 27.442 27.457 26.113 26.656 26.590 24.956
30.703 29.550 29.910 28.573 29.415 28.845 28.165
33.672 32.799 31.594 31.349 31.487 32.380 32.439
26.072 26.575 27.388 25.987 27.189 27.054 26.051
27.337 26.385 26.458 25.781 26.402 27.721 25.954
30.142 29.734 30.410 29.221 30.118 29.577 29.037
31.351 31.375 31.755 30.622 30.859 31.308 29.542
34.487 32.092 32.931 31.192 32.122 30.144 29.900
31.727 30.858 30.870 31.419 40.000 30.405 29.907
30.679 30.415 30.276 29.816 30.604 29.850 28.394
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ERneg07SH449ERneg07SH494ERneg07SH572ERneg08RMH111ERneg08RMH359ERneg08RMH456ERneg08RMH539
24.802 24.257 25.200 26.604 24.232 30.310 26.871
28.309 28.126 28.871 31.901 28.323 35.093 29.547
28.510 28.454 28.497 33.897 27.669 33.321 30.593
28.662 29.363 30.609 35.938 28.707 40.000 31.901
33.347 33.529 34.642 40.000 34.816 40.000 34.810
25.426 25.715 26.247 30.404 24.838 35.849 27.089
26.594 27.120 27.123 29.203 26.126 31.896 27.755
30.898 30.487 31.222 32.323 29.488 31.915 32.584
31.229 31.309 31.915 33.985 30.696 40.000 32.244
26.724 27.994 27.718 31.420 27.773 33.174 29.390
29.917 29.430 26.564 32.617 28.470 34.516 29.653
30.983 30.323 31.742 33.947 29.368 34.298 30.433
28.359 28.118 27.840 30.886 27.330 34.361 30.026
27.191 26.843 27.913 29.459 26.382 32.712 28.555
30.791 30.709 30.696 40.000 30.837 40.000 32.272
31.482 30.996 31.670 40.000 32.013 18.801 32.055
29.240 29.898 30.322 33.274 28.398 35.451 30.965
40.000 40.000 40.000 25.073 40.000 40.000 40.000
26.850 26.897 27.609 31.640 25.880 40.000 28.912
22.828 23.268 23.971 29.634 22.788 32.664 24.937
27.555 27.857 27.800 31.045 27.003 40.000 28.807
31.249 30.713 31.065 40.000 30.270 37.003 32.126
27.407 27.356 29.735 31.542 26.747 32.846 30.332
34.315 34.927 34.105 40.000 33.658 18.265 39.210
31.542 30.967 31.156 40.000 31.064 35.563 31.913
28.105 27.434 27.140 29.061 25.919 30.791 28.757
27.609 28.033 29.206 30.040 27.622 30.521 28.216
29.642 27.756 31.760 33.511 31.330 34.820 30.604
28.503 27.913 27.865 32.140 27.710 35.003 29.646
29.454 29.841 30.232 34.304 28.661 33.512 31.749
27.671 28.055 29.695 34.139 27.470 40.000 30.592
30.760 30.290 33.136 32.768 30.317 34.413 32.192
25.589 25.454 26.732 28.586 25.634 31.392 27.003
35.162 40.000 22.901 40.000 33.651 40.000 40.000
36.581 36.539 38.111 27.599 35.988 32.258 40.000
28.077 28.255 28.975 33.371 27.518 35.076 30.303
30.739 30.839 31.509 34.512 30.013 38.741 32.812
25.782 25.411 29.624 26.609 24.728 31.818 28.779
26.622 27.112 28.088 31.263 26.636 33.184 28.581
31.167 31.873 32.465 33.458 31.025 40.000 33.190
28.294 28.845 30.247 30.585 27.884 33.015 30.231
27.512 27.668 28.217 29.724 27.031 34.547 28.984
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24.809 25.326 25.667 28.544 25.259 29.850 26.691
27.901 28.163 29.468 32.814 27.973 36.336 29.510
26.394 26.613 27.316 31.048 25.786 32.207 28.609
28.800 29.058 29.430 35.722 28.274 40.000 30.722
23.703 24.244 25.348 28.174 23.694 31.596 25.994
29.866 29.306 30.145 30.680 29.425 29.479 30.187
28.020 28.451 28.463 34.521 27.675 35.988 30.265
28.908 29.148 29.384 32.678 28.812 35.452 30.066
24.218 24.618 26.485 28.291 24.425 31.140 27.313
33.586 33.827 35.725 34.681 33.049 10.792 40.000
30.187 30.278 31.573 33.625 30.052 35.311 31.841
29.023 29.027 29.731 33.613 28.423 35.543 31.554
29.001 29.437 29.382 32.045 28.981 33.064 29.330
28.207 28.964 29.711 31.030 27.283 33.278 29.272
27.126 27.538 28.975 30.145 26.858 33.305 28.320
35.555 34.695 29.200 40.000 34.957 34.590 35.240
29.317 30.038 31.128 34.486 28.790 36.292 31.939
25.935 26.350 26.653 31.262 25.549 32.601 27.757
28.541 29.007 28.736 29.633 28.509 31.559 29.473
29.398 29.387 29.466 34.127 29.424 24.034 30.836
40.000 40.000 40.000 40.000 35.100 40.000 40.000
23.337 23.587 24.928 27.607 22.492 30.451 24.522
24.625 25.003 25.316 28.023 23.574 30.343 26.296
28.340 28.451 29.077 33.162 27.479 35.396 30.349
28.971 29.249 30.096 40.000 27.594 37.269 31.165
29.275 28.954 30.567 32.514 28.817 35.050 31.766
30.676 30.318 31.110 32.892 28.818 35.297 30.650
31.719 32.893 32.687 31.979 31.230 36.186 34.189
28.376 28.927 29.306 36.624 27.757 40.000 30.712
30.522 30.721 30.833 34.838 29.908 33.053 32.047
27.055 26.254 26.657 29.835 26.615 31.446 27.891
23.586 23.886 23.763 31.647 23.433 32.955 25.354
31.410 31.844 30.497 35.472 30.999 33.371 33.535
28.590 28.362 29.294 33.034 28.057 40.000 30.107
28.303 30.410 30.354 35.399 28.818 40.000 31.790
29.877 30.265 30.628 40.000 29.486 40.000 32.015
30.849 31.388 30.438 34.763 30.187 36.162 32.054
29.328 29.561 31.084 34.524 29.403 37.608 31.825
29.300 29.527 30.950 32.016 29.365 33.967 30.455
29.031 28.782 29.427 32.472 28.223 35.753 29.945
26.560 26.584 27.622 30.291 25.563 32.511 28.750
28.007 28.025 29.114 32.376 27.434 35.117 30.286
30.159 29.435 30.966 34.402 29.531 21.533 32.019
27.590 27.341 28.022 31.169 26.298 33.689 29.512
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28.816 29.249 29.105 34.198 29.051 35.049 30.675
27.790 27.884 28.540 32.467 27.455 37.920 30.191
28.745 28.689 29.662 32.310 23.966 40.000 30.822
31.952 31.555 31.800 34.747 31.111 35.836 32.235
29.589 30.543 30.082 32.767 29.946 35.923 32.185
25.964 26.368 27.050 29.774 26.066 33.097 27.958
27.778 40.000 29.557 36.131 27.792 40.000 29.797
30.423 30.834 31.674 33.915 30.223 40.000 32.405
28.359 28.457 27.437 29.812 28.104 30.830 28.120
26.915 26.521 27.063 32.225 26.392 35.047 28.553
24.779 28.215 27.199 28.146 24.614 31.813 31.474
28.761 28.763 29.653 40.000 27.904 34.256 30.514
26.462 26.267 27.177 31.274 26.496 33.651 28.215
29.515 29.254 31.031 34.775 28.772 36.208 31.766
27.628 26.989 27.956 31.680 27.491 37.108 29.668
29.483 29.176 31.754 32.884 29.624 35.579 32.371
28.662 28.695 29.312 31.750 27.920 33.416 30.142
29.319 28.825 29.587 32.427 28.880 34.744 30.954
29.568 30.603 31.590 40.000 29.530 40.000 31.557
27.681 27.387 28.183 35.647 27.144 40.000 29.957
27.361 27.376 27.282 29.922 26.708 30.378 27.252
30.287 30.625 32.365 38.539 30.034 38.925 32.421
25.905 25.852 26.814 30.908 24.565 34.496 28.561
29.486 29.356 29.998 33.789 29.350 35.884 31.041
30.647 31.536 31.439 40.000 30.084 33.490 33.231
32.397 32.866 33.587 40.000 31.759 34.218 34.953
32.055 40.000 40.000 40.000 31.909 40.000 40.000
28.143 28.832 29.692 32.058 28.165 33.750 29.868
29.369 29.148 28.841 35.397 28.113 35.567 31.258
36.920 40.000 40.000 40.000 40.000 40.000 34.652
27.722 29.640 29.479 30.331 29.391 33.416 28.429
28.248 28.631 29.090 32.796 28.421 37.040 30.821
28.854 28.910 29.185 31.669 28.642 34.382 30.174
29.375 29.406 30.295 37.573 28.716 40.000 32.136
28.713 28.861 29.725 34.200 27.910 35.888 29.670
25.818 25.074 25.731 28.564 24.015 30.376 26.461
28.693 28.501 28.878 35.486 27.727 40.000 31.326
29.358 29.819 29.911 40.000 29.034 36.444 30.441
27.866 27.964 28.245 31.032 26.848 35.474 29.898
28.896 28.149 29.487 29.972 29.007 31.530 30.169
32.551 32.784 33.370 36.899 31.943 35.819 33.329
29.606 29.923 29.764 35.452 28.431 40.000 30.107
29.379 29.641 31.026 34.361 28.254 36.787 32.236
28.542 28.636 29.514 33.742 27.863 32.661 31.106
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33.589 40.000 40.000 35.896 32.853 40.000 36.735
31.229 30.916 31.008 33.167 30.946 34.732 32.166
30.302 30.537 31.190 34.202 29.755 40.000 31.462
30.363 26.347 28.182 40.000 32.817 40.000 30.543
29.420 29.632 30.260 31.642 30.108 33.557 31.804
30.703 30.006 29.409 32.786 30.181 34.359 31.461
27.309 27.815 28.924 29.593 26.339 31.971 27.642
32.337 33.693 28.409 40.000 29.878 32.533 40.000
29.146 28.282 30.031 30.864 28.925 32.180 31.125
31.359 33.046 33.746 40.000 32.754 40.000 35.604
27.130 27.333 26.722 29.828 26.889 33.124 28.076
31.878 31.218 40.000 35.344 30.700 40.000 40.000
27.882 28.497 28.943 32.821 27.398 36.109 29.584
27.771 29.006 29.901 33.187 28.327 36.109 30.594
27.269 27.641 28.941 32.670 27.131 34.531 29.354
29.506 30.574 31.780 34.489 30.571 36.714 31.939
28.987 29.132 29.133 32.235 28.400 33.533 30.595
20.643 20.197 21.756 25.748 19.031 28.378 22.385
26.313 26.736 26.370 28.582 26.091 32.517 26.466
30.554 30.401 30.135 34.001 29.527 35.356 32.312
28.065 28.266 28.837 31.062 27.718 32.168 28.381
26.373 26.362 26.815 32.733 25.100 34.462 28.443
27.194 27.830 29.002 34.034 27.340 31.318 30.562
28.555 28.870 29.691 34.778 28.724 40.000 32.777
27.754 27.340 27.928 30.918 27.307 31.715 28.433
27.776 26.489 28.119 30.602 26.804 33.048 29.120
28.164 28.780 30.156 35.261 27.701 25.692 30.644
31.599 32.330 33.126 40.000 30.840 40.000 33.598
25.809 25.953 26.620 30.294 25.326 33.827 27.366
27.028 27.385 27.611 31.239 26.913 33.898 29.188
40.000 30.027 31.123 40.000 29.010 40.000 32.385
27.639 27.634 28.454 31.676 27.190 32.867 29.429
25.355 24.840 25.857 28.124 23.396 28.304 26.993
32.318 33.226 32.477 34.409 33.188 36.279 32.977
28.410 28.466 28.282 32.911 27.792 37.187 30.579
28.500 28.714 29.077 30.510 28.664 31.870 30.178
28.240 27.539 28.105 31.535 27.090 33.118 29.141
27.900 26.726 28.344 29.516 27.451 34.089 29.608
27.746 28.640 27.898 32.763 28.013 34.493 28.414
25.509 25.631 26.124 27.262 25.265 29.553 26.793
25.655 25.769 25.795 28.599 25.437 30.415 26.533
28.984 29.788 30.457 36.318 28.217 36.148 31.749
27.741 28.382 28.678 35.116 27.579 35.347 29.506
30.807 31.321 32.167 28.610 30.597 40.000 33.381
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34.710 37.294 32.531 37.201 33.534 40.000 32.582
30.047 30.287 30.343 40.000 28.628 33.797 31.695
27.628 27.436 27.502 33.046 26.804 33.736 29.775
27.341 27.616 28.461 31.376 26.250 40.000 28.025
28.317 28.230 28.733 33.628 27.073 40.000 29.665
30.290 30.141 31.551 33.918 28.757 35.396 30.517
28.332 27.112 28.965 34.225 27.316 33.246 29.653
27.699 28.032 28.631 30.532 27.255 32.290 29.153
27.345 27.429 27.479 29.683 27.210 40.000 33.930
28.958 29.528 30.080 34.133 28.477 40.000 31.241
23.431 24.812 25.985 27.110 24.154 29.903 25.810
27.979 28.386 28.863 29.957 27.678 31.945 30.037
22.238 40.000 40.000 27.018 40.000 40.000 21.123
26.462 27.598 27.690 33.337 26.435 40.000 28.335
26.402 26.831 27.718 30.191 25.769 31.558 28.058
30.573 31.272 31.744 35.161 30.120 33.861 32.179
26.404 27.018 27.334 30.811 26.706 32.886 27.866
27.558 27.565 28.519 29.676 27.254 34.659 28.810
27.590 27.749 30.179 31.800 27.113 35.111 29.084
30.787 29.709 30.912 40.000 30.002 34.050 31.570
28.044 27.958 29.653 33.804 27.070 36.628 28.602
26.160 26.290 27.185 29.561 25.620 31.631 27.683
29.576 28.476 30.558 32.390 28.813 36.269 31.418
26.968 27.089 27.678 30.104 26.593 35.869 28.513
28.685 28.300 28.706 31.490 28.239 33.832 29.487
40.000 28.339 27.782 40.000 40.000 40.000 39.073
29.395 29.059 28.988 32.583 26.991 31.616 31.190
31.042 31.023 32.426 33.694 30.715 37.777 31.519
26.812 27.641 28.107 32.095 27.214 35.295 29.364
29.762 29.790 29.854 34.921 28.906 35.390 31.265
28.980 28.977 30.204 40.000 28.340 40.000 30.150
29.214 27.356 28.492 31.450 27.023 31.937 30.171
28.941 29.757 30.041 35.977 29.271 40.000 30.329
25.753 26.749 26.978 30.491 25.284 34.034 27.998
28.415 28.756 29.046 32.920 27.563 35.445 30.223
28.641 28.941 30.155 35.417 28.866 40.000 31.232
27.002 27.333 28.517 32.418 27.141 40.000 29.289
30.358 28.261 29.422 34.622 29.557 34.587 29.776
28.929 29.782 30.343 36.906 29.222 40.000 40.000
29.654 29.675 29.197 32.865 27.834 34.501 29.452
26.266 27.131 27.204 29.874 26.798 31.437 27.718
28.573 28.435 29.295 29.085 28.476 30.289 29.663
27.914 28.376 29.462 30.420 27.820 32.091 29.553
29.136 30.043 30.737 33.356 28.711 40.000 31.498
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28.694 29.156 30.096 35.684 27.794 40.000 31.232
26.146 26.153 27.245 32.199 25.538 34.983 28.282
30.509 30.694 30.723 33.698 30.001 40.000 32.288
28.208 27.991 29.093 40.000 27.327 40.000 31.019
28.282 27.641 28.331 31.991 27.380 33.837 28.824
28.372 28.663 29.776 34.867 28.030 35.917 30.152
29.302 29.802 30.392 30.846 28.982 34.103 31.035
27.305 27.263 27.901 33.729 26.439 34.858 29.309
28.084 28.800 32.256 32.737 29.285 40.000 32.857
28.698 28.665 29.268 32.270 28.554 33.626 29.954
26.081 26.402 27.194 32.251 25.329 33.811 28.324
28.751 28.789 29.963 30.821 28.686 33.645 31.124
30.240 31.076 32.063 33.966 29.896 40.000 32.405
26.555 26.330 27.541 28.946 26.176 32.353 26.923
25.200 25.734 24.903 27.631 26.005 30.390 25.994
29.101 28.822 29.921 29.541 28.885 32.732 30.163
30.622 29.807 31.261 33.015 29.820 33.731 31.520
30.965 31.892 32.574 34.018 29.571 33.974 33.176
30.213 30.451 30.407 34.965 29.571 35.966 31.599
29.220 28.633 30.490 31.473 28.377 36.763 30.967
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ERneg09RMH039ERnegHUN.07.033ERnegNSH.07.019ERnegP07.00207ERnegRPA.07.128ERnegWMD.07.057ERpos01.06.005
24.802 22.220 26.982 26.161 25.166 22.483 23.724
27.929 25.959 31.406 28.418 29.424 27.235 29.503
27.302 25.413 31.109 28.000 28.066 27.119 26.935
28.654 26.957 32.112 29.089 26.572 27.174 28.028
32.039 34.131 36.977 36.082 33.781 33.231 32.357
25.418 24.833 29.587 26.014 25.762 25.685 25.032
27.035 25.610 30.766 26.913 27.506 26.432 26.437
31.070 28.538 33.503 31.112 30.970 28.006 30.681
31.095 27.132 33.406 32.832 31.672 27.357 28.866
27.024 25.743 30.673 28.710 28.148 26.357 28.096
28.158 31.948 36.421 28.659 30.486 28.428 35.770
29.168 32.706 34.985 30.035 30.298 31.263 35.479
27.001 26.119 29.857 28.292 27.653 27.029 27.179
27.409 25.339 29.981 28.541 27.653 25.925 26.902
30.294 40.000 40.000 40.000 31.167 31.770 30.837
29.762 29.457 34.270 30.788 31.457 30.435 31.052
27.824 26.417 32.996 29.278 29.975 27.569 28.213
40.000 40.000 26.122 40.000 22.748 40.000 40.000
27.297 25.592 30.514 26.903 27.272 26.045 26.330
21.799 20.852 25.392 24.022 23.690 21.332 23.248
25.549 25.662 30.515 27.773 27.656 26.141 27.016
30.602 28.877 34.623 31.298 31.015 28.357 40.000
28.353 26.195 31.020 29.084 27.934 25.454 28.642
32.311 30.606 36.102 34.886 35.704 30.020 35.845
29.043 28.996 33.235 31.703 30.921 30.806 32.332
27.109 24.751 29.491 28.266 26.558 22.885 23.771
27.350 26.651 30.980 28.532 28.418 27.553 28.293
28.690 28.347 35.818 30.446 31.808 29.334 33.165
26.291 27.134 31.244 26.966 28.479 28.538 29.427
29.027 27.406 33.052 29.432 29.958 27.820 27.600
28.145 26.619 31.375 27.862 27.792 27.229 27.425
32.160 28.695 32.242 32.492 30.927 28.700 32.549
25.891 21.834 28.850 27.037 26.291 22.751 27.032
34.655 22.564 40.000 40.000 15.768 34.432 33.708
40.000 34.403 24.074 40.000 34.567 35.081 36.431
27.711 26.127 30.969 28.750 28.230 26.420 27.008
30.043 26.329 33.123 31.527 31.512 27.659 30.812
23.246 22.032 31.353 24.819 24.952 26.016 23.939
26.598 25.058 30.078 27.031 27.178 25.910 26.720
32.076 28.706 32.958 32.919 31.572 28.030 31.109
28.718 25.044 32.240 29.071 28.913 26.622 28.652
27.811 26.596 30.697 28.233 28.178 26.605 27.359
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23.570 22.759 28.276 25.694 25.792 23.838 24.999
28.099 27.251 31.767 28.063 28.949 28.467 28.130
26.124 23.965 30.294 26.572 27.165 25.174 26.178
28.762 27.268 32.028 29.284 29.150 27.456 28.428
24.370 23.277 29.021 24.384 24.685 24.912 24.593
29.136 26.496 31.025 31.129 30.102 27.207 29.897
26.872 25.703 31.323 27.655 27.871 26.773 27.600
29.098 25.816 32.051 29.927 30.129 27.117 29.005
25.306 23.522 29.127 26.328 25.942 24.441 24.650
36.235 31.910 36.659 34.095 34.621 34.473 32.180
29.958 28.609 33.067 31.080 30.749 28.819 29.931
28.313 26.445 32.211 29.132 28.591 26.819 28.054
28.733 27.454 31.569 29.177 29.789 27.249 29.074
26.658 25.358 30.827 27.903 28.096 24.999 28.936
26.909 25.829 30.780 27.252 27.763 26.452 27.631
32.621 35.535 31.216 36.038 40.000 40.000 36.089
29.382 27.603 31.999 28.718 29.113 27.290 30.797
25.392 25.409 29.163 27.081 26.799 24.700 26.359
27.283 26.283 30.880 30.592 30.162 26.260 28.661
29.272 26.909 32.526 29.935 28.963 27.649 28.974
33.735 35.581 40.000 40.000 40.000 40.000 36.252
22.703 21.763 26.308 24.094 23.870 22.772 22.121
25.493 21.619 28.840 26.349 24.995 22.131 25.864
28.736 26.099 32.637 27.497 29.398 27.219 28.200
28.384 25.798 31.555 28.822 29.138 26.819 28.852
29.516 25.695 31.806 30.573 29.908 27.324 28.951
30.211 27.862 33.866 30.664 30.618 28.523 30.723
32.735 30.934 34.741 30.816 32.423 30.350 31.623
26.973 26.344 30.319 27.137 28.054 26.446 26.600
29.650 26.747 31.977 29.503 30.547 26.573 29.559
25.775 26.031 30.678 27.588 27.425 25.918 26.019
23.066 22.490 27.433 24.218 24.037 22.655 23.350
28.965 30.503 33.507 31.556 34.600 28.511 35.378
28.563 25.821 30.607 30.097 28.629 26.921 28.044
28.828 26.198 30.621 29.208 29.436 26.964 28.521
29.669 28.324 32.935 30.411 31.833 29.125 30.117
30.778 29.873 33.561 30.397 30.571 29.481 30.608
29.816 26.644 32.591 29.528 30.095 27.594 29.416
29.704 27.220 32.421 30.244 30.035 27.308 30.779
28.997 27.095 32.162 29.166 28.730 28.119 28.457
26.205 22.751 29.470 27.661 27.281 23.029 26.181
27.881 26.256 30.861 28.878 28.550 27.240 28.049
29.080 25.467 32.699 29.476 28.290 29.459 29.224
27.053 26.344 31.839 27.690 28.086 27.056 28.241
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28.094 26.708 32.455 28.430 29.325 27.488 28.858
27.204 26.454 30.685 27.135 28.182 26.332 27.949
26.790 27.501 31.897 28.767 25.916 27.059 29.492
29.734 29.227 34.095 31.713 32.459 29.408 31.661
29.038 26.309 33.839 30.497 30.872 27.262 29.225
26.197 25.259 30.715 27.347 27.240 27.007 26.687
27.398 26.317 31.130 27.654 28.152 27.612 29.601
29.949 28.808 33.218 30.654 31.666 29.182 30.475
28.202 27.375 31.144 29.631 29.698 26.874 28.647
26.606 24.970 30.023 27.779 26.383 26.504 27.013
24.755 23.656 25.730 27.075 27.340 27.030 25.167
27.845 26.919 31.298 28.319 26.313 27.249 27.910
27.457 26.195 30.599 26.659 27.514 26.428 26.288
27.748 27.297 31.700 28.658 28.876 27.450 28.093
27.234 25.951 30.662 27.357 27.718 27.965 28.217
29.355 29.023 33.815 29.621 28.978 28.060 29.707
27.510 25.941 31.577 28.652 29.127 27.371 28.333
28.224 26.846 31.269 29.898 29.247 27.221 28.730
30.026 28.755 33.190 29.523 30.092 28.445 30.810
27.130 26.246 31.234 27.508 27.891 26.135 26.640
26.498 25.871 30.849 27.628 27.792 26.132 27.514
31.719 28.598 32.983 31.002 31.346 28.864 30.942
25.545 23.582 29.002 25.982 26.328 25.145 25.340
28.893 27.962 32.110 30.834 30.294 28.204 29.704
30.403 27.250 40.000 28.991 31.098 28.614 31.239
31.790 29.422 34.239 30.360 32.993 30.272 31.412
36.300 31.359 34.465 32.682 32.389 31.098 33.263
28.176 26.317 32.247 29.002 28.592 27.758 28.223
28.002 26.993 32.832 28.804 29.517 28.906 28.190
40.000 24.252 40.000 27.758 40.000 36.344 28.088
32.092 27.852 32.284 30.915 29.594 30.395 28.156
29.424 25.001 31.747 29.811 29.955 26.707 28.357
28.414 27.273 31.642 28.576 28.907 28.397 28.993
29.037 29.289 31.984 28.586 29.092 28.480 28.448
27.169 26.800 31.876 28.107 28.658 27.374 27.605
24.685 22.460 28.067 25.211 25.425 23.423 23.805
28.461 26.708 29.886 28.188 28.549 27.883 28.136
28.370 27.038 32.720 29.207 30.104 28.405 28.298
26.652 26.594 30.943 27.750 28.248 26.659 27.779
28.256 25.461 29.952 30.415 29.393 27.406 28.752
31.985 30.536 33.852 33.073 33.090 29.577 31.742
27.910 29.297 34.092 28.809 30.160 27.018 31.148
30.175 26.825 31.590 30.438 29.856 25.984 30.489
28.345 25.936 32.399 27.600 29.588 26.863 27.439
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35.391 30.370 33.075 34.102 34.527 32.333 40.000
30.411 30.390 35.390 31.520 31.620 30.303 31.768
30.166 29.122 34.055 30.439 28.062 29.639 30.428
27.429 37.283 32.755 40.000 38.189 33.567 31.308
29.082 28.774 33.614 30.587 30.844 27.830 30.574
29.039 28.958 32.574 30.581 30.756 29.641 29.647
26.613 25.019 31.077 27.105 27.764 25.603 27.702
32.004 32.297 34.360 32.365 32.174 29.990 33.508
28.922 26.161 32.113 30.530 30.571 27.469 29.075
32.375 27.167 34.754 32.572 32.123 28.341 32.418
26.816 24.257 29.339 28.655 28.051 25.531 26.148
30.814 30.144 36.487 31.928 40.000 30.018 40.000
26.835 25.722 30.232 27.374 28.221 27.222 27.015
28.245 25.105 31.492 28.949 28.697 26.986 27.975
26.786 24.550 30.093 27.494 27.487 25.147 26.693
32.106 26.757 31.762 30.385 30.853 27.004 31.738
28.599 28.939 32.695 28.467 28.887 28.159 29.241
20.181 18.324 25.077 21.016 20.891 19.288 20.332
25.660 24.295 28.711 27.524 26.753 23.893 26.608
28.550 28.496 32.972 30.629 30.900 30.550 30.953
27.561 26.747 30.563 28.645 29.170 27.136 28.464
25.112 24.042 29.055 26.383 26.570 24.981 26.243
28.558 26.113 30.552 28.222 28.246 27.023 27.316
28.667 25.248 30.970 28.595 28.579 26.653 27.487
26.962 25.540 30.659 28.163 27.888 26.900 28.020
26.465 25.067 30.900 28.227 28.394 25.482 27.226
28.476 26.498 31.538 28.597 28.821 26.087 27.911
31.490 29.124 33.713 31.925 31.388 29.146 30.422
24.703 24.267 28.895 26.360 25.771 25.470 25.799
28.715 26.693 30.446 28.294 27.897 27.427 26.712
29.163 26.787 31.686 29.925 30.091 28.028 28.171
27.466 25.832 30.829 27.552 27.846 26.031 27.194
23.246 21.800 26.941 24.487 25.692 22.098 24.655
33.135 32.864 35.634 40.000 32.872 32.491 33.377
27.453 26.793 31.507 28.672 28.702 27.957 27.990
28.216 27.631 32.238 28.464 30.092 27.602 28.054
26.814 26.006 31.373 28.040 27.975 27.139 27.799
27.776 25.688 30.297 28.909 28.180 26.124 27.063
27.563 27.403 32.089 28.287 28.519 28.311 28.405
25.204 23.625 29.544 26.370 26.076 25.563 25.519
24.854 23.087 29.273 26.000 25.980 24.564 25.840
28.947 27.057 32.148 28.767 28.901 27.926 27.703
27.545 27.017 31.257 28.418 28.965 26.967 28.063
30.069 28.114 33.927 30.828 30.263 28.783 29.405
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30.635 31.836 40.000 29.630 35.754 27.560 35.752
30.501 27.495 34.538 29.507 30.510 29.117 29.528
26.800 26.335 30.848 27.924 27.764 26.463 26.577
25.445 26.032 30.613 28.042 27.772 27.238 26.445
27.178 25.747 30.988 28.004 28.328 27.772 27.404
28.057 29.455 33.403 30.150 30.793 28.201 29.052
28.112 26.844 30.855 27.903 28.424 26.686 27.452
27.637 26.140 30.903 28.861 28.526 26.527 27.335
31.927 25.158 29.976 31.492 28.781 34.318 27.165
29.296 27.416 32.992 29.267 29.719 28.825 29.105
23.787 21.903 26.005 26.040 24.178 23.110 24.080
27.461 25.336 30.431 29.168 28.755 26.668 26.821
40.000 40.000 40.000 22.754 22.722 30.582 17.492
26.282 25.601 31.153 27.375 27.452 25.977 26.428
25.078 24.266 29.828 26.495 26.460 24.573 25.734
28.929 29.098 33.061 28.409 31.113 27.558 27.519
25.662 25.170 30.351 27.109 27.303 26.273 26.634
27.492 24.474 31.322 27.895 27.829 26.169 27.166
27.224 26.223 31.691 26.649 28.348 25.733 28.041
30.923 27.230 34.518 31.297 31.119 29.799 30.466
27.248 27.185 30.287 28.052 27.443 26.056 26.978
25.821 23.949 28.433 26.777 26.137 25.440 25.963
27.968 26.616 40.000 29.944 28.929 29.289 28.622
25.021 23.904 29.630 27.478 27.203 24.499 26.864
28.072 27.352 31.350 28.261 28.416 27.651 28.434
40.000 34.682 29.544 27.253 40.000 36.019 40.000
27.293 26.337 32.878 26.637 29.278 28.072 29.281
30.783 27.535 33.341 32.073 31.061 27.379 30.541
27.574 24.249 29.877 27.859 27.627 25.801 27.683
28.713 27.516 40.000 29.457 29.498 28.397 30.143
28.072 26.517 31.974 28.606 29.364 27.166 27.861
27.481 28.471 32.945 29.206 28.294 28.271 28.378
29.081 27.731 32.051 29.437 29.472 27.953 28.989
25.399 23.560 28.779 25.779 25.915 24.252 24.565
28.480 27.504 31.727 28.837 28.929 27.904 28.739
28.895 26.738 31.095 29.402 29.150 27.450 27.712
27.397 26.009 31.203 27.547 27.877 27.122 27.772
26.252 23.765 33.263 28.748 30.289 28.016 30.169
29.303 26.910 32.012 30.459 30.295 28.498 29.694
26.906 25.416 30.710 29.299 28.840 27.094 28.160
26.531 25.961 30.781 27.686 27.870 26.682 27.911
28.783 26.525 30.414 29.729 29.698 26.946 29.313
28.334 25.343 30.331 28.869 28.736 25.862 26.960
28.767 27.999 31.515 29.606 30.147 28.643 29.170
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27.001 25.915 31.921 28.275 28.493 26.992 28.008
25.643 23.633 28.605 26.682 26.677 24.459 26.430
30.429 28.752 33.969 30.334 30.950 29.933 30.863
27.191 26.195 30.608 27.862 27.948 27.384 26.563
26.643 25.965 30.934 27.686 28.501 26.743 27.356
29.400 26.288 31.470 29.365 28.644 27.233 28.431
29.377 26.250 31.893 30.394 30.267 26.823 29.368
26.877 25.883 30.238 27.405 27.867 26.542 27.006
29.791 26.278 32.717 29.899 29.919 28.218 27.017
28.450 26.966 32.054 29.417 29.480 27.355 29.039
26.075 23.959 29.398 26.410 25.896 24.887 25.459
27.956 23.003 30.412 30.153 28.645 24.656 28.391
31.359 29.163 32.475 31.286 30.743 28.491 31.175
25.838 24.784 30.109 24.256 26.135 26.835 26.337
25.636 26.019 29.610 25.430 26.899 26.759 26.952
29.569 26.141 32.398 30.284 30.066 26.247 28.779
30.031 28.914 33.195 30.356 30.643 30.407 30.068
30.597 40.000 35.704 28.944 31.612 30.482 40.000
29.628 28.643 40.000 31.705 30.831 29.154 29.816
29.427 25.144 32.556 29.789 30.113 27.465 29.029
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ERpos01.06.006ERpos01.08.034ERpos01.08.115ERpos01.08.128ERpos01.08.146ERpos01.09.017ERpos02TB004
23.481 24.172 24.466 24.310 24.799 25.113 27.660
28.205 28.489 28.795 28.288 29.305 28.146 31.394
26.118 25.605 27.551 27.058 27.201 26.521 28.055
27.360 28.242 28.595 28.114 28.190 27.966 30.627
32.276 32.538 33.982 33.186 32.873 33.252 37.150
23.855 25.285 25.536 25.363 24.935 25.910 28.478
26.531 26.355 26.878 26.682 27.043 26.026 29.041
28.559 30.253 30.073 29.852 31.504 32.025 33.228
28.493 29.010 30.414 30.776 30.140 32.261 34.142
26.966 27.209 28.153 27.673 27.343 27.832 30.102
31.013 32.529 29.541 30.017 32.471 34.662 33.517
31.820 33.290 30.211 31.954 35.491 35.637 34.050
26.335 27.567 27.600 27.294 27.419 27.174 30.612
25.900 27.448 27.478 27.127 27.150 26.931 29.712
28.962 30.440 31.374 31.419 29.428 30.821 32.570
30.323 30.940 32.372 32.657 31.365 33.098 40.000
27.899 28.174 29.337 29.235 28.795 28.673 30.657
40.000 40.000 40.000 34.223 33.638 40.000 40.000
25.970 26.340 26.293 25.968 26.183 26.204 28.371
22.771 23.499 23.441 22.576 23.149 23.508 26.147
26.793 26.942 27.679 26.725 27.065 27.289 29.393
29.955 30.900 31.126 30.971 30.872 30.811 32.857
27.061 27.347 26.876 26.414 27.406 27.241 30.086
34.994 35.045 32.857 33.310 40.000 34.487 35.993
30.655 31.638 32.790 32.843 31.254 33.205 34.759
23.484 21.761 23.867 25.415 21.944 24.884 28.342
27.439 28.571 27.552 28.083 28.471 28.093 30.587
31.379 40.000 32.021 32.060 40.000 32.534 35.189
27.903 28.060 28.539 28.604 28.119 29.032 30.770
28.083 28.822 29.172 28.728 28.763 29.292 29.648
26.520 26.886 27.742 27.472 27.341 28.430 29.836
29.937 29.482 29.995 29.862 31.769 30.973 33.749
25.451 25.987 26.153 25.895 26.194 26.629 26.440
31.968 35.258 31.714 32.860 34.446 22.398 33.914
40.000 40.000 40.000 40.000 20.518 37.431 23.963
26.892 27.354 28.026 27.590 27.630 27.194 30.609
29.860 29.304 31.344 30.567 30.217 31.370 33.635
21.219 22.992 24.674 26.121 22.224 20.926 26.856
25.847 25.495 26.776 26.592 26.288 25.787 28.899
30.312 30.087 31.170 30.692 31.066 31.662 34.152
27.641 27.959 28.703 27.970 28.151 28.354 29.599
26.510 27.570 27.775 27.493 27.721 28.000 29.566
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23.870 24.869 25.825 25.641 24.939 25.122 27.471
26.475 27.371 28.613 27.991 28.515 28.791 30.337
25.529 25.686 27.046 26.513 26.606 26.628 28.679
27.439 28.044 29.058 28.579 28.881 29.447 31.522
23.319 24.368 24.650 24.273 24.743 24.525 27.029
28.766 30.004 30.247 29.924 29.883 30.041 32.307
26.004 27.154 27.745 27.446 27.223 26.807 29.954
28.142 28.741 29.386 29.058 29.301 29.954 32.317
24.414 24.815 25.593 25.200 25.330 25.915 27.926
31.455 32.385 33.017 33.669 32.206 35.680 34.775
29.726 33.311 30.460 30.328 30.504 30.041 32.736
27.250 27.486 28.400 27.971 27.767 28.149 31.429
28.543 28.836 29.401 29.241 29.227 28.884 32.234
25.594 27.688 26.717 25.500 26.479 27.663 28.669
26.377 27.289 27.754 26.845 28.143 27.492 28.419
34.194 34.687 35.788 35.908 34.730 34.487 32.139
29.496 28.910 28.919 28.266 40.000 28.840 31.540
25.474 25.525 26.689 26.334 25.903 26.893 28.384
28.128 29.199 28.942 29.212 29.204 29.648 32.022
27.862 29.100 29.450 28.834 29.156 29.330 32.286
33.261 35.114 38.143 40.000 36.458 34.918 40.000
22.683 23.228 23.030 22.510 23.897 23.806 26.103
23.195 24.774 23.831 23.557 25.097 25.838 27.924
27.607 27.099 28.930 28.694 28.101 28.173 31.377
27.875 28.918 28.911 28.404 28.797 28.728 31.659
28.590 29.086 29.287 29.032 29.283 29.639 31.755
29.465 30.695 30.119 29.818 30.194 30.410 31.560
31.702 31.479 31.302 31.087 31.493 31.934 34.515
26.042 26.754 27.312 27.090 26.522 26.652 30.794
29.012 28.746 29.480 29.223 29.875 30.094 30.281
25.636 25.817 27.593 27.502 26.617 29.120 30.264
21.976 22.980 23.654 23.585 23.212 23.035 26.056
29.956 35.431 31.670 31.534 30.387 33.343 40.000
27.024 27.560 28.204 28.058 27.030 28.143 31.610
27.331 28.188 29.154 28.510 28.081 29.067 30.879
29.510 29.826 31.425 30.907 29.920 31.299 33.018
29.954 31.595 30.300 29.506 31.037 30.289 33.078
28.436 30.207 29.452 29.071 29.570 30.156 32.644
29.172 29.541 29.471 28.360 30.030 28.702 31.409
27.168 28.536 29.309 28.970 28.572 28.512 31.164
25.443 26.823 26.288 25.875 27.245 28.156 27.535
27.117 27.842 28.163 27.780 27.771 27.666 30.321
28.339 28.491 29.422 29.394 28.648 28.675 31.705
26.907 27.129 27.708 27.534 28.135 27.025 29.773
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28.322 28.568 29.168 28.591 28.454 28.843 31.364
26.999 27.178 28.102 27.363 27.714 28.076 30.465
27.726 27.699 28.762 28.474 28.065 27.632 31.125
30.828 28.125 27.640 27.774 27.991 32.801 36.553
28.913 29.101 29.369 29.614 29.006 29.137 31.517
26.059 26.352 26.817 26.699 26.969 26.302 28.896
27.221 28.702 28.588 27.820 28.352 27.745 31.039
30.091 29.923 31.112 30.873 30.448 30.505 32.397
27.790 28.149 28.529 28.220 28.651 28.822 30.308
25.882 26.688 27.058 26.543 25.440 27.359 29.551
22.852 25.094 26.773 26.530 24.014 25.966 25.820
27.094 27.416 28.166 27.961 27.273 26.997 30.424
26.636 26.247 27.203 26.727 26.760 26.396 28.634
27.916 27.014 28.887 28.270 28.302 27.268 31.422
27.404 26.612 28.292 28.029 27.189 27.150 30.200
28.858 30.018 29.214 29.055 29.428 30.094 32.510
27.447 27.487 28.821 28.504 27.801 28.493 30.358
27.966 27.790 29.127 28.847 28.501 29.325 31.459
29.566 30.376 30.084 29.351 30.666 30.587 33.123
25.850 26.281 27.495 27.342 27.813 27.169 29.271
26.825 27.291 27.200 26.697 27.426 26.895 29.070
29.621 29.912 30.543 29.870 30.275 29.064 32.578
24.459 25.303 26.147 25.273 25.621 25.658 28.672
28.351 29.211 29.814 29.973 29.396 29.868 32.545
30.380 31.649 31.174 30.229 31.560 32.037 29.284
30.006 31.173 32.650 31.487 30.652 33.065 31.421
32.598 33.180 32.268 32.068 33.002 34.546 33.642
27.937 28.387 28.700 28.478 28.918 28.708 30.991
27.233 28.528 28.342 28.595 27.939 28.910 29.604
34.546 28.170 40.000 40.000 34.939 40.000 40.000
26.865 27.677 28.864 29.259 27.753 28.109 32.790
27.587 28.465 28.849 28.794 28.889 28.818 32.014
26.910 28.283 29.145 28.986 28.770 28.487 30.685
28.975 29.567 29.569 29.123 30.307 29.765 31.651
26.842 27.962 28.502 28.491 28.316 27.765 30.073
23.909 24.963 25.049 24.502 24.865 24.754 27.660
27.842 28.183 28.637 28.191 28.296 27.530 30.622
28.171 28.259 29.300 28.637 29.761 28.739 31.570
25.439 26.462 27.212 26.676 27.294 27.358 28.181
27.945 28.321 29.243 28.231 29.344 29.947 31.371
30.885 31.881 32.577 32.611 32.371 33.613 31.080
29.762 30.562 29.699 29.285 30.287 29.951 32.066
29.548 29.661 30.375 29.884 31.185 30.239 31.837
27.412 28.841 28.934 28.746 28.449 28.909 28.944
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33.847 33.590 40.000 33.292 34.322 34.962 36.437
31.877 32.583 30.999 30.869 31.416 31.830 33.469
29.435 29.401 30.191 29.855 29.490 29.687 32.394
26.614 40.000 31.778 40.000 25.687 29.625 40.000
29.221 30.513 29.912 30.674 29.263 30.293 33.154
29.437 29.975 30.464 30.238 29.803 29.429 33.746
26.085 27.054 26.867 26.612 27.164 26.850 29.433
31.803 31.847 31.086 30.839 32.978 32.868 35.718
28.341 28.175 29.649 29.762 28.565 28.482 31.479
31.505 31.279 31.282 30.907 31.547 31.115 34.338
26.186 26.874 27.317 27.053 26.671 27.476 30.203
29.739 29.987 31.233 31.273 29.415 40.000 40.000
26.794 27.246 27.677 27.504 27.454 26.954 30.314
27.269 27.989 27.988 27.999 27.760 27.643 31.047
25.792 26.247 26.805 27.297 26.053 25.818 29.453
28.736 31.081 32.051 29.801 30.892 31.872 30.336
28.023 30.797 29.239 29.549 29.189 30.113 31.584
18.306 20.340 20.809 20.304 20.811 20.489 23.250
24.101 25.931 25.643 25.541 26.029 26.346 28.557
29.621 30.703 30.549 30.075 30.584 30.807 32.504
27.793 27.994 28.867 28.499 28.492 28.037 30.820
24.912 25.989 26.304 25.816 26.287 26.249 29.661
27.078 27.142 28.169 27.674 27.561 27.032 30.718
26.559 27.563 28.440 27.942 28.463 27.909 31.551
26.732 26.634 28.243 27.534 27.491 27.428 30.171
26.527 26.309 27.900 27.545 27.080 28.025 28.579
26.768 27.788 27.944 27.124 28.222 28.424 30.704
29.931 30.920 30.860 30.359 30.937 31.458 34.170
24.721 24.957 25.542 25.317 24.702 25.329 28.299
26.115 27.273 27.224 27.126 27.322 26.608 29.480
27.964 27.785 29.597 29.171 29.001 29.075 31.463
26.591 26.491 27.895 27.523 27.307 27.873 30.431
24.372 24.548 25.036 24.326 25.340 25.510 25.938
31.342 34.416 34.285 34.564 34.549 34.488 36.569
27.651 28.275 28.715 28.585 28.180 28.393 30.833
29.843 29.391 30.156 29.653 29.791 30.026 28.725
26.707 27.338 27.761 27.599 27.720 27.626 30.193
26.891 26.347 27.620 27.323 27.021 27.951 29.353
27.812 28.227 28.696 28.416 28.083 28.368 30.327
24.765 25.005 25.821 25.837 25.497 25.892 29.006
24.616 25.287 26.215 25.481 25.386 25.508 28.480
26.850 27.500 28.409 28.224 27.541 27.347 31.329
27.275 27.027 28.589 28.160 28.152 28.184 30.053
28.312 30.027 30.230 29.847 29.543 29.942 32.964
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40.000 40.000 32.855 40.000 40.000 34.687 40.000
28.354 29.123 30.035 40.000 28.786 29.512 29.999
25.886 26.240 27.548 27.153 27.409 27.451 29.523
26.313 26.680 27.148 26.527 26.664 27.034 29.438
26.579 27.525 27.815 27.574 27.985 28.028 30.039
27.118 29.230 29.240 28.613 28.689 29.386 32.726
26.552 26.929 27.729 27.676 27.195 27.976 29.293
26.522 27.204 28.128 27.864 27.667 27.974 30.053
27.641 27.156 28.391 29.274 28.484 27.385 29.855
28.520 28.972 29.728 29.055 28.951 28.593 31.694
23.292 23.667 23.732 23.946 23.705 23.649 27.355
26.780 27.245 27.280 27.518 27.628 27.785 30.857
40.000 15.393 40.000 22.918 40.000 40.000 16.706
25.736 26.725 27.196 26.802 27.501 26.320 29.435
25.146 26.167 26.154 25.672 25.654 25.065 27.977
28.065 27.923 29.846 30.027 30.112 30.515 30.714
25.517 26.569 27.347 26.791 26.955 26.710 28.112
26.604 26.806 27.300 27.229 27.240 26.486 29.788
26.058 27.818 27.122 26.287 27.893 28.121 30.134
29.753 30.363 30.982 30.555 30.214 30.441 32.735
25.960 26.693 27.725 26.923 27.177 26.722 29.804
25.064 25.201 26.212 25.627 25.252 26.242 28.150
27.292 27.746 28.901 28.390 27.438 28.125 30.914
25.127 26.600 26.927 26.445 26.543 26.177 29.862
27.326 27.708 28.443 28.191 28.043 28.744 31.810
25.125 35.137 37.406 26.318 40.000 40.000 36.546
28.218 29.134 29.226 28.944 29.152 28.841 26.840
30.495 29.454 28.796 27.155 29.672 28.444 31.531
25.611 25.963 26.814 26.368 27.221 26.261 29.503
28.631 28.480 29.808 29.055 28.801 29.232 32.504
27.555 28.481 28.791 28.745 28.670 28.541 31.185
26.749 27.628 28.026 27.797 28.143 28.299 29.217
28.027 27.955 29.675 29.504 28.710 29.414 31.505
24.150 24.668 25.565 24.833 24.654 25.233 28.466
28.249 28.812 28.733 28.571 28.410 29.062 30.914
27.369 27.595 29.104 28.645 28.223 28.097 40.000
27.057 27.311 28.107 27.438 27.406 26.874 29.866
28.911 29.274 30.817 30.705 29.266 31.645 32.011
28.751 29.275 30.078 29.432 29.321 28.648 32.806
27.322 28.608 28.162 28.255 27.814 27.830 30.886
26.946 26.977 27.802 27.736 27.199 27.654 29.226
28.494 27.799 29.438 28.708 28.149 28.939 29.905
26.518 26.704 28.454 27.639 26.921 28.279 30.657
28.279 28.478 29.441 29.252 30.544 30.042 32.055
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27.327 28.102 28.499 28.206 28.040 28.162 31.039
25.178 24.904 26.414 25.843 25.779 26.232 28.651
29.781 29.321 31.077 30.507 30.083 31.586 30.333
26.550 26.225 27.719 27.333 27.292 26.700 30.293
27.300 26.638 28.484 27.750 26.543 27.000 30.299
27.605 28.708 28.940 28.637 29.218 29.080 30.941
27.870 28.643 29.190 29.030 28.602 28.441 32.218
26.612 26.946 27.658 26.933 27.658 26.922 29.371
26.262 26.588 28.586 27.571 25.671 28.692 30.289
27.966 28.142 29.165 28.836 29.258 29.564 31.658
24.617 25.440 26.215 25.420 25.685 25.403 28.387
27.357 28.422 28.685 27.805 28.538 28.920 31.104
30.152 30.323 29.946 29.490 30.795 29.238 32.212
25.356 25.029 26.773 26.376 26.117 25.810 27.910
26.119 26.134 26.807 26.906 26.190 26.577 28.028
28.718 29.702 29.539 28.617 29.631 28.815 31.157
29.767 29.828 30.827 30.485 30.163 30.019 31.988
30.259 31.476 31.804 31.559 31.498 30.831 29.440
29.260 29.023 30.319 29.750 29.933 29.758 32.212
27.986 29.024 28.983 29.656 28.730 28.671 31.260
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ERpos02TB15ERpos05.08.033ERpos05.08.083ERpos05.08.099ERpos05.09.026ERpos05RMH329ERpos06RMH385
25.359 26.317 25.144 25.986 25.108 25.203 24.115
28.932 29.805 29.546 29.729 29.496 28.857 28.598
28.855 29.005 27.304 28.146 28.093 29.207 28.099
29.725 30.041 29.414 29.482 27.050 30.370 28.833
33.129 33.701 34.261 33.178 34.497 33.924 34.221
25.664 26.805 26.403 26.045 26.422 26.014 25.285
26.797 28.199 26.938 26.958 27.913 27.028 26.306
30.419 32.714 32.321 31.881 31.656 31.036 30.449
30.409 30.903 30.522 31.503 31.089 31.080 30.536
28.254 28.909 28.037 28.115 28.620 28.513 28.109
35.006 33.935 34.068 34.546 32.988 32.013 31.065
34.105 40.000 31.845 32.821 31.927 30.940 32.335
28.630 28.627 27.033 27.985 28.332 28.396 27.616
27.856 28.190 27.172 28.233 27.681 27.208 27.004
31.441 31.504 31.740 40.000 33.496 31.563 40.000
33.239 33.437 32.462 31.843 31.745 32.353 33.047
28.967 29.845 29.423 28.976 30.028 29.869 28.613
40.000 33.881 17.687 40.000 40.000 32.981 40.000
26.641 28.217 28.293 27.277 28.439 26.762 26.311
24.510 24.769 21.772 23.636 23.833 24.705 23.747
28.552 29.249 27.091 26.779 28.013 28.556 27.941
31.320 40.000 31.174 32.227 32.130 32.016 31.710
29.178 29.725 29.123 28.785 28.984 26.212 27.064
35.808 38.005 36.542 37.557 39.021 34.138 34.127
33.489 31.970 31.294 30.631 31.706 32.876 31.842
24.789 25.376 25.201 23.949 26.158 25.555 25.353
28.381 29.385 28.871 29.176 28.232 27.724 27.954
34.019 33.744 32.819 35.156 32.855 32.741 32.760
29.772 29.024 28.742 28.893 27.646 28.804 28.739
29.825 29.911 29.170 29.731 30.331 29.878 28.710
28.106 29.799 28.617 28.471 28.369 28.646 28.121
30.899 34.189 32.751 33.002 31.652 30.141 31.196
26.394 26.934 25.408 26.928 26.824 26.461 25.812
31.456 25.351 35.149 34.352 30.864 32.087 31.522
24.424 36.592 36.488 31.595 24.976 36.401 40.000
28.701 29.626 27.627 28.975 28.971 29.872 28.123
31.503 31.171 30.488 29.694 30.914 31.106 30.227
28.295 24.491 23.013 24.350 23.409 25.584 22.823
27.677 27.868 27.166 27.227 27.761 27.153 26.549
31.388 32.885 31.890 31.922 30.985 31.878 31.047
29.602 29.473 29.213 28.440 28.547 29.232 28.011
27.959 28.884 28.226 28.653 28.350 27.532 27.703
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26.057 25.492 24.680 25.699 25.905 26.118 25.146
28.495 29.428 28.696 29.025 28.865 29.186 28.063
25.918 27.388 27.415 27.114 28.247 27.345 26.524
29.575 29.775 29.508 29.202 29.007 29.678 28.906
24.478 25.389 25.136 25.934 26.055 25.078 23.709
30.000 30.107 29.300 30.231 30.799 29.705 29.080
29.161 28.772 27.666 28.080 28.167 29.375 28.445
29.552 30.127 29.396 30.201 29.645 29.957 28.967
25.988 26.785 25.071 25.457 25.505 25.848 25.267
31.876 34.208 35.371 32.649 40.000 34.542 32.244
31.572 31.479 31.133 31.095 31.280 30.310 30.268
29.335 29.867 29.304 28.944 29.452 29.956 29.063
29.729 30.324 29.717 29.736 29.988 29.990 29.170
27.478 28.966 27.294 28.709 29.487 27.122 27.471
28.201 28.939 27.994 28.536 28.272 27.423 27.674
27.158 28.224 26.829 34.661 35.155 34.881 35.595
31.528 31.916 30.391 30.940 30.456 29.424 29.388
27.335 27.176 26.179 27.144 26.933 26.848 25.752
29.212 30.019 27.638 28.483 29.250 29.074 28.268
29.544 30.785 29.668 29.149 30.173 30.094 29.192
40.000 40.000 40.000 35.012 40.000 34.868 38.267
24.127 23.907 22.642 23.739 24.399 24.560 22.560
25.780 27.460 26.511 26.302 26.233 24.314 24.192
29.019 29.689 28.541 28.816 29.258 29.952 28.959
30.048 30.801 28.335 28.681 29.621 31.054 29.448
29.734 30.605 29.558 30.035 30.534 29.845 29.102
31.197 30.828 30.869 31.231 31.407 30.565 29.393
30.820 33.428 33.639 32.433 33.526 32.622 31.978
29.704 29.008 28.013 28.667 29.074 29.094 28.386
30.808 29.802 29.942 30.619 30.057 31.224 29.838
28.272 27.123 26.405 25.799 27.634 27.641 27.359
24.337 24.184 23.825 24.273 24.657 24.751 23.720
29.569 35.877 40.000 33.733 34.288 32.673 32.215
29.094 29.929 27.510 28.877 29.294 28.981 28.322
30.267 29.827 28.472 29.087 29.471 30.129 28.593
31.347 31.041 30.846 30.588 31.672 31.416 30.639
31.479 32.844 31.120 30.674 31.637 31.403 30.943
30.534 32.033 30.207 31.113 31.179 30.727 30.107
30.997 31.977 30.431 30.969 30.878 29.147 29.008
29.425 29.501 29.153 29.544 29.389 29.543 28.456
26.686 27.593 26.537 26.710 27.010 27.215 26.081
29.218 29.483 27.960 28.568 28.621 29.147 28.301
31.010 30.455 30.419 29.801 30.944 30.674 30.708
28.259 28.608 28.477 28.550 28.897 28.544 27.639
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30.159 30.066 29.471 30.157 29.906 30.225 29.549
28.969 28.918 28.031 28.755 29.091 28.827 28.146
29.438 29.665 29.134 29.098 29.507 29.496 28.722
31.728 29.779 29.716 30.905 30.439 31.759 31.214
29.661 30.315 29.207 29.551 30.418 29.812 28.556
26.723 27.796 27.139 27.262 27.336 26.989 26.309
29.230 29.297 28.567 28.980 29.230 29.364 28.123
30.812 31.803 30.634 31.386 30.555 31.178 30.784
28.524 29.432 28.443 29.526 29.955 28.401 27.131
28.005 28.617 28.074 27.720 27.611 27.874 27.180
25.941 27.289 23.482 28.683 24.583 25.854 24.795
28.637 28.959 29.192 28.744 28.484 29.232 27.813
27.993 29.777 28.268 28.552 28.152 26.986 26.534
29.859 28.795 28.986 27.924 29.214 29.690 28.627
29.315 29.212 28.395 28.253 28.615 28.761 27.883
31.203 31.441 30.275 30.815 30.370 29.867 31.130
28.829 29.518 28.863 29.015 29.119 29.229 28.198
29.629 29.325 28.950 29.510 29.095 29.563 29.117
31.337 32.398 30.976 30.186 31.570 31.134 30.001
27.368 30.434 28.152 28.608 28.701 28.101 27.688
27.511 29.273 27.443 28.403 28.686 27.509 27.189
32.146 31.403 30.566 32.189 31.653 31.121 30.803
26.287 26.408 25.658 26.298 26.368 27.348 26.296
30.424 30.382 30.230 28.403 30.941 31.113 29.444
32.989 32.274 31.325 32.049 32.214 31.292 31.012
33.375 32.323 33.182 33.626 32.504 32.521 31.851
40.000 34.040 40.000 40.000 40.000 40.000 32.082
29.330 29.934 28.511 29.393 29.896 29.614 28.662
29.341 29.265 29.272 28.895 29.282 29.982 28.673
40.000 29.201 28.417 37.539 28.303 28.817 38.240
29.890 29.005 30.006 28.071 30.607 29.652 28.668
28.944 29.687 29.335 29.766 29.626 29.079 28.652
29.804 29.138 28.616 29.353 29.372 30.021 29.219
29.807 31.682 29.816 31.278 30.171 29.736 29.784
29.167 29.807 28.716 28.840 29.007 29.863 28.933
26.664 26.365 25.154 25.548 25.416 26.191 25.221
29.143 30.209 29.197 29.359 29.262 29.644 28.726
29.870 30.667 30.120 29.396 30.462 30.166 29.582
27.931 28.852 27.307 28.263 28.241 28.342 27.028
29.082 30.150 30.028 29.935 29.792 28.837 28.355
32.849 34.173 31.423 32.660 32.103 33.357 31.786
31.011 32.544 30.824 31.994 31.129 29.542 29.121
30.786 31.835 29.943 31.932 31.227 31.013 29.398
28.258 29.385 29.334 29.625 28.705 29.300 28.154
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40.000 38.524 35.494 34.802 34.889 34.074 33.551
33.396 32.771 32.256 32.347 32.594 31.851 30.707
30.807 30.875 30.988 30.894 29.302 30.975 29.514
28.734 37.233 31.279 25.308 40.000 31.286 28.535
31.488 32.116 30.958 31.087 30.071 30.352 30.586
30.164 30.606 30.322 31.460 30.144 31.171 30.327
28.081 28.814 28.035 27.621 26.130 27.825 26.823
31.911 35.412 33.294 35.491 40.000 33.916 33.198
29.319 29.593 29.531 30.323 29.930 29.416 28.982
40.000 40.000 33.320 32.231 33.643 33.135 32.063
28.039 28.257 26.948 27.975 27.661 27.805 27.267
31.874 30.980 40.000 30.407 32.217 31.759 40.000
29.001 28.033 27.732 28.534 27.727 28.534 28.228
29.615 29.421 28.007 29.193 26.555 29.422 28.638
27.952 27.769 27.569 27.401 27.780 28.430 28.232
30.314 31.717 31.072 33.651 31.337 30.991 30.010
29.640 31.678 29.435 30.139 29.914 29.516 30.298
21.645 20.792 20.756 20.637 20.863 21.701 21.093
26.010 26.961 24.811 26.324 26.102 26.256 25.291
31.007 31.818 31.058 30.761 31.443 30.878 30.647
28.696 30.049 29.525 28.946 29.227 28.318 27.978
27.191 27.631 26.804 26.818 26.771 27.388 26.689
28.978 29.175 27.368 28.857 27.982 29.128 28.431
29.536 30.599 28.821 29.362 29.013 29.387 29.234
28.178 28.524 28.086 28.207 28.443 28.783 27.816
27.986 28.067 27.807 27.936 28.291 27.776 27.144
28.853 30.146 29.066 28.731 29.688 29.918 28.396
32.222 32.291 31.985 31.620 31.329 32.487 31.462
26.902 27.101 25.600 26.371 26.934 26.494 25.790
26.686 28.216 29.015 27.886 28.807 27.846 27.084
29.786 29.901 29.249 29.982 29.639 30.324 29.554
28.311 29.152 28.360 28.566 27.999 28.581 27.858
25.497 25.027 24.395 24.036 25.629 25.458 23.868
32.476 34.750 34.051 33.378 34.169 32.773 33.297
28.511 29.879 29.218 28.992 29.556 29.244 28.163
29.417 30.118 29.042 28.021 30.444 28.911 29.260
28.383 29.089 27.570 28.140 28.701 28.765 28.248
28.336 27.829 27.151 28.393 27.238 27.919 27.305
29.126 29.527 28.557 29.097 29.295 28.602 28.146
25.864 26.921 26.566 26.330 27.110 26.020 25.478
26.524 26.611 26.180 26.268 26.397 26.806 25.543
30.111 30.336 28.806 28.678 29.483 30.421 29.380
29.116 30.407 28.511 28.395 29.752 28.782 28.153
31.610 30.935 30.410 30.812 30.815 31.758 30.895
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40.000 40.000 35.847 40.000 40.000 30.480 32.857
29.560 31.898 30.931 29.613 31.811 30.293 28.987
27.284 28.787 28.633 27.800 29.096 27.972 26.904
27.740 28.388 26.597 26.146 27.441 28.437 27.464
28.800 29.266 28.177 28.683 28.384 28.735 28.188
30.198 32.646 31.626 32.096 30.275 30.222 29.547
28.370 28.093 29.036 28.231 28.738 28.440 27.993
28.035 29.012 27.818 28.947 28.357 28.019 28.038
28.650 27.936 27.634 27.928 27.503 28.145 27.171
29.523 30.521 30.100 28.999 30.091 30.173 29.064
24.998 24.383 23.192 24.789 24.547 24.832 24.288
28.904 28.793 27.311 28.497 28.401 28.918 28.278
23.161 21.875 22.570 40.000 40.000 40.000 20.443
27.745 27.920 27.069 27.245 27.684 27.474 25.694
26.497 27.191 26.507 27.323 27.745 26.840 26.500
30.928 30.834 30.147 31.260 28.484 30.134 29.335
27.150 27.923 27.685 27.118 27.985 27.319 26.862
27.869 28.430 28.462 28.293 28.577 27.988 27.117
28.229 29.607 28.792 27.960 29.548 28.628 26.665
31.108 30.836 32.163 30.993 32.506 31.051 30.742
28.148 28.666 27.370 28.700 28.035 28.147 27.424
26.978 27.441 26.618 26.801 26.773 26.483 26.438
29.164 28.914 28.816 29.109 29.602 29.202 26.796
27.425 27.443 27.742 27.440 27.866 27.768 25.897
28.974 29.965 29.681 28.753 29.966 29.174 28.412
40.000 28.290 26.253 38.022 40.000 28.556 37.464
30.621 29.654 28.900 29.952 29.442 29.383 28.645
31.934 32.153 31.234 31.243 32.208 31.450 30.253
28.275 27.867 26.014 26.385 27.760 28.362 26.968
30.260 30.552 29.976 28.137 29.948 29.699 29.155
29.478 29.926 29.181 29.470 29.306 29.245 28.691
28.634 29.188 28.248 30.169 28.116 28.408 27.920
30.064 30.110 29.957 29.718 29.543 30.695 29.401
26.731 25.410 26.102 25.277 26.015 27.039 25.807
30.053 31.374 28.268 28.641 30.016 29.527 28.986
29.288 29.669 28.610 29.967 28.972 29.794 29.546
28.005 28.872 28.884 29.678 28.673 27.814 27.605
32.806 30.445 30.038 28.809 30.776 31.564 30.389
30.412 30.888 29.576 30.917 30.163 30.845 30.086
29.706 30.283 28.599 31.398 30.968 29.057 28.717
27.550 28.600 28.729 27.733 28.205 27.467 27.111
29.125 30.652 29.281 29.017 30.087 28.551 27.837
27.766 28.002 28.028 28.089 28.238 28.366 27.737
29.768 30.503 29.859 28.755 30.576 30.021 28.898
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29.494 29.365 28.920 28.468 28.758 30.043 28.995
27.479 26.666 25.959 26.810 26.194 27.145 26.115
30.344 30.608 31.673 31.071 31.794 31.185 30.004
28.504 29.441 27.404 27.875 28.313 29.353 27.902
28.032 28.459 28.490 26.931 28.873 28.070 26.968
28.783 29.851 28.320 29.564 29.624 29.723 28.541
29.577 30.242 29.089 29.711 29.714 29.954 29.167
28.265 28.545 27.252 28.421 28.172 28.159 27.316
30.414 29.144 29.668 26.726 26.445 28.700 28.038
29.338 29.613 29.971 28.937 29.701 29.461 28.755
26.947 26.840 26.526 26.335 26.129 27.500 26.149
29.365 29.400 29.111 28.892 29.424 29.886 29.204
31.578 32.152 31.667 31.881 31.982 29.990 29.666
26.255 26.069 26.437 25.895 27.155 26.095 25.991
26.256 27.652 27.135 27.320 27.222 26.601 25.642
30.520 31.714 29.517 30.292 30.535 28.913 28.914
31.490 31.617 30.881 30.715 31.084 31.041 30.324
31.958 32.573 31.860 31.899 32.103 31.535 30.775
30.323 31.687 30.529 31.347 31.271 31.150 29.641
29.627 29.143 29.940 28.944 30.300 29.448 29.251
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ERpos06RMH431ERpos06RMH432ERpos06RMH500ERpos07AH465ERpos07RMH004ERpos07RMH008ERpos07RMH028
25.661 24.294 24.435 26.172 23.297 24.005 26.553
29.486 28.929 28.777 29.800 27.983 28.301 31.951
28.792 28.112 28.300 30.479 26.745 28.084 32.461
29.828 28.758 30.024 30.639 27.802 28.788 40.000
33.797 40.000 34.797 35.382 33.608 34.332 38.734
26.264 25.173 25.772 26.733 24.180 25.350 30.163
27.309 26.232 26.254 28.117 25.433 26.591 28.237
31.306 30.195 30.487 31.634 29.665 31.671 32.409
30.767 30.167 30.164 31.892 29.876 40.000 40.000
29.041 28.084 28.597 29.199 26.766 27.912 31.056
30.510 28.738 32.737 34.697 30.771 31.835 33.859
32.176 31.134 34.246 35.319 31.614 32.025 32.506
28.964 27.549 27.012 29.382 26.597 28.136 31.394
28.303 26.913 26.815 28.786 25.799 26.845 29.238
32.580 31.239 40.000 40.000 29.756 29.666 40.000
33.384 32.742 33.665 34.422 31.566 31.449 36.405
29.238 28.257 28.833 30.111 27.187 27.887 32.514
40.000 40.000 24.970 40.000 40.000 40.000 40.000
26.935 26.227 26.971 27.181 24.588 26.101 30.335
25.436 23.377 23.145 25.535 23.115 23.356 29.523
28.877 27.365 28.274 29.638 26.604 26.967 30.341
31.611 30.661 31.759 32.014 30.121 31.018 40.000
28.450 27.187 28.947 28.029 23.786 27.147 29.387
36.388 34.363 37.279 36.086 33.586 33.935 40.000
34.378 32.381 33.685 38.267 32.086 30.235 34.755
27.234 25.582 23.989 28.162 23.672 24.606 26.205
28.689 28.163 28.162 29.456 27.489 28.324 28.931
34.591 40.000 33.037 40.000 32.579 31.212 34.089
30.024 29.007 29.947 30.453 28.463 26.771 31.478
30.731 28.677 28.344 30.783 27.770 28.674 33.033
28.192 27.448 28.220 29.474 26.588 27.866 33.503
31.531 30.516 31.907 32.967 29.333 31.316 30.589
27.466 26.263 25.682 27.027 25.483 26.304 28.700
33.144 31.058 33.651 40.000 33.211 32.102 33.107
40.000 40.000 40.000 26.451 39.163 40.000 25.310
28.840 27.270 28.094 29.724 26.676 28.280 33.040
31.439 30.132 30.874 32.023 29.463 30.612 33.730
25.341 23.532 24.070 26.238 24.680 22.056 26.316
27.281 26.666 27.854 28.053 25.306 26.945 30.199
33.038 30.751 31.212 32.589 30.627 31.168 33.783
29.239 27.166 28.951 29.939 27.272 28.892 30.359
28.831 27.373 27.180 28.782 26.413 26.742 29.522
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26.050 24.846 24.980 26.498 24.500 25.135 28.317
29.550 28.141 28.586 30.062 27.437 27.544 32.213
26.532 25.590 26.532 27.185 25.474 26.747 30.145
29.785 28.297 29.361 30.933 27.884 29.494 38.299
25.291 23.756 24.390 25.555 22.966 24.390 27.938
30.671 29.852 29.346 30.156 28.752 29.073 30.640
29.238 27.711 28.620 30.323 27.006 28.347 33.720
30.044 28.894 29.326 30.396 27.994 29.291 32.874
26.451 24.437 24.981 26.855 24.196 24.990 28.747
32.792 32.581 32.348 33.582 31.353 31.809 34.444
31.886 30.235 30.238 31.847 29.459 30.812 32.156
29.736 28.302 29.530 31.156 27.526 28.952 33.295
30.163 28.833 29.924 30.514 28.088 29.615 31.762
28.072 25.844 24.895 30.047 25.813 28.528 30.170
27.546 26.371 27.244 28.250 25.940 26.644 30.117
36.023 35.500 34.867 35.090 34.909 34.746 31.639
30.371 29.181 31.666 31.511 27.906 29.076 32.927
26.967 26.025 26.441 26.889 24.598 25.659 30.964
30.119 29.005 28.096 29.780 28.520 28.194 29.387
30.024 28.938 29.613 30.754 28.186 29.289 34.255
40.000 34.346 33.741 40.000 35.339 37.057 36.784
24.326 21.975 23.194 25.698 22.085 23.590 27.133
25.247 24.575 25.906 26.030 22.344 25.248 26.764
29.796 28.983 29.326 30.194 27.550 29.209 33.236
30.886 28.446 30.640 31.694 27.929 28.539 40.000
30.247 29.371 29.282 30.564 28.263 29.530 32.315
30.051 29.939 30.551 30.885 29.027 30.499 32.943
32.706 31.508 33.173 32.609 31.554 31.639 32.839
28.868 27.261 28.990 30.105 26.124 27.052 35.936
31.166 30.622 30.947 31.692 29.026 29.477 33.497
28.722 28.005 27.540 30.359 26.397 26.732 28.881
24.440 23.422 24.354 25.242 22.639 23.892 31.434
32.891 31.400 33.355 34.119 40.000 31.418 33.997
29.606 28.392 27.966 30.312 27.561 28.489 32.115
30.138 28.407 29.578 31.137 27.857 28.657 33.782
31.622 29.477 30.623 32.428 28.909 30.073 34.583
31.832 30.588 31.579 32.043 29.552 31.340 34.443
31.014 29.598 30.497 30.959 28.771 30.448 34.652
29.815 28.995 30.367 29.630 27.697 28.963 31.253
29.469 28.251 28.898 30.481 27.525 28.896 32.189
27.818 25.551 26.327 28.240 25.376 27.267 29.765
29.035 27.730 28.706 30.069 27.338 27.871 32.563
30.872 29.708 30.746 32.025 28.698 29.667 35.767
28.528 27.579 28.137 29.413 26.762 27.544 30.166
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30.463 29.042 30.318 31.018 28.162 29.168 33.297
28.940 27.260 28.582 30.014 26.999 27.581 32.249
29.748 28.459 29.026 29.845 26.594 28.451 32.375
31.889 31.190 32.249 33.077 30.881 31.726 33.778
29.910 29.011 29.627 30.722 28.718 29.960 32.365
27.307 26.816 26.976 28.168 25.757 26.085 28.849
28.835 27.547 28.946 29.807 26.934 28.246 33.458
31.030 29.847 30.797 31.344 28.910 30.839 33.276
28.951 27.868 28.278 29.268 27.109 28.940 29.942
28.340 26.630 27.566 28.827 26.244 27.144 31.728
24.670 24.294 24.226 22.961 24.769 24.596 31.909
28.697 27.511 28.862 29.705 26.858 27.223 32.677
27.139 26.187 27.985 27.793 25.781 26.689 31.115
30.066 28.674 29.460 30.426 27.805 29.498 40.000
28.848 27.628 29.359 29.944 27.357 27.207 31.700
32.285 30.513 31.555 33.353 28.322 30.907 33.132
28.861 28.218 29.101 29.719 27.382 27.760 30.501
29.762 29.222 29.639 30.257 28.138 27.561 31.515
31.095 29.942 31.500 32.047 28.270 30.399 40.000
28.527 27.029 27.441 28.643 25.834 26.608 32.640
27.673 27.072 27.859 27.887 26.246 26.716 29.427
31.001 30.111 31.066 31.030 29.174 30.903 36.632
27.248 26.145 26.766 28.080 25.128 26.292 30.431
30.747 29.663 29.692 31.711 28.825 29.955 33.420
32.357 30.841 32.175 32.881 29.578 31.476 33.039
33.952 40.000 32.722 34.095 31.213 32.222 40.000
32.963 31.213 40.000 33.638 31.370 32.435 37.530
29.651 28.082 28.841 30.146 27.350 28.459 32.111
30.476 28.573 29.217 31.370 28.180 28.406 34.029
26.329 33.471 40.000 40.000 33.339 40.000 40.000
29.136 29.951 28.092 30.867 29.707 28.795 30.719
30.235 28.882 28.686 30.277 27.874 28.735 32.608
30.069 28.770 29.757 30.598 28.403 29.323 31.594
30.212 29.120 30.799 31.015 27.993 29.975 40.000
29.572 27.506 29.039 30.076 27.180 27.778 33.629
26.363 24.154 25.293 27.660 23.804 25.135 28.798
29.117 27.746 29.520 30.264 27.174 28.424 34.049
30.186 29.163 29.166 31.246 27.914 28.068 36.338
28.397 26.799 27.751 28.326 26.044 27.486 30.294
30.016 28.400 28.442 29.899 27.984 28.164 28.952
33.733 33.387 32.063 33.662 31.609 32.576 35.964
30.034 28.238 30.426 30.311 27.639 29.660 32.700
30.435 28.789 31.345 31.760 27.362 30.512 36.832
29.710 28.300 28.039 29.791 27.199 29.281 32.304
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34.203 32.253 37.056 34.014 31.789 33.995 35.617
32.812 30.343 30.795 33.257 30.262 32.561 33.763
30.944 29.767 31.395 32.010 29.025 29.955 33.578
35.223 34.950 26.129 33.592 34.154 25.747 40.000
31.645 31.050 30.859 31.588 29.949 29.786 31.173
32.082 29.943 29.956 32.031 29.305 30.022 33.140
28.227 26.513 27.992 28.703 26.497 27.392 29.313
31.868 32.512 34.253 34.359 30.541 31.824 40.000
29.806 29.262 29.230 30.235 28.397 28.886 29.669
33.081 32.531 34.398 40.000 31.621 31.786 40.000
28.683 27.545 27.236 29.218 26.460 27.623 30.886
40.000 30.880 40.000 40.000 29.989 29.891 34.221
29.147 27.278 27.984 29.514 26.942 27.403 31.907
29.915 28.710 28.914 30.497 27.521 29.053 33.193
28.140 26.915 28.111 29.432 26.303 27.157 32.514
31.610 30.292 30.793 31.816 28.886 31.263 33.712
30.432 29.212 28.860 31.570 28.381 30.514 31.986
21.961 20.946 20.561 23.108 18.948 20.956 25.812
26.907 26.137 25.226 28.573 24.951 26.824 27.260
31.286 29.890 30.410 32.031 29.706 30.337 34.099
28.628 28.092 28.476 29.131 27.211 27.894 29.736
27.672 25.932 27.056 28.686 25.636 26.368 32.507
29.268 27.639 29.180 30.419 27.053 27.169 33.627
30.299 28.217 29.402 30.482 27.549 28.625 33.476
28.363 27.420 28.009 29.822 26.871 28.111 30.900
28.175 27.283 27.468 28.399 26.021 24.950 30.073
29.410 27.722 29.328 30.311 27.217 28.106 25.996
32.232 31.378 31.998 32.851 30.175 31.748 40.000
26.867 25.462 25.897 27.829 25.294 25.629 29.274
27.366 26.907 27.512 28.666 25.834 27.425 30.804
29.975 28.624 29.402 31.285 28.257 28.693 35.117
28.233 26.860 28.067 29.244 26.683 26.767 30.690
25.616 23.386 25.185 26.562 23.314 24.783 26.852
32.543 34.606 31.968 34.231 31.973 33.394 34.444
28.977 28.146 28.403 29.497 27.086 27.959 31.993
30.031 29.852 28.148 30.540 28.640 29.593 29.747
28.833 27.745 28.614 29.246 26.715 27.550 32.454
29.570 27.413 27.330 29.216 27.009 28.122 29.192
29.138 28.344 29.227 30.044 27.221 28.341 31.745
26.294 25.568 25.754 27.251 24.762 25.647 27.146
27.080 25.714 26.332 27.804 24.893 25.928 28.358
29.782 28.311 29.801 30.700 26.882 28.758 35.362
29.217 27.972 28.916 29.581 27.206 27.697 33.622
32.029 30.025 31.681 32.433 28.894 30.511 35.740
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34.674 32.340 35.444 32.619 33.383 40.000 40.000
29.797 29.066 29.319 30.957 27.734 28.985 31.363
28.048 26.681 27.578 28.364 25.804 28.022 31.827
28.547 27.044 27.601 28.877 26.716 27.014 31.063
29.123 27.467 28.719 29.756 26.731 27.995 33.572
30.551 28.932 30.886 30.966 29.120 28.945 33.164
28.600 27.436 28.257 29.404 26.380 27.633 32.282
28.411 27.175 27.588 28.805 26.564 28.189 30.498
28.377 26.284 27.179 28.595 27.012 27.975 30.154
29.814 28.679 29.546 30.779 27.796 29.225 33.014
25.424 24.398 24.577 25.922 23.432 24.233 26.939
28.981 27.846 27.948 29.460 26.773 28.216 30.028
40.000 20.668 16.784 40.000 19.858 40.000 40.000
27.905 26.254 26.799 28.811 25.542 27.312 33.000
26.803 25.273 26.458 27.463 24.747 26.687 29.413
31.195 29.140 30.687 32.815 28.796 29.984 32.672
27.490 26.772 27.046 28.180 25.952 26.841 30.037
28.199 27.055 27.863 28.851 26.182 27.136 30.712
27.874 27.022 28.849 29.036 26.764 28.503 30.586
31.375 30.127 31.105 31.513 29.504 29.961 33.769
28.346 26.770 27.732 29.066 26.140 27.789 32.524
27.130 25.438 25.530 27.455 25.039 26.404 29.149
28.918 27.600 29.167 30.076 27.663 27.836 30.971
27.984 26.434 28.055 28.420 25.714 27.458 30.687
29.219 28.409 28.961 30.158 27.943 28.607 30.547
40.000 26.263 40.000 40.000 40.000 40.000 37.597
30.349 27.965 29.841 30.138 27.971 28.267 30.801
31.875 30.720 32.162 31.263 29.856 30.718 33.919
28.345 26.852 27.387 28.825 25.550 27.823 32.316
30.446 29.074 30.509 30.715 28.590 29.342 32.062
29.542 28.029 28.778 30.323 27.337 28.395 32.577
28.790 26.961 28.067 29.708 26.971 27.009 30.710
30.581 29.166 30.163 31.666 28.417 29.968 34.654
26.754 25.153 25.686 28.346 24.454 25.022 29.742
29.655 28.704 29.642 30.159 27.564 28.792 32.829
29.797 28.169 29.500 30.037 27.346 29.010 35.519
28.528 27.263 28.065 28.866 26.099 27.910 32.640
33.100 31.176 31.249 34.829 30.218 29.244 33.782
30.533 29.380 30.591 31.475 28.453 29.826 35.570
29.013 27.556 28.321 28.955 27.057 28.205 32.830
27.616 26.666 27.458 28.102 25.981 26.825 29.466
29.210 28.498 28.390 29.060 27.245 27.914 28.171
28.677 27.891 27.420 29.659 27.274 28.314 29.151
29.930 28.396 29.295 31.123 28.371 28.936 32.242
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29.561 27.624 29.655 30.733 27.270 28.186 34.726
27.469 25.893 27.257 28.347 24.997 25.855 31.774
31.636 30.649 30.523 32.503 30.481 30.098 33.781
28.583 26.920 27.844 29.856 25.980 27.982 40.000
28.646 27.219 28.093 28.796 26.546 27.948 29.800
29.023 28.196 28.883 29.739 27.095 28.647 33.194
30.075 29.022 29.453 30.278 27.916 28.602 31.924
28.131 26.208 27.276 29.544 26.103 27.431 32.099
28.162 26.101 27.723 29.014 25.594 28.247 30.963
29.555 28.663 29.368 30.755 28.175 29.151 30.828
27.220 25.156 26.958 28.192 24.615 26.143 31.693
29.803 29.138 28.892 30.444 28.161 28.875 31.728
31.315 31.481 30.977 30.067 28.644 30.209 32.672
26.804 26.556 25.500 27.574 25.548 26.427 28.337
26.486 26.582 26.682 27.091 25.709 26.295 27.164
29.520 28.551 28.670 29.150 27.215 29.316 30.079
30.704 30.583 30.291 31.775 29.524 29.960 32.390
31.955 30.743 31.039 31.934 30.073 30.185 32.844
31.223 29.985 30.036 40.000 29.151 29.278 33.099
30.277 28.450 28.701 30.636 28.168 28.785 32.800
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ERpos07RMH031ERpos07RMH188ERpos07RMH294ERpos07SH484ERpos07WH137ERpos08RMH072ERpos08RMH482
25.196 31.469 24.789 25.060 24.421 20.973 24.041
29.510 40.000 28.491 29.045 28.818 26.271 27.887
29.562 30.708 28.973 27.838 27.619 25.170 25.744
31.347 40.000 30.207 27.871 29.157 25.364 25.666
34.406 40.000 33.813 32.099 33.340 30.876 33.977
25.885 33.633 25.716 25.021 25.579 22.902 24.545
26.686 33.330 26.619 26.891 26.790 24.983 25.974
31.190 33.510 31.255 30.770 31.411 26.159 31.174
31.835 34.573 32.656 30.567 30.626 25.680 28.623
28.480 40.000 27.944 27.729 28.140 24.430 27.777
31.306 40.000 33.607 32.341 32.783 34.154 31.653
30.292 40.000 34.678 32.699 32.813 32.712 31.438
27.998 35.274 28.896 27.947 27.966 25.992 27.792
27.094 34.161 27.590 26.530 26.949 22.906 26.456
31.631 40.000 30.958 28.873 30.846 26.144 29.905
32.730 40.000 33.174 31.788 32.147 28.479 30.196
29.389 37.093 28.419 28.213 28.731 24.681 27.376
40.000 40.000 40.000 36.969 20.390 33.129 40.000
26.877 35.402 26.423 26.003 26.566 23.793 24.953
25.440 32.875 24.159 22.951 24.168 20.588 22.918
28.590 35.407 28.283 26.920 27.788 25.253 27.014
32.154 40.000 31.057 30.464 31.788 27.818 30.455
29.573 33.693 29.005 28.758 28.479 26.399 27.555
37.768 40.000 38.393 40.000 35.289 36.132 36.767
33.286 40.000 32.073 30.410 32.329 28.154 29.554
27.840 32.630 26.534 24.499 24.949 20.304 22.651
28.132 34.166 28.580 29.177 28.611 26.537 28.000
32.259 40.000 30.977 31.030 32.969 30.177 29.914
28.641 40.000 29.791 28.444 29.363 23.783 27.065
28.919 31.749 29.123 28.642 28.489 25.029 28.559
28.791 36.389 28.476 27.841 27.988 25.232 27.402
32.326 34.449 32.296 31.595 32.482 28.589 30.815
26.572 29.960 25.976 25.557 26.251 21.581 25.532
32.513 35.537 34.565 30.203 32.802 30.704 30.832
40.000 40.000 24.967 35.564 21.142 34.270 40.000
29.931 40.000 29.013 28.116 28.038 25.119 27.265
30.894 39.082 31.068 29.656 30.841 24.095 29.772
24.455 30.964 28.554 22.206 23.229 17.422 21.090
26.784 33.662 26.925 25.863 27.181 23.169 26.416
32.206 40.000 40.000 31.512 32.054 27.786 30.645
27.816 33.781 27.908 27.719 28.479 25.321 28.461
27.610 33.899 28.532 27.697 27.486 25.846 27.017
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25.311 32.212 24.589 23.992 25.036 21.319 24.553
28.700 36.371 27.654 28.517 28.118 26.386 27.994
27.752 31.453 23.443 25.830 25.250 23.225 25.442
30.294 40.000 28.464 28.733 28.964 25.877 28.093
25.607 32.298 24.850 24.275 24.374 22.357 21.065
29.893 30.454 30.280 28.943 30.099 26.243 29.856
29.456 40.000 28.260 27.115 27.841 24.253 26.752
30.181 40.000 28.367 29.183 29.552 25.106 28.748
25.867 32.022 26.154 25.275 25.236 22.230 24.306
33.904 37.076 32.791 32.436 31.731 30.132 32.100
30.511 40.000 30.224 30.867 30.039 27.809 29.757
29.912 36.638 27.354 27.924 28.700 25.435 27.542
30.432 34.280 28.881 29.419 29.623 25.130 28.722
29.411 33.905 28.992 27.617 25.510 25.240 26.653
27.969 33.485 28.898 27.667 27.631 25.849 26.252
34.888 40.000 33.828 32.320 34.262 31.247 34.658
31.045 40.000 30.972 30.583 31.300 28.473 29.461
26.458 33.725 25.876 25.105 26.618 21.868 25.410
28.777 34.264 29.318 28.594 29.046 24.287 28.096
30.455 40.000 30.002 28.497 29.235 26.335 28.451
35.494 40.000 38.497 40.000 40.000 32.484 36.534
24.292 31.258 24.278 23.115 23.767 20.371 22.537
26.876 31.295 26.438 26.701 26.064 23.664 25.414
29.388 35.602 28.605 28.504 29.007 24.409 27.275
31.003 40.000 29.758 29.019 30.870 26.292 28.224
29.886 34.221 29.398 29.126 29.998 24.542 29.117
30.360 34.151 30.141 29.774 30.148 27.805 30.207
32.703 34.707 33.015 32.771 32.879 27.176 31.777
30.249 35.020 29.168 27.428 28.270 24.839 27.310
31.386 31.553 30.971 29.588 29.807 25.320 28.265
27.103 34.515 27.456 25.586 27.058 22.238 24.525
24.385 33.021 23.576 22.799 23.220 20.514 22.657
31.157 40.000 31.121 31.959 31.185 33.394 30.599
29.630 40.000 29.529 28.039 28.248 25.197 27.666
29.556 40.000 28.863 27.244 28.753 25.368 28.129
30.785 37.090 29.953 30.233 29.965 25.660 29.039
32.492 40.000 32.859 31.921 31.929 28.755 30.962
31.366 37.783 30.404 30.033 30.486 27.492 29.873
30.715 33.589 29.952 29.691 30.434 28.838 29.112
28.963 37.259 29.074 28.436 28.626 25.810 27.698
27.005 31.368 27.568 26.846 27.093 21.473 25.631
28.878 36.497 28.593 27.617 28.426 24.231 27.209
40.000 37.863 30.168 28.750 29.659 27.071 29.198
27.925 37.390 27.346 27.162 27.861 24.977 26.911
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
30.556 36.701 30.214 28.462 29.215 26.274 28.122
29.551 40.000 28.748 27.891 28.196 25.973 27.119
29.379 40.000 29.475 27.536 29.212 25.292 28.416
31.836 40.000 32.091 31.424 32.603 27.309 31.027
29.656 40.000 30.274 28.299 29.513 26.216 28.561
26.784 34.838 26.155 26.196 26.759 23.726 25.744
29.850 35.785 28.869 27.668 28.317 26.083 27.547
30.279 40.000 31.541 29.914 31.085 26.376 29.268
27.790 31.031 27.954 28.355 28.606 25.333 27.209
28.520 36.419 27.731 26.725 27.504 24.864 26.665
22.905 30.189 23.202 25.020 24.323 27.288 24.850
29.321 36.218 28.625 27.224 28.331 24.190 27.664
27.519 34.500 28.379 26.499 27.766 24.656 26.998
29.781 37.637 29.336 28.298 28.762 24.310 27.593
28.312 40.000 27.870 27.552 28.605 25.489 26.745
30.995 40.000 31.565 29.914 31.203 28.401 30.908
28.337 35.416 28.194 27.868 28.594 25.379 27.911
29.229 20.724 28.703 27.696 29.288 24.960 28.501
31.369 40.000 31.085 30.903 31.621 29.306 31.236
27.936 34.809 28.507 26.664 26.800 25.261 25.984
27.685 30.963 27.480 26.826 27.981 25.181 26.773
32.175 38.212 31.442 30.782 31.059 28.365 30.417
27.117 35.150 26.797 25.259 26.311 22.764 24.971
29.943 36.304 28.994 29.147 28.904 25.392 28.387
31.838 31.758 31.921 40.000 32.075 28.254 31.324
32.519 33.178 32.518 32.660 31.758 27.739 30.513
40.000 40.000 40.000 34.772 40.000 31.179 40.000
29.618 35.097 28.520 28.155 28.794 24.853 27.920
30.114 33.281 28.820 28.504 29.513 25.787 28.070
40.000 40.000 40.000 39.388 40.000 40.000 40.000
30.202 35.121 30.056 29.372 28.405 25.313 28.120
29.717 34.822 29.610 28.752 29.588 23.320 28.256
29.665 35.137 29.024 28.371 29.128 25.915 28.603
29.769 40.000 30.724 29.778 30.319 27.771 29.235
29.831 40.000 29.473 28.221 28.231 25.384 27.004
26.457 33.041 26.546 24.630 25.916 22.405 24.383
29.903 35.341 29.691 28.666 28.327 26.133 27.017
30.309 40.000 29.980 27.660 28.809 25.037 27.971
27.188 34.168 26.753 25.745 26.974 25.374 26.494
28.658 32.543 27.973 28.887 28.461 25.417 28.336
32.752 34.876 32.483 32.838 33.968 28.216 32.514
30.850 40.000 30.355 29.877 31.019 29.709 30.392
31.535 40.000 30.447 30.498 31.708 27.503 30.775
29.468 29.996 28.832 28.484 28.321 24.079 28.325
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40.000 40.000 32.819 34.987 36.164 35.635 40.000
31.577 37.012 31.308 31.772 31.091 30.838 31.867
31.272 40.000 31.541 29.580 30.747 27.313 25.645
28.525 40.000 25.687 40.000 40.000 40.000 32.158
29.233 40.000 30.045 30.205 30.859 27.348 29.982
31.426 40.000 31.186 30.180 30.239 26.694 27.967
28.352 32.019 27.077 27.641 27.645 25.126 25.138
40.000 40.000 40.000 34.523 33.243 32.588 31.871
29.092 33.742 28.377 28.992 29.783 24.145 28.994
34.592 36.565 32.112 33.404 40.000 26.106 31.210
28.614 34.911 28.045 26.873 27.645 24.078 26.810
40.000 22.368 31.266 29.613 31.207 26.524 30.898
28.598 35.732 28.682 27.755 27.571 25.670 26.738
29.862 37.632 29.651 28.196 29.141 24.564 26.204
29.229 36.105 27.959 26.154 27.467 23.084 27.174
31.972 34.994 31.053 30.278 33.524 26.904 32.167
29.007 36.472 30.084 29.786 29.625 27.733 29.772
21.101 27.355 21.002 20.324 21.079 17.058 20.015
25.098 40.000 26.281 24.959 27.694 22.016 25.748
31.090 36.831 30.985 29.822 30.670 27.831 30.119
28.178 33.985 28.778 27.986 28.688 24.988 28.208
27.490 40.000 27.469 25.236 26.923 23.018 25.555
29.790 40.000 28.132 27.245 28.609 25.245 26.689
30.314 37.007 30.302 29.004 28.987 26.012 27.937
28.460 33.287 28.716 26.954 27.419 24.582 26.947
27.252 31.534 26.304 26.351 27.573 22.243 26.223
30.022 36.527 28.595 27.975 28.579 25.751 27.632
33.126 40.000 31.838 31.130 31.903 27.851 30.269
26.901 34.662 26.695 25.507 25.797 24.458 25.479
28.097 34.128 27.464 27.040 27.205 24.361 26.448
30.652 40.000 30.173 28.900 29.389 25.224 28.272
28.350 33.500 27.603 26.929 27.732 24.236 26.644
25.809 28.564 25.586 24.252 25.285 19.399 23.434
32.605 38.569 32.172 32.264 34.050 30.106 33.314
29.005 37.421 28.556 28.042 27.769 25.289 27.054
28.419 32.798 27.492 28.555 29.331 25.605 28.218
28.079 33.854 28.346 27.357 28.153 24.872 27.288
27.709 32.956 27.914 26.868 28.080 23.881 27.615
28.485 35.457 28.610 27.419 28.744 25.310 27.248
26.076 32.458 26.205 25.625 25.870 24.245 25.227
26.447 31.869 25.628 25.385 25.876 22.345 25.056
30.481 37.827 30.410 28.857 28.987 26.066 27.728
29.090 36.626 27.858 28.180 28.524 25.575 26.992
31.721 40.000 31.740 29.839 30.533 27.408 29.907
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35.463 40.000 40.000 27.834 40.000 40.000 40.000
29.978 32.680 30.349 29.304 29.094 26.301 28.900
27.586 34.149 27.645 27.583 27.329 24.012 26.143
27.938 34.483 28.201 26.912 26.963 24.400 25.859
28.671 40.000 28.576 27.828 28.221 25.400 27.283
31.726 40.000 29.584 30.542 31.114 26.991 28.770
29.063 31.092 27.891 26.944 28.558 24.260 28.190
27.387 33.170 28.889 27.432 27.658 24.406 26.878
26.786 35.463 26.933 26.699 28.361 24.542 27.515
29.866 40.000 29.451 29.156 29.111 26.128 28.294
25.075 31.062 24.842 23.574 24.883 20.650 23.727
29.019 34.121 28.112 28.034 28.395 24.484 27.919
40.000 40.000 23.522 40.000 40.000 19.252 40.000
27.962 35.656 27.758 26.122 26.752 23.575 25.914
27.427 31.479 26.596 25.636 26.198 24.118 26.667
30.193 31.456 30.652 30.422 29.976 23.189 29.585
27.473 31.097 26.531 26.349 26.988 24.015 25.365
28.152 35.356 28.206 26.508 27.706 24.071 27.264
28.338 35.016 29.675 27.216 28.456 27.855 27.285
31.404 37.420 31.597 29.445 30.405 26.716 30.485
28.537 36.787 27.397 27.355 27.774 25.172 27.258
27.119 33.056 27.680 25.337 25.432 24.289 25.524
28.577 36.379 30.612 28.131 27.869 25.787 26.274
27.954 35.465 25.943 26.505 27.336 23.216 27.237
28.773 40.000 28.440 27.710 28.463 26.018 27.495
28.740 40.000 27.803 38.585 40.000 24.509 27.481
29.201 29.195 29.906 28.769 29.318 25.996 27.932
33.474 40.000 31.475 31.125 31.205 29.315 29.681
28.327 35.545 27.383 27.457 26.932 24.257 26.602
30.516 39.405 29.719 29.076 30.238 25.399 29.114
29.550 40.000 28.208 28.644 28.299 25.387 28.591
28.663 36.389 30.223 27.954 27.809 26.668 26.585
29.964 37.188 29.047 29.402 29.392 25.929 29.158
26.519 35.765 26.668 25.195 25.516 22.751 24.692
30.650 40.000 29.897 28.925 29.041 27.736 28.463
29.618 36.818 28.661 28.044 28.658 25.045 27.945
28.290 35.860 27.690 27.106 27.810 24.711 27.436
31.809 40.000 30.149 29.445 29.917 26.065 28.074
30.872 40.000 29.737 29.630 30.299 26.937 26.988
29.512 35.083 29.473 29.211 28.247 27.054 28.644
27.455 33.383 27.197 27.458 27.324 24.338 26.956
28.046 31.062 27.992 27.670 28.925 24.750 28.607
28.517 34.884 28.391 26.829 27.376 24.074 26.829
30.799 40.000 29.339 29.503 29.146 25.359 28.220
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30.783 40.000 28.335 27.980 28.530 24.860 28.172
27.232 34.488 26.793 25.532 26.895 22.124 25.161
31.380 34.964 30.483 30.700 30.782 27.193 29.898
29.706 40.000 28.827 27.399 27.824 24.974 27.529
28.179 34.769 27.585 26.604 27.903 22.955 26.841
29.716 35.798 28.955 28.303 28.743 24.612 28.237
30.361 34.545 29.749 29.421 29.552 25.906 28.066
27.691 35.528 28.687 27.278 27.325 24.358 26.487
29.128 35.512 26.386 27.028 27.579 23.741 26.481
29.700 35.375 28.823 28.564 29.038 25.321 28.361
27.788 33.627 26.150 25.762 26.297 22.821 24.650
30.519 35.097 29.777 28.096 28.656 25.013 28.158
31.226 40.000 30.797 30.977 32.111 30.352 30.466
25.365 33.677 26.153 25.146 25.534 24.482 24.784
25.656 31.454 26.561 26.496 26.350 23.743 25.764
30.083 32.779 29.834 29.775 28.998 27.062 29.309
30.530 33.573 30.066 30.659 30.746 28.857 30.203
31.115 30.828 31.602 30.626 30.807 28.198 30.093
30.259 35.949 30.211 29.845 29.756 27.271 29.497
29.599 36.806 29.692 26.780 28.952 24.772 28.557
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ERpos09SH079ERpos601377ERpos700282ERpos700423PostMnPsNormK100650PostMnPsNormK100808PostMnPsNormK100812
24.760 27.542 26.118 26.807 27.955 25.248 26.029
29.343 31.880 29.335 31.524 30.912 28.745 28.899
26.519 31.423 28.646 32.391 26.642 27.467 27.543
27.410 33.843 29.392 34.032 31.381 28.506 29.397
34.048 37.717 34.756 40.000 40.000 33.057 34.174
25.528 28.826 24.921 28.565 28.200 25.812 25.936
26.734 28.826 26.383 28.233 29.141 26.838 27.022
31.977 32.650 32.468 31.411 32.646 30.293 31.194
30.410 31.960 31.305 31.578 35.446 31.884 32.705
28.112 30.207 28.646 29.847 31.511 28.451 29.101
31.184 33.816 31.710 34.527 31.493 28.704 29.211
35.449 40.000 32.402 40.000 33.629 31.388 33.496
28.899 30.299 28.000 29.661 30.342 29.740 29.340
27.572 28.912 27.373 28.498 30.181 27.421 28.264
31.798 34.411 40.000 40.000 35.378 31.760 33.958
31.385 34.279 33.391 35.040 40.000 32.691 33.262
28.578 31.569 29.174 31.700 31.168 29.054 29.037
40.000 40.000 40.000 23.723 40.000 40.000 40.000
26.670 29.333 27.078 28.473 28.130 25.814 25.679
24.154 26.687 22.515 27.487 27.712 24.874 25.584
27.843 30.784 28.147 30.444 30.030 27.819 28.063
31.575 34.059 31.849 34.773 33.921 40.000 31.757
27.837 30.639 28.162 31.091 28.421 24.672 26.204
35.614 40.000 35.814 40.000 40.000 34.520 35.062
31.313 33.962 32.628 33.943 40.000 40.000 24.407
24.144 27.410 25.021 26.506 29.238 26.130 27.948
28.296 30.430 28.278 30.050 31.063 29.271 28.882
33.360 35.341 32.227 33.546 37.501 35.541 34.870
29.578 32.685 29.927 31.373 31.040 29.125 28.598
28.569 31.908 28.986 32.271 29.100 30.190 29.846
28.414 31.627 28.474 31.936 30.387 27.905 27.948
31.432 32.589 30.604 33.278 33.570 30.639 31.014
25.489 28.210 26.498 27.838 25.566 27.748 27.062
30.350 23.918 40.000 19.841 40.000 34.904 33.990
40.000 27.085 35.484 40.000 40.000 35.552 40.000
27.981 30.669 28.862 31.199 30.748 27.850 28.833
31.009 32.880 31.259 32.794 34.778 31.651 32.481
22.783 26.712 23.390 25.517 27.187 24.341 25.926
26.465 29.334 27.759 28.772 28.506 26.337 26.394
32.143 34.561 32.193 32.942 34.455 32.171 32.590
27.915 30.522 28.164 31.567 30.444 28.527 29.028
28.719 29.900 26.840 28.778 29.522 28.070 28.514
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25.277 27.308 25.378 26.276 28.922 26.178 27.088
28.607 30.969 29.136 30.752 31.501 29.245 29.299
26.894 26.974 27.379 28.161 28.068 26.034 25.880
29.267 32.001 29.606 32.757 31.517 29.172 29.635
23.170 26.530 23.494 26.857 27.335 24.718 25.206
30.313 31.151 29.902 30.063 32.903 30.585 32.107
27.509 32.485 29.089 31.617 29.494 27.731 28.508
30.428 32.477 29.514 31.469 33.043 30.237 30.905
26.297 27.422 25.195 27.601 28.349 26.490 26.628
33.158 33.830 33.727 33.322 34.318 34.191 32.685
31.215 33.078 30.702 32.363 33.180 31.199 32.059
28.768 32.372 30.044 32.664 31.130 28.451 28.528
29.942 31.800 29.769 31.220 32.099 29.380 30.484
27.416 29.153 25.787 28.161 28.990 26.841 27.856
28.116 29.248 26.860 28.393 29.536 27.769 27.762
32.416 35.645 36.562 34.780 28.338 26.919 35.644
30.695 33.169 30.502 32.866 30.676 27.937 29.030
26.731 28.770 26.974 28.998 29.699 27.070 27.720
30.426 29.735 27.306 29.515 33.419 30.976 31.555
29.676 32.433 29.695 32.266 31.922 29.525 30.193
36.603 40.000 36.163 40.000 40.000 40.000 40.000
24.644 26.312 23.691 25.964 26.032 22.916 23.829
25.741 27.735 25.342 27.788 26.574 23.052 24.546
28.993 32.894 29.162 31.634 31.398 29.517 29.681
28.597 33.175 30.406 34.328 32.653 29.389 30.128
30.946 31.799 30.120 32.056 31.996 30.081 30.450
31.233 32.326 30.191 32.070 32.316 30.371 30.855
33.411 34.500 32.177 34.769 34.576 32.221 33.263
27.898 32.564 29.491 33.085 30.476 27.011 28.129
27.710 33.674 31.323 33.625 28.554 29.520 28.728
26.820 29.606 28.217 29.084 30.796 28.534 29.292
23.793 26.735 24.292 27.357 26.877 23.949 24.694
29.783 40.000 32.571 32.695 34.114 40.000 32.893
28.708 30.952 28.905 31.125 31.254 28.739 29.334
28.801 31.999 29.478 31.744 32.018 29.699 30.332
30.268 33.932 30.696 33.945 32.756 29.869 30.515
31.644 33.472 31.994 33.757 33.569 30.577 31.597
30.998 32.971 31.246 32.914 32.374 29.519 30.432
30.488 32.010 29.116 32.007 31.668 29.594 30.336
28.325 32.193 28.932 31.819 31.468 28.908 29.246
27.007 28.730 27.090 28.475 26.806 26.201 27.347
28.113 31.398 28.811 31.646 30.653 28.355 28.845
30.273 33.669 28.338 35.209 31.440 28.908 29.487
27.097 30.364 28.427 30.013 29.547 27.522 27.844
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
29.034 32.253 29.839 32.839 31.757 29.184 30.143
27.837 31.088 28.824 31.190 30.036 27.989 28.166
29.591 31.759 28.627 31.446 31.050 29.122 29.552
32.131 34.003 31.536 32.280 33.069 32.045 32.982
29.290 31.649 30.231 31.396 31.749 29.900 30.252
26.938 29.277 26.891 29.033 29.238 27.143 27.029
27.955 31.705 28.745 31.829 30.658 27.884 28.583
31.223 32.851 30.708 33.340 33.222 30.528 31.181
28.942 29.848 28.483 29.445 31.090 28.968 29.245
27.566 30.171 27.881 30.574 29.942 27.620 28.055
25.614 25.333 22.932 25.027 28.045 27.713 26.900
28.394 31.149 29.639 31.038 30.598 27.479 27.946
27.488 29.446 26.709 30.057 28.890 26.566 26.860
27.768 32.241 30.046 33.059 40.000 28.503 29.276
27.932 31.394 28.031 32.029 30.259 28.060 28.819
31.034 33.848 31.551 33.285 34.340 30.746 32.128
28.461 30.617 28.872 30.859 30.865 28.643 28.951
29.716 32.414 29.860 31.627 33.251 30.210 30.133
31.227 33.837 30.021 40.000 33.432 30.487 30.781
27.787 30.574 28.387 30.386 30.177 27.195 27.805
27.658 30.220 27.150 29.529 28.871 26.994 27.221
30.874 33.459 30.747 33.353 32.822 40.000 31.282
25.828 29.674 27.194 29.168 28.489 25.598 26.226
30.072 33.136 30.451 32.209 33.692 30.674 31.304
28.624 36.301 30.917 34.514 27.908 31.345 29.818
29.988 40.000 32.916 34.959 30.452 32.180 30.794
40.000 40.000 32.848 35.941 33.881 32.422 32.568
29.555 31.576 29.540 31.878 31.838 28.931 29.823
28.312 33.445 29.971 32.931 28.620 28.273 28.677
36.175 33.670 40.000 40.000 35.522 35.363 40.000
27.289 30.782 28.000 30.287 31.542 29.817 29.034
29.274 30.992 29.009 30.911 31.985 30.096 30.398
28.929 31.044 29.364 29.554 31.838 29.830 30.408
30.490 32.117 30.566 34.447 31.493 28.838 29.567
28.649 32.018 28.943 31.485 30.220 28.188 28.278
25.220 28.525 25.470 28.101 27.530 25.198 26.038
28.205 32.143 29.290 32.602 30.073 27.933 28.513
29.204 32.226 31.082 32.797 31.535 28.695 29.744
26.896 29.729 26.482 29.830 29.513 27.436 27.570
29.924 30.427 29.655 29.866 32.150 29.699 30.753
30.587 35.373 34.094 34.697 29.456 33.835 32.791
31.206 32.400 29.482 32.816 31.033 29.020 29.228
31.299 40.000 30.725 33.283 31.918 30.331 30.134
27.490 32.135 29.338 32.633 27.553 28.842 27.918
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34.060 40.000 33.664 35.653 35.486 30.371 34.159
32.417 36.959 31.901 34.466 33.568 30.183 32.612
28.892 33.057 29.960 32.588 32.361 30.346 30.787
27.525 33.809 29.865 40.000 40.000 38.763 40.000
31.164 32.263 31.033 32.316 34.272 32.085 32.522
30.193 33.743 30.704 32.245 32.572 30.634 31.314
27.381 29.725 27.502 29.425 29.859 26.835 27.164
40.000 29.362 33.140 40.000 33.295 29.539 31.618
30.318 30.148 29.681 30.326 32.140 30.237 30.535
32.955 36.228 33.628 34.466 34.173 32.278 32.526
28.852 29.619 27.859 30.084 30.742 28.536 29.136
40.000 33.884 30.903 33.770 40.000 40.000 32.275
27.782 30.678 27.491 31.121 30.652 29.134 29.316
27.221 31.393 28.435 31.576 31.593 28.893 29.622
27.594 31.113 28.931 30.408 29.339 27.296 27.643
29.028 34.420 31.829 33.000 28.602 31.696 31.855
30.806 32.481 30.177 31.381 32.211 29.389 30.144
21.383 25.010 20.317 24.133 23.162 21.426 21.947
27.119 30.620 25.817 28.386 28.951 27.004 27.395
30.958 33.291 30.866 32.139 33.663 31.133 32.184
28.333 30.613 28.194 30.281 30.357 28.425 28.932
26.572 29.985 27.320 30.273 29.564 26.855 27.790
27.136 31.097 28.799 31.547 31.656 29.010 29.464
28.932 31.403 29.543 32.153 40.000 28.526 29.586
28.244 29.808 27.908 30.178 29.705 28.113 28.439
27.156 29.592 27.782 29.482 28.042 28.141 28.169
29.069 31.792 28.911 33.986 30.387 27.684 28.398
31.597 35.220 32.685 35.844 33.738 30.563 31.277
25.747 29.032 26.143 28.606 27.906 26.035 26.433
27.481 30.933 27.037 29.667 28.668 27.043 26.838
28.996 40.000 30.056 33.398 31.783 29.219 29.571
27.133 30.169 27.677 30.414 29.881 27.757 28.314
24.283 27.585 24.706 26.222 25.040 24.666 25.243
40.000 35.070 33.317 33.964 38.283 35.036 35.189
28.537 30.808 29.212 31.085 31.273 28.435 28.388
27.749 30.885 29.233 30.085 27.429 30.019 29.804
28.226 30.759 28.555 30.891 30.750 28.098 28.576
27.641 30.012 27.365 29.395 28.607 28.464 29.077
29.018 31.201 29.033 30.845 30.680 28.398 28.892
26.606 27.759 25.954 26.942 28.017 25.921 26.324
26.128 28.570 25.893 27.556 29.061 26.443 27.432
28.045 32.648 29.574 32.899 31.007 28.364 28.596
28.111 31.555 28.614 32.271 30.377 28.013 28.053
30.140 34.655 32.284 34.064 33.322 30.154 31.226
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33.427 40.000 40.000 35.672 40.000 33.123 33.135
28.937 32.620 29.353 32.788 28.817 29.577 29.252
26.850 30.447 27.974 30.518 29.485 26.841 27.169
26.852 30.663 28.178 30.046 29.860 27.362 28.391
28.388 31.459 28.554 31.391 30.252 27.656 28.565
29.350 32.182 29.422 31.398 31.761 29.292 30.459
27.767 31.637 27.617 30.807 28.214 40.000 28.266
28.875 29.446 27.668 29.676 30.571 28.382 29.172
28.033 29.238 27.037 28.812 31.143 31.152 30.119
29.338 32.270 29.758 31.936 31.871 28.929 29.137
25.776 26.413 24.219 25.769 27.238 24.961 25.823
29.463 30.574 28.353 30.145 31.730 28.911 29.805
24.142 40.000 23.222 27.583 27.154 23.075 20.008
26.735 30.992 27.533 30.093 29.573 27.082 27.438
27.723 28.536 23.665 27.674 29.331 26.422 26.728
27.686 35.015 31.844 35.166 29.019 29.748 28.583
27.184 28.725 27.072 29.162 27.686 27.513 27.590
26.509 29.894 25.917 29.272 29.418 27.397 27.845
27.792 31.383 28.336 29.387 29.818 27.370 28.138
32.016 32.784 31.417 32.442 33.678 31.271 31.699
27.474 30.387 27.542 30.320 30.084 27.529 27.573
27.353 28.460 25.843 27.994 29.100 26.906 27.563
27.868 31.031 28.626 29.563 30.233 28.415 28.517
27.126 29.523 26.522 29.964 30.605 27.190 28.375
29.070 30.919 29.542 30.159 31.292 28.961 29.400
40.000 40.000 26.409 40.000 34.674 34.456 35.296
26.157 33.169 28.500 32.066 25.708 28.884 27.278
31.477 33.337 30.653 33.524 30.739 28.651 29.128
26.798 30.671 27.746 29.971 29.172 27.736 27.547
28.763 31.860 30.659 40.000 40.000 29.490 30.522
28.430 30.784 28.836 31.448 31.885 28.917 29.482
28.148 29.678 27.805 29.072 30.080 27.560 28.542
29.288 32.484 30.179 32.717 32.153 29.962 30.465
24.887 29.096 26.100 28.528 27.595 25.438 25.671
29.163 32.055 29.833 31.041 31.971 29.310 29.715
29.635 31.971 29.942 32.924 31.837 28.702 29.581
28.478 30.998 27.548 30.580 30.066 27.750 28.784
29.312 33.162 32.271 32.932 34.481 32.303 33.119
29.929 33.115 30.362 34.430 40.000 29.622 30.356
28.226 30.661 28.802 30.112 31.024 28.541 29.209
27.352 29.528 27.192 28.681 29.528 27.482 27.685
29.685 28.883 28.823 28.306 31.167 29.329 29.556
28.835 29.425 28.075 29.304 30.971 28.387 29.251
30.341 31.540 30.075 31.454 31.133 29.187 29.568
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28.060 32.062 29.764 33.797 31.073 28.256 28.890
26.283 29.543 27.155 29.074 29.655 26.897 27.529
30.098 32.795 31.816 32.306 29.153 29.977 30.136
27.612 31.622 28.447 32.238 29.512 27.366 28.435
27.356 29.942 28.636 29.873 30.913 28.024 28.758
29.686 32.137 29.486 32.427 30.859 28.653 29.191
29.489 31.515 29.566 30.707 32.308 29.806 30.429
27.630 29.994 27.632 30.623 29.771 27.286 28.121
28.136 30.568 27.498 29.091 31.575 28.382 28.402
29.283 30.437 29.574 30.946 32.232 29.972 30.661
26.240 29.376 26.858 29.738 29.323 26.134 26.880
30.242 30.628 29.797 30.381 32.149 30.572 31.479
32.508 32.876 30.023 34.070 32.254 29.748 31.401
25.330 28.488 25.363 27.830 29.040 27.044 27.701
26.690 28.397 26.396 26.838 28.311 26.484 26.779
31.212 30.917 28.404 31.114 32.189 29.842 30.304
30.808 32.802 30.366 32.807 31.982 30.039 30.087
29.231 35.006 40.000 34.566 28.781 30.757 29.268
30.558 33.469 31.317 32.444 32.670 30.705 30.692
29.838 31.354 29.899 30.881 31.698 29.991 30.291
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PostMnPsNormK100833PostMnPsNormK100856PostMnPsNormK100862PostMnPsNormK100866PostMnPsNormK100895PostMnPsNormK100896PostMnPsNormK100904
24.555 23.989 24.363 23.707 24.474 24.077 24.565
28.334 27.760 28.182 27.749 28.597 28.326 28.302
27.421 27.041 27.323 26.836 27.227 27.118 27.775
28.448 28.230 28.259 28.115 28.963 27.830 29.181
32.896 32.293 33.385 32.797 33.661 33.324 33.462
26.424 25.717 25.837 25.029 26.047 26.080 25.792
27.166 26.581 26.411 26.269 27.116 26.801 26.737
30.082 29.630 30.351 29.244 31.623 30.621 29.161
40.000 30.462 30.649 30.200 30.802 30.309 31.204
28.204 27.742 27.463 27.971 28.343 27.749 28.329
28.385 28.643 29.697 29.149 30.303 31.000 29.009
31.763 31.942 32.405 32.033 32.423 32.629 32.741
28.745 29.069 29.169 27.923 29.595 29.506 28.409
27.372 26.843 26.841 26.708 27.198 26.286 27.239
31.977 31.622 31.780 31.235 32.160 31.151 31.895
32.021 32.238 33.099 32.352 33.663 32.226 32.286
28.590 28.419 28.685 28.280 29.043 28.713 28.892
24.772 40.000 32.754 40.000 40.000 40.000 40.000
25.783 25.472 25.334 25.081 25.848 24.999 25.685
24.752 24.422 24.948 23.449 24.655 24.494 24.709
28.368 27.567 27.869 27.420 28.083 27.461 28.090
30.802 30.417 30.860 30.535 31.366 30.791 31.296
25.073 24.477 23.183 25.007 23.637 22.450 24.327
34.752 36.180 34.522 34.175 33.883 35.571 34.896
34.480 36.501 40.000 34.412 35.082 35.056 34.205
26.359 26.710 25.936 25.590 26.481 26.446 26.066
28.603 27.945 28.363 27.643 28.746 28.201 28.368
33.494 40.000 33.009 33.223 33.585 33.736 40.000
29.173 28.286 28.894 28.428 28.600 28.379 28.604
29.476 28.737 29.642 28.564 29.558 29.390 29.690
27.469 26.926 27.148 26.899 27.672 27.020 27.665
29.550 29.134 29.476 29.434 29.521 28.220 29.993
27.247 26.822 26.846 26.333 27.289 27.136 26.944
32.760 32.459 30.912 30.640 33.257 35.464 32.362
40.000 40.000 40.000 36.138 37.153 40.000 40.000
27.195 27.069 27.271 27.001 27.617 26.929 27.790
31.072 30.974 31.125 30.350 31.188 30.726 30.970
24.508 24.482 25.462 24.165 26.040 25.783 24.197
26.523 25.824 26.454 26.350 26.875 26.502 26.616
31.251 31.053 31.645 30.861 31.599 31.031 31.504
28.468 28.437 28.188 27.902 28.890 28.974 28.282
28.002 27.498 27.353 27.472 27.962 27.340 27.831
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25.902 25.588 25.942 25.710 26.199 25.653 26.036
29.128 28.479 28.491 27.712 29.205 28.913 29.010
25.534 25.438 25.503 25.414 26.268 26.266 25.828
28.422 28.380 28.423 28.115 29.098 28.682 29.033
24.584 24.424 24.143 23.601 24.636 24.495 24.288
30.249 30.076 29.991 29.352 30.365 30.203 30.178
27.981 27.524 27.672 27.432 28.256 27.750 28.348
29.275 29.028 28.994 28.910 29.641 28.916 29.640
25.216 24.832 25.138 25.059 25.353 25.307 25.488
32.704 33.228 40.000 32.056 33.596 33.916 32.430
30.532 30.416 30.636 30.070 31.102 31.185 30.887
28.512 28.016 28.490 27.857 28.674 28.242 28.502
28.794 28.589 29.003 28.498 29.443 28.802 29.098
27.457 26.715 27.250 26.862 27.689 27.729 27.039
27.806 27.383 27.321 26.861 27.577 27.337 27.273
40.000 34.424 40.000 33.173 27.392 40.000 40.000
28.705 27.962 27.719 28.116 28.216 27.431 28.417
26.541 26.001 26.545 26.071 27.049 26.785 26.727
29.750 29.664 29.548 28.925 29.852 29.712 29.591
29.108 28.705 28.866 28.811 29.409 29.211 29.218
40.000 37.200 40.000 34.680 40.000 40.000 40.000
22.243 22.166 23.096 22.601 23.235 22.942 23.169
22.717 22.267 22.350 22.635 22.224 20.918 22.924
29.219 28.538 28.945 27.900 29.311 29.545 28.819
28.814 28.411 28.738 28.350 29.515 28.867 29.216
29.576 29.125 29.645 28.975 29.853 29.440 29.839
29.900 29.367 29.295 29.311 29.781 29.572 29.149
31.644 31.251 31.480 31.507 31.629 31.528 31.846
26.944 26.494 26.734 26.882 26.942 25.937 27.558
29.023 28.211 29.274 28.690 29.122 28.725 29.758
27.420 26.714 27.753 27.428 27.310 26.650 27.626
23.868 23.576 23.867 23.539 24.027 23.622 23.832
31.483 31.696 31.300 31.232 32.361 33.139 31.859
28.232 27.556 28.169 27.746 28.707 28.115 28.294
29.276 29.001 28.446 27.821 28.963 28.544 29.399
28.562 28.914 29.713 29.121 30.679 29.562 30.317
30.913 29.695 30.082 30.225 29.965 29.079 30.694
28.799 28.698 29.112 29.054 29.571 28.972 29.477
29.425 29.478 28.761 29.356 29.228 28.680 29.577
28.613 28.364 28.483 28.225 29.195 28.824 28.932
25.940 25.807 26.780 26.047 26.954 26.433 26.944
28.258 28.080 28.131 27.847 28.514 28.116 28.355
29.548 28.998 29.124 29.049 29.571 29.038 29.671
27.807 27.246 27.450 27.115 27.880 27.385 27.592
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29.309 28.994 29.027 28.477 29.731 29.028 29.341
28.187 28.108 27.260 27.222 28.085 27.468 27.804
28.945 28.199 28.302 27.778 29.249 28.504 28.679
31.378 31.609 31.984 31.494 32.082 31.592 32.130
28.659 28.943 28.794 28.688 28.888 29.099 28.958
27.189 26.544 26.583 26.283 27.077 27.043 26.636
27.913 27.571 27.754 27.641 28.263 27.831 28.225
29.728 29.718 29.513 29.962 30.314 29.792 30.676
28.696 28.231 28.450 27.973 28.686 28.469 28.433
27.445 27.083 27.094 26.568 27.465 26.857 27.375
27.611 27.479 26.620 23.818 27.010 29.259 26.302
27.451 26.946 27.389 27.242 28.174 27.726 27.771
26.513 26.031 26.313 26.110 26.968 26.213 26.541
28.610 28.147 28.417 28.234 29.310 28.736 28.938
28.283 27.996 28.024 27.626 28.876 28.171 28.483
31.283 29.678 29.233 30.306 29.411 28.100 30.360
28.788 28.596 28.535 28.332 28.859 28.653 28.607
29.859 29.701 29.591 28.998 30.097 29.663 29.677
29.930 29.094 28.865 29.519 29.599 28.947 30.013
27.028 26.549 26.427 26.318 27.174 26.686 27.275
27.476 26.511 26.954 26.681 27.377 26.971 27.124
30.093 29.693 29.606 29.421 30.531 29.796 30.525
25.890 25.467 25.859 25.466 26.423 25.924 25.978
30.049 29.347 30.243 29.758 30.669 30.279 30.045
30.788 30.653 30.670 30.576 30.741 30.153 31.147
32.480 31.755 31.262 30.912 31.826 31.267 32.185
31.707 31.348 31.437 31.631 31.932 33.825 31.561
28.612 28.301 28.305 28.313 29.158 28.680 29.105
28.210 27.835 28.239 28.458 28.492 27.956 28.593
38.578 34.447 35.666 35.263 34.370 33.617 28.828
30.083 28.840 29.412 28.333 30.034 30.775 29.664
29.292 28.831 28.953 28.528 29.085 28.787 29.271
29.848 29.330 29.513 29.129 29.797 29.605 29.797
28.746 28.660 28.120 28.488 28.684 27.596 28.575
28.545 28.057 28.008 27.859 28.630 28.340 28.559
24.292 24.205 25.005 24.593 25.207 24.908 25.462
27.844 27.585 27.817 27.617 28.630 27.955 28.495
28.478 28.283 28.039 28.032 28.822 28.164 28.949
27.224 26.943 27.395 26.220 27.763 27.539 27.557
29.754 29.823 29.475 28.751 29.769 29.811 29.346
33.261 32.904 32.902 33.097 31.840 32.914 32.823
28.475 28.445 28.509 27.482 28.716 28.527 28.738
28.909 28.786 28.716 29.298 30.010 29.366 29.517
28.109 27.770 27.920 27.615 28.222 28.135 28.488
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30.825 31.095 31.299 32.886 31.108 31.086 31.986
30.578 30.586 30.135 30.646 31.134 30.498 30.812
30.146 29.891 29.877 29.960 30.322 29.818 30.117
33.676 40.000 30.181 35.790 36.980 37.001 40.000
31.753 31.058 31.088 30.795 31.462 30.919 30.922
30.295 30.083 30.145 29.751 30.708 30.459 30.870
26.427 26.306 26.603 26.355 27.227 26.775 26.636
30.287 28.812 29.508 30.073 30.263 29.393 30.154
29.777 29.261 29.548 29.062 29.931 29.815 29.460
32.409 31.053 31.419 31.212 31.427 30.502 32.045
27.599 27.601 27.372 27.242 27.946 27.057 27.870
40.000 31.146 32.160 31.319 40.000 31.139 31.677
28.806 28.631 28.336 27.760 28.677 28.222 28.717
28.703 28.241 28.265 27.746 28.819 27.988 28.640
27.604 27.220 27.045 26.552 27.591 27.048 27.579
31.269 30.884 30.196 30.631 31.020 30.351 31.422
29.763 29.197 29.325 29.637 29.875 29.672 29.462
21.097 20.741 20.595 20.503 21.541 21.078 20.974
27.474 26.323 26.165 26.512 26.876 26.381 27.230
30.886 30.800 30.518 30.090 30.941 31.045 30.617
28.134 27.737 28.053 27.485 28.232 27.789 28.236
26.431 26.391 26.538 25.893 27.066 26.582 26.845
28.882 28.382 27.971 27.601 28.723 27.751 29.039
28.650 28.686 28.163 28.079 28.951 28.118 29.025
28.796 28.591 28.251 28.298 28.440 28.652 28.280
27.096 26.715 27.475 27.035 27.636 27.703 27.409
27.635 27.306 27.543 27.357 27.813 27.261 28.055
30.389 30.047 30.620 29.965 31.023 30.500 31.457
26.215 25.914 25.951 25.491 26.413 25.898 26.151
27.125 26.542 26.749 26.110 26.988 26.201 27.123
28.988 28.740 28.621 28.623 29.303 28.833 29.163
27.868 27.617 27.589 27.045 27.991 27.754 28.070
23.627 23.446 24.383 24.074 24.359 24.270 24.612
34.678 33.632 40.000 33.927 34.221 34.135 34.269
28.240 27.779 28.102 27.994 28.447 28.194 28.434
29.827 29.801 29.727 29.107 29.592 30.005 29.430
27.860 27.489 27.714 27.519 28.202 27.876 27.795
28.295 27.976 28.020 27.437 28.317 27.970 28.185
28.140 28.152 28.320 27.750 28.611 28.364 28.010
25.983 25.589 25.519 25.438 26.057 25.679 25.849
26.673 26.384 26.181 25.860 26.794 26.204 26.604
28.342 28.058 28.088 27.737 28.773 28.119 29.053
27.746 27.315 27.587 27.388 28.209 27.615 27.804
29.543 29.078 29.628 29.394 30.109 28.763 30.295
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32.040 32.356 40.000 36.363 40.000 35.471 40.000
28.868 28.664 28.810 28.392 29.100 28.951 29.522
26.574 26.112 26.359 26.169 26.997 26.492 26.857
27.835 27.509 27.797 26.759 28.050 27.870 27.320
27.965 27.864 27.573 27.279 27.994 27.627 27.764
29.182 28.662 29.099 28.879 29.549 28.979 28.065
27.436 26.885 27.592 26.965 27.950 27.189 27.816
27.878 27.395 27.947 27.596 28.073 27.619 27.862
29.740 30.154 28.777 27.993 30.109 32.897 30.770
29.115 28.753 28.853 28.787 29.149 28.892 29.416
24.888 24.579 24.060 24.000 24.786 23.946 24.784
28.910 28.376 28.475 27.475 28.668 28.104 28.678
40.000 40.000 40.000 40.000 22.150 40.000 40.000
26.597 26.613 26.760 26.188 27.176 26.862 26.953
26.615 26.246 26.097 25.543 26.726 26.156 26.360
29.175 28.875 28.646 27.722 29.189 28.579 30.341
27.271 27.023 26.886 26.573 27.457 26.985 27.255
27.332 26.976 27.401 26.652 27.532 26.942 27.335
27.292 26.702 26.924 26.989 27.575 26.488 26.677
30.547 30.266 30.135 30.329 31.060 30.499 30.968
27.591 27.383 27.219 26.949 27.906 27.545 27.819
26.761 26.365 26.281 25.631 26.795 26.066 26.409
28.307 28.044 28.141 28.221 28.996 28.532 28.495
26.547 26.389 26.475 26.670 27.098 26.436 27.338
28.805 28.640 28.529 28.020 29.443 29.182 28.621
40.000 35.188 40.000 38.233 40.000 36.202 38.569
28.787 28.359 28.578 28.480 28.806 28.883 29.172
29.087 28.708 30.012 28.722 29.429 29.289 29.226
27.702 27.437 27.450 27.123 27.763 28.135 27.473
29.148 28.979 29.182 29.237 29.857 29.227 29.789
28.431 28.160 28.457 28.115 28.917 28.420 28.893
28.041 27.954 28.108 27.432 28.697 28.630 28.001
29.703 29.240 29.382 29.453 29.971 29.522 30.059
25.866 25.163 25.487 24.807 25.992 25.544 25.576
28.842 28.438 28.471 28.430 28.601 27.242 28.987
28.145 28.164 28.220 28.171 28.604 28.262 28.657
27.414 27.110 27.110 26.612 27.543 26.785 27.444
31.715 32.548 32.224 31.108 32.638 32.589 32.032
29.326 29.126 29.411 28.716 29.640 29.225 29.788
28.339 27.802 28.200 27.898 28.685 28.245 28.237
27.468 27.094 27.234 26.849 27.771 27.888 27.314
28.854 28.618 28.383 28.259 28.963 28.861 28.567
27.939 27.914 27.957 27.509 28.369 27.787 28.150
29.170 28.750 29.012 28.103 29.279 29.141 29.106
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28.203 27.983 27.884 27.587 28.517 27.873 28.460
26.692 25.908 26.390 26.040 26.843 26.295 26.984
29.990 29.767 29.382 29.429 29.887 30.305 29.555
27.317 27.113 27.016 27.083 27.911 27.245 27.821
27.558 27.261 27.494 27.567 28.250 27.618 27.874
27.912 27.498 28.208 27.815 28.466 27.952 28.161
29.594 28.922 29.122 28.680 29.441 29.229 29.109
26.970 26.955 27.348 26.869 27.775 26.903 27.617
28.540 28.425 28.155 27.344 29.069 29.836 28.800
29.790 29.641 29.228 29.008 29.732 29.482 30.108
25.657 25.678 25.926 25.445 26.469 25.850 26.367
30.176 30.126 29.629 29.560 29.841 29.659 29.416
30.164 28.950 29.145 29.715 29.425 28.286 30.099
27.676 26.869 26.820 26.705 27.100 27.131 26.844
26.702 26.424 26.561 26.168 26.875 26.897 26.163
29.447 29.064 29.008 28.882 29.257 28.160 29.563
30.053 29.764 30.023 29.615 30.738 30.485 30.720
30.378 40.000 30.680 30.317 30.504 31.041 30.498
30.315 30.282 30.101 29.755 31.183 31.443 30.251
29.217 28.583 29.221 29.015 29.790 29.588 29.313
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PostMnPsNormK100936PostMnPsNormK101017PostMnPsNormK101034PostMnPsNormK101062PostMnPsNormK101068PostMnPsNormK101070PostMnPsNormK102426
24.727 24.317 24.613 24.625 24.428 24.297 25.977
28.257 28.150 28.295 28.181 28.025 28.219 28.947
27.323 27.194 27.503 26.959 27.191 27.215 27.298
29.175 28.310 28.744 28.142 28.556 28.534 29.236
33.200 33.418 33.016 32.614 33.060 33.054 40.000
25.719 25.741 25.906 25.629 25.770 25.874 25.991
26.840 26.994 27.067 26.783 26.614 26.658 27.258
29.651 29.893 30.108 29.634 30.734 30.442 30.606
30.907 30.898 30.782 30.770 30.524 30.544 31.935
28.302 28.026 27.938 27.739 27.943 28.242 28.838
28.675 30.198 29.187 29.200 29.314 30.189 28.994
30.719 32.022 33.341 31.706 31.987 33.390 31.740
28.570 29.486 28.894 28.755 28.336 29.151 28.661
27.318 26.388 27.058 26.736 27.212 27.167 28.297
40.000 31.360 31.407 31.417 31.523 31.802 32.070
32.472 32.065 32.398 32.790 33.034 32.964 33.942
28.689 29.062 28.949 28.731 28.976 28.825 29.158
32.226 40.000 40.000 38.537 40.000 40.000 40.000
25.804 25.239 25.758 25.275 25.711 25.564 26.886
24.499 24.549 24.663 24.474 24.357 24.197 25.136
28.051 27.840 28.274 27.726 27.732 27.681 28.273
30.729 31.076 30.935 30.615 30.757 31.087 31.528
25.419 22.911 23.886 23.009 24.203 23.772 26.018
34.101 34.454 33.828 34.533 33.673 34.792 34.412
34.143 33.861 34.570 36.379 34.578 26.775 35.220
27.189 25.663 26.341 26.620 25.494 25.630 27.584
28.475 28.034 28.065 28.096 28.094 28.228 28.542
34.041 33.841 33.398 40.000 34.213 40.000 34.023
28.474 28.496 28.843 28.482 28.835 28.860 28.807
29.555 29.452 29.343 29.394 29.285 29.277 28.952
27.525 27.335 27.691 26.969 27.078 27.403 27.807
29.748 29.729 40.000 28.878 29.875 29.562 31.453
26.811 27.089 26.726 27.104 27.093 26.818 26.665
31.651 35.591 30.528 33.178 31.253 31.088 34.452
36.447 40.000 35.320 36.422 40.000 40.000 35.122
27.880 27.219 27.584 27.068 27.540 27.562 28.426
31.003 31.088 30.733 30.753 31.020 31.479 31.887
25.097 26.451 25.540 24.881 24.505 25.419 25.666
26.392 26.599 26.714 26.180 26.066 26.664 27.215
31.622 31.419 31.403 31.320 31.174 31.052 31.867
28.666 28.740 28.406 28.505 28.643 28.652 28.859
27.895 27.312 27.470 27.617 27.638 27.800 28.081
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25.926 25.817 25.860 25.681 25.684 25.922 26.338
28.790 28.909 29.066 28.431 28.693 28.699 29.438
25.816 26.362 25.704 25.936 25.632 26.036 26.365
28.831 28.669 28.814 28.655 28.587 29.252 29.805
24.521 24.455 24.402 24.288 24.493 24.306 25.101
30.403 30.592 30.360 30.430 29.977 30.194 30.672
28.252 28.055 27.775 27.669 27.647 27.963 28.359
29.258 29.020 29.051 40.000 29.108 29.468 30.180
25.406 25.639 25.790 25.227 25.366 25.331 26.504
33.559 33.727 32.405 32.750 32.747 33.288 33.313
30.629 30.942 30.525 30.695 30.605 30.538 31.558
28.748 28.322 28.583 28.160 28.271 28.506 28.768
29.395 28.887 28.995 29.008 28.941 29.000 30.089
26.834 27.781 26.621 26.881 26.111 26.954 27.435
27.480 27.398 27.558 27.638 27.319 27.386 27.477
34.332 34.896 35.843 36.152 40.000 37.006 28.961
28.731 27.452 28.092 27.809 27.861 28.086 28.645
26.460 27.157 26.569 26.636 26.422 26.676 27.271
29.925 29.809 29.367 29.590 30.103 29.637 30.881
29.230 29.118 29.268 28.899 28.822 29.417 29.984
40.000 37.313 40.000 38.595 40.000 40.000 34.962
24.354 23.213 23.091 22.826 22.688 23.153 23.791
22.958 21.816 22.642 21.691 22.413 21.983 23.682
29.181 29.478 28.675 29.136 28.895 29.141 30.140
29.384 29.318 29.075 28.652 28.920 28.857 29.561
29.412 29.101 29.353 29.463 29.705 29.419 30.453
29.283 29.734 30.091 29.444 29.527 29.391 30.636
31.979 31.153 31.655 31.445 31.615 31.979 32.845
27.572 26.300 26.856 26.376 26.713 27.019 27.652
29.244 28.894 28.758 28.829 28.948 28.582 28.465
27.311 27.447 27.535 27.416 27.610 27.434 28.295
23.963 24.023 23.949 23.658 23.830 23.892 24.475
32.060 31.987 31.457 32.169 31.861 31.670 33.230
28.293 28.192 28.228 28.248 28.571 28.370 29.001
29.483 28.559 28.873 28.744 28.925 28.843 29.998
29.502 29.896 30.156 30.274 29.487 30.112 30.843
30.534 29.461 30.067 30.162 30.135 29.615 30.996
29.378 29.026 29.269 28.915 29.158 29.437 29.782
29.573 28.800 29.175 28.763 28.589 29.253 29.835
28.831 28.841 28.968 28.670 28.610 28.820 29.090
26.284 26.921 26.541 26.444 26.463 26.627 27.674
28.346 28.480 28.172 28.122 28.360 28.251 28.853
29.361 29.333 29.767 28.945 29.215 29.373 29.955
27.675 27.548 27.582 27.164 27.528 27.561 28.092
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29.429 29.373 29.247 28.960 29.320 29.272 29.725
27.607 27.703 28.068 27.754 27.672 28.252 28.346
28.721 28.737 28.267 28.555 29.066 28.670 29.427
32.082 32.142 32.734 31.518 32.047 32.328 32.535
28.982 29.291 28.997 29.349 28.955 29.416 29.886
26.536 26.926 26.941 26.554 26.549 26.630 26.973
28.087 27.976 28.332 27.756 27.994 27.959 28.262
30.585 30.437 29.919 30.146 29.795 30.394 31.125
28.391 28.594 28.356 28.337 28.583 28.421 29.254
27.408 27.002 27.342 26.836 27.156 27.029 27.683
26.547 28.243 27.074 27.377 27.240 26.624 26.977
27.648 28.264 27.711 27.257 27.445 27.836 28.028
26.762 26.472 26.559 26.379 26.584 26.583 26.846
29.027 28.803 28.649 28.705 28.980 29.152 29.532
28.259 28.093 28.342 28.313 28.377 28.338 29.227
29.761 28.200 30.227 29.131 29.510 29.323 30.223
28.644 28.888 28.639 28.526 28.728 28.747 29.711
29.723 29.840 29.572 29.304 29.484 29.857 30.449
30.090 29.587 29.512 29.043 29.056 29.608 30.464
27.275 27.073 26.890 26.736 26.861 26.956 27.610
27.067 27.028 27.281 27.006 27.045 26.943 27.525
30.508 29.797 29.803 29.875 30.040 30.508 30.752
26.046 26.156 26.144 25.616 25.877 25.910 26.751
30.291 30.419 30.550 29.895 30.159 30.379 31.201
30.909 30.824 30.879 30.480 31.041 30.235 29.492
31.883 31.727 31.470 31.142 31.898 30.638 30.934
31.445 31.560 31.466 32.144 31.731 31.429 32.480
29.116 28.805 28.570 28.585 28.647 29.021 29.357
28.339 28.312 28.471 28.255 28.292 28.317 28.677
39.423 32.827 38.733 37.755 32.758 33.908 38.294
29.266 31.581 28.757 29.650 29.244 29.394 30.141
29.230 29.025 28.938 28.966 29.216 28.927 30.279
30.131 29.904 29.694 29.517 29.533 29.673 29.881
28.902 27.719 28.679 28.402 28.514 28.484 28.951
28.383 28.656 28.660 28.244 28.082 28.268 29.472
25.229 25.050 25.423 24.995 25.022 25.120 25.757
28.332 28.165 28.116 27.913 28.112 28.176 28.472
28.903 28.470 28.706 28.415 28.559 28.672 29.533
27.291 27.869 27.055 27.263 27.180 27.192 27.945
29.798 29.902 29.684 29.344 29.973 29.812 30.561
33.508 33.221 32.712 33.746 32.833 33.996 31.894
28.391 28.316 28.496 28.300 28.189 27.849 29.237
29.199 29.401 29.954 29.357 29.159 29.992 29.481
27.999 28.260 27.968 28.150 27.926 27.663 27.932
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32.573 31.582 32.372 31.316 32.024 31.767 32.388
31.111 30.631 30.797 29.921 30.770 30.509 31.017
30.179 30.005 30.255 29.920 30.039 29.987 30.792
26.850 26.540 40.000 37.496 40.000 40.000 35.662
31.160 40.000 31.395 31.663 31.292 31.585 31.862
30.657 30.621 29.993 30.484 30.187 30.442 31.358
26.708 26.728 26.263 26.527 26.671 26.801 27.326
29.878 30.182 29.930 29.068 31.242 29.200 30.150
29.509 29.782 29.583 29.528 29.935 29.841 30.731
31.366 30.757 31.560 31.015 30.976 30.863 32.127
28.247 27.531 28.003 27.427 27.861 27.605 28.749
31.197 31.725 40.000 31.279 31.297 32.050 40.000
28.579 28.437 28.720 28.656 28.676 28.766 29.254
28.957 28.545 28.647 28.321 28.429 28.282 29.261
27.656 27.158 27.284 27.061 27.115 26.982 27.743
31.354 30.691 31.335 31.343 30.802 31.296 30.384
29.438 29.337 29.934 29.397 29.358 29.803 29.535
20.967 21.323 21.028 20.604 21.141 20.896 21.576
26.613 27.175 26.516 26.791 26.678 26.441 28.083
30.911 31.309 30.870 30.459 30.629 30.961 31.578
28.033 28.336 28.046 27.993 27.963 28.043 28.769
26.859 26.782 26.679 26.375 26.374 26.545 27.252
29.197 28.149 28.535 28.043 28.559 28.462 29.316
29.508 28.190 28.455 28.284 28.322 28.578 29.512
28.398 28.531 28.526 28.168 28.086 28.631 28.881
27.341 27.649 27.154 27.320 27.308 27.392 27.672
27.991 27.909 27.644 27.641 27.703 27.580 28.732
30.789 30.870 30.623 30.159 30.727 30.571 31.335
26.109 26.079 26.206 25.923 26.009 26.014 26.675
26.973 26.798 26.973 26.709 26.700 26.690 27.551
29.169 28.680 28.790 28.796 28.888 28.953 29.822
27.571 27.873 27.850 27.772 27.760 27.605 28.142
24.231 24.501 24.218 24.168 24.223 24.313 24.804
33.580 33.833 33.564 33.627 33.315 33.714 33.661
28.074 28.609 28.313 27.974 27.944 28.265 28.593
29.053 30.238 29.736 29.397 30.146 29.596 29.737
27.943 28.191 27.940 27.645 28.007 27.851 28.443
28.458 28.035 28.312 28.305 28.274 28.180 29.103
28.122 28.623 28.165 28.163 28.160 28.192 29.275
25.817 25.821 26.083 25.730 25.702 26.001 26.611
26.850 26.779 26.772 26.161 25.932 26.585 26.961
28.549 28.613 28.590 28.226 28.242 28.641 29.133
27.718 27.816 28.043 27.653 27.688 27.823 28.174
30.456 29.467 29.904 29.500 29.756 30.129 31.220
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35.034 35.542 27.943 40.000 33.213 40.000 40.000
28.774 29.783 28.984 29.104 28.864 29.127 29.180
27.014 26.557 26.794 26.235 26.567 26.651 27.254
27.644 27.698 27.800 27.626 27.381 27.557 28.336
27.949 27.692 27.958 27.615 27.838 27.704 28.196
28.730 29.265 29.255 28.412 29.328 29.197 29.746
27.705 27.427 27.407 27.376 27.553 27.572 27.545
27.912 27.893 28.023 27.884 27.954 27.811 28.810
30.114 32.326 29.542 31.522 29.713 29.451 30.631
29.105 29.142 28.896 28.739 28.644 29.071 29.580
24.549 24.298 24.812 24.478 24.712 24.757 25.454
28.953 28.104 28.403 28.317 28.610 28.111 29.654
40.000 40.000 40.000 40.000 21.782 40.000 25.901
27.083 27.008 26.700 26.613 26.799 26.741 27.381
26.586 26.400 26.493 26.244 26.254 26.366 26.922
29.944 29.045 28.797 28.747 28.863 27.746 29.076
27.304 27.193 27.237 27.155 27.197 27.089 27.671
27.618 27.456 27.530 27.052 27.284 27.094 27.960
27.332 26.726 26.911 26.565 27.014 26.974 27.469
30.883 30.690 30.733 30.334 30.992 30.537 31.255
27.697 27.696 27.630 27.490 27.502 27.473 27.977
26.742 26.479 26.824 26.187 26.665 26.437 40.000
28.975 28.923 28.462 28.495 28.707 28.554 29.272
27.207 26.628 26.629 26.518 26.828 27.044 27.760
28.927 29.154 28.854 28.610 28.746 29.000 29.114
34.498 34.077 34.800 35.032 34.255 33.944 33.943
28.641 28.871 28.884 28.602 28.424 28.286 26.915
29.345 28.972 28.758 29.263 28.231 28.715 29.273
27.663 27.990 27.938 27.805 27.676 27.914 28.097
29.704 29.699 29.555 29.553 29.595 29.579 30.283
28.851 28.771 28.580 28.550 28.963 28.680 29.505
27.977 28.577 28.465 28.233 28.119 28.198 28.252
30.094 29.786 29.784 29.552 29.708 29.963 30.817
25.709 25.931 25.512 25.567 25.578 25.427 26.355
29.036 28.173 29.092 27.934 28.457 28.325 29.422
28.749 28.466 28.505 28.082 28.578 28.662 29.004
27.594 27.106 27.462 27.224 27.340 27.194 27.929
32.220 31.725 32.732 31.567 31.894 32.181 32.296
29.481 29.383 29.666 29.428 29.600 29.804 30.403
28.339 28.341 28.271 28.007 28.178 28.174 29.788
27.114 27.677 27.579 27.329 27.191 27.596 27.732
28.954 29.133 29.047 28.632 28.983 29.452 30.105
28.502 27.819 27.903 28.037 28.072 28.207 28.996
29.124 29.151 29.056 29.330 29.056 29.148 29.551
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28.458 28.030 28.251 27.891 28.151 28.214 28.853
26.483 26.165 26.592 26.309 26.377 26.406 27.111
30.019 29.939 29.632 29.646 29.603 30.109 30.013
28.036 27.668 27.406 27.276 27.574 27.721 28.517
27.938 27.821 27.772 27.428 27.782 28.016 28.594
28.250 27.815 27.747 27.843 27.814 28.084 28.740
29.247 29.545 29.787 29.251 29.413 29.447 30.276
27.366 27.484 27.784 27.204 27.524 27.542 27.853
29.247 30.172 28.362 28.905 28.576 28.626 29.043
29.390 29.458 29.372 29.181 29.273 29.412 30.094
26.368 26.102 26.094 25.982 25.900 26.023 26.640
29.593 29.223 29.589 29.439 29.528 29.267 30.066
29.563 28.834 29.808 29.105 29.500 28.950 30.431
26.899 27.152 27.351 26.966 27.181 26.849 27.308
26.125 26.939 26.979 26.631 26.763 26.804 26.840
29.590 28.665 29.104 29.064 28.893 29.207 30.099
30.054 30.329 30.304 30.439 30.222 30.362 30.437
30.651 31.776 30.785 30.855 30.573 30.109 29.131
30.572 31.137 30.649 30.242 30.250 30.605 31.045
29.414 29.531 29.597 29.323 29.457 29.509 29.668
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PostMnPsNormK102594PostMnPsNormK102686PostMnPsNormK104875PreMnPsNorm06AH275PreMnPsNorm06RMH457PreMnPsNorm06RMH469PreMnPsNorm06RMH501
25.144 25.693 24.595 26.906 28.396 27.195 26.844
28.493 29.034 28.039 30.195 31.923 30.057 29.990
27.594 27.492 27.120 27.658 34.899 31.718 31.381
29.039 30.501 28.901 29.929 40.000 32.949 32.736
33.878 34.524 32.970 34.659 40.000 40.000 35.580
26.198 26.380 25.945 27.725 29.738 27.580 27.373
27.304 27.583 26.648 28.326 29.246 27.829 27.591
30.633 31.604 29.477 31.068 31.236 31.021 29.722
31.295 31.958 30.960 32.909 32.687 40.000 32.932
28.463 28.870 28.116 29.478 31.149 29.962 29.477
29.141 29.040 27.982 30.313 32.528 30.888 31.146
40.000 33.670 30.581 33.129 34.823 32.347 34.014
29.256 30.085 29.328 30.400 32.213 30.323 30.272
27.822 28.165 27.365 29.338 30.182 28.697 28.397
40.000 33.396 40.000 40.000 37.156 34.343 40.000
32.903 33.478 32.764 34.226 40.000 40.000 40.000
28.950 29.031 28.572 29.695 32.908 31.864 31.051
40.000 28.610 40.000 40.000 25.775 40.000 40.000
26.119 25.966 25.629 26.940 29.861 28.072 27.736
24.961 25.578 24.746 26.269 29.785 26.902 26.402
28.149 28.481 27.852 29.298 32.225 30.928 30.644
31.137 32.332 30.872 31.783 40.000 34.980 33.143
25.558 25.608 24.905 26.393 28.432 27.416 26.600
35.643 35.045 34.118 36.297 36.684 35.777 40.000
40.000 35.989 35.235 35.151 37.778 37.718 37.385
27.212 26.829 26.436 28.944 28.383 27.572 27.393
28.443 29.289 28.528 29.960 30.517 29.199 28.825
37.035 40.000 40.000 40.000 36.845 34.570 35.702
29.241 29.672 28.977 30.139 32.187 30.970 30.707
29.544 29.560 29.486 29.416 36.146 32.750 32.222
27.579 28.129 27.526 28.668 33.573 30.272 30.152
30.145 30.348 29.834 31.397 29.999 30.216 30.431
27.209 27.032 26.798 26.561 31.446 29.464 28.850
32.858 33.212 40.000 34.613 40.000 31.422 35.471
40.000 40.000 35.377 40.000 40.000 40.000 40.000
28.085 28.116 27.640 28.640 32.346 30.432 29.943
32.004 32.197 31.320 33.655 36.180 34.214 33.007
25.320 25.902 24.739 26.611 29.763 27.798 27.334
26.754 27.543 26.451 27.622 30.695 29.060 28.536
31.505 31.944 31.675 32.953 33.794 33.924 33.416
28.795 28.785 28.378 29.449 31.539 30.686 30.253
28.065 28.515 27.550 29.312 31.192 28.884 28.384
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26.329 26.875 26.025 27.586 29.748 28.009 27.527
29.204 29.609 28.860 30.250 33.082 30.556 30.176
25.990 27.344 25.642 27.381 27.321 27.234 27.295
29.357 29.521 28.947 30.383 34.350 32.010 31.413
25.162 25.570 25.023 25.856 28.136 25.991 25.436
30.816 30.761 29.947 31.977 30.504 30.934 30.992
28.117 28.570 28.123 29.091 36.420 32.582 31.868
29.658 30.140 29.301 30.748 33.639 31.431 30.797
25.944 26.211 25.245 27.258 29.388 27.520 27.110
33.604 33.254 32.790 34.870 34.886 33.352 34.250
31.614 31.508 30.534 32.476 32.670 31.713 32.140
28.733 28.791 28.611 29.612 40.000 31.623 31.481
29.806 30.251 28.974 30.886 32.044 30.982 30.499
27.354 27.583 27.296 28.366 30.858 28.764 27.633
27.972 28.144 27.627 28.875 30.276 28.731 28.472
35.386 29.556 35.808 36.029 35.670 27.467 35.381
28.805 40.000 28.796 29.726 32.657 31.294 30.588
27.040 27.871 26.538 28.318 31.752 29.120 28.742
30.098 30.596 29.770 32.078 29.882 30.037 29.905
29.667 29.858 29.128 30.754 34.671 31.608 31.008
37.318 37.714 40.000 40.000 40.000 40.000 40.000
23.293 23.169 22.249 24.058 27.928 25.691 25.027
23.220 24.156 23.211 24.622 25.028 24.746 23.947
29.448 29.966 28.725 30.461 33.425 31.676 31.847
29.567 29.788 29.083 30.274 40.000 33.711 33.226
30.056 30.574 29.554 31.485 33.078 31.963 31.897
29.772 30.854 29.783 30.890 31.534 30.921 30.898
32.210 31.815 31.704 32.565 32.475 33.859 32.637
27.594 28.315 27.556 28.855 34.694 31.491 30.947
28.982 28.507 29.157 28.917 40.000 34.922 33.865
28.148 28.423 27.563 28.971 30.132 29.495 29.288
24.321 24.898 23.845 25.519 29.840 26.513 25.886
31.869 32.842 31.705 40.000 33.871 33.214 33.210
28.614 29.172 28.295 30.155 32.911 30.661 30.295
29.757 30.107 29.490 31.179 35.287 32.919 32.379
30.038 30.267 29.559 31.546 40.000 33.984 32.756
30.526 31.536 31.015 30.958 35.294 32.946 32.481
29.727 30.380 28.901 30.243 34.064 32.573 31.511
29.982 30.562 29.566 30.192 30.827 30.111 30.157
28.958 29.943 29.099 30.345 34.995 32.385 31.370
27.222 26.921 26.054 27.168 30.944 28.435 28.083
28.928 28.896 28.242 30.021 32.237 31.114 30.632
29.586 29.904 29.271 30.785 36.446 33.930 32.473
27.854 27.834 27.409 28.903 31.235 29.597 29.442
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29.616 30.026 29.353 30.649 34.982 32.736 31.994
28.434 28.582 27.920 28.969 33.596 31.304 30.215
29.620 29.073 29.244 30.314 32.901 40.000 30.602
31.995 33.607 32.077 33.650 33.190 33.388 33.480
29.858 30.472 29.014 30.217 32.290 31.659 31.417
26.877 27.735 26.657 28.366 30.758 28.746 28.437
28.037 28.155 27.842 29.438 34.420 31.803 30.370
30.671 30.790 30.395 31.986 35.111 32.648 31.938
28.687 28.721 28.188 30.218 30.016 29.302 29.284
27.690 28.135 27.350 28.826 32.221 29.969 29.837
26.817 27.586 27.324 28.847 30.071 28.847 29.052
27.822 28.071 27.535 29.182 31.921 30.765 30.271
26.642 27.541 26.493 27.962 31.605 28.986 28.609
29.184 29.965 28.683 30.394 34.836 32.314 32.018
28.778 28.832 28.162 29.550 40.000 30.779 30.349
30.935 31.481 30.842 31.840 33.231 32.806 32.414
29.332 29.250 28.769 30.138 31.624 30.660 30.798
30.183 30.621 29.495 30.934 33.155 31.748 31.185
30.162 30.519 29.691 31.379 40.000 31.171 31.606
27.200 27.458 27.108 28.741 32.885 30.437 30.031
27.195 27.686 26.929 28.374 29.379 28.432 28.175
30.603 31.613 40.000 32.165 35.711 33.217 32.309
27.396 27.505 25.688 27.304 31.560 29.227 28.504
30.377 30.738 29.863 31.689 34.462 33.014 31.861
30.272 30.712 30.892 28.771 40.000 34.954 34.227
31.710 30.636 32.352 29.311 40.000 36.493 37.711
31.898 31.773 31.360 33.326 35.864 34.531 33.198
29.203 29.559 28.941 30.332 32.407 31.381 31.091
28.490 28.614 28.283 28.754 34.535 31.525 30.710
40.000 36.483 38.594 40.000 40.000 32.844 38.321
29.380 29.865 29.841 31.309 32.936 31.011 30.535
29.730 30.259 29.557 31.097 33.154 31.376 30.871
30.048 30.377 29.584 31.262 32.315 31.479 31.644
28.885 29.193 29.059 29.818 36.470 31.921 31.405
28.395 29.017 28.142 29.647 32.558 31.272 30.802
25.521 25.618 24.809 26.555 29.143 28.017 27.530
28.483 29.138 28.333 29.274 33.822 32.113 31.644
29.072 29.251 28.700 29.886 35.137 32.454 32.065
27.289 28.195 27.363 28.978 31.442 29.951 29.570
29.990 30.159 29.571 31.066 30.475 30.093 30.218
33.196 31.585 32.698 31.890 36.917 36.289 35.431
28.936 29.011 28.216 29.663 31.845 30.334 29.940
29.524 29.409 29.077 29.892 32.675 31.792 31.694
28.280 28.010 28.174 28.077 35.709 32.208 32.185
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32.176 32.602 31.409 33.781 35.424 35.541 36.693
31.760 31.726 30.821 31.912 33.163 33.149 32.670
30.648 30.900 30.180 30.999 33.422 31.774 31.336
35.954 40.000 40.000 40.000 40.000 36.716 40.000
31.515 32.029 31.529 33.350 32.506 32.548 32.185
30.958 31.416 30.451 32.222 34.105 32.222 31.945
26.618 27.600 26.597 28.518 29.427 29.116 28.721
29.721 30.954 30.987 30.449 33.414 33.528 32.364
29.959 30.210 29.283 31.266 30.500 30.200 30.046
31.888 31.852 31.860 40.000 40.000 34.984 34.813
28.486 28.538 27.876 29.723 31.032 29.672 29.160
31.830 31.841 40.000 40.000 36.383 33.132 33.341
29.250 29.359 29.108 30.375 32.809 30.818 30.498
29.137 29.829 28.763 30.181 33.772 31.570 31.136
27.852 27.950 27.698 29.077 32.431 30.853 30.336
31.468 31.566 31.430 30.150 35.209 33.171 33.206
29.807 30.366 29.400 30.951 32.313 31.309 31.211
21.722 21.805 21.112 22.278 26.901 24.021 23.018
27.833 27.690 27.303 28.201 31.060 28.536 28.004
31.322 31.845 30.814 31.999 33.445 32.430 31.991
28.329 28.675 27.858 29.665 30.192 29.287 28.989
27.179 27.708 26.856 28.601 32.515 30.044 29.302
29.181 29.410 29.306 29.914 34.270 31.598 31.251
29.696 29.662 29.097 29.941 40.000 32.954 31.965
28.561 28.955 28.553 29.409 31.429 29.914 29.896
27.358 27.792 26.951 27.570 32.403 29.450 29.041
27.978 28.711 27.963 29.238 33.735 31.261 30.116
30.977 31.788 30.529 32.268 40.000 35.220 34.250
26.529 26.836 25.946 27.565 30.283 28.067 27.291
27.011 27.468 27.221 28.051 29.945 28.135 28.075
29.712 29.651 29.452 30.663 36.536 32.804 32.557
28.265 28.288 27.875 29.338 30.928 29.632 30.620
24.981 24.468 23.941 24.699 27.918 26.825 26.180
33.935 33.671 33.715 36.022 35.853 33.484 33.619
28.621 29.550 28.167 29.422 31.660 30.463 30.169
29.735 29.349 29.523 29.247 31.960 31.124 30.616
28.312 28.433 27.534 29.093 31.927 30.397 30.004
28.571 28.876 28.336 29.831 30.839 29.351 29.379
28.370 28.424 28.348 29.439 33.584 31.129 30.407
26.127 26.271 26.226 27.195 28.396 26.924 26.623
26.624 27.835 26.886 28.536 28.808 28.166 27.660
28.575 29.060 28.458 30.003 35.945 31.907 31.649
28.106 27.990 27.571 29.057 33.609 30.636 30.605
30.116 31.942 29.932 31.153 36.038 40.000 33.196
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33.599 40.000 32.801 36.074 40.000 34.061 40.000
29.001 29.674 29.142 29.216 32.596 30.918 31.464
27.122 27.592 26.755 28.158 30.378 29.055 28.991
28.396 28.183 27.302 29.017 32.372 30.338 29.942
29.029 28.497 28.041 29.352 32.840 30.604 30.024
30.005 29.806 28.608 30.684 32.746 30.921 29.861
27.762 27.655 27.515 28.139 33.711 31.167 40.000
28.369 29.056 27.980 29.476 30.012 28.895 28.770
29.648 30.664 30.666 31.778 32.370 29.637 31.959
29.299 29.927 28.856 30.534 33.700 31.312 30.643
25.504 26.393 24.956 26.268 26.452 26.019 25.972
29.503 29.517 28.893 30.340 31.814 30.567 30.375
21.175 40.000 40.000 40.000 26.290 25.667 40.000
27.238 27.339 26.850 28.527 34.477 30.813 29.879
27.168 27.279 26.565 27.924 29.462 28.652 28.065
29.887 31.240 30.288 29.604 37.302 34.119 34.393
27.596 28.750 27.296 27.988 30.503 29.027 28.530
27.998 28.894 27.265 29.022 30.458 29.166 29.273
27.392 27.673 26.883 28.565 30.257 28.863 28.255
31.324 31.382 30.723 31.704 34.005 32.328 31.821
28.396 28.335 28.105 29.233 33.697 30.274 30.022
27.184 27.361 26.574 28.270 30.288 28.512 28.341
28.620 29.170 28.462 29.916 31.911 30.325 29.896
27.496 28.452 26.948 28.605 31.871 29.571 29.377
28.801 29.224 28.292 30.107 31.348 30.253 30.035
36.429 35.719 35.392 40.000 40.000 36.253 40.000
27.838 27.967 28.795 26.427 34.161 32.314 32.503
29.326 29.986 28.678 30.526 34.366 32.509 31.723
27.696 28.409 27.649 28.100 40.000 30.372 29.657
29.698 40.000 29.213 30.367 40.000 31.349 31.070
29.492 29.638 28.688 29.941 32.342 31.194 30.995
28.484 28.318 27.869 29.213 31.682 30.022 29.342
30.000 30.356 29.883 31.241 35.261 32.711 32.287
26.304 26.574 25.378 27.548 31.013 28.890 28.322
29.378 29.998 29.176 30.378 32.409 30.546 30.121
28.646 29.238 28.555 29.989 34.902 32.185 31.842
27.896 28.653 27.549 29.038 33.040 29.939 29.495
32.362 32.226 31.423 32.462 40.000 34.100 34.852
30.048 30.234 29.861 31.012 35.640 33.072 32.997
28.895 28.970 28.173 29.837 31.859 30.079 30.198
27.369 27.832 27.268 28.801 30.375 28.797 28.536
29.216 30.482 28.615 30.329 29.414 29.736 29.468
28.759 29.359 28.230 29.826 31.557 30.164 29.924
29.133 29.831 29.153 30.556 33.394 31.475 31.634
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28.779 29.109 28.495 29.559 34.225 32.492 31.983
26.988 27.558 26.627 28.085 33.187 29.619 28.970
29.860 30.962 29.920 29.918 33.737 32.525 31.816
27.922 28.564 27.611 28.975 34.429 32.244 31.323
28.544 28.773 27.859 29.332 30.796 29.641 29.514
28.075 28.873 28.089 29.506 32.665 31.040 31.050
29.864 29.980 29.108 31.461 31.906 31.046 30.502
27.836 27.755 27.045 28.626 33.056 30.184 29.023
28.592 28.980 28.900 30.578 34.942 32.330 31.484
30.008 30.577 29.603 31.168 32.539 31.140 30.539
26.548 26.960 26.606 27.644 31.434 29.370 28.752
30.817 31.011 30.055 31.086 33.105 31.540 31.868
29.682 30.863 30.686 30.860 33.745 31.403 31.294
27.665 27.547 27.175 28.241 29.461 28.390 27.859
26.932 26.969 26.905 28.105 28.563 27.597 27.347
29.751 30.228 29.368 30.691 30.748 30.164 29.955
30.581 30.942 30.049 31.339 33.087 32.013 31.882
30.532 29.560 30.796 28.943 36.875 34.162 35.235
30.523 30.928 30.318 31.728 33.583 32.281 31.616
29.762 29.680 29.392 31.216 32.844 31.030 31.013
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PreMnPsNorm09RMH068PreMnPsNorm09SH125PreMnPsNorm601387PreMnPsNorm700698PreMnPsNorm700836PreMnPsNormK100806PreMnPsNormK100814
25.106 25.609 24.324 25.990 26.732 24.407 24.836
29.381 28.753 28.088 29.094 30.145 27.468 27.908
28.351 27.796 26.469 29.321 30.122 27.597 28.034
29.446 29.512 27.476 29.865 30.483 28.446 28.952
35.011 34.177 32.161 40.000 36.165 33.904 34.314
27.499 26.266 25.026 25.898 27.154 25.394 25.574
27.339 27.030 26.163 26.510 27.534 26.282 26.260
32.462 30.555 29.801 30.429 31.619 28.142 29.777
31.656 40.000 31.192 40.000 32.837 30.248 30.714
28.659 28.955 27.331 29.238 29.753 27.929 28.266
32.014 28.733 27.026 28.837 29.742 28.316 28.580
40.000 32.492 32.041 33.912 32.527 31.114 31.694
30.241 29.721 28.636 29.577 29.787 28.435 28.470
26.925 28.063 26.617 28.103 28.332 26.656 27.286
40.000 31.579 30.166 31.938 32.706 31.481 31.425
32.947 32.897 30.519 34.265 34.292 31.996 32.831
29.583 28.961 27.073 28.687 29.755 28.124 28.448
40.000 40.000 40.000 24.906 40.000 40.000 23.530
26.386 25.893 24.969 26.185 27.242 25.339 25.665
24.825 25.629 23.033 25.291 26.129 24.036 24.472
28.635 28.255 26.904 27.981 28.955 27.465 27.937
31.487 31.762 29.931 32.201 32.483 30.539 31.060
23.975 25.762 26.010 27.434 27.666 24.099 25.147
36.017 34.603 33.837 34.304 34.464 33.130 33.737
32.436 40.000 31.838 34.432 40.000 36.320 33.636
26.904 26.420 25.107 27.240 28.087 25.077 25.772
28.480 28.221 27.606 27.857 29.163 27.340 28.160
32.623 35.036 32.632 34.377 36.107 33.831 33.516
29.138 29.441 29.037 28.986 29.927 27.964 27.883
30.376 29.514 28.143 30.258 31.093 29.020 29.487
28.380 28.125 26.924 28.025 28.636 27.086 27.607
29.474 31.033 30.217 30.377 31.291 28.842 29.840
27.694 27.593 26.684 27.773 28.501 26.700 26.907
31.962 35.421 32.356 33.777 33.088 33.990 32.037
40.000 35.757 36.711 40.000 35.464 40.000 40.000
28.039 28.039 26.191 28.248 29.215 26.805 27.551
31.917 32.392 30.474 31.879 32.533 30.065 31.355
26.359 25.820 23.831 24.916 26.101 24.343 24.320
27.410 26.654 25.683 26.600 27.793 26.195 26.449
32.389 32.296 31.056 32.330 32.597 30.799 31.333
29.997 28.505 26.839 28.339 29.465 27.799 28.164
28.239 28.229 27.140 28.649 28.822 27.196 27.389
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26.415 26.467 24.552 26.923 27.173 25.312 25.777
29.522 29.727 27.717 29.604 30.048 28.297 28.973
27.502 26.172 24.805 26.336 27.240 25.458 25.629
30.170 29.400 27.793 29.388 30.237 28.366 28.446
25.037 25.318 23.790 24.999 25.727 23.889 23.982
31.135 30.522 29.075 30.960 31.601 29.136 29.672
29.133 28.733 26.493 28.947 30.038 27.378 27.928
30.096 29.912 28.493 30.124 30.901 28.574 29.211
25.933 26.034 24.126 26.388 26.839 24.509 25.190
35.418 32.592 32.400 32.764 33.175 32.086 32.302
31.742 31.130 30.325 31.156 31.867 29.820 29.920
29.918 28.963 27.534 28.853 30.227 28.303 28.622
30.175 29.668 28.142 29.636 30.481 28.182 28.738
28.463 28.066 26.959 27.332 27.939 26.601 26.193
28.253 27.755 26.834 27.482 27.937 26.667 26.737
28.853 28.604 35.849 40.000 40.000 40.000 40.000
28.419 28.970 28.109 28.856 29.521 27.796 28.467
27.767 27.326 25.854 27.508 28.124 25.596 26.003
29.807 30.671 29.893 31.200 31.283 28.714 29.352
30.449 29.969 28.280 29.672 30.374 28.594 28.946
40.000 40.000 40.000 33.567 37.954 33.801 34.461
23.610 22.814 20.599 23.401 23.967 21.779 22.209
22.937 24.302 23.464 40.000 24.689 22.082 23.135
30.430 29.747 27.862 30.506 30.678 28.589 29.112
30.010 29.691 27.555 29.687 30.705 27.877 40.000
30.728 30.254 28.969 30.509 31.513 29.095 29.603
30.636 30.758 29.890 30.447 31.174 28.623 29.324
31.201 31.737 31.165 32.119 32.865 31.234 31.951
27.479 27.828 26.739 28.079 29.099 26.575 26.973
30.788 29.028 28.448 32.087 32.205 29.726 30.059
27.021 27.837 26.812 28.686 29.489 27.474 27.727
24.903 24.549 22.645 24.954 25.541 23.210 23.726
33.041 32.105 31.579 33.044 32.983 30.679 31.402
29.139 29.042 27.615 29.443 29.925 27.859 28.424
29.850 30.163 28.406 29.994 30.875 28.441 28.958
31.289 30.845 28.629 29.883 30.728 28.757 28.833
30.666 31.404 29.672 30.336 31.830 29.861 30.419
30.565 30.114 28.077 30.545 31.320 28.548 29.279
29.290 29.777 29.108 28.962 29.498 28.678 29.061
30.277 29.100 27.881 29.311 29.971 28.336 28.562
27.451 26.879 25.044 27.647 27.917 24.781 25.982
29.029 28.789 27.390 28.978 29.520 27.700 28.023
30.076 29.672 28.254 30.191 31.101 28.943 29.268
28.752 28.076 26.837 28.058 28.819 27.268 27.492
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30.124 29.772 28.175 29.785 31.005 28.795 29.296
28.628 28.380 26.755 27.938 29.065 27.337 27.347
29.371 29.644 27.967 29.136 30.042 27.207 27.781
31.631 32.430 31.720 31.797 32.397 31.277 31.432
29.980 29.353 28.230 29.440 30.671 28.377 29.386
27.991 26.977 26.035 27.218 27.871 27.091 27.131
28.840 28.277 26.790 28.158 29.249 26.909 27.187
31.306 30.909 29.286 30.719 31.614 29.019 29.725
29.424 28.978 27.766 28.971 29.770 28.183 28.357
28.223 28.081 26.306 27.843 28.572 26.621 27.202
30.015 27.115 25.702 27.318 27.689 26.592 26.257
28.584 27.924 26.640 27.989 29.287 27.227 27.275
27.311 27.021 25.773 26.652 27.707 26.083 26.352
30.181 29.578 28.149 29.408 30.263 28.272 28.479
28.892 28.497 26.996 28.072 29.166 27.867 27.964
29.616 31.673 30.156 31.386 31.659 29.252 30.046
30.079 29.292 27.613 28.937 29.641 27.895 28.117
29.951 30.393 28.881 30.023 30.928 28.670 29.301
30.212 30.125 29.158 29.759 30.287 28.607 29.541
28.159 27.843 26.115 27.829 28.722 26.819 26.755
28.623 27.272 26.456 26.768 28.062 26.356 26.727
30.955 30.997 29.538 31.197 31.825 29.578 29.946
27.115 26.071 24.045 27.108 28.195 25.181 25.647
31.154 30.709 29.143 30.938 31.570 29.429 30.079
31.797 30.052 30.314 31.769 32.326 30.245 30.866
32.416 31.052 31.974 40.000 34.575 40.000 32.419
40.000 33.292 30.713 31.277 32.857 30.726 31.083
29.626 29.417 27.837 29.032 30.215 27.668 28.066
29.219 28.619 27.162 29.663 30.174 27.917 28.440
40.000 32.896 34.657 40.000 29.155 39.192 33.748
31.863 29.899 29.663 29.875 30.748 29.614 29.206
29.630 30.402 28.076 31.065 30.838 28.331 29.038
30.168 30.184 28.416 30.553 30.961 29.034 29.171
29.155 29.203 28.250 29.378 30.091 28.018 28.632
29.435 28.387 26.975 29.018 29.504 27.387 27.814
25.340 24.902 23.026 24.995 25.947 23.970 24.348
28.838 28.392 27.380 28.378 29.329 27.850 27.877
29.725 29.375 27.242 29.715 30.823 28.631 29.150
28.536 27.936 26.446 27.430 28.600 27.017 27.102
30.286 29.859 28.892 29.880 30.640 29.094 29.411
33.205 40.000 33.100 33.966 34.095 32.608 32.338
28.321 28.438 27.271 27.535 29.255 27.294 28.132
29.963 29.749 27.591 29.326 30.310 27.931 29.263
29.766 28.473 28.427 29.988 30.410 27.851 28.447
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32.032 40.000 30.949 32.500 33.210 31.764 31.364
31.190 30.431 29.763 31.786 32.180 29.572 30.277
30.638 30.160 29.379 30.688 31.167 29.760 30.124
30.876 40.000 29.830 34.937 40.000 40.000 33.320
32.558 31.745 31.527 32.156 32.440 30.753 31.419
30.488 31.070 29.354 31.416 31.265 29.771 30.360
27.976 27.498 25.879 27.279 28.334 26.241 26.534
34.294 32.046 31.071 30.985 30.826 29.977 30.616
30.785 29.949 29.087 30.352 30.655 28.777 29.349
32.169 32.762 31.041 32.960 34.251 31.033 31.489
28.280 28.789 27.103 28.813 29.223 27.255 27.918
32.374 32.289 30.137 32.149 40.000 30.901 31.298
28.868 28.870 27.280 28.821 29.687 27.841 27.827
29.277 29.621 27.531 29.901 30.445 27.751 28.563
28.447 28.115 26.028 28.120 29.148 26.956 27.380
31.605 32.181 29.341 31.422 32.454 30.226 31.723
31.425 30.049 29.171 30.159 30.410 28.927 29.343
21.974 21.387 18.895 22.053 22.668 20.199 20.796
26.736 27.651 25.600 27.150 27.838 25.291 26.910
31.523 31.304 29.941 31.482 31.663 29.830 30.406
29.362 28.171 27.260 28.562 29.050 27.510 27.884
27.393 27.403 25.045 27.841 28.400 25.928 26.539
28.743 29.387 27.415 28.755 29.973 28.070 28.356
29.504 29.224 27.566 29.521 30.449 28.458 28.967
28.739 28.454 26.365 28.467 28.910 28.000 27.815
28.049 27.866 26.224 28.183 28.649 26.821 27.206
28.465 28.393 26.813 27.672 29.112 27.176 27.203
32.057 31.698 29.581 32.539 33.218 30.074 31.026
26.798 26.252 24.783 26.461 27.391 25.473 25.670
27.943 27.141 26.429 26.987 27.623 26.929 26.829
29.785 29.893 28.049 29.853 30.968 28.706 29.411
28.902 27.890 26.507 27.935 28.597 27.101 27.143
25.011 24.220 22.414 25.186 25.598 22.844 23.627
36.292 34.984 34.609 33.869 34.151 32.376 33.249
29.432 28.779 27.507 28.587 29.451 27.720 28.063
30.707 30.170 29.712 30.624 30.912 29.647 29.459
28.998 28.353 26.897 28.464 29.493 27.177 27.616
28.218 29.228 28.031 29.675 29.750 27.601 28.016
28.834 28.918 27.416 28.857 29.257 27.928 28.131
26.763 26.018 24.729 25.966 26.632 25.272 25.562
27.395 27.491 25.600 27.619 28.063 25.799 26.090
29.527 28.728 27.151 28.490 29.744 27.549 28.126
29.181 27.958 27.122 28.388 29.110 27.433 27.769
30.675 30.593 29.174 30.841 32.208 29.255 30.113
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40.000 33.684 32.184 32.691 34.603 33.158 32.749
29.360 29.499 28.904 28.814 29.975 28.256 28.534
28.158 27.102 25.795 27.072 28.037 26.014 26.273
29.353 27.496 25.962 28.346 28.966 27.271 27.388
28.670 28.373 26.656 28.201 29.183 27.411 27.649
30.042 29.515 28.121 29.836 30.384 28.019 28.675
28.394 28.739 26.924 28.291 29.505 27.191 27.462
28.538 28.364 27.077 28.385 29.200 27.311 27.437
32.059 30.260 27.744 29.264 29.231 29.699 28.785
30.504 28.961 28.292 29.442 30.241 28.262 28.579
24.870 25.600 24.334 25.370 25.940 24.479 25.005
28.928 40.000 27.747 29.444 30.140 27.888 28.623
40.000 40.000 40.000 19.587 18.520 19.214 20.373
28.029 27.384 25.970 27.448 28.268 26.254 26.782
27.545 26.902 25.262 26.715 27.586 25.406 25.773
30.395 29.445 28.593 30.831 31.808 28.997 29.515
27.681 27.988 26.191 28.407 28.989 26.762 27.452
28.306 27.552 26.775 27.595 28.717 26.878 27.108
28.225 27.763 27.013 27.017 28.192 26.338 26.700
31.648 31.063 29.843 31.474 31.947 29.807 30.018
28.233 28.325 26.496 27.978 28.673 27.402 27.442
26.448 27.301 25.199 27.316 27.776 25.765 26.237
29.504 28.803 27.379 28.819 29.632 27.998 28.322
27.666 27.807 26.024 27.734 28.528 26.398 26.959
30.561 29.168 27.582 29.330 29.989 27.913 28.195
40.000 40.000 24.446 36.065 38.492 40.000 36.976
30.051 27.304 27.802 29.064 30.364 28.678 28.259
29.986 30.306 29.059 31.786 31.791 30.475 30.285
28.407 27.394 26.016 27.808 28.521 27.667 27.445
30.382 30.014 28.325 30.227 30.764 28.838 29.577
29.783 29.324 27.734 28.914 29.811 27.710 28.515
29.514 27.643 25.646 27.974 28.582 27.206 27.436
30.682 29.981 28.762 30.332 31.249 29.267 29.713
26.793 25.665 24.090 26.021 26.940 24.925 25.192
28.618 29.619 28.624 29.411 30.037 27.990 29.067
29.671 29.461 27.686 29.675 30.438 28.107 28.748
27.748 28.009 26.784 28.272 28.843 26.988 27.459
31.212 31.057 29.516 31.609 32.955 30.974 31.193
30.432 30.269 28.823 30.323 31.004 28.989 29.454
29.305 28.703 27.302 28.902 29.782 27.393 28.020
28.188 27.534 26.513 27.261 27.980 26.768 27.008
29.536 29.641 28.144 29.533 29.921 28.226 28.418
28.459 28.673 27.274 29.118 29.446 27.532 28.133
30.457 29.606 28.443 29.482 30.683 28.475 28.720
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29.096 28.571 26.864 28.744 29.909 27.538 28.208
26.875 27.093 25.415 27.153 28.145 25.644 26.094
31.865 31.005 30.312 31.515 32.006 29.722 29.867
28.893 28.118 26.240 28.238 29.620 26.869 27.609
28.699 28.275 26.943 28.207 28.982 27.191 27.432
28.995 28.816 27.268 28.787 29.064 27.547 27.643
30.103 30.022 28.654 29.885 30.492 28.536 28.982
27.459 27.461 25.355 27.774 28.450 26.197 26.735
30.835 29.287 26.856 27.980 29.658 28.290 28.693
29.856 30.258 28.352 30.572 30.885 28.940 29.343
27.095 26.598 24.661 26.415 27.496 25.180 25.656
40.000 30.656 28.948 30.943 31.018 29.310 30.006
29.496 31.094 31.157 29.915 30.714 29.108 29.565
28.181 27.615 26.300 27.138 28.133 26.759 26.841
28.475 26.700 25.660 27.086 27.416 26.439 26.161
29.141 30.197 28.966 29.228 29.918 28.667 29.230
31.229 30.243 29.571 30.203 30.792 29.536 29.763
32.497 29.612 29.829 31.166 32.604 30.120 30.574
31.628 30.862 29.199 30.805 31.173 30.432 30.434
30.053 29.619 28.387 29.618 30.469 28.430 29.170
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PreMnPsNormK100816PreMnPsNormK100817PreMnPsNormK100820PreMnPsNormK100824PreMnPsNormK100849PreMnPsNormK100888PreMnPsNormK100894
24.567 24.335 23.879 24.444 24.806 24.897 24.704
28.056 28.034 27.918 28.042 28.285 28.280 27.644
27.744 27.959 27.807 28.085 27.950 28.373 27.305
28.718 28.586 28.617 29.140 28.788 28.858 28.494
40.000 34.065 35.083 33.682 34.213 35.601 33.929
25.836 25.908 25.930 25.797 25.568 25.992 25.325
26.439 26.628 26.515 26.495 26.380 26.732 26.119
29.916 30.596 30.231 29.226 30.275 30.223 30.026
31.140 30.410 31.474 31.156 31.063 30.852 31.152
28.215 28.050 27.952 28.483 28.375 28.340 27.896
28.798 29.342 30.372 29.867 28.103 28.890 27.980
32.224 32.997 33.001 32.549 31.712 32.716 30.805
29.181 28.840 29.175 27.896 29.308 29.161 28.670
26.867 26.842 26.432 27.090 27.158 27.554 27.139
30.903 30.870 30.878 31.348 30.683 31.704 30.699
32.789 32.463 32.221 33.507 32.338 32.657 31.713
28.313 28.643 29.045 28.887 28.272 28.302 27.862
40.000 40.000 40.000 25.339 40.000 40.000 40.000
25.711 25.284 25.613 25.716 25.769 25.666 25.415
24.190 24.261 24.003 24.263 24.141 24.907 24.060
27.793 27.570 27.575 27.548 27.630 28.122 27.181
30.972 31.222 31.298 31.525 30.726 31.123 30.439
23.858 23.252 22.275 24.186 25.437 24.848 25.019
35.030 35.595 33.786 34.347 33.727 35.177 34.054
35.181 33.431 36.207 35.038 33.487 33.554 32.795
25.790 25.041 25.184 26.270 25.753 25.721 25.056
27.990 27.605 27.883 28.206 27.992 28.494 28.122
32.976 32.533 33.523 34.682 33.188 34.233 32.076
28.773 28.185 28.514 28.046 28.875 28.653 28.680
29.360 29.620 29.780 30.169 29.187 29.725 28.989
27.409 27.407 27.334 27.267 27.341 27.702 27.093
29.025 29.231 29.547 29.116 29.771 29.375 29.647
26.991 27.224 27.404 27.237 26.905 27.194 26.788
31.257 31.489 34.484 33.733 35.870 32.207 31.894
40.000 21.420 35.463 21.724 35.983 40.000 16.133
27.211 27.130 27.262 27.661 27.195 27.542 27.231
30.603 30.768 31.237 31.351 30.535 31.149 31.049
24.492 25.364 26.111 24.769 25.008 24.731 24.162
26.211 26.724 26.473 26.255 26.291 27.052 26.085
31.479 30.900 31.012 31.400 31.256 31.557 31.039
28.128 28.392 28.819 28.405 27.756 28.013 27.315
27.497 27.429 27.501 27.392 27.251 27.992 27.293
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25.851 25.841 25.701 26.112 25.622 26.111 25.301
28.630 28.756 29.004 28.662 28.608 28.351 27.816
25.781 26.032 26.276 25.965 25.692 25.572 25.101
28.075 28.772 28.656 28.493 27.978 29.009 28.138
23.886 24.161 23.718 23.722 23.802 24.159 23.736
29.708 30.205 30.086 29.875 29.697 30.020 29.063
27.623 27.866 27.753 27.972 27.413 28.101 27.150
29.085 29.454 29.382 29.167 29.023 29.549 28.847
25.024 25.166 25.577 25.498 25.022 25.321 24.479
32.769 32.833 34.023 32.873 32.111 32.254 31.735
30.475 30.776 30.677 30.391 30.625 30.473 30.195
28.444 28.561 28.684 28.452 28.296 28.549 28.151
28.805 28.817 28.614 28.831 28.674 28.935 28.434
27.175 27.132 27.452 26.253 27.076 27.035 27.148
26.916 26.754 26.690 26.480 26.825 27.234 25.843
35.899 37.047 35.282 40.000 35.105 34.811 34.299
28.180 27.370 27.016 27.696 28.305 28.554 28.373
26.035 26.424 26.784 26.437 26.239 26.426 25.652
29.424 29.537 29.564 29.788 29.513 29.902 29.341
29.128 29.217 29.569 29.272 28.891 29.254 28.695
35.402 36.342 34.993 34.232 36.299 37.966 36.647
22.425 22.800 23.050 23.092 21.834 22.566 21.477
22.875 22.140 22.193 21.597 23.030 23.805 23.971
28.574 29.082 29.890 29.282 28.846 29.169 28.521
28.366 28.636 28.679 28.588 27.813 28.585 27.863
29.430 29.576 30.035 29.728 29.382 29.651 29.220
29.217 29.239 29.484 28.928 29.358 29.471 29.141
31.019 30.920 31.201 32.013 31.973 31.676 30.853
26.661 26.716 25.900 26.867 27.038 27.269 26.941
30.181 30.383 29.869 30.446 29.778 30.433 29.822
27.806 27.786 27.765 28.055 28.055 28.487 27.787
23.596 23.882 23.716 23.861 23.413 23.990 23.223
31.010 32.336 32.209 31.142 31.485 32.265 31.861
28.265 28.445 28.816 28.281 28.204 28.856 28.307
28.664 28.429 28.396 28.862 28.680 29.130 28.667
29.213 30.435 29.911 29.612 29.266 29.900 28.773
30.191 29.669 29.313 29.515 30.653 30.421 30.292
29.252 29.511 29.347 29.195 29.121 29.307 29.020
28.867 28.744 28.149 28.660 29.152 29.528 29.513
28.512 28.592 28.919 28.626 28.363 28.720 28.201
25.873 26.226 26.894 26.853 25.614 26.284 25.552
27.963 28.190 28.000 28.030 28.026 28.307 27.821
29.388 29.339 29.307 29.184 29.090 29.790 28.666
27.397 27.425 27.511 27.679 27.655 27.770 27.047
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29.070 29.292 29.209 29.445 29.245 28.971 28.342
27.416 27.483 26.767 27.384 27.594 27.245 27.389
28.127 28.305 27.361 27.723 27.449 27.854 27.369
31.306 31.058 31.824 31.274 30.766 31.400 31.552
28.773 28.805 28.709 29.512 29.085 28.914 28.336
27.099 27.427 27.567 27.118 27.228 27.443 26.189
27.265 27.561 27.519 27.390 27.108 27.708 26.891
29.294 29.797 29.616 29.996 28.822 29.767 29.349
28.369 28.418 28.714 28.649 28.452 28.572 27.891
27.012 26.875 26.784 26.914 27.209 27.169 26.595
26.855 27.854 28.274 26.766 26.512 26.582 24.657
27.260 27.628 27.722 27.729 27.185 27.654 26.979
26.435 26.443 26.125 26.192 26.384 26.605 25.981
28.376 28.746 28.564 28.425 28.360 28.574 28.351
28.168 28.011 28.049 27.905 27.752 28.226 27.705
29.848 28.929 27.800 29.778 30.387 30.345 30.580
28.264 28.362 28.686 28.298 28.224 28.469 27.750
29.256 29.023 30.036 29.484 28.725 29.505 29.094
28.559 29.021 28.659 28.893 29.150 29.456 29.441
26.900 27.053 27.103 27.375 26.817 26.767 26.014
26.902 26.781 26.692 26.271 27.018 27.052 26.285
29.827 30.314 29.899 30.144 29.744 30.318 29.765
25.788 25.972 25.911 26.010 25.434 25.980 24.879
30.005 30.356 30.754 30.342 29.432 29.894 29.587
31.053 30.663 30.205 30.841 31.138 31.174 30.530
31.638 31.863 33.006 33.155 32.536 32.422 32.217
31.050 31.158 32.908 32.452 31.477 31.943 30.915
27.905 28.062 28.407 28.349 27.870 28.157 27.609
28.499 28.541 28.457 28.552 28.088 28.736 27.629
34.078 33.264 34.245 38.908 36.621 37.077 33.707
29.668 30.527 30.783 29.984 30.871 30.353 29.732
29.319 29.227 29.306 29.740 29.220 29.528 29.098
29.072 29.213 29.150 29.562 28.733 29.403 28.414
28.521 27.800 27.584 28.272 28.433 28.607 28.643
27.700 28.278 28.170 27.875 27.356 28.191 26.726
24.438 24.431 24.405 24.767 24.223 24.692 23.780
27.980 28.251 27.769 27.909 28.193 28.071 27.291
28.656 28.787 28.462 29.037 28.758 28.564 28.120
26.983 27.179 27.929 27.345 27.511 27.106 26.564
29.545 29.570 29.560 29.602 29.389 29.253 28.432
32.474 33.104 32.745 33.539 32.516 33.174 33.265
27.398 27.656 28.255 27.683 28.307 27.699 27.556
28.685 29.271 29.226 29.060 28.003 29.175 28.526
28.251 28.456 28.782 28.645 28.175 28.352 27.749
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31.935 32.362 31.463 31.934 31.223 31.720 31.256
30.203 29.735 30.218 30.821 29.705 30.525 29.714
29.531 29.739 29.655 29.662 29.831 29.907 29.641
35.973 31.938 34.766 36.573 40.000 40.000 33.491
31.380 31.313 31.540 31.423 31.013 31.557 31.162
30.174 30.404 30.333 30.706 30.315 30.432 29.627
26.495 26.496 26.517 26.348 26.283 26.878 26.367
30.228 30.229 31.060 28.661 30.484 30.622 31.488
29.171 29.912 29.776 29.589 29.350 29.202 28.940
31.400 31.072 31.077 31.250 31.511 32.059 31.567
27.670 27.640 27.531 27.726 27.747 28.064 27.350
31.199 31.404 31.722 31.685 30.722 31.646 40.000
27.851 27.801 27.292 27.944 28.160 28.481 27.514
28.271 28.220 28.275 28.454 27.815 28.698 27.879
27.409 26.984 26.795 27.148 27.226 27.600 26.541
30.508 29.886 30.636 31.422 30.134 30.950 30.874
29.662 29.779 29.397 29.474 29.306 29.942 29.145
20.347 21.328 20.816 20.664 19.841 21.472 19.728
26.607 26.687 26.334 26.298 25.794 26.708 26.691
30.513 30.498 30.977 30.502 29.952 30.586 29.619
27.858 27.952 28.024 27.686 27.879 28.036 27.189
26.706 26.215 26.226 26.593 25.973 26.895 25.743
27.989 28.125 27.764 28.397 28.344 28.166 27.995
28.478 28.341 28.189 28.934 28.146 28.378 28.118
28.068 27.816 28.078 28.029 27.680 28.869 27.549
27.203 27.411 27.925 27.483 26.959 27.241 26.846
27.298 27.245 27.185 27.484 27.126 27.724 27.220
30.454 30.806 31.172 31.238 30.105 30.693 30.196
26.398 26.065 25.826 25.568 25.801 26.170 25.298
26.870 27.278 26.738 26.800 27.402 27.255 26.516
28.793 28.577 28.432 29.318 28.220 28.969 28.582
27.311 27.499 27.323 27.369 27.174 27.546 26.854
23.555 23.954 24.470 24.314 23.369 23.859 23.065
32.676 33.214 33.549 33.211 32.691 36.632 35.567
28.138 28.153 28.521 28.170 27.919 28.242 27.543
30.128 30.046 30.532 29.881 29.651 29.926 29.334
27.581 27.973 28.098 27.737 27.436 28.154 27.241
28.233 27.875 27.577 28.035 28.255 28.404 27.767
28.147 28.616 28.580 28.265 28.349 28.480 27.761
25.386 25.648 25.518 25.467 25.369 25.824 25.148
26.081 26.121 26.236 26.247 25.852 26.763 25.219
27.881 28.361 28.280 28.235 27.830 27.997 27.599
27.902 28.023 28.057 27.956 27.920 27.905 27.289
29.568 29.515 29.846 29.981 29.386 29.919 29.634
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32.337 34.517 31.630 35.391 33.505 40.000 32.796
28.286 28.708 28.667 28.087 28.749 28.572 28.042
26.280 26.463 26.112 26.420 26.188 26.562 26.004
27.589 27.682 27.795 27.572 27.197 27.399 26.288
27.653 27.642 27.372 27.529 27.528 27.745 26.939
28.871 29.290 29.193 28.961 28.639 29.381 28.686
27.433 27.544 27.332 27.435 27.433 27.896 27.032
27.721 27.664 27.533 27.644 27.512 27.843 27.358
29.000 29.874 30.414 31.646 28.459 28.576 26.845
28.766 28.615 29.237 29.002 28.324 28.758 28.085
24.979 24.796 23.667 24.540 24.783 24.789 24.774
28.402 28.028 27.823 28.340 28.660 28.798 28.363
22.177 22.143 40.000 40.000 40.000 40.000 40.000
26.605 26.634 26.809 26.611 26.521 26.849 26.260
25.882 25.790 25.821 25.551 25.797 26.346 25.546
28.720 29.535 28.236 29.674 29.140 28.901 28.214
27.054 27.134 27.229 27.454 27.103 27.539 26.937
27.136 27.174 27.077 27.291 27.223 27.272 26.598
26.853 26.849 26.790 26.712 27.331 27.208 27.030
30.261 30.362 30.673 29.742 30.162 30.534 29.732
27.406 27.312 27.080 27.269 27.062 27.608 26.984
26.056 26.088 25.858 26.429 26.205 26.613 25.814
28.289 28.495 28.708 28.492 28.583 28.499 28.148
26.470 26.839 26.431 27.195 26.341 26.803 26.389
28.425 28.725 28.991 28.552 28.168 28.621 27.700
40.000 40.000 40.000 40.000 40.000 37.981 40.000
28.678 28.857 29.231 29.052 28.754 28.680 27.987
30.848 30.484 30.319 30.080 31.042 31.293 30.320
27.589 28.325 27.505 28.045 27.773 27.757 26.991
28.897 28.718 29.406 29.634 28.917 29.857 28.842
28.437 28.636 28.572 28.371 28.035 28.411 28.095
27.910 28.402 28.327 27.886 27.140 28.052 26.521
29.471 29.609 29.515 29.913 29.444 29.732 29.106
25.561 25.436 25.707 25.437 24.901 25.616 24.580
28.205 27.971 27.987 27.852 28.747 29.021 28.730
28.318 28.299 28.575 28.783 28.159 28.384 27.976
27.263 27.098 26.594 27.220 27.327 27.627 27.189
31.364 31.043 30.832 32.235 30.398 31.744 30.105
29.192 29.473 29.140 29.598 29.573 29.543 29.285
27.997 27.868 28.140 28.081 27.939 27.677 27.071
27.170 27.266 27.341 27.181 27.233 27.311 26.516
28.772 28.736 28.965 29.031 28.745 28.489 27.879
27.978 27.787 28.088 28.082 27.905 28.456 28.014
28.853 28.984 28.945 28.860 28.569 28.874 27.876
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27.849 27.793 27.635 27.983 27.457 27.788 27.182
26.187 26.590 26.226 26.263 26.106 26.749 25.872
29.949 30.274 30.393 30.080 30.000 29.906 29.066
27.184 27.429 27.262 27.726 26.776 27.397 27.154
27.403 27.728 27.382 27.668 27.244 27.470 27.139
27.762 28.092 28.085 28.060 27.716 28.460 27.744
29.176 29.262 29.375 29.508 29.275 30.001 29.185
26.843 26.835 26.833 27.014 26.919 27.237 26.251
28.519 28.991 29.312 29.009 28.642 27.715 27.748
28.980 28.746 29.336 29.435 28.866 29.598 28.343
25.608 25.666 25.524 25.863 25.568 26.073 25.112
29.884 29.682 29.448 29.169 29.966 30.469 29.877
29.127 29.151 28.465 27.964 29.778 30.750 30.446
27.168 26.998 26.776 26.518 26.855 27.069 26.216
26.924 26.922 26.400 26.524 26.680 26.678 25.603
28.611 28.446 28.201 28.203 29.324 29.166 29.322
29.842 30.121 29.878 29.735 29.892 30.434 29.599
30.552 31.379 31.251 30.956 30.783 31.038 30.748
30.360 30.808 31.257 30.473 30.463 30.487 29.784
29.093 29.191 28.882 29.172 28.798 28.919 28.841
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PreMnPsNormK100900PreMnPsNormK100935PreMnPsNormK101020PreMnPsNormK101024PreMnPsNormK101035PreMnPsNormK101037PreMnPsNormK101058
24.308 24.542 25.086 24.495 25.002 24.049 26.080
28.198 28.088 28.366 28.071 28.301 28.175 28.817
27.366 28.170 28.236 27.481 27.731 27.465 27.514
28.665 28.813 29.341 28.587 29.092 27.918 28.906
33.288 34.081 33.670 33.142 33.765 32.846 40.000
25.758 25.776 26.296 25.556 26.210 25.994 26.029
26.522 26.559 27.187 26.675 27.129 26.584 27.091
30.325 30.472 29.782 29.665 29.981 29.949 31.312
30.808 30.418 31.602 30.963 30.813 31.080 32.254
27.738 28.178 28.502 27.854 28.182 27.559 28.681
28.385 29.020 28.913 28.157 29.063 29.521 29.057
32.010 31.704 31.974 31.923 32.009 32.401 32.717
28.866 28.670 29.660 28.868 28.847 28.441 29.296
27.212 26.760 27.789 26.967 27.345 26.662 28.384
30.906 31.356 40.000 31.497 31.746 31.434 31.639
32.136 33.577 34.059 31.965 31.686 32.472 32.499
28.394 28.827 28.888 28.386 29.076 28.793 28.778
34.465 26.323 33.657 40.000 40.000 40.000 40.000
25.592 25.493 25.874 25.517 25.843 25.187 26.073
24.497 24.440 25.005 24.484 25.060 24.171 25.382
27.794 27.820 28.455 28.021 28.414 27.557 27.992
30.660 31.125 31.397 30.739 30.870 30.895 31.518
25.264 23.287 25.500 24.669 25.041 22.751 25.486
34.212 34.898 34.149 33.974 33.759 36.386 33.860
34.107 33.600 26.043 34.852 34.232 34.631 33.026
25.894 25.505 26.825 26.126 26.759 25.600 26.814
28.260 27.874 27.799 27.776 28.689 28.122 28.966
33.576 32.546 34.257 33.647 33.901 33.683 33.758
28.939 28.667 29.052 29.022 29.166 28.767 28.630
29.299 29.464 29.951 29.539 29.852 29.769 29.283
27.372 27.476 27.839 27.430 27.798 27.114 28.258
29.039 28.894 29.903 29.207 29.569 29.366 30.466
26.667 27.081 27.158 26.688 26.960 27.168 26.079
31.936 33.441 31.951 33.501 32.243 34.973 33.453
23.853 22.673 40.000 40.000 36.988 23.517 40.000
27.484 27.318 27.866 27.587 27.870 27.092 27.860
31.034 30.713 31.526 31.263 30.691 31.016 31.838
24.957 25.356 25.919 25.082 25.360 25.664 25.029
26.161 26.501 26.666 26.185 26.760 26.304 26.730
31.193 31.165 31.857 31.239 30.841 31.264 32.301
27.924 28.503 28.767 28.079 28.608 28.507 28.236
27.510 27.337 27.893 27.809 27.975 27.454 28.136
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25.875 25.850 26.206 25.713 26.091 25.742 26.780
28.259 28.998 29.050 28.721 29.144 28.598 29.045
25.379 25.908 25.800 25.866 26.196 25.964 26.261
28.533 28.539 29.484 28.402 28.867 28.914 29.063
24.467 23.948 24.975 24.476 24.920 24.462 24.975
29.682 30.033 29.819 29.763 30.352 29.751 31.383
27.827 27.771 28.588 27.713 27.881 27.767 28.080
29.108 28.902 29.451 29.017 29.138 29.066 30.328
24.867 25.085 25.336 24.884 25.109 25.160 26.299
32.091 33.438 32.532 33.265 33.015 34.189 32.517
30.529 30.698 30.683 30.525 30.417 30.934 31.146
28.466 28.547 29.333 28.610 28.793 28.506 28.858
28.942 28.901 29.549 28.969 29.133 28.926 29.747
26.906 27.830 27.031 26.996 27.457 26.898 27.760
27.200 26.812 27.744 27.316 27.812 26.855 27.024
34.934 35.063 28.926 35.951 40.000 36.516 40.000
28.551 27.475 28.787 28.231 28.332 27.359 28.797
26.300 26.437 26.908 26.274 26.466 26.849 27.418
29.477 29.148 29.889 29.606 29.368 30.061 31.101
28.838 29.883 29.166 28.852 29.411 28.859 30.173
40.000 34.294 40.000 40.000 40.000 40.000 40.000
22.447 22.691 22.762 22.179 22.651 23.130 23.185
23.669 22.160 23.843 23.100 22.804 21.814 24.173
28.769 29.547 29.403 29.035 28.887 29.165 30.052
28.898 28.637 29.808 28.948 29.130 28.884 28.565
29.268 29.443 29.975 29.441 29.628 29.532 30.424
29.606 29.590 29.787 29.596 29.440 29.388 30.376
31.121 30.924 32.103 31.478 32.041 31.685 31.964
27.344 26.460 27.981 27.217 27.137 26.181 27.445
29.462 30.247 30.156 29.467 29.075 29.209 29.690
27.717 27.872 27.947 27.978 27.512 27.702 28.852
23.500 23.866 24.146 23.787 23.910 23.761 24.843
30.625 31.425 32.488 31.391 31.588 31.969 31.912
28.361 28.339 28.577 28.191 28.217 28.119 29.741
29.109 28.520 29.946 29.009 29.373 28.735 29.707
29.789 29.988 30.437 29.360 29.800 29.982 30.214
30.460 29.656 30.973 30.319 30.915 29.525 30.081
28.969 29.690 29.272 28.966 29.220 28.923 29.920
29.147 28.365 29.733 29.244 29.697 28.789 29.726
28.378 28.819 29.350 28.545 29.060 28.808 28.911
25.900 25.882 26.435 25.894 25.697 26.654 26.549
28.269 28.107 28.556 28.063 28.586 27.995 28.849
29.369 29.129 29.894 29.249 29.775 29.187 29.527
27.282 27.603 27.900 27.327 28.018 27.293 28.105
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28.936 29.263 29.975 28.875 29.397 29.062 29.308
27.956 27.166 28.331 27.871 28.494 27.315 27.467
28.495 27.366 28.904 28.587 28.182 29.047 28.292
31.824 31.022 32.589 31.776 31.747 31.994 32.822
28.783 28.844 29.881 28.618 29.187 29.279 29.313
26.572 27.344 26.793 26.677 27.127 26.537 27.512
27.611 27.319 28.023 28.488 28.242 27.731 27.696
30.185 29.207 30.572 29.926 30.055 30.191 29.945
28.132 28.564 28.498 28.170 28.646 28.549 29.121
27.186 27.011 28.035 27.246 27.727 26.863 27.721
26.439 27.100 26.822 26.840 26.280 28.455 27.328
27.333 27.708 28.096 27.640 27.784 27.440 27.899
26.487 26.555 26.889 26.331 26.981 26.189 26.954
28.535 28.674 29.384 28.771 29.300 28.846 28.921
28.250 28.376 28.492 28.345 28.666 27.881 28.345
30.960 29.335 30.981 30.668 30.682 28.943 28.917
28.357 28.152 28.805 28.535 28.726 28.663 28.691
29.676 29.384 30.487 29.822 29.579 29.634 30.421
29.441 28.468 30.247 29.504 29.864 28.854 28.912
26.444 27.101 27.365 26.656 27.464 26.841 27.183
26.765 26.909 27.249 26.816 27.288 26.659 27.187
30.123 30.124 31.098 30.264 30.219 29.706 30.735
25.657 25.889 26.210 25.494 26.184 25.687 25.989
29.607 29.986 30.233 29.870 29.919 30.406 31.291
31.136 30.395 31.313 30.949 31.174 30.638 28.341
32.247 31.814 32.263 32.328 31.772 32.317 30.548
31.288 32.231 31.952 32.275 32.028 31.706 31.926
28.239 28.051 29.443 28.467 28.920 28.489 28.410
28.136 28.708 28.837 28.423 28.601 28.094 28.451
32.014 34.121 34.150 40.000 36.519 35.700 31.644
28.208 30.126 29.932 29.200 30.325 30.143 30.687
29.096 28.987 29.687 29.126 29.014 28.896 30.233
29.523 29.456 29.975 29.475 29.571 29.412 29.650
28.809 28.097 29.211 28.831 28.964 27.901 28.708
28.162 28.007 28.698 28.089 28.449 28.216 28.318
24.916 24.282 25.276 24.424 24.754 24.819 25.074
28.008 28.234 28.559 27.972 28.477 27.827 28.111
28.263 28.920 29.518 28.166 29.165 28.101 28.988
26.921 27.583 27.708 27.072 27.463 27.463 27.838
29.115 29.430 29.538 29.393 29.744 29.694 30.091
33.757 31.937 33.446 33.078 32.402 33.461 31.795
28.530 27.880 28.776 27.660 28.129 28.077 27.876
28.765 28.547 29.506 28.551 29.905 28.380 29.581
28.159 28.490 28.750 28.291 28.015 27.994 27.350
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31.742 31.899 31.498 40.000 32.607 31.785 32.119
30.520 29.683 31.240 30.404 30.621 30.479 30.792
30.057 29.802 30.418 30.309 30.624 29.814 30.283
35.877 40.000 26.167 35.432 40.000 37.233 36.590
31.564 31.537 30.127 31.285 31.478 31.186 32.394
30.400 30.263 30.913 30.254 30.244 30.555 31.072
26.617 26.404 27.239 26.661 26.960 26.702 27.141
29.878 30.565 29.836 30.945 30.690 30.815 30.353
29.231 29.443 29.443 29.522 29.471 29.852 30.839
32.377 31.310 32.089 31.795 31.500 30.777 32.198
27.660 27.486 28.012 27.751 27.687 27.526 28.932
40.000 30.795 40.000 31.732 31.518 31.360 32.223
28.397 28.024 29.259 28.558 28.777 28.203 28.818
28.713 28.050 29.175 28.603 28.577 28.420 29.296
27.556 27.386 28.134 27.317 27.691 26.908 27.555
30.916 30.002 31.307 30.376 30.772 30.173 28.894
29.560 29.822 29.789 29.427 29.743 29.298 30.073
20.676 21.120 21.344 20.510 20.975 20.738 21.061
26.667 26.625 27.506 26.551 26.773 26.499 27.633
30.530 30.251 31.162 30.699 30.756 30.937 31.484
27.951 27.751 28.259 27.847 27.957 27.869 28.402
26.782 26.226 27.292 26.642 26.482 26.366 27.454
28.460 27.966 29.121 28.263 28.942 27.907 28.590
28.836 28.594 29.456 28.549 28.873 28.323 29.202
27.875 28.368 28.646 28.303 28.808 28.223 28.333
26.779 27.468 27.357 27.022 27.058 27.635 27.265
27.742 27.478 28.574 27.566 28.084 27.579 27.851
30.672 30.940 31.574 30.571 30.508 30.605 31.792
25.630 26.018 26.273 25.814 26.428 25.814 26.379
27.028 26.903 27.282 26.848 27.555 26.797 27.346
29.031 28.682 29.869 29.090 29.844 28.673 29.728
27.654 27.389 27.977 27.603 28.169 27.546 27.818
23.798 23.786 24.130 23.562 23.894 24.385 23.990
34.468 32.841 34.189 34.363 34.401 34.444 40.000
27.853 28.043 28.661 28.139 28.450 28.239 28.655
29.849 30.072 29.609 30.137 30.230 30.134 27.662
27.555 27.650 28.160 27.497 28.025 27.752 28.976
28.132 28.076 28.600 28.280 28.175 28.220 27.864
27.529 28.554 28.220 27.823 28.706 28.500 28.774
25.501 25.613 25.747 25.551 26.312 25.514 26.365
26.319 26.043 26.776 26.491 26.459 26.562 27.088
28.029 28.216 29.055 28.264 28.895 28.266 28.507
27.674 27.846 28.045 27.467 28.090 28.141 28.253
29.899 29.414 31.030 29.678 29.980 29.708 30.138
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32.056 34.903 34.603 33.362 32.598 32.636 40.000
28.849 28.641 29.435 29.258 29.045 28.831 28.092
26.572 26.367 27.341 26.501 27.139 26.501 26.974
27.419 27.739 27.925 27.552 27.696 27.675 27.937
28.009 27.622 28.340 27.606 28.213 27.559 27.786
28.869 28.956 29.152 28.654 28.965 28.850 29.489
27.996 27.684 28.231 27.357 27.837 27.334 27.531
27.776 27.699 28.209 27.731 28.229 27.745 28.829
29.239 29.861 29.291 29.755 30.883 31.333 29.991
28.607 28.945 29.605 28.600 29.213 29.180 28.755
24.487 24.804 24.882 24.744 25.149 24.232 25.901
28.725 28.254 29.276 28.865 28.620 28.331 29.921
40.000 40.000 22.311 40.000 40.000 40.000 18.643
26.658 26.660 27.386 26.639 27.202 26.604 27.208
26.516 26.219 26.758 26.202 26.434 25.987 26.491
29.747 29.128 30.324 29.304 29.221 28.995 28.639
27.202 27.242 27.641 27.218 27.463 27.100 27.583
27.315 27.126 27.538 27.287 27.847 27.053 27.574
27.299 27.000 27.524 27.144 27.131 27.061 27.599
30.487 29.945 30.909 30.508 30.562 30.337 31.294
27.461 27.675 28.275 27.528 28.090 27.248 28.024
26.430 26.023 26.945 26.433 26.583 26.260 27.136
28.199 28.547 28.492 27.873 28.899 28.331 28.901
26.511 26.664 27.496 26.828 27.246 26.548 27.283
28.487 28.600 28.848 28.249 29.044 28.809 29.033
36.361 40.000 34.359 35.342 38.958 39.118 40.000
28.340 28.920 29.112 28.366 29.074 28.883 25.695
30.283 30.743 30.197 30.198 29.182 29.545 31.126
26.799 28.618 27.732 27.030 27.754 27.710 28.177
29.262 29.273 29.811 29.122 29.473 28.983 29.925
28.611 28.219 29.182 28.474 28.993 28.513 28.711
27.559 28.281 28.165 27.348 27.955 28.145 27.623
29.704 29.661 30.168 29.407 30.016 29.651 30.263
24.982 25.743 25.793 25.348 25.837 25.518 25.494
28.978 28.001 29.273 29.210 29.411 27.877 28.967
28.182 28.796 29.112 28.517 28.811 28.175 29.352
27.604 27.033 28.088 27.318 28.008 26.824 28.265
31.518 31.246 32.117 31.338 31.531 31.851 30.997
29.750 29.628 30.225 29.500 29.645 29.106 30.520
27.890 27.813 28.369 27.950 28.218 28.043 28.864
26.787 27.291 27.275 27.098 27.588 27.262 27.676
27.991 28.760 28.586 28.352 29.445 28.644 29.532
28.037 27.922 28.675 28.085 28.287 27.948 29.014
29.205 28.457 29.512 28.849 29.157 29.186 29.348
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28.254 27.632 28.930 27.963 28.511 27.802 28.328
26.326 26.076 27.149 26.331 26.514 26.540 27.317
29.428 29.995 29.643 29.427 30.838 29.784 29.049
27.384 27.503 28.483 27.331 27.871 27.402 27.662
27.445 27.593 28.096 27.670 27.997 27.472 28.112
27.858 27.898 28.294 28.036 28.040 27.619 28.817
29.037 28.951 29.296 29.468 29.390 29.499 30.510
27.145 26.881 27.360 26.881 27.474 27.121 27.512
27.852 29.833 29.445 28.444 29.181 29.463 28.863
29.364 28.997 30.215 29.634 29.506 29.224 29.835
25.886 25.701 26.691 25.804 26.237 25.693 26.388
29.946 29.930 30.476 30.393 29.502 29.239 31.208
29.917 28.820 30.048 30.103 30.145 29.608 29.905
26.926 27.452 27.201 27.162 27.928 27.107 27.084
26.185 27.006 26.179 26.071 27.293 26.308 26.918
29.288 28.673 30.015 29.376 29.644 28.478 29.625
29.955 30.239 30.205 29.632 30.662 30.408 30.142
30.688 30.980 30.726 30.635 31.155 40.000 28.298
29.678 30.998 30.150 30.257 30.812 30.450 30.976
28.982 28.829 29.422 29.125 29.351 29.436 30.423
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PreMnPsNormK101059PreMnPsNormK101090PreMnPsNormK102431PreMnPsNormK102623PreMnPsNormK102626
25.102 25.332 24.195 24.923 24.076
27.905 28.881 28.345 28.228 27.774
28.152 28.609 27.066 27.212 26.921
28.906 28.690 28.294 28.851 28.348
34.393 36.179 32.524 33.173 32.312
25.769 26.505 25.833 25.756 25.333
26.589 27.262 26.553 26.796 26.424
30.352 31.866 29.877 30.213 29.355
30.918 31.184 30.528 31.103 30.620
28.417 28.742 27.902 28.195 27.597
28.994 30.308 28.093 27.850 27.959
32.660 32.661 31.166 31.883 30.890
28.982 29.912 28.744 30.314 29.112
27.386 27.712 26.932 27.249 26.809
31.082 31.826 30.920 30.612 31.125
32.755 33.027 32.279 31.404 31.623
28.572 29.035 28.253 28.362 28.054
40.000 40.000 33.864 31.771 40.000
25.754 26.108 25.495 25.923 25.097
24.247 25.527 24.204 24.085 24.003
27.643 28.536 27.659 27.843 27.457
40.000 31.571 30.360 30.775 30.548
24.736 23.882 24.226 26.792 25.569
40.000 34.613 34.960 34.664 34.580
33.265 36.341 34.836 32.970 33.798
26.520 26.405 25.726 25.730 25.902
28.332 28.929 28.400 28.780 28.399
33.331 34.072 34.545 32.663 32.999
28.420 29.134 28.742 29.478 28.769
29.504 30.591 28.837 28.784 28.769
27.787 28.103 27.356 27.943 27.237
29.027 29.655 30.334 30.191 29.422
26.982 28.060 26.620 26.611 26.421
32.240 34.406 40.000 33.183 31.626
20.947 40.000 37.464 40.000 40.000
27.576 28.249 26.945 27.390 27.002
30.806 31.292 30.294 31.062 30.450
24.589 25.743 25.768 24.185 24.359
26.188 27.225 26.194 26.533 26.131
31.216 32.003 30.937 31.321 30.759
28.262 29.186 28.295 27.987 27.863
27.662 27.974 27.061 28.093 27.579
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26.096 26.661 25.554 25.549 25.317
28.845 28.917 28.353 28.742 28.313
25.750 26.170 25.829 25.980 25.220
28.932 28.922 28.644 28.904 28.515
23.972 24.344 24.624 25.162 24.515
29.913 30.845 29.786 29.844 30.087
27.931 28.840 27.489 27.658 27.338
29.307 29.864 28.918 29.076 29.067
25.392 25.884 24.977 24.984 24.652
32.676 33.154 32.368 32.760 32.231
30.746 31.164 30.843 31.139 30.361
28.704 29.240 28.172 28.531 27.918
29.084 29.793 28.331 29.001 28.696
27.398 28.088 26.782 27.874 27.080
27.290 27.468 27.150 27.476 27.249
37.246 35.978 40.000 40.000 28.049
28.382 28.151 28.500 29.566 28.735
26.416 27.577 26.490 26.262 26.032
29.372 30.438 29.887 29.687 29.399
29.241 30.507 28.702 29.177 28.657
34.650 40.000 40.000 40.000 40.000
22.551 23.692 21.964 21.688 21.921
22.082 23.476 22.534 24.827 22.890
29.796 29.880 28.807 28.848 28.223
28.620 29.404 28.446 28.312 28.407
29.675 30.384 29.402 29.475 28.979
29.175 30.112 29.677 30.168 29.019
31.676 31.841 31.787 31.606 30.943
26.922 27.365 26.870 28.104 27.148
30.481 30.499 28.913 29.143 28.571
28.111 28.828 27.321 27.627 27.337
23.757 24.712 23.504 23.616 23.335
31.494 32.455 30.876 31.436 32.189
28.350 29.416 28.018 28.397 28.149
28.743 29.015 28.955 29.336 28.725
29.642 29.851 29.746 29.417 29.540
29.434 30.163 30.378 30.924 30.152
29.659 29.907 28.397 29.670 28.807
29.358 29.088 29.456 30.280 29.654
28.825 29.464 28.234 28.808 28.069
25.799 27.515 25.961 25.377 25.592
28.195 28.622 28.110 28.119 27.903
29.306 30.135 29.049 29.430 28.998
27.398 28.248 27.375 27.476 26.954
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29.291 29.777 28.970 29.354 28.619
27.442 27.060 27.806 28.070 27.888
27.598 28.990 28.783 28.489 28.090
31.463 32.288 31.124 32.312 31.694
29.229 29.515 28.523 28.516 28.272
27.481 28.052 26.646 26.520 26.112
27.296 28.207 27.763 27.827 27.526
29.307 30.252 29.750 30.349 29.622
28.418 29.289 28.306 28.222 27.871
27.256 27.886 27.165 27.336 27.106
26.618 27.769 26.864 25.871 26.281
27.549 28.332 27.303 27.859 27.029
26.608 27.127 26.198 26.752 26.026
28.676 29.513 28.332 29.207 28.353
28.259 28.897 28.012 28.159 27.941
29.630 29.157 30.617 32.041 30.553
28.364 29.073 28.343 28.523 28.008
29.430 30.211 29.508 29.624 29.241
28.354 29.283 29.641 30.722 29.466
27.088 27.556 26.654 27.130 26.347
26.984 27.536 26.869 27.113 26.634
30.267 30.594 29.582 30.778 29.762
25.833 26.726 25.563 25.288 25.154
29.964 31.048 29.659 29.857 29.727
30.755 31.716 30.326 30.635 30.591
32.252 32.864 32.192 32.129 31.909
31.458 33.488 31.915 31.434 30.427
28.090 28.793 28.545 28.702 28.314
28.910 29.161 27.623 27.942 27.882
37.699 34.430 40.000 40.000 36.834
30.503 30.695 30.175 30.017 29.327
29.337 29.962 28.966 29.162 28.786
29.235 29.721 29.525 29.431 29.201
28.350 28.510 28.475 29.544 28.152
28.090 28.357 27.885 27.797 27.775
24.586 25.280 24.426 24.195 24.565
28.086 28.608 27.957 28.564 27.872
29.033 29.047 28.327 28.698 28.095
27.274 28.030 27.530 27.640 26.927
29.516 29.915 29.593 29.379 29.136
32.584 33.199 34.306 33.087 33.672
27.086 28.198 28.323 28.014 27.068
29.069 28.644 28.386 29.786 29.000
28.224 28.776 27.953 28.307 27.513
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31.552 31.931 30.704 31.535 31.220
30.798 30.948 29.677 30.927 30.481
29.871 30.272 30.102 30.639 29.760
25.087 29.726 40.000 36.814 26.151
31.237 31.594 31.697 31.825 31.174
30.271 31.116 30.193 30.123 30.265
26.473 27.477 26.402 26.621 26.039
29.516 31.301 29.122 31.289 29.366
29.401 30.072 29.375 29.598 29.270
32.210 32.279 31.315 31.510 31.196
27.591 28.472 27.452 27.754 27.490
31.057 31.905 31.122 31.046 30.780
28.279 28.559 28.469 28.711 28.401
28.338 29.106 27.989 28.314 28.111
27.837 27.982 27.006 27.274 27.057
30.718 31.079 30.484 31.414 31.098
29.899 30.058 29.293 29.792 29.220
21.735 21.675 20.533 20.755 20.569
26.642 26.235 27.213 27.566 27.026
30.528 31.606 30.377 30.245 30.744
27.977 28.462 27.866 28.098 27.437
26.305 27.474 26.364 26.086 26.358
28.386 28.589 28.523 28.880 28.494
28.665 28.841 28.208 28.619 27.929
28.216 28.988 27.911 28.106 28.033
27.135 28.089 26.663 26.923 26.552
27.262 27.752 27.993 27.996 27.445
31.027 31.606 29.635 30.369 30.079
26.318 26.674 25.897 26.177 25.859
26.915 27.817 27.109 27.403 26.687
29.249 29.338 28.710 29.191 28.727
27.592 28.274 27.553 27.780 27.400
23.635 25.089 23.419 23.252 23.276
32.474 40.000 33.637 33.581 33.280
28.160 28.843 28.123 28.375 27.641
29.424 30.761 29.999 30.277 29.413
27.616 28.429 27.705 27.814 27.370
28.336 28.851 28.005 28.222 27.909
28.401 29.156 27.890 28.393 28.066
25.755 26.418 25.530 25.834 25.523
26.302 27.269 26.175 26.129 26.165
28.646 28.738 28.260 28.428 27.954
28.118 28.473 27.579 27.887 27.294
29.927 30.242 29.339 30.398 29.609
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33.649 33.219 33.462 33.631 32.083
28.347 29.082 29.004 29.159 28.503
26.386 27.074 26.360 26.945 26.004
27.661 28.748 27.020 26.900 26.818
28.055 27.994 27.826 27.889 27.738
28.915 29.884 28.946 27.704 28.407
27.666 28.343 27.283 27.524 26.917
27.787 28.569 27.427 27.812 27.488
29.786 30.719 30.066 29.255 29.406
28.624 29.322 28.671 28.937 28.416
24.970 25.067 24.622 25.569 24.777
28.662 29.540 28.516 28.252 40.000
40.000 40.000 24.378 40.000 22.609
26.544 27.384 26.499 26.861 26.194
26.061 27.011 25.903 26.705 26.334
29.894 29.697 29.548 29.597 29.361
27.189 28.037 26.960 27.085 26.718
27.282 27.788 27.230 27.585 27.046
27.046 27.807 27.310 27.436 26.640
30.543 31.253 30.498 30.869 30.303
27.452 28.083 27.566 27.727 27.313
26.300 27.045 26.392 26.297 26.226
28.354 29.161 28.955 28.462 27.812
26.672 27.261 26.360 27.002 26.483
28.394 29.332 28.517 28.668 28.129
40.000 40.000 40.000 40.000 27.987
29.042 29.358 28.566 28.395 28.249
30.644 31.422 29.324 29.525 28.909
28.064 28.310 27.239 27.587 26.768
29.377 29.792 28.873 29.470 29.042
28.464 28.961 28.188 28.704 28.116
27.807 28.977 27.661 27.179 27.445
29.786 30.156 29.531 29.716 29.339
25.515 26.333 25.164 25.223 25.048
28.570 28.746 28.884 29.525 28.689
28.374 29.227 27.860 28.579 27.985
27.621 27.930 27.120 27.945 27.623
31.537 32.108 32.201 30.531 31.383
29.248 30.155 29.104 29.675 29.269
27.910 28.675 27.878 27.420 27.452
27.175 27.983 27.190 27.342 26.888
28.829 29.116 28.873 28.914 28.610
28.000 28.721 27.539 28.312 27.833
29.027 29.650 29.386 29.201 28.962
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27.900 28.319 27.659 27.987 27.610
25.923 27.006 26.374 26.443 26.116
30.393 30.008 29.488 29.981 29.199
27.642 28.013 27.069 27.538 27.001
27.632 28.113 27.148 27.961 27.340
28.097 29.003 27.691 28.345 27.520
29.097 30.197 29.148 29.157 28.746
27.121 27.984 26.608 26.790 26.712
28.313 29.022 27.941 28.183 27.212
29.121 29.881 29.267 29.145 28.988
25.983 26.576 25.737 25.969 25.677
29.814 30.768 29.610 29.867 29.647
28.645 29.058 29.536 31.852 30.158
27.111 27.897 27.068 27.042 26.970
26.706 27.274 26.388 26.441 26.359
28.207 28.897 29.068 29.942 28.914
29.979 30.712 30.236 30.281 29.807
31.035 31.563 30.203 30.584 30.114
30.576 31.302 30.246 30.759 30.024
28.999 29.912 29.089 29.277 28.871
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Supplementary Table 2A: Differentially expressed co-regulators
Entrez Gene ID Gene Symbol Comparison P-value
Adjusted_P-value
(Benjamini-Hochberg)
857 CAV1 Cancer-Normal 5.32E-37 1.94E-34
221037 JMJD1C Cancer-Normal 3.08E-20 1.60E-18
5325 PLAGL1 Cancer-Normal 5.05E-20 2.05E-18
221895 JAZF1 Cancer-Normal 1.56E-19 5.70E-18
9318 COPS2 Cancer-Normal 4.41E-19 1.46E-17
6595 SMARCA2 Cancer-Normal 1.15E-17 3.22E-16
10399 GNB2L1 Cancer-Normal 2.20E-17 5.74E-16
8850 PCAF Cancer-Normal 7.91E-17 1.81E-15
23414 ZFPM2 Cancer-Normal 1.90E-16 3.86E-15
57658 CALCOCO1 Cancer-Normal 3.73E-16 6.80E-15
6604 SMARCD3 Cancer-Normal 3.61E-16 6.80E-15
5629 PROX1 Cancer-Normal 5.97E-16 1.04E-14
4331 MNAT1 Cancer-Normal 1.03E-14 1.58E-13
83714 NRIP2 Cancer-Normal 1.04E-14 1.58E-13
10957 PNRC1 Cancer-Normal 1.50E-14 2.10E-13
6840 SVIL Cancer-Normal 4.21E-14 5.69E-13
8648 NCOA1 Cancer-Normal 4.65E-14 6.07E-13
2308 FOXO1 Cancer-Normal 5.50E-14 6.92E-13
10114 HIPK3 Cancer-Normal 9.31E-14 1.06E-12
2934 GSN Cancer-Normal 9.23E-14 1.06E-12
29123 ANKRD11 Cancer-Normal 9.93E-14 1.10E-12
1025 CDK9 Cancer-Normal 2.85E-13 3.06E-12
23309 SIN3B Cancer-Normal 4.65E-13 4.85E-12
473 RERE Cancer-Normal 5.35E-13 5.43E-12
25942 SIN3A Cancer-Normal 9.50E-13 9.38E-12
4255 MGMT Cancer-Normal 9.82E-13 9.43E-12
8554 PIAS1 Cancer-Normal 1.69E-12 1.58E-11
25898 RCHY1 Cancer-Normal 1.74E-12 1.59E-11
9063 PIAS2 Cancer-Normal 1.89E-12 1.68E-11
51720 UIMC1 Cancer-Normal 2.33E-12 1.97E-11
11331 PHB2 Cancer-Normal 2.54E-12 2.10E-11
23013 SPEN Cancer-Normal 3.31E-12 2.57E-11
9039 UBA3 Cancer-Normal 3.79E-12 2.82E-11
1387 CREBBP Cancer-Normal 5.21E-12 3.73E-11
11143 MYST2 Cancer-Normal 1.09E-11 7.49E-11
10587 TXNRD2 Cancer-Normal 1.44E-11 9.74E-11
10891 PPARGC1A Cancer-Normal 1.56E-11 1.03E-10
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9759 HDAC4 Cancer-Normal 2.25E-11 1.47E-10
10521 DDX17 Cancer-Normal 2.39E-11 1.53E-10
3275 PRMT2 Cancer-Normal 2.56E-11 1.59E-10
4841 NONO Cancer-Normal 2.57E-11 1.59E-10
53335 BCL11A Cancer-Normal 3.31E-11 1.96E-10
9968 MED12 Cancer-Normal 3.32E-11 1.96E-10
51586 MED15 Cancer-Normal 3.91E-11 2.27E-10
9322 TRIP10 Cancer-Normal 4.16E-11 2.37E-10
135112 NCOA7 Cancer-Normal 4.25E-11 2.39E-10
27043 PELP1 Cancer-Normal 5.34E-11 2.95E-10
6602 SMARCD1 Cancer-Normal 6.04E-11 3.24E-10
9611 NCOR1 Cancer-Normal 7.63E-11 3.98E-10
1028 CDKN1C Cancer-Normal 8.12E-11 4.09E-10
7041 TGFB1I1 Cancer-Normal 8.17E-11 4.09E-10
9667 SAFB2 Cancer-Normal 9.75E-11 4.81E-10
6129 RPL7 Cancer-Normal 1.15E-10 5.49E-10
7520 XRCC5 Cancer-Normal 1.16E-10 5.49E-10
10902 BRD8 Cancer-Normal 1.43E-10 6.71E-10
8409 UXT Cancer-Normal 1.62E-10 7.47E-10
10445 MCRS1 Cancer-Normal 2.12E-10 9.69E-10
133522 PPARGC1B Cancer-Normal 2.66E-10 1.18E-09
10155 TRIM28 Cancer-Normal 2.76E-10 1.20E-09
9320 TRIP12 Cancer-Normal 4.80E-10 2.04E-09
9321 TRIP11 Cancer-Normal 5.44E-10 2.28E-09
7205 TRIP6 Cancer-Normal 7.69E-10 3.19E-09
7332 UBE2L3 Cancer-Normal 9.54E-10 3.91E-09
64324 NSD1 Cancer-Normal 1.62E-09 6.49E-09
23543 RBM9 Cancer-Normal 1.77E-09 7.03E-09
5036 PA2G4 Cancer-Normal 2.81E-09 1.09E-08
64210 MMS19 Cancer-Normal 3.33E-09 1.28E-08
23421 ITGB3BP Cancer-Normal 3.66E-09 1.38E-08
10197 PSME3 Cancer-Normal 4.29E-09 1.60E-08
23411 SIRT1 Cancer-Normal 5.54E-09 2.03E-08
11218 DDX20 Cancer-Normal 6.19E-09 2.24E-08
26524 LATS2 Cancer-Normal 8.60E-09 3.08E-08
9265 PSCD3 Cancer-Normal 9.39E-09 3.30E-08
10524 HTATIP Cancer-Normal 1.29E-08 4.35E-08
6830 SUPT6H Cancer-Normal 1.28E-08 4.35E-08
84458 LCOR Cancer-Normal 1.57E-08 5.26E-08
23132 RAD54L2 Cancer-Normal 1.63E-08 5.40E-08
4088 SMAD3 Cancer-Normal 1.73E-08 5.64E-08
8031 NCOA4 Cancer-Normal 1.77E-08 5.70E-08
9733 SART3 Cancer-Normal 2.01E-08 6.42E-08
6130 LOC100132910.RPL7ACancer-Normal 2.72E-08 8.63E-08
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7110 TMF1 Cancer-Normal 2.89E-08 8.93E-08
8493 PPM1D Cancer-Normal 3.80E-08 1.16E-07
9282 MED14 Cancer-Normal 5.02E-08 1.51E-07
9612 NCOR2 Cancer-Normal 5.39E-08 1.61E-07
9219 MTA2 Cancer-Normal 7.05E-08 2.09E-07
5705 PSMC5 Cancer-Normal 7.49E-08 2.21E-07
7337 UBE3A Cancer-Normal 9.94E-08 2.90E-07
10474 TADA3L Cancer-Normal 1.04E-07 3.01E-07
1655 DDX5 Cancer-Normal 1.65E-07 4.67E-07
2274 FHL2 Cancer-Normal 1.64E-07 4.67E-07
2314 FLII Cancer-Normal 1.70E-07 4.78E-07
5970 RELA Cancer-Normal 1.84E-07 5.12E-07
6047 RNF4 Cancer-Normal 1.92E-07 5.32E-07
11124 FAF1 Cancer-Normal 2.08E-07 5.71E-07
8721 EDF1 Cancer-Normal 2.14E-07 5.83E-07
9604 RNF14 Cancer-Normal 2.39E-07 6.46E-07
29843 SENP1 Cancer-Normal 2.62E-07 6.99E-07
6760 SS18 Cancer-Normal 3.17E-07 8.39E-07
2033 EP300 Cancer-Normal 4.06E-07 1.06E-06
63925 ZNF335 Cancer-Normal 4.08E-07 1.06E-06
2647 BLOC1S1 Cancer-Normal 4.15E-07 1.08E-06
10865 ARID5A Cancer-Normal 5.36E-07 1.38E-06
166 AES Cancer-Normal 6.28E-07 1.60E-06
79718 TBL1XR1 Cancer-Normal 7.10E-07 1.79E-06
23462 HEY1 Cancer-Normal 7.72E-07 1.93E-06
1660 DHX9 Cancer-Normal 1.11E-06 2.73E-06
6907 TBL1X Cancer-Normal 1.37E-06 3.33E-06
10401 PIAS3 Cancer-Normal 1.50E-06 3.61E-06
57492 ARID1B Cancer-Normal 1.61E-06 3.85E-06
7157 TP53 Cancer-Normal 2.04E-06 4.84E-06
2874 D4S234E.GPS2 Cancer-Normal 2.41E-06 5.67E-06
9325 TRIP4 Cancer-Normal 2.65E-06 6.19E-06
9326 ZNHIT3 Cancer-Normal 2.90E-06 6.74E-06
51366 UBR5 Cancer-Normal 3.33E-06 7.69E-06
10923 SUB1 Cancer-Normal 4.11E-06 9.39E-06
1487 CTBP1 Cancer-Normal 4.32E-06 9.80E-06
890 CCNA2 Cancer-Normal 5.04E-06 1.13E-05
10513 APPBP2 Cancer-Normal 5.13E-06 1.15E-05
6871 TADA2L Cancer-Normal 5.80E-06 1.29E-05
8178 ELL Cancer-Normal 7.48E-06 1.66E-05
3192 HNRNPU Cancer-Normal 7.69E-06 1.69E-05
55827 IQWD1 Cancer-Normal 9.96E-06 2.16E-05
8289 ARID1A Cancer-Normal 9.95E-06 2.16E-05
22938 SNW1 Cancer-Normal 1.12E-05 2.40E-05
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8125 ANP32A Cancer-Normal 1.30E-05 2.75E-05
57727 NCOA5 Cancer-Normal 1.59E-05 3.33E-05
8841 HDAC3 Cancer-Normal 1.61E-05 3.35E-05
1488 CTBP2 Cancer-Normal 1.92E-05 3.98E-05
55629 PNRC2 Cancer-Normal 2.23E-05 4.56E-05
10291 SF3A1 Cancer-Normal 2.54E-05 5.06E-05
9319 TRIP13 Cancer-Normal 3.15E-05 6.24E-05
6774 STAT3 Cancer-Normal 4.06E-05 8.01E-05
8085 MLL2 Cancer-Normal 4.53E-05 8.88E-05
9031 BAZ1B Cancer-Normal 4.55E-05 8.88E-05
9584 RBM39 Cancer-Normal 4.89E-05 9.50E-05
7329 UBE2I Cancer-Normal 5.54E-05 1.06E-04
8295 TRRAP Cancer-Normal 7.24E-05 1.38E-04
2185 PTK2B Cancer-Normal 7.52E-05 1.42E-04
4734 NEDD4 Cancer-Normal 9.88E-05 1.85E-04
10691 GMEB1 Cancer-Normal 1.02E-04 1.91E-04
994 CDC25B Cancer-Normal 1.30E-04 2.41E-04
898 CCNE1 Cancer-Normal 1.37E-04 2.52E-04
5901 RAN Cancer-Normal 1.69E-04 3.07E-04
11315 PARK7 Cancer-Normal 1.81E-04 3.28E-04
55898 UNC45A Cancer-Normal 1.86E-04 3.34E-04
8805 TRIM24 Cancer-Normal 2.28E-04 4.04E-04
3146 HMGB1 Cancer-Normal 3.13E-04 5.52E-04
10499 NCOA2 Cancer-Normal 3.18E-04 5.56E-04
122953 ZNF143.JDP2 Cancer-Normal 3.17E-04 5.56E-04
5728 PTEN Cancer-Normal 3.70E-04 6.36E-04
3276 PRMT1 Cancer-Normal 4.02E-04 6.89E-04
80324 PUS1 Cancer-Normal 4.36E-04 7.40E-04
6942 TCF20 Cancer-Normal 4.38E-04 7.41E-04
896 CCND3 Cancer-Normal 5.97E-04 9.95E-04
2521 FUS Cancer-Normal 7.47E-04 1.24E-03
10498 CARM1 Cancer-Normal 7.99E-04 1.32E-03
115950 ZNF653 Cancer-Normal 8.79E-04 1.45E-03
29982 NRBF2 Cancer-Normal 1.00E-03 1.64E-03
1616 DAXX Cancer-Normal 1.07E-03 1.74E-03
5925 RB1 Cancer-Normal 1.24E-03 2.01E-03
8202 NCOA3 Cancer-Normal 2.23E-03 3.56E-03
6996 TDG Cancer-Normal 3.50E-03 5.49E-03
5469 MED1 Cancer-Normal 3.80E-03 5.79E-03
9862 MED24 Cancer-Normal 3.93E-03 5.96E-03
9112 MTA1 Cancer-Normal 4.45E-03 6.72E-03
8204 NRIP1 Cancer-Normal 4.88E-03 7.31E-03
3066 HDAC2 Cancer-Normal 5.93E-03 8.80E-03
6597 SMARCA4 Cancer-Normal 6.76E-03 9.91E-03
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23532 PRAME Cancer-Normal 6.86E-03 1.00E-02
6605 SMARCE1 Cancer-Normal 1.07E-02 1.52E-02
92283 ZNF461 Cancer-Normal 1.16E-02 1.65E-02
55806 HR Cancer-Normal 1.53E-02 2.15E-02
9994 CASP8AP2 Cancer-Normal 1.66E-02 2.31E-02
96764 TGS1 Cancer-Normal 2.46E-02 3.37E-02
10451 VAV3 Cancer-Normal 2.83E-02 3.87E-02
26060 APPL1 Cancer-Normal 3.07E-02 4.15E-02
10451 VAV3 ERneg-ERpos 1.59E-16 1.45E-14
595 CCND1 ERneg-ERpos 1.02E-12 7.46E-11
10902 BRD8 ERneg-ERpos 1.55E-12 9.41E-11
4255 MGMT ERneg-ERpos 4.67E-12 2.43E-10
11315 PARK7 ERneg-ERpos 2.19E-11 7.98E-10
1382 CRABP2 ERneg-ERpos 3.35E-11 1.02E-09
6907 TBL1X ERneg-ERpos 1.34E-10 3.49E-09
9326 ZNHIT3 ERneg-ERpos 2.00E-10 4.88E-09
10401 PIAS3 ERneg-ERpos 2.44E-10 5.56E-09
57658 CALCOCO1 ERneg-ERpos 2.68E-10 5.75E-09
10445 MCRS1 ERneg-ERpos 5.28E-10 1.07E-08
10987 COPS5 ERneg-ERpos 7.21E-10 1.32E-08
1387 CREBBP ERneg-ERpos 6.89E-10 1.32E-08
25803 SPDEF ERneg-ERpos 8.14E-10 1.42E-08
473 RERE ERneg-ERpos 1.07E-09 1.77E-08
4331 MNAT1 ERneg-ERpos 1.22E-09 1.94E-08
2647 BLOC1S1 ERneg-ERpos 2.10E-09 3.19E-08
84458 LCOR ERneg-ERpos 2.81E-09 4.10E-08
8841 HDAC3 ERneg-ERpos 4.34E-09 6.10E-08
6595 SMARCA2 ERneg-ERpos 4.51E-09 6.10E-08
51366 UBR5 ERneg-ERpos 4.84E-09 6.31E-08
5705 PSMC5 ERneg-ERpos 5.51E-09 6.93E-08
8289 ARID1A ERneg-ERpos 6.54E-09 7.70E-08
10155 TRIM28 ERneg-ERpos 7.42E-09 8.47E-08
6604 SMARCD3 ERneg-ERpos 1.64E-08 1.76E-07
9667 SAFB2 ERneg-ERpos 3.40E-08 3.35E-07
7251 TSG101 ERneg-ERpos 4.69E-08 4.39E-07
10474 TADA3L ERneg-ERpos 4.99E-08 4.55E-07
2521 FUS ERneg-ERpos 5.42E-08 4.61E-07
7110 TMF1 ERneg-ERpos 5.28E-08 4.61E-07
7520 XRCC5 ERneg-ERpos 5.43E-08 4.61E-07
9584 RBM39 ERneg-ERpos 6.81E-08 5.52E-07
8878 SQSTM1 ERneg-ERpos 7.57E-08 6.00E-07
166 AES ERneg-ERpos 8.61E-08 6.54E-07
23013 SPEN ERneg-ERpos 8.59E-08 6.54E-07
1655 DDX5 ERneg-ERpos 1.20E-07 8.76E-07
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1025 CDK9 ERneg-ERpos 1.36E-07 9.34E-07
8721 EDF1 ERneg-ERpos 1.39E-07 9.38E-07
10521 DDX17 ERneg-ERpos 1.48E-07 9.82E-07
6830 SUPT6H ERneg-ERpos 1.57E-07 1.02E-06
2274 FHL2 ERneg-ERpos 1.64E-07 1.05E-06
8493 PPM1D ERneg-ERpos 1.73E-07 1.09E-06
10399 GNB2L1 ERneg-ERpos 2.01E-07 1.22E-06
57727 NCOA5 ERneg-ERpos 2.15E-07 1.29E-06
9611 NCOR1 ERneg-ERpos 2.23E-07 1.31E-06
55827 IQWD1 ERneg-ERpos 2.90E-07 1.66E-06
51282 SCAND1 ERneg-ERpos 3.18E-07 1.79E-06
4582 MUC1 ERneg-ERpos 3.79E-07 2.10E-06
6047 RNF4 ERneg-ERpos 5.21E-07 2.80E-06
10524 HTATIP ERneg-ERpos 5.67E-07 3.00E-06
22938 SNW1 ERneg-ERpos 6.21E-07 3.24E-06
9968 MED12 ERneg-ERpos 6.37E-07 3.27E-06
10587 TXNRD2 ERneg-ERpos 6.66E-07 3.38E-06
8085 MLL2 ERneg-ERpos 6.79E-07 3.40E-06
126382 NR2C2AP ERneg-ERpos 9.34E-07 4.61E-06
23414 ZFPM2 ERneg-ERpos 9.84E-07 4.79E-06
10197 PSME3 ERneg-ERpos 1.00E-06 4.81E-06
25942 SIN3A ERneg-ERpos 1.01E-06 4.81E-06
57492 ARID1B ERneg-ERpos 1.11E-06 5.19E-06
51720 UIMC1 ERneg-ERpos 1.18E-06 5.44E-06
11143 MYST2 ERneg-ERpos 1.30E-06 5.93E-06
5704 PSMC4 ERneg-ERpos 1.33E-06 6.00E-06
57178 ZMIZ1 ERneg-ERpos 1.69E-06 7.53E-06
64324 NSD1 ERneg-ERpos 2.12E-06 9.22E-06
6760 SS18 ERneg-ERpos 2.40E-06 1.03E-05
23309 SIN3B ERneg-ERpos 2.84E-06 1.21E-05
2874 D4S234E.GPS2 ERneg-ERpos 2.98E-06 1.25E-05
1022 CDK7 ERneg-ERpos 3.41E-06 1.41E-05
6130 LOC100132910.RPL7AERneg-ERpos 4.79E-06 1.90E-05
6774 STAT3 ERneg-ERpos 5.03E-06 1.97E-05
9063 PIAS2 ERneg-ERpos 5.58E-06 2.16E-05
1616 DAXX ERneg-ERpos 6.27E-06 2.39E-05
55898 UNC45A ERneg-ERpos 7.14E-06 2.63E-05
5970 RELA ERneg-ERpos 7.65E-06 2.79E-05
9733 SART3 ERneg-ERpos 8.08E-06 2.92E-05
8409 UXT ERneg-ERpos 9.00E-06 3.22E-05
3065 HDAC1 ERneg-ERpos 9.30E-06 3.30E-05
857 CAV1 ERneg-ERpos 1.07E-05 3.68E-05
4841 NONO ERneg-ERpos 1.21E-05 4.14E-05
7818 DAP3 ERneg-ERpos 1.25E-05 4.22E-05
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3192 HNRNPU ERneg-ERpos 1.34E-05 4.48E-05
9604 RNF14 ERneg-ERpos 1.42E-05 4.70E-05
8805 TRIM24 ERneg-ERpos 1.49E-05 4.90E-05
8648 NCOA1 ERneg-ERpos 1.71E-05 5.57E-05
5036 PA2G4 ERneg-ERpos 2.11E-05 6.71E-05
9759 HDAC4 ERneg-ERpos 2.10E-05 6.71E-05
9320 TRIP12 ERneg-ERpos 2.23E-05 7.01E-05
9318 COPS2 ERneg-ERpos 2.26E-05 7.06E-05
1488 CTBP2 ERneg-ERpos 2.31E-05 7.16E-05
602 BCL3 ERneg-ERpos 2.52E-05 7.73E-05
56924 PAK6 ERneg-ERpos 2.56E-05 7.78E-05
8554 PIAS1 ERneg-ERpos 3.16E-05 9.31E-05
7329 UBE2I ERneg-ERpos 3.92E-05 1.14E-04
2033 EP300 ERneg-ERpos 4.16E-05 1.19E-04
7041 TGFB1I1 ERneg-ERpos 4.18E-05 1.19E-04
9321 TRIP11 ERneg-ERpos 4.44E-05 1.26E-04
10114 HIPK3 ERneg-ERpos 5.12E-05 1.43E-04
64210 MMS19 ERneg-ERpos 5.38E-05 1.49E-04
8178 ELL ERneg-ERpos 6.17E-05 1.69E-04
6602 SMARCD1 ERneg-ERpos 7.27E-05 1.97E-04
10923 SUB1 ERneg-ERpos 7.75E-05 2.08E-04
24148 PRPF6 ERneg-ERpos 8.08E-05 2.14E-04
2314 FLII ERneg-ERpos 8.94E-05 2.32E-04
29843 SENP1 ERneg-ERpos 9.84E-05 2.53E-04
3275 PRMT2 ERneg-ERpos 1.00E-04 2.55E-04
7050 TGIF1 ERneg-ERpos 1.13E-04 2.87E-04
6597 SMARCA4 ERneg-ERpos 1.20E-04 2.99E-04
9039 UBA3 ERneg-ERpos 1.26E-04 3.14E-04
9282 MED14 ERneg-ERpos 1.31E-04 3.22E-04
142 PARP1 ERneg-ERpos 1.35E-04 3.32E-04
7157 TP53 ERneg-ERpos 1.45E-04 3.53E-04
6129 RPL7 ERneg-ERpos 1.52E-04 3.67E-04
221895 JAZF1 ERneg-ERpos 1.55E-04 3.71E-04
8125 ANP32A ERneg-ERpos 1.57E-04 3.75E-04
23054 NCOA6 ERneg-ERpos 1.65E-04 3.88E-04
7341 SUMO1 ERneg-ERpos 1.65E-04 3.88E-04
79718 TBL1XR1 ERneg-ERpos 1.66E-04 3.88E-04
7332 UBE2L3 ERneg-ERpos 1.67E-04 3.89E-04
10498 CARM1 ERneg-ERpos 1.94E-04 4.46E-04
9325 TRIP4 ERneg-ERpos 2.14E-04 4.86E-04
9112 MTA1 ERneg-ERpos 2.20E-04 4.95E-04
6871 TADA2L ERneg-ERpos 2.29E-04 5.13E-04
55629 PNRC2 ERneg-ERpos 2.75E-04 6.08E-04
23421 ITGB3BP ERneg-ERpos 2.91E-04 6.41E-04
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25898 RCHY1 ERneg-ERpos 3.33E-04 7.28E-04
898 CCNE1 ERneg-ERpos 3.39E-04 7.31E-04
221037 JMJD1C ERneg-ERpos 3.99E-04 8.52E-04
5763 PTMS ERneg-ERpos 4.48E-04 9.51E-04
63925 ZNF335 ERneg-ERpos 4.81E-04 1.01E-03
1660 DHX9 ERneg-ERpos 5.12E-04 1.07E-03
5702 PSMC3 ERneg-ERpos 5.32E-04 1.11E-03
10513 APPBP2 ERneg-ERpos 5.54E-04 1.15E-03
4088 SMAD3 ERneg-ERpos 6.46E-04 1.32E-03
7205 TRIP6 ERneg-ERpos 6.49E-04 1.32E-03
115950 ZNF653 ERneg-ERpos 6.72E-04 1.35E-03
23132 RAD54L2 ERneg-ERpos 6.75E-04 1.35E-03
23462 HEY1 ERneg-ERpos 6.71E-04 1.35E-03
7337 UBE3A ERneg-ERpos 7.01E-04 1.38E-03
10499 NCOA2 ERneg-ERpos 7.06E-04 1.39E-03
9612 NCOR2 ERneg-ERpos 7.68E-04 1.48E-03
27043 PELP1 ERneg-ERpos 8.09E-04 1.55E-03
5925 RB1 ERneg-ERpos 8.13E-04 1.55E-03
6605 SMARCE1 ERneg-ERpos 8.41E-04 1.59E-03
51586 MED15 ERneg-ERpos 9.50E-04 1.79E-03
9219 MTA2 ERneg-ERpos 9.92E-04 1.86E-03
11218 DDX20 ERneg-ERpos 1.12E-03 2.08E-03
4734 NEDD4 ERneg-ERpos 1.17E-03 2.17E-03
6421 SFPQ ERneg-ERpos 1.25E-03 2.31E-03
3148 HMGB2 ERneg-ERpos 1.27E-03 2.32E-03
10432 RBM14 ERneg-ERpos 1.34E-03 2.43E-03
6840 SVIL ERneg-ERpos 2.14E-03 3.81E-03
79084 WDR77 ERneg-ERpos 2.14E-03 3.81E-03
23543 RBM9 ERneg-ERpos 2.20E-03 3.90E-03
51588 PIAS4 ERneg-ERpos 2.32E-03 4.10E-03
5300 PIN1 ERneg-ERpos 2.35E-03 4.13E-03
90480 GADD45GIP1 ERneg-ERpos 2.37E-03 4.14E-03
1072 CFL1 ERneg-ERpos 2.42E-03 4.20E-03
11331 PHB2 ERneg-ERpos 2.52E-03 4.36E-03
5728 PTEN ERneg-ERpos 2.68E-03 4.62E-03
3146 HMGB1 ERneg-ERpos 3.00E-03 5.12E-03
26524 LATS2 ERneg-ERpos 3.05E-03 5.15E-03
53335 BCL11A ERneg-ERpos 3.03E-03 5.15E-03
80324 PUS1 ERneg-ERpos 3.52E-03 5.87E-03
8295 TRRAP ERneg-ERpos 3.50E-03 5.87E-03
23411 SIRT1 ERneg-ERpos 3.60E-03 5.95E-03
573 BAG1 ERneg-ERpos 4.14E-03 6.77E-03
9322 TRIP10 ERneg-ERpos 4.28E-03 6.97E-03
9031 BAZ1B ERneg-ERpos 4.46E-03 7.23E-03
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10291 SF3A1 ERneg-ERpos 4.55E-03 7.36E-03
7249 TSC2 ERneg-ERpos 4.61E-03 7.41E-03
1028 CDKN1C ERneg-ERpos 4.87E-03 7.73E-03
11124 FAF1 ERneg-ERpos 5.02E-03 7.94E-03
10048 RANBP9 ERneg-ERpos 5.29E-03 8.28E-03
5757 PTMA ERneg-ERpos 7.90E-03 1.23E-02
8850 PCAF ERneg-ERpos 9.02E-03 1.39E-02
122953 ZNF143.JDP2 ERneg-ERpos 9.11E-03 1.40E-02
26060 APPL1 ERneg-ERpos 9.58E-03 1.46E-02
6294 SAFB ERneg-ERpos 9.91E-03 1.50E-02
6881 TAF10 ERneg-ERpos 1.14E-02 1.71E-02
10011 SRA1 ERneg-ERpos 1.38E-02 2.04E-02
10865 ARID5A ERneg-ERpos 1.39E-02 2.06E-02
1487 CTBP1 ERneg-ERpos 1.45E-02 2.12E-02
8204 NRIP1 ERneg-ERpos 1.44E-02 2.12E-02
8900 CCNA1 ERneg-ERpos 1.52E-02 2.21E-02
8202 NCOA3 ERneg-ERpos 1.60E-02 2.31E-02
26205 GMEB2 ERneg-ERpos 1.78E-02 2.54E-02
83637 ZMIZ2 ERneg-ERpos 2.06E-02 2.91E-02
64919 BCL11B ERneg-ERpos 2.21E-02 3.08E-02
83714 NRIP2 ERneg-ERpos 2.21E-02 3.08E-02
8819 SAP30 ERneg-ERpos 2.36E-02 3.28E-02
896 CCND3 ERneg-ERpos 2.55E-02 3.52E-02
2185 PTK2B ERneg-ERpos 2.74E-02 3.75E-02
7533 YWHAH ERneg-ERpos 3.11E-02 4.22E-02
857 CAV1 ERneg-Normal 2.21E-38 8.08E-36
6595 SMARCA2 ERneg-Normal 4.28E-25 3.13E-23
57658 CALCOCO1 ERneg-Normal 7.10E-25 3.70E-23
4255 MGMT ERneg-Normal 3.84E-23 1.75E-21
6604 SMARCD3 ERneg-Normal 4.73E-23 1.92E-21
10399 GNB2L1 ERneg-Normal 5.91E-23 2.16E-21
4331 MNAT1 ERneg-Normal 8.93E-23 2.96E-21
9318 COPS2 ERneg-Normal 2.44E-22 7.43E-21
221037 JMJD1C ERneg-Normal 8.14E-22 2.28E-20
221895 JAZF1 ERneg-Normal 1.03E-21 2.51E-20
23414 ZFPM2 ERneg-Normal 1.97E-21 4.22E-20
10902 BRD8 ERneg-Normal 2.79E-21 5.66E-20
473 RERE ERneg-Normal 3.62E-21 6.96E-20
1387 CREBBP ERneg-Normal 2.21E-20 4.04E-19
1025 CDK9 ERneg-Normal 2.53E-19 4.20E-18
10445 MCRS1 ERneg-Normal 7.77E-19 1.18E-17
23013 SPEN ERneg-Normal 1.60E-18 2.24E-17
25942 SIN3A ERneg-Normal 5.78E-18 7.54E-17
8648 NCOA1 ERneg-Normal 6.65E-18 8.37E-17
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23309 SIN3B ERneg-Normal 9.13E-18 1.11E-16
10155 TRIM28 ERneg-Normal 1.27E-17 1.50E-16
51720 UIMC1 ERneg-Normal 1.62E-17 1.85E-16
9667 SAFB2 ERneg-Normal 1.88E-17 2.08E-16
10521 DDX17 ERneg-Normal 1.96E-17 2.11E-16
5325 PLAGL1 ERneg-Normal 2.28E-17 2.37E-16
7520 XRCC5 ERneg-Normal 3.39E-17 3.43E-16
10114 HIPK3 ERneg-Normal 4.80E-17 4.49E-16
10587 TXNRD2 ERneg-Normal 5.10E-17 4.65E-16
8850 PCAF ERneg-Normal 5.60E-17 4.86E-16
9063 PIAS2 ERneg-Normal 7.05E-17 5.98E-16
11143 MYST2 ERneg-Normal 7.82E-17 6.49E-16
9611 NCOR1 ERneg-Normal 9.68E-17 7.85E-16
9968 MED12 ERneg-Normal 1.09E-16 8.63E-16
8554 PIAS1 ERneg-Normal 3.75E-16 2.73E-15
84458 LCOR ERneg-Normal 4.18E-16 2.99E-15
4841 NONO ERneg-Normal 1.54E-15 1.03E-14
6840 SVIL ERneg-Normal 1.76E-15 1.15E-14
9759 HDAC4 ERneg-Normal 2.80E-15 1.76E-14
9039 UBA3 ERneg-Normal 3.53E-15 2.18E-14
5705 PSMC5 ERneg-Normal 4.09E-15 2.47E-14
25898 RCHY1 ERneg-Normal 6.04E-15 3.46E-14
6907 TBL1X ERneg-Normal 6.07E-15 3.46E-14
8409 UXT ERneg-Normal 7.72E-15 4.33E-14
10401 PIAS3 ERneg-Normal 1.09E-14 6.03E-14
7110 TMF1 ERneg-Normal 1.19E-14 6.51E-14
6830 SUPT6H ERneg-Normal 1.23E-14 6.60E-14
2647 BLOC1S1 ERneg-Normal 1.35E-14 7.15E-14
83714 NRIP2 ERneg-Normal 1.38E-14 7.17E-14
3275 PRMT2 ERneg-Normal 1.54E-14 7.92E-14
64324 NSD1 ERneg-Normal 1.97E-14 9.99E-14
9326 ZNHIT3 ERneg-Normal 2.24E-14 1.12E-13
10197 PSME3 ERneg-Normal 2.38E-14 1.17E-13
6602 SMARCD1 ERneg-Normal 2.49E-14 1.21E-13
7041 TGFB1I1 ERneg-Normal 3.51E-14 1.66E-13
10524 HTATIP ERneg-Normal 4.22E-14 1.98E-13
10474 TADA3L ERneg-Normal 4.33E-14 2.00E-13
8493 PPM1D ERneg-Normal 4.56E-14 2.08E-13
9320 TRIP12 ERneg-Normal 5.33E-14 2.40E-13
29123 ANKRD11 ERneg-Normal 5.59E-14 2.49E-13
11331 PHB2 ERneg-Normal 8.34E-14 3.67E-13
6129 RPL7 ERneg-Normal 1.06E-13 4.61E-13
9321 TRIP11 ERneg-Normal 1.27E-13 5.45E-13
1655 DDX5 ERneg-Normal 1.65E-13 6.91E-13
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2274 FHL2 ERneg-Normal 2.09E-13 8.57E-13
8721 EDF1 ERneg-Normal 2.53E-13 1.02E-12
51586 MED15 ERneg-Normal 2.82E-13 1.13E-12
5036 PA2G4 ERneg-Normal 3.06E-13 1.21E-12
27043 PELP1 ERneg-Normal 3.12E-13 1.23E-12
2934 GSN ERneg-Normal 3.24E-13 1.26E-12
51366 UBR5 ERneg-Normal 3.65E-13 1.40E-12
166 AES ERneg-Normal 5.22E-13 1.96E-12
6047 RNF4 ERneg-Normal 6.60E-13 2.43E-12
6130 LOC100132910.RPL7AERneg-Normal 6.70E-13 2.44E-12
9733 SART3 ERneg-Normal 7.28E-13 2.63E-12
64210 MMS19 ERneg-Normal 8.69E-13 3.11E-12
7332 UBE2L3 ERneg-Normal 8.83E-13 3.13E-12
10957 PNRC1 ERneg-Normal 8.97E-13 3.15E-12
11315 PARK7 ERneg-Normal 9.64E-13 3.32E-12
8289 ARID1A ERneg-Normal 1.60E-12 5.47E-12
9322 TRIP10 ERneg-Normal 1.74E-12 5.89E-12
8841 HDAC3 ERneg-Normal 2.06E-12 6.88E-12
10451 VAV3 ERneg-Normal 2.77E-12 9.11E-12
7205 TRIP6 ERneg-Normal 2.97E-12 9.68E-12
1028 CDKN1C ERneg-Normal 4.63E-12 1.46E-11
6760 SS18 ERneg-Normal 4.66E-12 1.46E-11
23421 ITGB3BP ERneg-Normal 5.39E-12 1.68E-11
5970 RELA ERneg-Normal 6.80E-12 2.10E-11
5629 PROX1 ERneg-Normal 1.05E-11 3.23E-11
57492 ARID1B ERneg-Normal 1.41E-11 4.28E-11
2308 FOXO1 ERneg-Normal 1.56E-11 4.72E-11
9604 RNF14 ERneg-Normal 1.76E-11 5.25E-11
23543 RBM9 ERneg-Normal 2.41E-11 7.15E-11
9282 MED14 ERneg-Normal 2.66E-11 7.82E-11
55827 IQWD1 ERneg-Normal 3.48E-11 1.02E-10
11218 DDX20 ERneg-Normal 3.53E-11 1.02E-10
2874 D4S234E.GPS2 ERneg-Normal 4.77E-11 1.36E-10
57727 NCOA5 ERneg-Normal 4.86E-11 1.38E-10
23132 RAD54L2 ERneg-Normal 5.13E-11 1.44E-10
4088 SMAD3 ERneg-Normal 5.36E-11 1.49E-10
2314 FLII ERneg-Normal 7.22E-11 2.00E-10
9584 RBM39 ERneg-Normal 7.37E-11 2.02E-10
22938 SNW1 ERneg-Normal 7.98E-11 2.17E-10
2033 EP300 ERneg-Normal 9.31E-11 2.52E-10
29843 SENP1 ERneg-Normal 1.10E-10 2.94E-10
23411 SIRT1 ERneg-Normal 1.22E-10 3.25E-10
26524 LATS2 ERneg-Normal 1.49E-10 3.94E-10
9612 NCOR2 ERneg-Normal 1.81E-10 4.73E-10
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9219 MTA2 ERneg-Normal 2.84E-10 7.36E-10
7337 UBE3A ERneg-Normal 3.06E-10 7.86E-10
135112 NCOA7 ERneg-Normal 3.27E-10 8.34E-10
8085 MLL2 ERneg-Normal 4.25E-10 1.08E-09
79718 TBL1XR1 ERneg-Normal 4.67E-10 1.18E-09
3192 HNRNPU ERneg-Normal 6.14E-10 1.54E-09
63925 ZNF335 ERneg-Normal 7.90E-10 1.95E-09
7157 TP53 ERneg-Normal 1.34E-09 3.26E-09
10923 SUB1 ERneg-Normal 1.74E-09 4.17E-09
6774 STAT3 ERneg-Normal 1.83E-09 4.37E-09
23462 HEY1 ERneg-Normal 2.15E-09 5.08E-09
2521 FUS ERneg-Normal 2.16E-09 5.08E-09
133522 PPARGC1B ERneg-Normal 2.18E-09 5.10E-09
8178 ELL ERneg-Normal 2.32E-09 5.40E-09
1660 DHX9 ERneg-Normal 2.37E-09 5.49E-09
9325 TRIP4 ERneg-Normal 2.41E-09 5.53E-09
1488 CTBP2 ERneg-Normal 2.76E-09 6.30E-09
11124 FAF1 ERneg-Normal 4.57E-09 1.02E-08
6871 TADA2L ERneg-Normal 5.79E-09 1.27E-08
10513 APPBP2 ERneg-Normal 1.20E-08 2.60E-08
7329 UBE2I ERneg-Normal 1.28E-08 2.76E-08
8125 ANP32A ERneg-Normal 1.34E-08 2.87E-08
55898 UNC45A ERneg-Normal 1.37E-08 2.91E-08
10891 PPARGC1A ERneg-Normal 1.90E-08 3.95E-08
7251 TSG101 ERneg-Normal 1.90E-08 3.95E-08
8805 TRIM24 ERneg-Normal 3.07E-08 6.26E-08
55629 PNRC2 ERneg-Normal 3.18E-08 6.41E-08
9265 PSCD3 ERneg-Normal 3.33E-08 6.64E-08
10865 ARID5A ERneg-Normal 3.46E-08 6.86E-08
10987 COPS5 ERneg-Normal 4.43E-08 8.73E-08
8031 NCOA4 ERneg-Normal 5.09E-08 9.98E-08
8878 SQSTM1 ERneg-Normal 5.76E-08 1.12E-07
1616 DAXX ERneg-Normal 1.05E-07 2.05E-07
1487 CTBP1 ERneg-Normal 2.35E-07 4.50E-07
898 CCNE1 ERneg-Normal 3.82E-07 7.18E-07
10291 SF3A1 ERneg-Normal 3.95E-07 7.40E-07
4734 NEDD4 ERneg-Normal 5.17E-07 9.59E-07
9031 BAZ1B ERneg-Normal 6.50E-07 1.19E-06
3065 HDAC1 ERneg-Normal 6.63E-07 1.20E-06
1382 CRABP2 ERneg-Normal 7.10E-07 1.28E-06
126382 NR2C2AP ERneg-Normal 7.83E-07 1.40E-06
8295 TRRAP ERneg-Normal 8.60E-07 1.53E-06
10498 CARM1 ERneg-Normal 9.78E-07 1.73E-06
10499 NCOA2 ERneg-Normal 1.01E-06 1.79E-06
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595 CCND1 ERneg-Normal 1.32E-06 2.31E-06
115950 ZNF653 ERneg-Normal 2.92E-06 5.00E-06
5728 PTEN ERneg-Normal 3.59E-06 6.06E-06
3146 HMGB1 ERneg-Normal 4.66E-06 7.84E-06
5925 RB1 ERneg-Normal 4.95E-06 8.29E-06
80324 PUS1 ERneg-Normal 5.52E-06 9.20E-06
2185 PTK2B ERneg-Normal 6.43E-06 1.06E-05
1022 CDK7 ERneg-Normal 8.22E-06 1.35E-05
53335 BCL11A ERneg-Normal 8.26E-06 1.35E-05
9112 MTA1 ERneg-Normal 8.25E-06 1.35E-05
5704 PSMC4 ERneg-Normal 8.96E-06 1.45E-05
6597 SMARCA4 ERneg-Normal 8.93E-06 1.45E-05
122953 ZNF143.JDP2 ERneg-Normal 9.19E-06 1.48E-05
51282 SCAND1 ERneg-Normal 1.45E-05 2.29E-05
9319 TRIP13 ERneg-Normal 2.00E-05 3.14E-05
5702 PSMC3 ERneg-Normal 2.36E-05 3.70E-05
10691 GMEB1 ERneg-Normal 2.77E-05 4.30E-05
3276 PRMT1 ERneg-Normal 3.30E-05 5.10E-05
896 CCND3 ERneg-Normal 4.35E-05 6.67E-05
7341 SUMO1 ERneg-Normal 4.91E-05 7.47E-05
6605 SMARCE1 ERneg-Normal 6.19E-05 9.33E-05
5757 PTMA ERneg-Normal 6.85E-05 1.02E-04
10048 RANBP9 ERneg-Normal 7.13E-05 1.06E-04
890 CCNA2 ERneg-Normal 7.51E-05 1.11E-04
7050 TGIF1 ERneg-Normal 1.04E-04 1.51E-04
8202 NCOA3 ERneg-Normal 1.04E-04 1.51E-04
6942 TCF20 ERneg-Normal 1.38E-04 1.99E-04
24148 PRPF6 ERneg-Normal 1.60E-04 2.30E-04
994 CDC25B ERneg-Normal 1.74E-04 2.49E-04
5901 RAN ERneg-Normal 1.96E-04 2.80E-04
8204 NRIP1 ERneg-Normal 2.53E-04 3.55E-04
10432 RBM14 ERneg-Normal 5.16E-04 7.16E-04
25803 SPDEF ERneg-Normal 6.50E-04 8.99E-04
29982 NRBF2 ERneg-Normal 6.78E-04 9.34E-04
5763 PTMS ERneg-Normal 1.13E-03 1.53E-03
6996 TDG ERneg-Normal 1.17E-03 1.59E-03
26060 PPL1 ERneg-Normal 1.29E-03 1.74E-03
83637 ZMIZ2 ERneg-Normal 2.12E-03 2.82E-03
79084 WDR77 ERneg-Normal 2.48E-03 3.27E-03
9862 MED24 ERneg-Normal 2.49E-03 3.27E-03
96764 TGS1 ERneg-Normal 2.79E-03 3.64E-03
92283 ZNF461 ERneg-Normal 3.94E-03 5.14E-03
56924 PAK6 ERneg-Normal 4.53E-03 5.86E-03
7249 TSC2 ERneg-Normal 6.27E-03 8.03E-03
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57178 ZMIZ1 ERneg-Normal 7.49E-03 9.56E-03
30836 DNTTIP2 ERneg-Normal 9.12E-03 1.16E-02
5300 PIN1 ERneg-Normal 1.03E-02 1.31E-02
3066 HDAC2 ERneg-Normal 1.16E-02 1.46E-02
672 BRCA1 ERneg-Normal 1.98E-02 2.43E-02
573 BAG1 ERneg-Normal 2.07E-02 2.54E-02
6881 TAF10 ERneg-Normal 2.29E-02 2.79E-02
23054 NCOA6 ERneg-Normal 2.71E-02 3.28E-02
5629 PROX1 ERpos-Normal 6.63E-13 3.03E-11
83714 NRIP2 ERpos-Normal 6.59E-09 9.25E-08
53335 BCL11A ERpos-Normal 1.04E-12 4.23E-11
857 CAV1 ERpos-Normal 1.08E-27 3.93E-25
10891 PPARGC1A ERpos-Normal 3.41E-09 5.66E-08
5325 PLAGL1 ERpos-Normal 3.71E-14 2.71E-12
2934 GSN ERpos-Normal 1.61E-08 2.02E-07
2308 FOXO1 ERpos-Normal 5.25E-10 1.01E-08
6496 SIX3 ERpos-Normal 5.96E-03 1.45E-02
10957 PNRC1 ERpos-Normal 7.59E-10 1.39E-08
135112 NCOA7 ERpos-Normal 4.68E-07 4.17E-06
8850 PCAF ERpos-Normal 2.67E-10 5.74E-09
9265 PSCD3 ERpos-Normal 1.94E-05 1.07E-04
8900 CCNA1 ERpos-Normal 4.56E-03 1.19E-02
1028 CDKN1C ERpos-Normal 1.10E-05 6.68E-05
133522 PPARGC1B ERpos-Normal 1.32E-06 1.00E-05
23414 ZFPM2 ERpos-Normal 1.96E-08 2.31E-07
7041 TGFB1I1 ERpos-Normal 7.51E-05 3.26E-04
10114 HIPK3 ERpos-Normal 6.97E-07 5.78E-06
55806 HR ERpos-Normal 3.64E-03 9.69E-03
221895 JAZF1 ERpos-Normal 1.13E-11 3.44E-10
221037 JMJD1C ERpos-Normal 1.94E-12 7.07E-11
6840 SVIL ERpos-Normal 7.65E-08 8.03E-07
6604 SMARCD3 ERpos-Normal 7.70E-08 8.03E-07
57658 CALCOCO1 ERpos-Normal 1.54E-07 1.56E-06
64919 BCL11B ERpos-Normal 5.03E-03 1.29E-02
4088 SMAD3 ERpos-Normal 1.01E-03 3.18E-03
9318 COPS2 ERpos-Normal 4.97E-11 1.21E-09
5469 MED1 ERpos-Normal 3.13E-03 8.52E-03
25898 RCHY1 ERpos-Normal 2.67E-06 1.95E-05
29123 ANKRD11 ERpos-Normal 3.90E-08 4.45E-07
6595 SMARCA2 ERpos-Normal 5.10E-09 7.45E-08
51720 UIMC1 ERpos-Normal 2.28E-05 1.19E-04
23543 RBM9 ERpos-Normal 1.38E-04 5.61E-04
10399 GNB2L1 ERpos-Normal 4.14E-09 6.30E-08
9039 UBA3 ERpos-Normal 7.22E-06 4.71E-05
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64210 MMS19 ERpos-Normal 8.87E-04 2.84E-03
9063 PIAS2 ERpos-Normal 1.24E-05 7.28E-05
8648 NCOA1 ERpos-Normal 5.87E-07 4.99E-06
7337 UBE3A ERpos-Normal 2.78E-03 7.68E-03
7332 UBE2L3 ERpos-Normal 2.65E-04 9.77E-04
10865 ARID5A ERpos-Normal 1.99E-03 5.72E-03
8554 PIAS1 ERpos-Normal 6.56E-06 4.36E-05
1025 CDK9 ERpos-Normal 8.26E-06 5.20E-05
23309 SIN3B ERpos-Normal 5.38E-06 3.71E-05
25942 SIN3A ERpos-Normal 1.22E-05 7.28E-05
51586 MED15 ERpos-Normal 1.55E-05 8.84E-05
11143 MYST2 ERpos-Normal 6.36E-05 2.87E-04
9322 TRIP10 ERpos-Normal 7.49E-06 4.80E-05
5036 PA2G4 ERpos-Normal 1.04E-03 3.25E-03
23411 SIRT1 ERpos-Normal 2.21E-04 8.24E-04
9321 TRIP11 ERpos-Normal 2.95E-04 1.08E-03
23421 ITGB3BP ERpos-Normal 5.11E-04 1.73E-03
9759 HDAC4 ERpos-Normal 4.55E-05 2.16E-04
8031 NCOA4 ERpos-Normal 2.94E-05 1.49E-04
6602 SMARCD1 ERpos-Normal 5.88E-05 2.68E-04
9604 RNF14 ERpos-Normal 1.52E-02 3.21E-02
27043 PELP1 ERpos-Normal 2.03E-05 1.11E-04
11218 DDX20 ERpos-Normal 4.16E-04 1.42E-03
4331 MNAT1 ERpos-Normal 1.63E-06 1.21E-05
11331 PHB2 ERpos-Normal 1.26E-06 9.79E-06
7205 TRIP6 ERpos-Normal 1.33E-04 5.46E-04
26524 LATS2 ERpos-Normal 3.18E-04 1.15E-03
6129 RPL7 ERpos-Normal 6.72E-05 2.99E-04
9611 NCOR1 ERpos-Normal 3.58E-04 1.26E-03
23013 SPEN ERpos-Normal 5.34E-05 2.50E-04
10521 DDX17 ERpos-Normal 1.83E-04 7.11E-04
3275 PRMT2 ERpos-Normal 2.89E-05 1.49E-04
473 RERE ERpos-Normal 3.44E-05 1.70E-04
10587 TXNRD2 ERpos-Normal 8.96E-05 3.85E-04
9320 TRIP12 ERpos-Normal 3.37E-04 1.20E-03
4255 MGMT ERpos-Normal 1.22E-04 5.08E-04
23462 HEY1 ERpos-Normal 9.00E-03 2.05E-02
9612 NCOR2 ERpos-Normal 1.83E-03 5.38E-03
8409 UXT ERpos-Normal 2.13E-04 8.01E-04
23132 RAD54L2 ERpos-Normal 9.13E-04 2.90E-03
9968 MED12 ERpos-Normal 1.55E-04 6.23E-04
10691 GMEB1 ERpos-Normal 1.67E-02 3.49E-02
9667 SAFB2 ERpos-Normal 6.21E-04 2.02E-03
1487 CTBP1 ERpos-Normal 6.75E-03 1.60E-02
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1387 CREBBP ERpos-Normal 1.82E-04 7.11E-04
63925 ZNF335 ERpos-Normal 7.08E-03 1.67E-02
4841 NONO ERpos-Normal 5.54E-05 2.56E-04
11124 FAF1 ERpos-Normal 1.80E-03 5.33E-03
7110 TMF1 ERpos-Normal 1.65E-02 3.45E-02
7157 TP53 ERpos-Normal 2.45E-02 4.92E-02
6130 LOC100132910.RPL7AERpos-Normal 5.87E-03 1.44E-02
1660 DHX9 ERpos-Normal 1.18E-02 2.60E-02
5901 RAN ERpos-Normal 8.64E-03 1.98E-02
2314 FLII ERpos-Normal 7.16E-03 1.67E-02
57178 ZMIZ1 ERpos-Normal 5.31E-03 1.33E-02
602 BCL3 ERpos-Normal 6.03E-04 2.01E-03
90480 GADD45GIP1 ERpos-Normal 9.62E-03 2.17E-02
10451 VAV3 ERpos-Normal 5.41E-03 1.33E-02
9319 TRIP13 ERpos-Normal 5.34E-03 1.33E-02
1382 CRABP2 ERpos-Normal 5.29E-03 1.33E-02
595 CCND1 ERpos-Normal 3.62E-04 1.26E-03
4582 MUC1 ERpos-Normal 7.33E-05 3.22E-04
25803 SPDEF ERpos-Normal 1.94E-04 7.39E-04
890 CCNA2 ERpos-Normal 1.87E-04 7.20E-04
23532 PRAME ERpos-Normal 1.27E-02 2.77E-02
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Supplementary Table 2B: Up-regulated coregulators
Fold Change (log2)
Entrez ID Symbol
Up-regulated 
in ER+ cancers
-4.207 1 57178 ZMIZ1 yes
-1.712 2 602 BCL3 yes
-2.794 3 90480 GADD45GIP1 yes
-1.781 4 10451 VAV3 yes
-1.652 5 9319 TRIP13 yes
-1.853 6 1382 CRABP2 yes
-1.690 7 595 CCND1 yes
-2.383 8 4582 MUC1 yes
-2.297 9 25803 SPDEF yes
-2.284 10 890 CCNA2 yes
-2.154 11 23532 PRAME yes
-3.851 12 898 CCNE1
-1.583
-4.710
-2.337
-1.772
-1.606
-2.550
-2.083
-2.949
-1.467
-1.703
-1.586
-1.616
-1.636
-1.662
-1.549
-1.688
-1.748
-1.892
-1.224
-1.569
-1.657
-1.341
-1.663
-1.441
-3.391
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-1.527
-1.608
-1.346
-1.051
-2.983
-1.269
-1.423
-1.328
-2.287
-1.335
-1.455
-1.657
-2.254
-2.285
-1.341
-1.385
-1.112
-1.327
-1.278
-0.999
-1.877
-1.171
-1.376
-1.593
-1.368
-1.623
-1.018
-1.657
-1.695
-1.894
-1.536
-0.931
-1.404
-1.393
-1.321
-2.074
-1.162
-1.085
-1.046
-1.172
-2.071
-1.112
-0.938
-1.183
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-1.438
-1.253
-0.869
-1.230
-0.884
-0.870
-1.705
-1.080
-1.099
-1.347
-1.073
-0.902
-0.858
-0.964
-0.918
-1.892
-1.054
-1.315
-1.101
-1.152
-0.975
-1.485
-0.929
-0.835
-1.369
-1.076
-1.405
-0.983
-1.029
-1.190
-0.949
-1.287
-0.922
-0.837
-1.518
-1.040
1.988
-1.365
-1.014
-0.866
-0.935
-0.910
-0.937
-0.849
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-1.105
-0.751
-0.713
-0.884
-1.186
-0.899
0.977
-0.835
-0.797
-0.675
-0.912
-0.641
-0.836
-0.875
-1.203
-0.998
-0.687
1.731
-0.729
-0.664
-0.690
-0.704
-1.194
-0.971
-0.888
-1.057
-0.604
-0.620
-0.694
-0.757
-0.591
-0.731
-1.040
-1.430
-0.589
-0.864
-0.687
-0.959
-1.007
-0.835
-0.720
-1.184
-0.948
-0.598
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2.396
-1.025
-1.312
-0.997
-0.893
-0.784
-0.652
-0.682
-2.787
-2.382
-1.587
-1.717
-1.382
-2.667
-2.153
-1.446
-1.491
-1.853
-1.085
-1.205
-1.313
-3.479
-1.484
-1.323
-1.334
-1.254
-1.142
-1.321
-1.228
-1.086
-1.450
-1.207
-1.586
-1.291
-1.151
-1.290
-1.152
-1.635
-1.059
-1.453
-0.985
-1.173
-1.346
-1.299
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-1.356
-1.089
-1.427
-1.160
-1.582
-1.388
-1.087
-1.077
-1.498
-1.264
-1.212
-2.337
-0.973
-1.190
-1.151
-1.082
-1.201
-1.170
-1.036
-1.474
-0.895
-1.256
-1.245
-1.477
-1.344
-0.920
-1.224
-0.920
-1.443
-1.147
-1.129
-1.432
-1.147
-1.128
-1.273
-1.004
-1.015
-0.922
-0.880
-1.023
-0.920
-1.250
-0.790
-0.862
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-1.105
-1.904
-1.018
-1.024
-1.424
-1.116
-1.093
-0.830
-1.067
-0.922
-1.419
-1.039
-0.803
-1.061
-1.627
-1.226
-1.273
-1.530
-0.943
-1.025
-1.577
-1.518
-0.961
-0.961
-0.910
-1.085
-1.071
-1.053
-0.729
-0.763
-1.158
-0.947
-0.792
-1.147
-1.574
-0.934
-0.769
-1.175
-1.017
-1.240
-1.180
-1.009
-1.242
-1.122
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-0.980
1.938
-0.695
-0.957
-0.966
-0.933
-0.608
-1.267
-1.509
-0.896
-1.340
-0.846
-1.149
-1.315
-1.144
-0.919
-0.798
-1.130
-1.708
-0.834
-0.652
-0.937
-1.237
-0.615
-0.794
-0.661
-0.821
-0.659
-1.009
-0.929
-1.220
-0.910
-0.859
-0.606
-1.125
-1.194
-0.817
1.571
-0.645
-0.770
-0.841
-1.673
-0.677
-0.588
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-0.754
-1.038
-1.142
-0.636
-0.589
-0.590
-0.831
-0.812
-1.038
-1.259
-0.835
-0.993
-0.900
-0.690
-1.286
1.661
-0.693
-1.596
-0.725
1.190
-1.596
-0.790
-0.626
-0.616
-0.892
-4.832
-2.514
-3.211
-2.520
-2.947
-2.233
-2.244
-2.067
-2.060
-2.177
-3.035
-2.120
-2.358
-1.998
-2.381
-1.542
-2.242
-2.264
-2.118
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-2.160
-1.774
-2.630
-1.986
-2.322
-3.000
-1.642
-2.720
-2.041
-2.798
-2.385
-2.335
-2.406
-1.810
-2.068
-1.673
-1.446
-2.182
-2.085
-2.184
-1.413
-2.178
-2.481
-1.790
-1.728
-2.255
-1.665
-1.642
-5.508
-1.801
-1.478
-1.645
-1.379
-1.967
-3.099
-1.757
-1.725
-1.947
-1.922
-1.738
-1.527
-1.859
-2.206
-1.749
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-2.138
-1.463
-1.840
-2.408
-1.734
-3.392
-1.451
-1.516
-1.344
-1.756
-1.378
-2.659
-2.210
-2.547
-1.354
-1.662
-1.667
-1.285
-2.045
-1.816
-2.825
-2.036
-2.097
-1.363
-3.720
-1.652
-2.675
-2.844
-2.161
-1.233
-1.542
-1.862
-1.513
-1.289
-1.595
-2.825
-1.553
-1.639
-1.425
-1.631
-1.534
-1.825
-1.730
-1.689
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-1.210
-2.363
-2.575
-1.382
-1.219
-1.487
-1.635
-1.769
-2.306
-1.399
-1.944
-1.167
-2.102
-1.337
-1.542
-1.907
-1.418
-1.282
-1.519
-1.998
-1.042
-1.679
-1.197
-3.292
-1.078
-1.213
-1.807
-2.366
-1.934
-0.953
-1.273
-0.902
-1.091
-1.385
2.700
-1.276
-1.821
-0.969
-0.949
-1.730
-0.948
-1.221
-1.239
-1.543
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-1.385
-1.710
-1.619
-1.791
-1.429
-0.943
-1.183
-1.249
-2.198
-1.309
-0.766
-1.134
-1.294
-0.917
1.193
-0.682
-1.283
-0.840
-1.070
-0.918
-1.878
-0.818
-0.775
2.050
-0.993
-1.034
-0.896
-1.317
-0.803
-0.861
-1.827
-0.654
-1.658
-1.767
-0.803
-1.274
-1.201
-0.881
-0.592
-1.048
-1.241
-1.794
-0.853
-0.910
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-0.599
-0.788
-0.936
-1.041
-1.674
-1.217
-0.692
-0.821
-3.982
-3.912
-3.769
-3.582
-3.489
-2.588
-2.506
-2.426
-2.172
-2.128
-1.999
-1.967
-1.781
-1.769
-1.683
-1.652
-1.560
-1.472
-1.446
-1.428
-1.385
-1.365
-1.361
-1.361
-1.358
-1.331
-1.316
-1.236
-1.231
-1.198
-1.196
-1.193
-1.153
-1.152
-1.147
-1.131
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-1.129
-1.111
-1.094
-1.048
-1.035
-1.035
-1.029
-1.025
-1.012
-1.008
-1.006
-0.991
-0.989
-0.983
-0.983
-0.980
-0.975
-0.969
-0.950
-0.942
-0.940
-0.936
-0.924
-0.921
-0.921
-0.920
-0.912
-0.911
-0.908
-0.896
-0.894
-0.891
-0.874
-0.840
-0.829
-0.804
-0.795
-0.770
-0.767
-0.749
-0.728
-0.713
-0.696
-0.695
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-0.684
-0.669
-0.656
-0.646
-0.620
-0.611
-0.610
-0.609
-0.598
-0.592
0.625
0.672
0.703
0.742
0.761
0.937
0.997
1.617
1.821
1.926
2.648
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Up-regulated 
in ER- cancers
Associated 
with Cell 
Growth and 
Proliferation 
according to 
IPA
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes yes
yes
yes
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Supplementary Table 3: List of microarray breast cancer datasets used in survival analysis
Study GEO accession  Number of samples
Schmidt et al., 2008 GSE11121 200
Pawitan et al., 2005 GSE1456 159
Symmans et al., 2010 GSE17705 298
Wang et al., 2006 GSE2034 286
Hatzis et al., 2011 GSE25055 310
Hatzis et al., 2011 GSE25065 198
Miller et al., 2005 GSE3494 251
Loi et al., 2007 GSE6532 327
Desmedt et al., 2007 GSE7390 198
Curtis et al., 2012 (METABRIC) EGAS00000000083 1992
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Supplementary Table 3: List of microarray breast cancer datasets used in survival analysis
Platform
Affymetrix HG133A
Affymetrix HG133A
Affymetrix HG133A
Affymetrix HG133A
Affymetrix HG133A
Affymetrix HG133A
Affymetrix HG133A
Affymetrix HG133A
Affymetrix HG133A
Illumina HT-12 v3
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Supplementary Table 4: Nuclear receptors and co-regulators significantly associated with patient survival on both Affymetrix and Illumina platforms
r.index :  Number of times out of 1000 bootstraps of Univariate Cox Regression in which the gene were found to be significantly associated with survival (Univariate Cox Regression P-value <= 0.05)
Multivariate Cox P-value : P-value of multivariate Cox regression adjusted for ER status and Node status, multiple testing corrected using Benjamin Hochberge method
P-values are adjusted using Benjamini-Hochberg method
Entrez Gene ID Gene Symbol probe r.index
univariate cox 
hazard_ratio
1028 CDKN1C 213348_at 990 0.728
1072 CFL1 200021_at 996 3.580
1660 DHX9 212107_s_at 762 0.809
23532 PRAME 204086_at 960 1.213
2521 FUS 217370_x_at 981 0.707
2908 GR 201866_s_at 985 0.608
2934 GSN 214040_s_at 909 0.702
29893 PSMC3IP 213951_s_at 864 1.574
3148 HMGB2 208808_s_at 787 1.197
5036 PA2G4 208676_s_at 915 1.756
5241 PR 208305_at 1000 0.583
5467 PPARδ 208044_s_at 967 2.326
6130 RPL7A 217740_x_at 959 0.379
64324 NSD1 219084_at 816 2.015
6595 SMARCA2 212257_s_at 1000 0.607
672 BRCA1 204531_s_at 972 2.032
890 CCNA2 213226_at 1000 1.636
898 CCNE1 213523_at 998 1.541
9319 TRIP13 204033_at 1000 1.509
AFFYMETRIX ARRAYS
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Supplementary Table 4: Nuclear receptors and co-regulators significantly associated with patient survival on both Affymetrix and Illumina platforms
:  Number of times out of 1000 bootstraps of Univariate Cox Regression in which the gene were found to be significantly associated with survival (Univariate Cox Regression P-value <= 0.05)
: P-value of multivariate Cox regression adjusted for ER status and Node status, multiple testing corrected using Benjamin Hochberge method
univariate cox 
(adj. P-value)
multivariate cox 
hazard ratio
multivariate cox 
(adj. P-value) probe r.index
1.184E-04 0.753 4.931E-03 ILMN_1718565 859
6.805E-05 2.751 1.234E-02 ILMN_1705617 983
8.421E-03 0.680 7.290E-04 ILMN_1690965 826
1.698E-04 1.149 4.564E-02 ILMN_2306033 964
1.184E-04 0.639 1.225E-04 ILMN_2306066 774
1.184E-04 0.723 3.815E-02 ILMN_2389347 981
2.942E-03 0.605 4.931E-03 ILMN_1787518 822
2.594E-03 1.781 1.165E-03 ILMN_2396948 800
7.520E-03 1.191 3.815E-02 ILMN_1654268 984
1.312E-03 1.628 1.923E-02 ILMN_1728984 1000
4.769E-07 0.608 3.592E-04 ILMN_1811014 989
3.024E-04 1.867 3.815E-02 ILMN_1674282 937
2.489E-04 0.415 9.479E-03 ILMN_1740749 842
3.928E-03 2.104 1.918E-02 ILMN_1686136 914
4.562E-07 0.566 7.219E-06 ILMN_1791702 935
9.794E-05 2.610 1.051E-05 ILMN_2311089 881
3.881E-09 1.518 1.705E-04 ILMN_1786125 999
1.254E-06 1.392 9.479E-03 ILMN_2374425 991
4.589E-10 1.480 1.051E-05 ILMN_1796589 998
AFFYMETRIX ARRAYS
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:  Number of times out of 1000 bootstraps of Univariate Cox Regression in which the gene were found to be significantly associated with survival (Univariate Cox Regression P-value <= 0.05)
univariate cox 
hazard_ratio
univariate cox 
(adj. P-value)
multivariate cox 
hazard ratio
multivariate cox 
(adj. P-value)
0.761 3.334E-03 0.784 1.227E-02
1.645 2.516E-04 1.440 1.227E-02
1.720 4.082E-03 1.516 3.505E-02
1.251 2.962E-04 1.163 1.789E-02
1.434 6.527E-03 1.493 7.594E-03
0.474 1.829E-04 0.479 1.086E-03
0.657 6.527E-03 0.674 1.723E-02
1.402 5.415E-03 1.437 7.594E-03
1.336 1.932E-04 1.246 7.594E-03
1.844 6.093E-07 1.732 1.829E-05
0.795 2.067E-04 0.834 7.712E-03
1.595 8.681E-04 1.403 2.161E-02
0.750 3.998E-03 0.759 1.120E-02
1.957 1.356E-03 1.743 1.227E-02
0.742 1.284E-03 0.754 6.754E-03
1.514 2.503E-03 1.552 6.754E-03
1.422 5.411E-06 1.292 6.754E-03
1.292 3.079E-05 1.214 1.227E-02
1.311 1.859E-05 1.220 7.594E-03
ILLUMMINA ARRAYS (METABRIC DATASETS)
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Supplementary Table 5A: Over-represented functional annotations of up-regulated co-regulators
Category Functions
Cellular Growth and Proliferation proliferation
Gene Expression transcription
Cell Death and Survival apoptosis
Cellular Growth and Proliferation proliferation
Gene Expression transcription
Cell Death and Survival cell death
Cancer genital tumor
Cell Morphology morphology
Cellular Movement invasion
Cancer ovarian cancer
Cellular Growth and Proliferation growth
Cancer endometrial carcinoma
Cancer epithelial ovarian cancer
Endocrine System Disorders epithelial ovarian cancer
Cellular Movement invasion
Cancer non-small cell lung cancer
Respiratory Disease non-small cell lung cancer
Cell Death and Survival apoptosis
DNA Replication, Recombination, and RepairDNA damage response
Cancer lymphocytic leukemia
Cellular Growth and Proliferation stimulation
Supplementary Table 5B: Canonical pathways significantly enriched with down-regulated co-regulators
Cell values represents the significance of the over-representation (Bonferroni adjusted P-values)
IPA Canonical Pathways Cancer-Normal
Estrogen Receptor Signaling 4.736E-18
RAR Activation 2.374E-21
Glucocorticoid Receptor Signaling 2.988E-10
Aryl Hydrocarbon Receptor Signaling 1.974E-06
TR-RXR Activation 2.988E-09
PPAR Signaling 3.762E-11
Chronic Myeloid Leukemia Signaling 4.125E-05
Cell Cycle: G1-S Checkpoint Regulation 3.058E-03
Estrogen-Dependent Breast Cancer Signaling 1.430E-05
Prostate Cancer Signaling 1.217E-05
Androgen Signaling 1.974E-05
PPARë±-RXRë± Activation 2.603E-04
Small Cell Lung Cancer Signaling 7.681E-03
Cyclins and Cell Cycle Regulation
Hereditary Breast Cancer Signaling 2.486E-02
VDR-RXR Activation 9.670E-05
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Non-Small Cell Lung Cancer Signaling
FXR-RXR Activation 2.663E-03
PXR-RXR Activation
Estrogen Biosynthesis 2.116E-03
p53 Signaling 4.420E-04
Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency
Pancreatic Adenocarcinoma Signaling
Glioma Signaling
Molecular Mechanisms of Cancer
ErbB2-ErbB3 Signaling
Estrogen-mediated S-phase Entry
Thyroid Cancer Signaling
Role of BRCA1 in DNA Damage Response
Xenobiotic Metabolism Signaling 8.043E-03
Hypoxia Signaling in the Cardiovascular System
JAK-Stat Signaling
Prolactin Signaling
Wnt-ë_-catenin Signaling
FLT3 Signaling in Hematopoietic Progenitor Cells
Endometrial Cancer Signaling
Huntington's Disease Signaling
Granzyme A Signaling 3.511E-02
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Supplementary Table 5A: Over-represented functional annotations of up-regulated co-regulators
Functions Annotation p-Value Predicted Activation StateActivation z-score
proliferation of cells 1.03E-05 Increased 2.307
transcription of RNA 5.10E-07  -0.128
apoptosis 1.85E-04  -1.967
proliferation of tumor cell lines 1.69E-06 Increased 2.075
transcription of DNA 2.61E-05  0.832
cell death of tumor cell lines 2.74E-04  0.119
genital tumor 1.60E-04   
morphology of cells 3.70E-04   
invasion of cells 1.21E-04  0.095
ovarian cancer 5.89E-05   
arrest in growth of tumor cell lines 6.78E-07   
endometrial carcinoma 9.32E-04   
epithelial ovarian cancer 1.27E-04   
epithelial ovarian cancer 1.27E-04   
invasion of tumor cell lines 4.29E-04  0.44
non-small cell lung cancer 3.85E-05   
non-small cell lung cancer 3.85E-05   
apoptosis of breast cancer cell lines 7.51E-04   
DNA damage response of cells 1.34E-04   
lymphocytic leukemia 6.32E-04   
stimulation of cells 9.42E-04   
Supplementary Table 5B: Canonical pathways significantly enriched with down-regulated co-regulators
Cell values represents the significance of the over-representation (Bonferroni adjusted P-values)
ERneg-ERpos ERneg-Normal ERpos-Normal
7.506E-13 1.498E-28 2.920E-04
4.736E-24 1.498E-27 1.190E-11
1.886E-14 5.963E-16 9.450E-06
2.067E-05 1.886E-14 6.244E-04
1.533E-05 2.988E-14 1.246E-05
4.847E-04 3.762E-12 1.275E-06
1.190E-08 5.963E-11 8.819E-03
1.246E-05 7.506E-09
7.506E-07 9.450E-09
4.736E-08 2.988E-08
1.190E-07 1.605E-07
2.215E-07 3.431E-02
6.101E-04 7.169E-07
1.533E-03 2.988E-06
2.429E-06 2.486E-05
2.663E-05 2.988E-03
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4.221E-03 4.847E-05
7.506E-05 2.920E-04
7.681E-04 1.217E-03
1.464E-03
4.847E-03 1.533E-03
5.963E-03 4.847E-03
1.464E-03 5.438E-03
5.694E-03 1.430E-02
1.110E-02 2.067E-02
1.720E-03 2.374E-02
2.603E-02
2.854E-02
3.353E-02
3.676E-02
3.431E-04
5.193E-03
9.235E-03
1.036E-02
1.110E-02
1.398E-02
1.843E-02
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Molecules # Molecules
BCL3,CCNA2,CCND1,CRABP2,GADD45GIP1,MUC1,PRAME,SPDEF,VAV3,ZMIZ110
BCL3,CCNA2,CCND1,CRABP2,PRAME,SPDEF,TRIP13,VAV3,ZMIZ19
BCL3,CCNA2,CCND1,CRABP2,GADD45GIP1,MUC1,PRAME,VAV38
CCNA2,CCND1,CRABP2,GADD45GIP1,MUC1,PRAME,VAV3,ZMIZ18
BCL3,CCNA2,CRABP2,PRAME,SPDEF,TRIP13,ZMIZ17
BCL3,CCND1,CRABP2,MUC1,PRAME,VAV36
CCND1,CRABP2,MUC1,PRAME,SPDEF,VAV36
BCL3,CCNA2,CCND1,MUC1,SPDEF,VAV36
CCNA2,CCND1,MUC1,SPDEF,VAV35
CCND1,CRABP2,MUC1,PRAME,VAV35
CCND1,GADD45GIP1,MUC1,PRAME4
CCNA2,CCND1,CRABP2,TRIP134
CCND1,CRABP2,MUC1,VAV34
CCND1,CRABP2,MUC1,VAV34
CCNA2,MUC1,SPDEF,VAV3 4
CCNA2,CCND1,MUC1,PRAME4
CCNA2,CCND1,MUC1,PRAME4
CCND1,CRABP2,MUC1 3
BCL3,CCND1,VAV3 3
BCL3,CCND1,ZMIZ1 3
CCNA2,CCND1,MUC1 3
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplementary Table 6A: Numbers of highly correlated co-regulators associated with each nuclear receptors at a correlation cutoff of 0.7
Cell value = numbers highly correlated co-regulators (Spearman Rank Correlation >= 0.7 or <= -0.7)
A
R
E
R
-α
E
R
-β
E
R
R
-α
E
R
R
-β
E
R
R
-γ
H
N
F
4
γ
D
A
X
1
S
H
P
R
E
V
-E
R
B
-α
PreMnPsNorm 0 0 0 0 4 1 18 0 0 0
PostMnPsNorm 0 0 2 0 0 8 80 0 0 1
ERpos 4 0 1 0 0 1 0 0 0 0
ERneg 0 0 0 2 0 0 0 16 3 0
PreMnPsNorm 0 0 3 0 0 0 0 0 0 0
PostMnPsNorm 0 0 0 0 0 2 0 0 0 0
ERpos 0 0 0 0 0 0 0 0 0 0
ERneg 0 0 0 0 0 0 0 0 0 0
Positive correlations 
(Sperman Rank 
Correlation >= 0.7)
Positive correlations 
(Sperman Rank 
Correlation <= - 0.7)
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Supplementary Table 6B: Numbers of highly correlated co-regulators associated with each nuclear receptors at a correlation cutoff of 0.6
Cell value = numbers highly correlated co-regulators (Spearman Rank Correlation >= 06 or <= -0.6)
A
R
E
R
-α
E
R
-β
E
R
R
-α
E
R
R
-β
E
R
R
-γ
H
N
F
4
γ
D
A
X
1
S
H
P
R
E
V
-E
R
B
-α
PreMnPsNorm 4 6 2 0 20 7 47 0 0 0
PostMnPsNorm 3 1 3 0 2 31 131 1 0 22
ERpos 22 4 14 1 5 35 0 0 0 0
ERneg 1 12 18 5 3 0 1 46 15 1
PreMnPsNorm 0 0 21 0 0 1 0 0 0 0
PostMnPsNorm 0 0 4 0 0 3 1 0 0 0
ERpos 0 0 0 1 0 0 0 0 0 0
ERneg 2 0 0 0 0 0 0 0 0 0
Positive correlations 
(Sperman Rank 
Correlation >= 0.6)
Positive correlations 
(Sperman Rank 
Correlation <= - 0.6)
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Supplementary Table 6A: Numbers of highly correlated co-regulators associated with each nuclear receptors at a correlation cutoff of 0.7
Cell value = numbers highly correlated co-regulators (Spearman Rank Correlation >= 0.7 or <= -0.7)
R
E
V
-E
R
B
-β
LX
R
-β
LX
R
-α
F
X
R
-α
P
X
R
C
A
R
T
R
2
T
R
4
T
LX
P
N
R
C
O
U
P
-T
F
I
C
O
U
P
-T
F
II
E
A
R
2
G
R
M
R
N
U
R
7
7
N
U
R
R
1
N
O
R
1
0 21 0 0 0 23 5 10 0 5 17 34 2 0 40 10 18 3
3 0 0 0 0 1 0 6 2 0 51 44 0 3 43 1 3 0
0 23 2 1 0 2 0 23 0 0 3 40 3 1 0 5 0 0
31 29 23 0 1 0 4 74 0 0 0 0 4 13 13 8 0 1
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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Supplementary Table 6B: Numbers of highly correlated co-regulators associated with each nuclear receptors at a correlation cutoff of 0.6
Cell value = numbers highly correlated co-regulators (Spearman Rank Correlation >= 06 or <= -0.6)
R
E
V
-E
R
B
-β
LX
R
-β
LX
R
-α
F
X
R
-α
P
X
R
C
A
R
T
R
2
T
R
4
T
LX
P
N
R
C
O
U
P
-T
F
I
C
O
U
P
-T
F
II
E
A
R
2
G
R
M
R
N
U
R
7
7
N
U
R
R
1
N
O
R
1
1 58 0 0 1 58 20 29 0 36 58 69 8 0 80 40 61 28
5 2 1 0 2 1 3 36 16 0 122 113 0 4 108 3 16 1
0 54 18 9 0 22 0 51 0 0 13 81 18 5 2 38 0 0
63 84 58 0 27 0 39 124 0 0 0 9 21 43 50 36 7 40
0 0 0 0 0 0 2 2 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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S
F
-1
LR
H
-1
G
C
N
F
P
R
P
P
A
R
-α
P
P
A
R
δ
P
P
A
R
-γ
R
A
R
-α
R
A
R
-β
R
A
R
-γ
R
O
R
-α
R
O
R
-β
R
O
R
-γ
R
X
R
-α
R
X
R
-β
R
X
R
-γ
T
R
-α
T
R
-β
0 0 13 1 0 52 1 31 0 60 5 0 33 2 29 0 0 9
5 3 1 1 0 17 1 9 97 111 2 0 109 2 53 1 6 0
0 0 0 0 16 27 0 4 0 21 1 0 41 62 29 1 30 0
0 8 0 0 44 55 0 1 0 35 0 0 0 10 17 0 0 0
0 0 0 0 0 0 5 0 1 0 0 0 0 0 0 1 0 0
0 0 0 0 0 0 31 0 0 0 0 0 0 0 0 1 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
S
F
-1
LR
H
-1
G
C
N
F
P
R
P
P
A
R
-α
P
P
A
R
δ
P
P
A
R
-γ
R
A
R
-α
R
A
R
-β
R
A
R
-γ
R
O
R
-α
R
O
R
-β
R
O
R
-γ
R
X
R
-α
R
X
R
-β
R
X
R
-γ
T
R
-α
T
R
-β
0 3 40 11 0 80 1 55 26 88 21 0 71 6 68 0 7 31
56 6 26 1 1 83 3 65 145 158 23 0 162 4 118 2 57 4
0 2 2 0 55 59 2 24 3 40 5 9 77 124 48 27 72 1
0 40 0 6 80 93 2 6 6 67 5 1 0 34 39 0 10 0
0 0 1 1 0 0 40 0 1 0 0 0 0 4 0 22 0 0
0 0 1 3 0 0 94 0 0 0 0 0 0 0 0 3 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
V
D
R
H
N
F
-4
α
48 0
100 0
27 0
39 0
0 0
0 0
0 0
0 0
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
V
D
R
H
N
F
-4
α
79 0
143 0
61 0
74 0
0 0
0 0
0 0
0 0
